<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21041580</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-3704</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Annals of internal medicine</Title><ISOAbbreviation>Ann Intern Med</ISOAbbreviation></Journal><ArticleTitle>Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.</ArticleTitle><Pagination><StartPage>600</StartPage><EndPage>606</EndPage><MedlinePgn>600-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7326/0003-4819-153-9-201011020-00010</ELocationID><Abstract><AbstractText>The U.S. Food and Drug Administration (FDA) Amendments Act of 2007 mandated that the FDA develop a system for using automated health care data to identify risks of marketed drugs and other medical products. The Observational Medical Outcomes Partnership is a public-private partnership among the FDA, academia, data owners, and the pharmaceutical industry that is responding to the need to advance the science of active medical product safety surveillance by using existing observational databases. The Observational Medical Outcomes Partnership's transparent, open innovation approach is designed to systematically and empirically study critical governance, data resource, and methodological issues and their interrelationships in establishing a viable national program of active drug safety surveillance by using observational data. This article describes the governance structure, data-access model, methods-testing approach, and technology development of this effort, as well as the work that has been initiated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08560, USA. PStang@its.jnj.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Racoosin</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>J Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Welebob</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Scarnecchia</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Woodcock</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Intern Med</MedlineTA><NlmUniqueID>0372351</NlmUniqueID><ISSNLinking>0003-4819</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055818" MajorTopicYN="N">Public-Private Sector Partnerships</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014495" MajorTopicYN="N">Universities</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pii">153/9/600</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20945505</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD.</ArticleTitle><Pagination><StartPage>292</StartPage><EndPage>299</EndPage><MedlinePgn>292-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.2051</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">There is a growing interest in using longitudinal observational databases for drug safety signal detection, but most of the existing statistical methods are tailored towards spontaneous reporting. Here a sequential set of methods for detecting and filtering drug safety signals in longitudinal databases is presented.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Longitudinal GPS (LGPS) is a modification of the Gamma Poisson Shrinker (GPS) that uses person time rather than case counts for the estimation of the expected number of events. Longitudinal Evaluation of Observational Profiles of Adverse events Related to Drugs (LEOPARD) is a method that can be used to automatically discard false drug-event associations caused by protopathic bias or misclassification of the dates of the adverse events by comparing prior event prescription rates to post event prescription rates. LEOPARD can generate a single test statistic, or a visualization that can be used for more qualitative information on the relationship between drug and event. Both methods were evaluated using data simulated using the Observational medical dataset SIMulator (OSIM), including the dataset used in the Observational Medical Outcomes Partnership (OMOP) cup, a recent public competition for signal detection methods. The Mean Average Precision (MAP) was used for performance measurement.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">On the OMOP cup data, LGPS achieved a MAP of 0.245, and the combination of LGPS and LEOPARD achieved a MAP of 0.260, the highest score in the competition.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The sequential use of LGPS and LEOPARD have proven to be a useful novel set of methods for drug safety signal detection on longitudinal health records.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. m.schuemie@erasmusmc.nl</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):714-7. doi: 10.1002/pds.2151.</RefSource><PMID Version="1">21638520</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20945505</ArticleId><ArticleId IdType="doi">10.1002/pds.2051</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21811110</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2011</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-5487</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Epidemiology (Cambridge, Mass.)</Title><ISOAbbreviation>Epidemiology</ISOAbbreviation></Journal><ArticleTitle>What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.</ArticleTitle><Pagination><StartPage>629</StartPage><EndPage>631</EndPage><MedlinePgn>629-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/EDE.0b013e318228ca1d</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY 10027, USA. madigan@stat.columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epidemiology</MedlineTA><NlmUniqueID>9009644</NlmUniqueID><ISSNLinking>1044-3983</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Epidemiology. 2011 Sep;22(5):636-7. doi: 10.1097/EDE.0b013e318228cccb.</RefSource><PMID Version="1">21811112</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D057186" MajorTopicYN="N">Comparative Effectiveness Research</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036262" MajorTopicYN="Y">Empirical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019370" MajorTopicYN="Y">Observation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="N">Pharmacoepidemiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21811110</ArticleId><ArticleId IdType="doi">10.1097/EDE.0b013e318228ca1d</ArticleId><ArticleId IdType="pii">00001648-201109000-00006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22037893</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Validation of a common data model for active safety surveillance research.</ArticleTitle><Pagination><StartPage>54</StartPage><EndPage>60</EndPage><MedlinePgn>54-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/amiajnl-2011-000376</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Systematic analysis of observational medical databases for active safety surveillance is hindered by the variation in data models and coding systems. Data analysts often find robust clinical data models difficult to understand and ill suited to support their analytic approaches. Further, some models do not facilitate the computations required for systematic analysis across many interventions and outcomes for large datasets. Translating the data from these idiosyncratic data models to a common data model (CDM) could facilitate both the analysts' understanding and the suitability for large-scale systematic analysis. In addition to facilitating analysis, a suitable CDM has to faithfully represent the source observational database. Before beginning to use the Observational Medical Outcomes Partnership (OMOP) CDM and a related dictionary of standardized terminologies for a study of large-scale systematic active safety surveillance, the authors validated the model's suitability for this use by example.</AbstractText><AbstractText Label="VALIDATION BY EXAMPLE" NlmCategory="UNASSIGNED">To validate the OMOP CDM, the model was instantiated into a relational database, data from 10 different observational healthcare databases were loaded into separate instances, a comprehensive array of analytic methods that operate on the data model was created, and these methods were executed against the databases to measure performance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There was acceptable representation of the data from 10 observational databases in the OMOP CDM using the standardized terminologies selected, and a range of analytic methods was developed and executed with sufficient performance to be useful for active safety surveillance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>J Marc</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Regenstrief Institute, Indiana University, School of Medicine, Indianapolis, Indiana, USA. moverhage@regenstrief.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="N">Health Services Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019370" MajorTopicYN="N">Observation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22037893</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pii">amiajnl-2011-000376</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878&#x2013;86</Citation><ArticleIdList><ArticleId IdType="pubmed">10861324</ArticleId></ArticleIdList></Reference><Reference><Citation>Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1557642</ArticleId><ArticleId IdType="pubmed">10861325</ArticleId></ArticleIdList></Reference><Reference><Citation>Moses LE. Measuring effects without randomized trials? Options, problems, challenges. Med Care 1995;33(4 suppl):AS8&#x2013;14</Citation><ArticleIdList><ArticleId IdType="pubmed">7723464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 1998;317:1185&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28700</ArticleId><ArticleId IdType="pubmed">9794851</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med 2010;153:600&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership [Internet]
Common Data Model, ETL Process, &amp; Terminologies; c2009&#x2013;2011. 2009. 
http://omop.fnih.org/ETLProcess (accessed 25 Jul 2011).</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership [Internet]
OMOP Standardized Terminologies; c2009&#x2013;2011. http://omop.fnih.org/vocabularies (accessed 25 Jul 2011).</Citation></Reference><Reference><Citation>Brown J, Lane K, Moore K, et al. 
Database Models to Implement the FDA Sentinel Initiative. Final Report [Internet]. 2009.  FDA-2009-N-0192&#x2013;005. http://www.regulations.gov/#!documentDetail;D=FDA-2009-N-0192-0005 (accessed 5 Mar 2010).</Citation></Reference><Reference><Citation>Ryan PB, Mera R, Merrill GH. Opportunities and Challenges in Leveraging Observational Data for Pharmacovigilance. Washington, DC: AMIA Pharmacovigilance and Informatics Summit, 2007</Citation></Reference><Reference><Citation>Gliklich RE, Dreyer NA, eds. Registries for Evaluating Patient Outcomes: A User's Guide. Prepared by Outcome DEcIDE Center, AHRQ Publication No 07-EHC001-1. Rockville (MD): Agency for Healthcare Research and Quality, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">21204321</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Level Seven International [Internet]
HL7 Reference Information Model; c2007&#x2013;2011. http://www.hl7.org/implement/standards/rim.cfm (accessed 18 Nov 2010).</Citation></Reference><Reference><Citation>i2b2: Informatics for Integrating Biology &amp; the Bedside [Internet]. https://www.i2b2.org (accessed 18 Nov 2010).</Citation></Reference><Reference><Citation>HMO Research Network [Internet]. c2011. http://www.hmoresearchnetwork.org (accessed 18 Nov 2010).</Citation></Reference><Reference><Citation>Reisinger SJ, Ryan PB, O'Hara DJ, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc 2010;17:652&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000752</ArticleId><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership [Internet]
OSCAR&#x2014;Observational Source Characteristics Analysis Report (OSCAR) Design Specification and Feasibility Assessment; c2009&#x2013;2011. http://omop.fnih.org/OSCAR (accessed 3 Dec 2010).</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership [Internet]
Generalized Review of OSCAR Unified Checking; c2009&#x2013;2011. http://omop.fnih.org/GROUCH (accessed 11 Jan 2011).</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership [Internet]
OMOP Cup; c2009&#x2013;2011. http://omop.fnih.org/omopcup (accessed 11 Jan 2011).</Citation></Reference><Reference><Citation>Dinu V, Nadkarni P.
Guidelines for the effective use of entity-attribute-value modeling for biomedical databases. Int J Med Inform
2007;76:769&#x2013;79 doi:10.1016/j.ijmedinf.2006.09.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2006.09.023</ArticleId><ArticleId IdType="pmc">PMC2110957</ArticleId><ArticleId IdType="pubmed">17098467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22262596</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>21 Suppl 1</Volume><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.</ArticleTitle><Pagination><StartPage>82</StartPage><EndPage>89</EndPage><MedlinePgn>82-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.2321</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To overview the methods used in the Mini-Sentinel systematic reviews of validation studies of algorithms to identify health outcomes in administrative and claims data and to describe lessons learned in the development of search strategies, including their ability to identify articles from previous systematic reviews which used different search strategies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Literature searches were conducted using PubMed and the citation database of the Iowa Drug Information Service. Embase was searched for some outcomes. The searches were based on a strategy developed by the Observational Medical Outcomes Partnership (OMOP) researchers. All citations were reviewed by two investigators. Exclusion criteria were applied at abstract and full-text review stages to ultimately identify algorithm validation studies that used data sources from the USA or Canada, as the results of these studies were considered most likely to generalize to Mini-Sentinel data. Nonvalidated algorithms were reviewed if fewer than five algorithm validation studies were identified.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results of this project are described in the separate articles and reports written on algorithms to identify each outcome of interest.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The Mini-Sentinel systematic reviews of algorithms to identify health outcomes in administrative and claims data are expected to be relatively complete, despite some limitations. Algorithm validation studies are inconsistently indexed in PubMed, creating challenges in conducting systematic reviews of these studies. Google Scholar searches, which can perform text word searches of electronically available articles, are suggested as a strategy to identify studies that are not captured through searches of standard citation databases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carnahan</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, The University of Iowa College of Public Health, Iowa City, IA 52242, USA. ryan-carnahan@uiowa.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moores</LastName><ForeName>Kevin G</ForeName><Initials>KG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004864" MajorTopicYN="N">Equipment and Supplies</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="N">Insurance Claim Review</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012196" MajorTopicYN="Y">Review Literature as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054928" MajorTopicYN="Y">Validation Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22262596</ArticleId><ArticleId IdType="doi">10.1002/pds.2321</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22683994</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2012</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases.</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>696</EndPage><MedlinePgn>689-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2012.05.002</ELocationID><Abstract><AbstractText>Large electronic databases of health care information, such as administrative claims and electronic health records, are available and are being used in a number of public health settings, including drug safety surveillance. However, because of a lack of standardization, clinical terminologies may differ across databases. With the aid of existing resources and expert coders, we have developed mapping tables to convert ICD-9-CM diagnosis codes used in some existing databases to SNOMED-CT and MedDRA. In addition, previously developed definitions for specific health outcomes of interest were mapped to the same standardized vocabularies. We evaluated how vocabulary mapping affected (1) the retention of clinical data from two test databases, (2) the semantic space of outcome definitions, (3) the prevalence of each outcome in the test databases, and (4) the reliability of analytic methods designed to detect drug-outcome associations in the test databases. Although vocabulary mapping affected the semantic space of some outcome definitions, as well as the prevalence of some outcomes in the test databases, it had only minor effects on the analysis of drug-outcome associations. Furthermore, both SNOMED-CT and MedDRA were viable for use as standardized vocabularies in systems designed to perform active medical product surveillance using disparate sources of observational data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, 9650 Rockville Pike, Bethesda, MD 20814, USA. reich@omop.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>Mitra</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D059019" MajorTopicYN="N">Clinical Coding</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="Y">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pii">S1532-0464(12)00069-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22692254</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-1948</ISSN><JournalIssue CitedMedium="Internet"><Volume>50 Suppl</Volume><Issue>0</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Medical care</Title><ISOAbbreviation>Med Care</ISOAbbreviation></Journal><ArticleTitle>A pragmatic framework for single-site and multisite data quality assessment in electronic health record-based clinical research.</ArticleTitle><Pagination><StartPage>S21</StartPage><EndPage>S29</EndPage><MedlinePgn>S21-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MLR.0b013e318257dd67</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Answers to clinical and public health research questions increasingly require aggregated data from multiple sites. Data from electronic health records and other clinical sources are useful for such studies, but require stringent quality assessment. Data quality assessment is particularly important in multisite studies to distinguish true variations in care from data quality problems.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We propose a "fit-for-use" conceptual model for data quality assessment and a process model for planning and conducting single-site and multisite data quality assessments. These approaches are illustrated using examples from prior multisite studies.</AbstractText><AbstractText Label="APPROACH" NlmCategory="METHODS">Critical components of multisite data quality assessment include: thoughtful prioritization of variables and data quality dimensions for assessment; development and use of standardized approaches to data quality assessment that can improve data utility over time; iterative cycles of assessment within and between sites; targeting assessment toward data domains known to be vulnerable to quality problems; and detailed documentation of the rationale and outcomes of data quality assessments to inform data users. The assessment process requires constant communication between site-level data providers, data coordinating centers, and principal investigators.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">A conceptually based and systematically executed approach to data quality assessment is essential to achieve the potential of the electronic revolution in health care. High-quality data allow "learning health care organizations" to analyze and act on their own information, to compare their outcomes to peers, and to address critical scientific questions from the population perspective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Anschutz Medical Center, Colorado Clinical and Translational Sciences Institute, University of Colorado, Aurora 80045, USA. michael.kahn@ucdenver.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raebel</LastName><ForeName>Marsha A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Glanz</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Riedlinger</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>John F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 RR025780</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HS019912</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HS019908</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1RR025780</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01HS019912-01</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01HS019908</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Care</MedlineTA><NlmUniqueID>0230027</NlmUniqueID><ISSNLinking>0025-7079</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Med Care. 2012 Jul;50 Suppl:S19-20. doi: 10.1097/MLR.0b013e3182588ee4.</RefSource><PMID Version="1">22692253</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D057186" MajorTopicYN="N">Comparative Effectiveness Research</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="N">Cooperative Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010043" MajorTopicYN="Y">Outcome and Process Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="N">Patient-Centered Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011785" MajorTopicYN="N">Quality Assurance, Health Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22692254</ArticleId><ArticleId IdType="mid">NIHMS522627</ArticleId><ArticleId IdType="pmc">PMC3833692</ArticleId><ArticleId IdType="doi">10.1097/MLR.0b013e318257dd67</ArticleId><ArticleId IdType="pii">00005650-201207001-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hanna KE. Think research: Using electronic medical records to bridge patient care and research.  [Accessed April 22, 2012];2005  Available at:  http://fastercures.org/objects/pdfs/comments/emr_whitepaper.pdf.</Citation></Reference><Reference><Citation>Wennberg DE, Wennberg JE. Addressing variations: is there hope for the future? Health Aff (Millwood) 2003;(suppl web exclusives):W3-614&#x2013;W3-617. doi: 10.1377/hlthaff.w3.614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.w3.614</ArticleId><ArticleId IdType="pubmed">15506164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg JE. Practice variations and health care reform: connecting the dots. Health Aff (Millwood) 2004;(suppl variation):VAR140&#x2013;VAR144. doi: 10.1377/hlthaff.var.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.var.140</ArticleId><ArticleId IdType="pubmed">15471778</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MG, Embi PJ. Toward reuse of clinical data for research and quality improvement: the end of the beginning? Ann Intern Med. 2009;151:359&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan WR, Wagner MM. Accuracy of data in computer-based patient records. J Am Med Inform Assoc. 1997;4:342&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61252</ArticleId><ArticleId IdType="pubmed">9292840</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronsky D, Haug PJ. Assessing the quality of clinical data in a computer-based record for calculating the pneumonia severity index. J Am Med Inform Assoc. 2000;7:55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61455</ArticleId><ArticleId IdType="pubmed">10641963</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KS, Fowles JB, Weiner JP. Review: electronic health records and the reliability and validity of quality measures: a review of the literature. Med Care Res Rev. 2010;67:503&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">20150441</ArticleId></ArticleIdList></Reference><Reference><Citation>Gryna FM, Chua RCH, De Feo JA, et al. Juran's Quality Planning and Analysis: For Enterprise Quality. 5. Boston: McGraw-Hill: 2007.</Citation></Reference><Reference><Citation>Juran JM, Gryna FM. Quality Planning and Analysis: From Product Development Through Use. 3. New York: McGraw-Hill: 1993.</Citation></Reference><Reference><Citation>Scannapieco M, Catarci T. Data quality under the computer science perspective. Ital J Arch Comput. 2002:1&#x2013;12.</Citation></Reference><Reference><Citation>Batini C, Cappiello C, Francalanci C, et al. Methodologies for data quality assessment and improvement. ACM Comput Surv. 2009;41:1&#x2013;52.</Citation></Reference><Reference><Citation>Batini C, Scannapieca M. Data Quality: Concepts, Methodologies and Techniques. Berlin; New York: Springer; 2006.</Citation></Reference><Reference><Citation>Wang R, Storey V, Firth C. A framework for analysis of data quality research. IEEE Tran on Knowl Data Eng. 1995;7:623&#x2013;640.</Citation></Reference><Reference><Citation>Tayi G, Ballou D. Examining data quality. Comm ACM. 1998;41:54&#x2013;57.</Citation></Reference><Reference><Citation>Abate M, Diegert K, Allen H. A hierarchical approach to improving data quality.  [Accessed April 22, 2012];Data Quality Journal. 1998 4 Available at:  http://www.dataquality.com/998abate.htm.</Citation></Reference><Reference><Citation>Pipino L, Lee Y, Wang R. Data quality assessment. Comm ACM. 2002;45:211&#x2013;218.</Citation></Reference><Reference><Citation>Redman TC. Data Quality: The Field Guide. Boston: Digital Press; 2001.</Citation></Reference><Reference><Citation>Maydanchik A. Data Quality Assessment. Bradley Beach, NJ: Technics Publications; 2007.</Citation></Reference><Reference><Citation>Wang R, Strong D. Beyond accuracy: what data quality means to data consumers. J Manag Inf Syst. 1996;12:5&#x2013;34.</Citation></Reference><Reference><Citation>Wand Y, Wang R. Anchoring data quality dimensions in ontological foundations. Comm ACM. 1996;39:86&#x2013;95.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership. OSCAR&#x2014;Observational Source Characteristics Analysis Report (OSCAR) Design Specification and Feasibility Assessment.  [Accessed July 31, 2011];2011  Available at:  http://omop.fnih.org/OSCAR.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership. Generalized Review of OSCAR Unified Checking.  [Accessed July 31, 2011];2011  Available at:  http://omop.fnih.org/GROUCH.</Citation></Reference><Reference><Citation>Bauck A, Bachman D, Riedlinger K, et al.  Developing a consistent structure for VDW QA checks.  [Accessed September 3, 2011];2011  Available at:  http://www.hmoresearchnetwork.org/archives/2011/concurrent/A1-02-Bauck.pdf.</Citation></Reference><Reference><Citation>Wennberg JE. Future directions for small area variations. Med Care. 1993;31:YS75&#x2013;YS80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8492591</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg JE. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ. 2002;325:961&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1124450</ArticleId><ArticleId IdType="pubmed">12399352</ArticleId></ArticleIdList></Reference><Reference><Citation>France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008;121:e687&#x2013;e692.</Citation><ArticleIdList><ArticleId IdType="pubmed">18310189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hambidge SJ, Glanz JM, France EK, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;296:1990&#x2013;1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">17062862</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullooly J, Drew L, DeStefano F, et al. Quality assessments of HMO diagnosis databases used to monitor childhood vaccine safety. Methods Inf Med. 2004;43:163&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">15136866</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullooly JP, Donahue JG, DeStefano F, et al. Predictive value of ICD-9-CM codes used in vaccine safety research. Methods Inf Med. 2008;47:328&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">18690366</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanz JM, Newcomer SR, Hambidge SJ, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011;165:749&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">21810637</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Robins JM. Confounding and misclassification. Am J Epidemiol. 1985;122:495&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">4025298</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, Holmes JH, Maro J, et al.  Design specifications for network prototype and cooperative to conduct population-based studies and safety surveillance.  [Accessed April 22, 2012];Effective Health Care Research Report No 13. 2009  Available at:  http://www.effectivehealthcare.ahrq.gov/ehc/products/54/50/2009_0728DEcIDE_DesignSpecNetCoopPopSafety.pdf.</Citation></Reference><Reference><Citation>Maro JC, Platt R, Holmes JH, et al. Design of a national distributed health data network. Ann Intern Med. 2009;151:341&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638403</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Davis R, Finkelstein J, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf. 2001;10:373&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">11802579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr. 2005;35:3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287880</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurry AJ, Gilbert CA, Reis BY, et al. A self-scaling, distributed information architecture for public health, research, and clinical care. J Am Med Inform Assoc. 2007;14:527&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2244902</ArticleId><ArticleId IdType="pubmed">17460129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornbrook MC, Hart G, Ellis JL, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr. 2005;35:12&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287881</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics. 1997;99:765&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">9164767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus R, Yih K, Platt R. Distributed data processing for public health surveillance. BMC Public Health. 2006;6:235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618842</ArticleId><ArticleId IdType="pubmed">16984658</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KM, Duddy A, Braun MM, et al. Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans. Pharmacoepidemiol Drug Saf. 2008;17:1137&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">18763248</ArticleId></ArticleIdList></Reference><Reference><Citation>President's Council of Advisors on Science and Technology. Report to the President Realizing the full potential of health information technology to improve healthcare for America: The path forward.  [Accessed April 22, 2012];2010  Available at:  http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-health-it-report.pdf.</Citation></Reference><Reference><Citation>Office of Extramural Research. NIH data sharing policy.  [Accessed February 25, 2012];2007  Available at:  http://grants.nih.gov/grants/policy/data_sharing/</Citation></Reference><Reference><Citation>Davidson B, Lee Y, Wang R. Developing data production maps: meeting patient discharge data submission requirements. Int J Healthcare Technol Manag. 2004;6:223&#x2013;240.</Citation></Reference><Reference><Citation>Arts DG, De Keizer NF, Scheffer GJ. Defining and improving data quality in medical registries: a literature review, case study, and generic framework. J Am Med Inform Assoc. 2002;9:600&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC349377</ArticleId><ArticleId IdType="pubmed">12386111</ArticleId></ArticleIdList></Reference><Reference><Citation>Riain C, Helfert M. An evaluation of data quality related problems patterns in healthcare information systems. Paper presented at: Lisbon, Portugal. IADIS virtual multi conference on computer science and information systems; 2005.</Citation></Reference><Reference><Citation>Mettler T, Rohner P, Baacke L. European Conference on Information Systems. National University of Ireland Galway; 2008. Improving data quality of health information systems&#x2014;a holistic design-oriented approach.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22929992</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-1948</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Medical care</Title><ISOAbbreviation>Med Care</ISOAbbreviation></Journal><ArticleTitle>Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods.</ArticleTitle><Pagination><StartPage>890</StartPage><EndPage>897</EndPage><MedlinePgn>890-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Drug safety monitoring relies primarily on spontaneous reporting, but electronic health care record databases offer a possible alternative for the detection of adverse drug reactions (ADRs).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the relative performance of different statistical methods for detecting drug-adverse event associations in electronic health care record data representing potential ADRs.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">Data from 7 databases across 3 countries in Europe comprising over 20 million subjects were used to compute the relative risk estimates for drug-event pairs using 10 different methods, including those developed for spontaneous reporting systems, cohort methods such as the longitudinal gamma poisson shrinker, and case-based methods such as case-control. The newly developed method "longitudinal evaluation of observational profiles of adverse events related to drugs" (LEOPARD) was used to remove associations likely caused by protopathic bias. Data from the different databases were combined by pooling of data, and by meta-analysis for random effects. A reference standard of known ADRs and negative controls was created to evaluate the performance of the method.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">The area under the curve of the receiver operator characteristic curve was calculated for each method, both with and without LEOPARD filtering.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The highest area under the curve (0.83) was achieved by the combination of either longitudinal gamma poisson shrinker or case-control with LEOPARD filtering, but the performance between methods differed little. LEOPARD increased the overall performance, but flagged several known ADRs as caused by protopathic bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Combinations of methods demonstrate good performance in distinguishing known ADRs from negative controls, and we assume that these could also be used to detect new drug safety signals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands. m.schuemie@erasmusmc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coloma</LastName><ForeName>Preciosa M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Straatman</LastName><ForeName>Huub</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Herings</LastName><ForeName>Ron M C</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Trifir&#xf2;</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Justin Neil</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Prieto-Merino</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Molokhia</LastName><ForeName>Mariam</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gini</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Innocenti</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mazzaglia</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Picelli</LastName><ForeName>Gino</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Scotti</LastName><ForeName>Lorenza</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>van der Lei</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sturkenboom</LastName><ForeName>Miriam C J M</ForeName><Initials>MC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0600621</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Care</MedlineTA><NlmUniqueID>0230027</NlmUniqueID><ISSNLinking>0025-7079</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055553">Prescription Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055553" MajorTopicYN="N">Prescription Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId><ArticleId IdType="doi">10.1097/MLR.0b013e31825f63bf</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23015364</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0258</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>30</Issue><PubDate><Year>2012</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Statistics in medicine</Title><ISOAbbreviation>Stat Med</ISOAbbreviation></Journal><ArticleTitle>Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.</ArticleTitle><Pagination><StartPage>4401</StartPage><EndPage>4415</EndPage><MedlinePgn>4401-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/sim.5620</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Expanded availability of observational healthcare data (both administrative claims and electronic health records) has prompted the development of statistical methods for identifying adverse events associated with medical products, but the operating characteristics of these methods when applied to the real-world data are unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied the performance of eight analytic methods for estimating of the strength of association-relative risk (RR) and associated standard error of 53 drug-adverse event outcome pairs, both positive and negative controls. The methods were applied to a network of ten observational healthcare databases, comprising over 130 million lives. Performance measures included sensitivity, specificity, and positive predictive value of methods at RR thresholds achieving statistical significance of p&#x2009;&lt;&#x2009;0.05 or p&#x2009;&lt;&#x2009;0.001 and with absolute threshold RR&#x2009;&gt;&#x2009;1.5, as well as threshold-free measures such as area under receiver operating characteristic curve (AUC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Although no specific method demonstrated superior performance, the aggregate results provide a benchmark and baseline expectation for risk identification method performance. At traditional levels of statistical significance (RR&#x2009;&gt;&#x2009;1, p&#x2009;&lt;&#x2009;0.05), all methods have a false positive rate &gt;18%, with positive predictive value &lt;38%. The best predictive model, high-dimensional propensity score, achieved an AUC&#x2009;&#x2009;=&#x2009;&#x2009;0.77. At 50% sensitivity, false positive rate ranged from 16% to 30%. At 10% false positive rate, sensitivity of the methods ranged from 9% to 33%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Systematic processes for risk identification can provide useful information to supplement an overall safety assessment, but assessment of methods performance suggests a substantial chance of identifying false positive associations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Pharmaceutical Research and Development LLC, Titusville, NJ 08560, USA. ryan@omop.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>J Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Racoosin</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Med</MedlineTA><NlmUniqueID>8215016</NlmUniqueID><ISSNLinking>0277-6715</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Stat Med. 2013 Mar 15;32(6):1073-4. doi: 10.1002/sim.5699.</RefSource><PMID Version="1">23413214</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stat Med. 2013 Mar 15;32(6):1075-7. doi: 10.1002/sim.5725.</RefSource><PMID Version="1">23413215</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="N">Insurance Claim Review</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="N">Pharmacoepidemiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId><ArticleId IdType="doi">10.1002/sim.5620</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21878461</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0334</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Statistical methods in medical research</Title><ISOAbbreviation>Stat Methods Med Res</ISOAbbreviation></Journal><ArticleTitle>Disproportionality methods for pharmacovigilance in longitudinal observational databases.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>56</EndPage><MedlinePgn>39-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0962280211403602</ELocationID><Abstract><AbstractText>Data mining disproportionality methods (PRR, ROR, EBGM, IC, etc.) are commonly used to identify drug safety signals in spontaneous report system (SRS) databases. Newer data sources such as longitudinal observational databases (LOD) provide time-stamped patient-level information and overcome some of the SRS limitations such as an absence of the denominator, total number of patients who consume a drug, and limited temporal information. Application of the disproportionality methods to LODs has not been widely explored. The scale of the LOD data provides an interesting computational challenge. Larger health claims databases contain information on more than 50 million patients and each patient has records for up to 10 years. In this article we systematically explore the application of commonly used disproportionality methods to simulated and real LOD data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zorych</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, USA. iz2129@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bate</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Methods Med Res</MedlineTA><NlmUniqueID>9212457</NlmUniqueID><ISSNLinking>0962-2802</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="Y">Drug Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21878461</ArticleId><ArticleId IdType="doi">10.1177/0962280211403602</ArticleId><ArticleId IdType="pii">0962280211403602</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23329543</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.</ArticleTitle><Pagination><StartPage>119</StartPage><EndPage>134</EndPage><MedlinePgn>119-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-012-0009-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There has been increased interest in using multiple observational databases to understand the safety profile of medical products during the postmarketing period. However, it is challenging to perform analyses across these heterogeneous data sources. The Observational Medical Outcome Partnership (OMOP) provides a Common Data Model (CDM) for organizing and standardizing databases. OMOP's work with the CDM has primarily focused on US databases. As a participant in the OMOP Extended Consortium, we implemented the OMOP CDM on the UK Electronic Healthcare Record database-The Health Improvement Network (THIN).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the study was to evaluate the implementation of the THIN database in the OMOP CDM and explore its use for active drug safety surveillance.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following the OMOP CDM specification, the raw THIN database was mapped into a CDM THIN database. Ten Drugs of Interest (DOI) and nine Health Outcomes of Interest (HOI), defined and focused by the OMOP, were created using the CDM THIN database. Quantitative comparison of raw THIN to CDM THIN was performed by execution and analysis of OMOP standardized reports and additional analyses. The practical value of CDM THIN for drug safety and pharmacoepidemiological research was assessed by implementing three analysis methods: Proportional Reporting Ratio (PRR), Univariate Self-Case Control Series (USCCS) and High-Dimensional Propensity Score (HDPS). A published study using raw THIN data was selected to examine the external validity of CDM THIN.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall demographic characteristics were the same in both databases. Mapping medical and drug codes into the OMOP terminology dictionary was incomplete: 25 % medical codes and 55 % drug codes in raw THIN were not listed in the OMOP terminology dictionary, representing 6 % condition occurrence counts, 4 % procedure occurrence counts and 7 % drug exposure counts in raw THIN. Seven DOIs had &lt;0.3 % and three DOIs had 1 % of unmapped drug exposure counts; each HOI had at least one definition with no or minimal (&#x2264;0.2 %) issues with unmapped condition occurrence counts, except for the upper gastrointestinal (UGI) ulcer hospitalization cohort. The application of PRR, USCCS and HDPS found, respectively, a sensitivity of 67, 78 and 50 %, and a specificity of 68, 59 and 76 %, suggesting that safety issues defined as known by the OMOP could be identified in CDM THIN, with imperfect performance. Similar PRR scores were produced using both CDM THIN and raw THIN, while the execution time was twice as fast on CDM THIN. There was close replication of demographic distribution, death rate and prescription pattern and trend in the published study population and the cohort of CDM THIN.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This research demonstrated that information loss due to incomplete mapping of medical and drug codes as well as data structure in the current CDM THIN limits its use for all possible epidemiological evaluation studies. Current HOIs and DOIs predefined by the OMOP were constructed with minimal loss of information and can be used for active surveillance methodological research. The OMOP CDM THIN can be a valuable tool for multiple aspects of pharmacoepidemiological research when the unique features of UK Electronic Health Records are incorporated in the OMOP library.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Epidemiology, Worldwide Safety Strategy, Pfizer, 219 E 42nd Street, Mail Stop 219/9/01, New York, NY 10017, USA. xiaofeng.zhou@pfizer.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murugesan</LastName><ForeName>Sundaresan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bhullar</LastName><ForeName>Harshvinder</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Bing</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Wentworth</LastName><ForeName>Chuck</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bate</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId><ArticleId IdType="doi">10.1007/s40264-012-0009-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):393-401</Citation><ArticleIdList><ArticleId IdType="pubmed">17066486</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22069180</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:41-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22262592</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2003 Jul 1;158(1):77-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12835289</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Inform Prim Care. 2004;12(3):171-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15606990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2009 Sep 1;151(5):341-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19638403</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2010 Nov 2;153(9):600-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2009 Jul;20(4):512-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2010 Nov-Dec;17(6):652-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2013 Feb;22(1):97-112</Citation><ArticleIdList><ArticleId IdType="pubmed">21680614</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 2011 Sep;65(9):770-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20515898</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2009 Feb;18(1):7-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18562396</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2013 Feb;22(1):39-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21878461</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 2009 Apr;63(4):332-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19240084</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:50-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22262593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Apr 1;367(9516):1075-1079</Citation><ArticleIdList><ArticleId IdType="pubmed">16581406</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):858-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20681003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19358225</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23396660</PMID><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1387-3741</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Health services &amp; outcomes research methodology</Title><ISOAbbreviation>Health Serv Outcomes Res Methodol</ISOAbbreviation></Journal><ArticleTitle>Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure.</ArticleTitle><Pagination><StartPage>58</StartPage><EndPage>67</EndPage><MedlinePgn>58-67</MedlinePgn></Pagination><Abstract><AbstractText>Observational healthcare databases represent a valuable resource for health economics, outcomes research, quality of care, drug safety, epidemiology and comparative effectiveness research. The methods used to identify a population for study in an observational healthcare database with the desired drug exposures of interest are complex and not consistent nor apparent in the published literature. Our research evaluates three drug classification systems and their impact on prevalence in the analysis of observational healthcare databases using opioids as a case in point. The standard terminologies compiled in the Observational Medical Outcomes Partnership's Common Data Model vocabulary were used to facilitate the identification of populations with opioid exposures. This study analyzed three distinct observational healthcare databases and identified patients with at least one exposure to an opioid as defined by drug codes derived through the application of three classification systems. Opioid code sets were created for each of the three classification systems and the number of identified codes was summarized. We estimated the prevalence of opioid exposure in three observational healthcare databases using the three defined code sets. In addition we compared the number of drug codes and distinct ingredients that were identified using these classification systems. We found substantial variation in the prevalence of opioid exposure identified using an individual classification system versus a composite method using multiple classification systems. To ensure transparent and reproducible research publications should include a description of the process used to develop code sets and the complete code set used in studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Defalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutical Research &amp; Development, L.L.C. 920 Route 202, Raritan, NJ 08869 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Soledad Cepeda</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Health Serv Outcomes Res Methodol</MedlineTA><NlmUniqueID>9815809</NlmUniqueID><ISSNLinking>1387-3741</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Classification systems</Keyword><Keyword MajorTopicYN="N">Coding standards</Keyword><Keyword MajorTopicYN="N">Drug exposures</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Observational databases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23396660</ArticleId><ArticleId IdType="pmc">PMC3566397</ArticleId><ArticleId IdType="doi">10.1007/s10742-012-0102-1</ArticleId><ArticleId IdType="pii">102</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballantyne JC, Mao J. Opioid therapy for chronic pain. N. Engl. J. Med. 2003;349(20):1943&#x2013;1953. doi: 10.1056/NEJMra025411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra025411</ArticleId><ArticleId IdType="pubmed">14614170</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J. Rheumatol. 2007;34(3):543&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">17343302</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda MS, Etropolski M, Weinstein R, Fife D, Boston R, Matcho A. Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States. BMC Palliat. Care. 2010;9:14. doi: 10.1186/1472-684X-9-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-684X-9-14</ArticleId><ArticleId IdType="pmc">PMC2905346</ArticleId><ArticleId IdType="pubmed">20565876</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Wu N, Fraser K, Boulanger L, Zhao Y. Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments. Curr. Med. Res. Opin. 2010;26(10):2507&#x2013;2516. doi: 10.1185/03007995.2010.518438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007995.2010.518438</ArticleId><ArticleId IdType="pubmed">20831456</ArticleId></ArticleIdList></Reference><Reference><Citation>David M, Adamson P, Stella Chang M, Leigh G, Hansen M. MBA: Health Research Data for the Real World: The MarketScan. Database. 2008;6:8.</Citation></Reference><Reference><Citation>Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst. Rev. 2007;3:CD004959.</Citation><ArticleIdList><ArticleId IdType="pubmed">17636781</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst. Rev. 2006;3:CD006146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16856116</ArticleId></ArticleIdList></Reference><Reference><Citation>Enhanced therapeutic classification system. http://www.firstdatabank.com/Products/therapeutic-classification-system-nddf.aspx (2011). Accessed 28 July 2011</Citation></Reference><Reference><Citation>Franklin GM, Stover BD, Turner JA, Fulton-Kehoe D, Wickizer TM. Early opioid prescription and subsequent disability among workers with back injuries: the disability risk identification study cohort. Spine (Phila Pa 1976) 2008;33(2):199&#x2013;204. doi: 10.1097/BRS.0b013e318160455c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0b013e318160455c</ArticleId><ArticleId IdType="pubmed">18197107</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589&#x2013;1594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1459894</ArticleId><ArticleId IdType="pubmed">16717269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher AM, Leighton-Scott J, van Staa TP. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study. Clin. Ther. 2009;31(8):1707&#x2013;1715. doi: 10.1016/j.clinthera.2009.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2009.08.022</ArticleId><ArticleId IdType="pubmed">19808129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy. 2000;20(6):629&#x2013;634. doi: 10.1592/phco.20.7.629.35174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1592/phco.20.7.629.35174</ArticleId><ArticleId IdType="pubmed">10853617</ArticleId></ArticleIdList></Reference><Reference><Citation>Goettsch WG, Sukel MP, van der Peet DL, van Riemsdijk MM, Herings RM. In-hospital use of opioids increases rate of coded postoperative paralytic ileus. Pharmacoepidemiol. Drug Saf. 2007;16(6):668&#x2013;674. doi: 10.1002/pds.1338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1338</ArticleId><ArticleId IdType="pubmed">17072916</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross DP, Stephens B, Bhambhani Y, Haykowsky M, Bostick GP, Rashiq S. Opioid prescriptions in canadian workers&#x2019; compensation claimants: prescription trends and associations between early prescription and future recovery. Spine (Phila Pa 1976) 2009;34(5):525&#x2013;531. doi: 10.1097/BRS.0b013e3181971dea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0b013e3181971dea</ArticleId><ArticleId IdType="pubmed">19247173</ArticleId></ArticleIdList></Reference><Reference><Citation>HCPCS general information. http://www.cms.gov/medhcpcsgeninfo/ (2011). Accessed 28 June 2011</Citation></Reference><Reference><Citation>i3 InVision Data Mart. http://www.i3global.com/content/File/10-24269%20InVision%20Data%20Mart%20Prod%20sheet.pdf (2010). Accessed 25 July 2011</Citation></Reference><Reference><Citation>Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag. Care. 2010;19(3):44&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20361548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick H, Derby LE, Vasilakis C, Fife D. The risk of seizures associated with tramadol. Pharmacotherapy. 1998;18(3):607&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong WJ, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann. Pharmacother. 2010;44(4):630&#x2013;640. doi: 10.1345/aph.1M520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1345/aph.1M520</ArticleId><ArticleId IdType="pubmed">20197473</ArticleId></ArticleIdList></Reference><Reference><Citation>Martell BA, O&#x2019;Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann. Intern. Med. 2007;146(2):116&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">17227935</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey GM, Dodds HN, Roberts CS, Servoss TJ, Blondell RD. Toxicology screening in orthopedic trauma patients predicting duration of prescription opioid use. J. Addict. Dis. 2005;24(4):31&#x2013;41. doi: 10.1300/J069v24n04_03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J069v24n04_03</ArticleId><ArticleId IdType="pubmed">16368655</ArticleId></ArticleIdList></Reference><Reference><Citation>Master Drug Data Base v2.5 (MDDB&#xae;). http://www.medi-span.com/master-drug-database.aspx (2011). Accessed 28 July 2011</Citation></Reference><Reference><Citation>National Drug Code Directory. http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm (2011). Accessed 28 July 2011</Citation></Reference><Reference><Citation>National Drug File-Reference Terminology (NDF-RT). http://www.va.gov/trm/StandardPage.asp?tid=5221&amp;lob=1 (2011). Accessed 28 July 2011</Citation></Reference><Reference><Citation>National Formulary. http://www.pbm.va.gov/NationalFormulary.aspx (2011). Accessed 28 July 2011</Citation></Reference><Reference><Citation>Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J. Pain Symptom Manag. 2008;35(2):214&#x2013;228. doi: 10.1016/j.jpainsymman.2007.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2007.03.015</ArticleId><ArticleId IdType="pubmed">18178367</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP Standard Terminologies. http://omop.fnih.org/vocabularies (2011). Accessed 25 July 2011</Citation></Reference><Reference><Citation>An Overview to RxNorm. http://www.nlm.nih.gov/research/umls/rxnorm/overview.html (2011). Accessed 28 July 2011</Citation></Reference><Reference><Citation>Parente ST, Kim SS, Finch MD, Schloff LA, Rector TS, Seifeldin R, Haddox JD. Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data. Am. J. Manag. Care. 2004;10(11 Pt 1):783&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623267</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradel V, Thirion X, Ronfle E, Masut A, Micallef J, Begaud B. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol. Drug Saf. 2004;13(7):473&#x2013;481. doi: 10.1002/pds.892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.892</ArticleId><ArticleId IdType="pubmed">15269931</ArticleId></ArticleIdList></Reference><Reference><Citation>Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin. Ther. 2005;27(7):1022&#x2013;1031. doi: 10.1016/j.clinthera.2005.06.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2005.06.024</ArticleId><ArticleId IdType="pubmed">16154481</ArticleId></ArticleIdList></Reference><Reference><Citation>Skurtveit S, Furu K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids&#x2014;a follow-up study of 17,074 men and women. Pain Med. 2010;11(6):805&#x2013;814. doi: 10.1111/j.1526-4637.2010.00870.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4637.2010.00870.x</ArticleId><ArticleId IdType="pubmed">20624237</ArticleId></ArticleIdList></Reference><Reference><Citation>Skurtveit S, Furu K, Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20&#xa0;years later&#x2013;a follow-up study of 13,390 men and women aged 40&#x2013;42&#xa0;years. Pharmacoepidemiol. Drug Saf. 2008;17(9):926&#x2013;933. doi: 10.1002/pds.1616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1616</ArticleId><ArticleId IdType="pubmed">18489010</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann. Intern. Med. 2010;153(9):600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study. Pain. 2010;150(2):332&#x2013;339. doi: 10.1016/j.pain.2010.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2010.05.020</ArticleId><ArticleId IdType="pmc">PMC2897915</ArticleId><ArticleId IdType="pubmed">20554392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions&#xa0;2000&#x2013;2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138(2):440&#x2013;449. doi: 10.1016/j.pain.2008.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2008.04.027</ArticleId><ArticleId IdType="pmc">PMC2668925</ArticleId><ArticleId IdType="pubmed">18547726</ArticleId></ArticleIdList></Reference><Reference><Citation>UMLS-Metathesaurus. http://www.nlm.nih.gov/research/umls/knowledge_sources/metathesaurus/index.html (2011). Accessed 26 July 2011</Citation></Reference><Reference><Citation>Victor TW, Alvarez NA, Gould E. Opioid prescribing practices in chronic pain management: guidelines do not sufficiently influence clinical practice. J. Pain. 2009;10(10):1051&#x2013;1057. doi: 10.1016/j.jpain.2009.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2009.03.019</ArticleId><ArticleId IdType="pubmed">19595639</ArticleId></ArticleIdList></Reference><Reference><Citation>Voaklander DC, Rowe BH, Dryden DM, Pahal J, Saar P, Kelly KD. Medical illness, medication use and suicide in seniors: a population-based case-control study. J. Epidemiol. Community Health. 2008;62(2):138&#x2013;146. doi: 10.1136/jech.2006.055533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.2006.055533</ArticleId><ArticleId IdType="pubmed">18192602</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Korff M, Merrill JO, Rutter CM, Sullivan M, Campbell CI, Weisner C. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy. Pain. 2011;152(6):1256&#x2013;1262. doi: 10.1016/j.pain.2011.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2011.01.005</ArticleId><ArticleId IdType="pmc">PMC3098951</ArticleId><ArticleId IdType="pubmed">21296498</ArticleId></ArticleIdList></Reference><Reference><Citation>White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain. 2009;10(9):976&#x2013;983. doi: 10.1016/j.jpain.2009.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2009.03.012</ArticleId><ArticleId IdType="pubmed">19556168</ArticleId></ArticleIdList></Reference><Reference><Citation>WHOCC-Structure and principles. http://www.whocc.no/atc/structure_and_principles/ (2011). 2011</Citation></Reference><Reference><Citation>Ytterberg SR, Mahowald ML, Woods SR. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum. 1998;41(9):1603&#x2013;1612. doi: 10.1002/1529-0131(199809)41:9&lt;1603::AID-ART10&gt;3.0.CO;2-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199809)41:9&lt;1603::AID-ART10&gt;3.0.CO;2-U</ArticleId><ArticleId IdType="pubmed">9751092</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorowitz RD, Smout RJ, Gassaway JA, Horn SD. Usage of pain medications during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP) Top Stroke Rehabil. 2005;12(4):37&#x2013;49. doi: 10.1310/C7MF-VLR0-CKDL-3C44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1310/C7MF-VLR0-CKDL-3C44</ArticleId><ArticleId IdType="pubmed">16698736</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23408560</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Statistical visualization for assessing performance of methods for safety surveillance using electronic databases.</ArticleTitle><Pagination><StartPage>503</StartPage><EndPage>509</EndPage><MedlinePgn>503-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.3419</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The success of an epidemiological study for drug safety surveillance or comparative effectiveness depends largely on design and analysis strategies besides data quality. The Observational Medical Outcomes Partnership (OMOP) methods community implemented a collection of statistical methods with extensive parameters allowing a wide variety of designs and analyses. Our objective was to develop a visualization tool to explore which parameter settings may enable better predictive properties for a given method in a database.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Performance measures were produced for each setting, including sensitivity (recall), specificity (1-FPR), AUC, MAP, and P(k). Multiple regressions with relevant parameters as main effects were run for performance measures on all test cases and subgroups. Heatmaps with sequential palettes to indicate the parameters' impacts on performance measures were generated based on matrices of the standardized coefficients (t-statistics) by parameter settings and test case subgroups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Heatmaps help researchers to explore design and analysis options of methods for evaluating a variety of drug-outcome relationships and also to explore data issues.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Statistical visualization through heatmaps is a useful tool for summarizing and presenting method performance results and for the exploration of the parameter settings for method performance characteristics and data limitations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. xiaochun@iupui.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>Siu</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rosenman</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="N">Pharmacoepidemiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23408560</ArticleId><ArticleId IdType="doi">10.1002/pds.3419</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23571771</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>546</EndPage><MedlinePgn>539-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/clpt.2013.24</ELocationID><Abstract><AbstractText>Signal-detection algorithms (SDAs) are recognized as vital tools in pharmacovigilance. However, their performance characteristics are generally unknown. By leveraging a unique gold standard recently made public by the Observational Medical Outcomes Partnership (OMOP) and by conducting a unique systematic evaluation, we provide new insights into the diagnostic potential and characteristics of SDAs that are routinely applied to the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). We find that SDAs can attain reasonable predictive accuracy in signaling adverse events. Two performance classes emerge, indicating that the class of approaches that address confounding and masking effects benefits safety surveillance. Our study shows that not all events are equally detectable, suggesting that specific events might be monitored more effectively using other data sources. We provide performance guidelines for several operating scenarios to inform the trade-off between sensitivity and specificity for specific use cases. We also propose an approach and demonstrate its application in identifying optimal signaling thresholds, given specific misclassification tolerances.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harpaz</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA. rharpaz@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuMouchel</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>LePendu</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bauer-Mehren</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>N H</ForeName><Initials>NH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 HG004028</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54-HG004028</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Pharmacol Ther. 2013 Jun;93(6):474-5. doi: 10.1038/clpt.2013.60.</RefSource><PMID Version="1">23689213</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Pharmacol Ther. 2013 Sep;94(3):312. doi: 10.1038/clpt.2013.107.</RefSource><PMID Version="1">23695184</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Pharmacol Ther. 2013 Sep;94(3):313. doi: 10.1038/clpt.2013.125.</RefSource><PMID Version="1">23756371</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="Y">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest/Disclosure</b>. No conflicts to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23571771</ArticleId><ArticleId IdType="mid">NIHMS525848</ArticleId><ArticleId IdType="pmc">PMC3857139</ArticleId><ArticleId IdType="doi">10.1038/clpt.2013.24</ArticleId><ArticleId IdType="pii">clpt201324</ArticleId></ArticleIdList><ReferenceList><Reference><Citation> [accessed Oct 2012];Adverse Event Reporting System.   http://www.fda.gov/cder/aers/default.htm.</Citation></Reference><Reference><Citation>Szarfman A, Machado SG, O&#x2019;Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA&#x2019;s spontaneous reports database. Drug Saf. 2002;25(6):381&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071774</ArticleId></ArticleIdList></Reference><Reference><Citation>Szarfman A, Tonning JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy. 2004;24(9):1099&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15460169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">19358225</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">17538548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7&#x2013;8):343&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">19187799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben M, Madigan D, Gerrits CM, Walsh L, van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111454</ArticleId></ArticleIdList></Reference><Reference><Citation>Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the Use of Data Mining in Pharmacovigilance. Drug Safety. 2005;28(11):981&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">16231953</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson W, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">17019675</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JG, Tonning JM, Szarfman A. Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned. Br J Clin Pharmacol. 2006;61(1):105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1884980</ArticleId><ArticleId IdType="pubmed">16390358</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 2010;33(6):475&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">20486730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg AM, Hauben M, Pearson RK, et al. An evaluation of three signal-detection algorithms using a highly inclusive reference event database. Drug Saf. 2009;32(6):509&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">19459718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg AM, Reisinger SJ, Pearson RK, O&#x2019;Hara DJ, Hall K. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Information Journal. 2007;41(5):633&#x2013;643.</Citation></Reference><Reference><Citation>Hauben M, Reich L. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: A retrospective evaluation. Journal of Clinical Pharmacology. 2005;45(4):378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15778418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman HP, Chen J, Gould AL, et al. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection. Clin Pharmacol Ther. 2007;82(2):173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">17507922</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks D, Woo EJ, Burwen DR, Perucci P, Braun MM, Ball R. Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf. 2005;14(9):601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15954077</ArticleId></ArticleIdList></Reference><Reference><Citation>Almenoff JS, LaCroix KK, Yuen NA, Fram D, DuMouchel W. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf. 2006;29(10):875&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">16970511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota K, Koide D, Hirai T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf. 2004;13(6):387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">15170768</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership (OMOP)  [accessed Oct 2012];  http://omop.fnih.org.</Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership. Annals of Internal Medicine. 2010;153(9):600&#x2013;W206.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Marc OJ, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am Stat. 1999;53(3):177&#x2013;190.</Citation></Reference><Reference><Citation>Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety. 2001;10(6):483&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel W, Fram D, Yang X, et al. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968&#x2013;2004) Ann Clin Psychiatry. 2008;20(1):21&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18297583</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin C, Blanch C, Lewis DJ, et al. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker. Pharmacoepidemiol Drug Saf. 2012;21(6):622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">21994119</ArticleId></ArticleIdList></Reference><Reference><Citation> [accessed Oct 2012];  http://www.oracle.com/us/industries/life-sciences/health-sciences-empirica-signal-364243.html.</Citation></Reference><Reference><Citation>YOUDEN WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins NJ, Schisterman EF. The inconsistency of &#x201c;optimal&#x201d; cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163(7):670&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1444894</ArticleId><ArticleId IdType="pubmed">16410346</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande G, Gogolak V, Sheila WS. Data Mining in Drug Safety: Review of Published Threshold Criteria for Defining Signals of Disproportionate Reporting. Pharmaceutical Medicine. 2010;24(1):37&#x2013;43.</Citation></Reference><Reference><Citation>Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The New Sentinel Network - Improving the Evidence of Medical-Product Safety. New England Journal of Medicine. 2009;361(7):645&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635947</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiology and Drug Safety. 2010;19(8):858&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917262</ArticleId><ArticleId IdType="pubmed">20681003</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin BJ, Finlay JA, Sterling K, et al. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA) Prostate Cancer Prostatic Dis. 2004;7(2):132&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">15007379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353(17):1773&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">16169887</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller P, van Puijenbroek E, Egberts A, Evans S. The reporting odds ratio versus the proportional reporting ratio: &#x2018;deuce&#x2019;. Pharmacoepidemiology and Drug Safety. 2004;13(8):525&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">15317032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24(6):743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15222664</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97(8A):32C&#x2013;43C.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopstadius J, Noren GN, Bate A, Edwards IR. Impact of stratification on adverse drug reaction surveillance. Drug Saf. 2008;31(11):1035&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">18840023</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown EG. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA) Drug Saf. 2003;26(3):145&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580645</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet C, Lagier G, Lillo-Le LA, Le BC, Venot A, Jaulent MC. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf. 2005;28(1):19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649103</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Zalkikar J, Tiwari RC. A Likelihood Ratio Test Based Method for Signal Detection With Application to FDA&#x2019;s Drug Safety Data. Journal of the American Statistical Association. 2011;106(496):1230&#x2013;1241.</Citation></Reference><Reference><Citation>Tisdale J, Miller D. Drug-Induced Diseases: Prevention, Detection, and Management. 2. American Society of Health-System Pharmacists; 2010.</Citation></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23648805</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-6256</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>American journal of epidemiology</Title><ISOAbbreviation>Am J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Evaluating the impact of database heterogeneity on observational study results.</ArticleTitle><Pagination><StartPage>645</StartPage><EndPage>651</EndPage><MedlinePgn>645-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/aje/kwt010</ELocationID><Abstract><AbstractText>Clinical studies that use observational databases to evaluate the effects of medical products have become commonplace. Such studies begin by selecting a particular database, a decision that published papers invariably report but do not discuss. Studies of the same issue in different databases, however, can and do generate different results, sometimes with strikingly different clinical implications. In this paper, we systematically study heterogeneity among databases, holding other study methods constant, by exploring relative risk estimates for 53 drug-outcome pairs and 2 widely used study designs (cohort studies and self-controlled case series) across 10 observational databases. When holding the study design constant, our analysis shows that estimated relative risks range from a statistically significant decreased risk to a statistically significant increased risk in 11 of 53 (21%) of drug-outcome pairs that use a cohort design and 19 of 53 (36%) of drug-outcome pairs that use a self-controlled case series design. This exceeds the proportion of pairs that were consistent across databases in both direction and statistical significance, which was 9 of 53 (17%) for cohort studies and 5 of 53 (9%) for self-controlled case series. Our findings show that clinical studies that use observational databases can be sensitive to the choice of database. More attention is needed to consider how the choice of data source may be affecting results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, 1255 Amsterdam Avenue, New York, NY 10027, USA. david.madigan@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>J Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>DuMouchel</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Berlin</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Epidemiol</MedlineTA><NlmUniqueID>7910653</NlmUniqueID><ISSNLinking>0002-9262</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019370" MajorTopicYN="N">Observation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">heterogeneity</Keyword><Keyword MajorTopicYN="N">methods</Keyword><Keyword MajorTopicYN="N">population characteristics</Keyword><Keyword MajorTopicYN="N">reproducibility of results</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23648805</ArticleId><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="doi">10.1093/aje/kwt010</ArticleId><ArticleId IdType="pii">kwt010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182327</ArticleId><ArticleId IdType="pubmed">16060722</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey Smith G, Ebrahim S. Epidemiology&#x2014;is it time to call it a day? Int J Epidemiol. 2001;30(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11171840</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayes LC, Horwitz RI, Feinstein AR. A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol. 1988;17(3):680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">3272133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart PB, Bolger AF, Papapanou PN, et al. Periodontal disease and atherosclerotic vascular disease: Does the evidence support an independent association? A scientific statement from the American Heart Association. Circulation. 2012;125(20):2520&#x2013;2544.</Citation><ArticleIdList><ArticleId IdType="pubmed">22514251</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd S. Debating the evidence: oral contraceptives containing drospirenone and risk of blood clots. Curr Drug Saf. 2011;6(3):132&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">22122386</ArticleId></ArticleIdList></Reference><Reference><Citation>Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021&#x2013;2029.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582059</ArticleId></ArticleIdList></Reference><Reference><Citation>Young SS, Karr A. Deming, data and observational studies. Significance. 2011;8(3):116&#x2013;120.</Citation></Reference><Reference><Citation>Vercellini P, Eskenazi B, Consonni D, et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(2):159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">20833638</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31(8):810&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">20102352</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande G, Rao S, Patole S, et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125(5):921&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">20403939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98(3):266&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611201</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PloS One. 2008;3(8):e3081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518111</ArticleId><ArticleId IdType="pubmed">18769481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401&#x2013;4415.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304(6):657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513370</ArticleId><ArticleId IdType="pubmed">20699457</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933354</ArticleId><ArticleId IdType="pubmed">20813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclure M. Demonstration of deductive meta-analysis: ethanol intake and risk of myocardial infarction. Epidemiol Rev. 1993;15(2):328&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">8174661</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet. 1991;338(8775):1127&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">1682553</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S. Can meta-analysis be salvaged? Am J Epidemiol. 1994;140(9):783&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">7977288</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy S. Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):311&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611207</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke JP. Why do the results of randomised and observational studies differ? BMJ. 2011;343:d7020.</Citation><ArticleIdList><ArticleId IdType="pubmed">22065658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23670723</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>8</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Assessment of case definitions for identifying acute liver injury in large observational databases.</ArticleTitle><Pagination><StartPage>651</StartPage><EndPage>661</EndPage><MedlinePgn>651-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0060-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Determining the aetiology of acute liver injury (ALI) may be challenging to both clinicians and researchers. Observational research is particularly useful in studying rare medical outcomes such as ALI; however, case definitions for ALI in previous observational studies lack consistency and sensitivity. ALI is a clinically important condition with various aetiologies, including drug exposure.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to evaluate four distinct case definitions for ALI across a diverse set of large observational databases, providing a better understanding of ALI prevalence and natural history.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Seven healthcare databases: GE Healthcare, MarketScan(&#xae;) Lab Database, Humana Inc., Partners HealthCare System, Regenstrief Institute, SDI Health (now IMS Health, Inc.), and the National Patient Care Database of the Veterans Health Administration.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated prevalence of ALI through the application of four distinct case definitions across seven observational healthcare databases. We described how laboratory and clinical characteristics of identified case populations varied across definitions and examined the prevalence of other hepatobiliary disorders among identified ALI cases that may decrease suspicion of drug-induced liver injury (DILI) in particular.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study demonstrated that increasing the restrictiveness of the case definition resulted in fewer cases, but greater prevalence of ALI clinical features. Considerable heterogeneity in the frequency of laboratory testing and results observed among cases meeting the most restrictive definition suggests that the clinical features, monitoring patterns and suspicion of ALI are highly variable among patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Creation of four distinct case definitions and application across a disparate set of observational databases resulted in significant variation in the prevalence of ALI. A greater understanding of the natural history of ALI through examination of electronic healthcare data can facilitate development of reliable and valid ALI case definitions that may enhance the ability to accurately identify associations between ALI and drug exposures. Considerable heterogeneity in laboratory values and frequency of laboratory testing among individuals meeting the criteria for ALI suggests that the evaluation of ALI is highly variable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Aaron J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>UNC Eshelman School of Pharmacy, Division of Pharmaceutical Policy and Outcomes, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. aj_katz@unc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Racoosin</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003955" MajorTopicYN="N">Diagnostic Tests, Routine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23670723</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0060-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Epidemiology. 1993 Nov;4(6):496-501</Citation><ArticleIdList><ArticleId IdType="pubmed">8268277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2008 May;17(5):523-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18215001</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2010 Sep;88(3):416-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20664536</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2003 Jan;98(1):175-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12526954</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2008 Dec;135(6):1924-34, 1934.e1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18955056</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2006 Apr 17;97(8A):61C-68C</Citation><ArticleIdList><ArticleId IdType="pubmed">16581331</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):708-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20582911</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2009 Jul;30(1):3-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19416132</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2005 Feb;14(2):75-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15386708</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):943-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18425988</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2007 Nov;102(11):2437-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17662100</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Surveill Summ. 2009 May 22;58(3):1-27</Citation><ArticleIdList><ArticleId IdType="pubmed">19478727</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2003 Mar 24;163(6):728-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12639207</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):953-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18425987</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1999 Dec;48(6):847-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10594489</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1994 Feb 14;154(3):311-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8297198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1993 Oct 1;119(7 Pt 1):576-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8363168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2006 Jul;15(7):444-53</Citation><ArticleIdList><ArticleId IdType="pubmed">16761308</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2004 Jul;58(1):71-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15206996</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 2004 Jul 15;117(2):87-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15234643</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2010 Dec 1;106(11):1594-601</Citation><ArticleIdList><ArticleId IdType="pubmed">21094360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2010 Nov 2;153(9):600-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Med. 2010 Nov;11(11):1718-25</Citation><ArticleIdList><ArticleId IdType="pubmed">21044262</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharm Ther. 2007 Oct;32(5):483-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17875115</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16540768</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2006 Jul;15(7):435-43</Citation><ArticleIdList><ArticleId IdType="pubmed">16761304</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomark Med. 2010 Jun;4(3):475-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20550481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23774519</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2014</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-1948</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>8 Suppl 3</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Medical care</Title><ISOAbbreviation>Med Care</ISOAbbreviation></Journal><ArticleTitle>Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems.</ArticleTitle><Pagination><StartPage>S45</StartPage><EndPage>S52</EndPage><MedlinePgn>S45-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MLR.0b013e31829b1e0b</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The need for a common format for electronic exchange of clinical data prompted federal endorsement of applicable standards. However, despite obvious similarities, a consensus standard has not yet been selected in the comparative effectiveness research (CER) community.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using qualitative metrics for data retrieval and information loss across a variety of CER topic areas, we compare several existing models from a representative sample of organizations associated with clinical research: the Observational Medical Outcomes Partnership (OMOP), Biomedical Research Integrated Domain Group, the Clinical Data Interchange Standards Consortium, and the US Food and Drug Administration.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">While the models examined captured a majority of the data elements that are useful for CER studies, data elements related to insurance benefit design and plans were most detailed in OMOP's CDM version 4.0. Standardized vocabularies that facilitate semantic interoperability were included in the OMOP and US Food and Drug Administration Mini-Sentinel data models, but are left to the discretion of the end-user in Biomedical Research Integrated Domain Group and Analysis Data Model, limiting reuse opportunities. Among the challenges we encountered was the need to model data specific to a local setting. This was handled by extending the standard data models.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">We found that the Common Data Model from the OMOP met the broadest complement of CER objectives. Minimal information loss occurred in mapping data from institution-specific data warehouses onto the data models from the standards we assessed. However, to support certain scenarios, we found a need to enhance existing data dictionaries with local, institution-specific information.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ogunyemi</LastName><ForeName>Omolola I</ForeName><Initials>OI</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Charles Drew University of Medicine and Science, Los Angeles, CA 90262, USA. lolaogunyemi@cdrewu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyeon-Eui</ForeName><Initials>HE</Initials></Author><Author ValidYN="Y"><LastName>Ashish</LastName><ForeName>Naveen</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Farzaneh</LastName><ForeName>Seena</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Boxwala</LastName><ForeName>Aziz</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01HS19913</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Care</MedlineTA><NlmUniqueID>0230027</NlmUniqueID><ISSNLinking>0025-7079</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057186" MajorTopicYN="N">Comparative Effectiveness Research</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018511" MajorTopicYN="Y">Systems Integration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="N">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId><ArticleId IdType="doi">10.1097/MLR.0b013e31829b1e0b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24117144</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1541-0420</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Biometrics</Title><ISOAbbreviation>Biometrics</ISOAbbreviation></Journal><ArticleTitle>Multiple self-controlled case series for large-scale longitudinal observational databases.</ArticleTitle><Pagination><StartPage>893</StartPage><EndPage>902</EndPage><MedlinePgn>893-902</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/biom.12078</ELocationID><Abstract><AbstractText>Characterization of relationships between time-varying drug exposures and adverse events (AEs) related to health outcomes represents the primary objective in postmarketing drug safety surveillance. Such surveillance increasingly utilizes large-scale longitudinal observational databases (LODs), containing time-stamped patient-level medical information including periods of drug exposure and dates of diagnoses for millions of patients. Statistical methods for LODs must confront computational challenges related to the scale of the data, and must also address confounding and other biases that can undermine efforts to estimate effect sizes. Methods that compare on-drug with off-drug periods within patient offer specific advantages over between patient analysis on both counts. To accomplish these aims, we extend the self-controlled case series (SCCS) for LODs. SCCS implicitly controls for fixed multiplicative baseline covariates since each individual acts as their own control. In addition, only exposed cases are required for the analysis, which is computationally advantageous. The standard SCCS approach is usually used to assess single drugs and therefore estimates marginal associations between individual drugs and particular AEs. Such analyses ignore confounding drugs and interactions and have the potential to give misleading results. In order to avoid these difficulties, we propose a regularized multiple SCCS approach that incorporates potentially thousands or more of time-varying confounders such as other drugs. The approach successfully handles the high dimensionality and can provide a sparse solution via an L&#x2081; regularizer. We present details of the model and the associated optimization procedure, as well as results of empirical investigations.</AbstractText><CopyrightInformation>&#xa9; 2013, The International Biometric Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Shawn E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, New York, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zorych</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5R01GM087600</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biometrics</MedlineTA><NlmUniqueID>0370625</NlmUniqueID><ISSNLinking>0006-341X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="Y">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="Y">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="Y">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="Y">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Big Data</Keyword><Keyword MajorTopicYN="N">Conditional Poisson regression</Keyword><Keyword MajorTopicYN="N">Cyclic coordinate descent</Keyword><Keyword MajorTopicYN="N">Drug safety</Keyword><Keyword MajorTopicYN="N">Postmarketing surveillance</Keyword><Keyword MajorTopicYN="N">Regularized regression</Keyword><Keyword MajorTopicYN="N">Self-controlled case series</Keyword><Keyword MajorTopicYN="N">Statistical computing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24117144</ArticleId><ArticleId IdType="doi">10.1111/biom.12078</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166220</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.</ArticleTitle><Pagination><StartPage>S15</StartPage><EndPage>S25</EndPage><MedlinePgn>S15-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0103-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Researchers using observational data to understand drug effects must make a number of analytic design choices that suit the characteristics of the data and the subject of the study. Review of the published literature suggests that there is a lack of consistency even when addressing the same research question in the same database.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize the degree of similarity or difference in the method and analysis choices made by observational database research experts when presented with research study scenarios.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">On-line survey using research scenarios on drug-effect studies to capture method selection and analysis choices that follow a dependency branching based on response to key questions.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Voluntary participants experienced in epidemiological study design solicited for participation through registration on the Observational Medical Outcomes Partnership website, membership in particular professional organizations, or links in relevant newsletters.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Description (proportion) of respondents selecting particular methods and making specific analysis choices based on individual drug-outcome scenario pairs. The number of questions/decisions differed based on stem questions of study design, time-at-risk, outcome definition, and comparator.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There is little consistency across scenarios, by drug or by outcome of interest, in the decisions made for design and analyses in scenarios using large healthcare databases. The most consistent choice was the cohort study design but variability in the other critical decisions was common.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is great variation among epidemiologists in the design and analytical choices that they make when implementing analyses in observational healthcare databases. These findings confirm that it will be important to generate empiric evidence to inform these decisions and to promote a better understanding of the impact of standardization on research implementation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, NJ, USA, pstang@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>J Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Welebob</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016021" MajorTopicYN="Y">Epidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166220</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0103-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S59-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1978 Jan;107(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">623085</ArticleId></ArticleIdList></Reference><Reference><Citation>J R Soc Med. 2007 Nov;100(11):526-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18048712</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):329-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16741894</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1996 Jun 1;143(11):1165-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8633607</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S143-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S95-106</Citation><ArticleIdList><ArticleId IdType="pubmed">24166227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1176-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S123-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Drug Saf. 2013 Apr;4(2):53-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25083251</ArticleId></ArticleIdList></Reference><Reference><Citation>Biom J. 2007 Feb;49(1):151-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17342957</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J. 1968 Apr 27;2(5599):199-205</Citation><ArticleIdList><ArticleId IdType="pubmed">5653025</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2008 Nov;19(6):766-79</Citation><ArticleIdList><ArticleId IdType="pubmed">18854702</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2005 Apr;58(4):323-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15862718</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2010 Aug 11;304(6):657-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20699457</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1995 Dec 13;274(22):1800-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7500513</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S83-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24166226</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2006 Apr 1;23(7):937-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16573796</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Mar 17;342:d1309</Citation><ArticleIdList><ArticleId IdType="pubmed">21415101</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2010 Sep 01;341:c4444</Citation><ArticleIdList><ArticleId IdType="pubmed">20813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S107-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24166228</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">24166225</ArticleId></ArticleIdList></Reference><Reference><Citation>Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):266-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16611201</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S181-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24166234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166222</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Defining a reference set to support methodological research in drug safety.</ArticleTitle><Pagination><StartPage>S33</StartPage><EndPage>S47</EndPage><MedlinePgn>S33-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0097-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Methodological research to evaluate the performance of methods requires a benchmark to serve as a referent comparison. In drug safety, the performance of analyses of spontaneous adverse event reporting databases and observational healthcare data, such as administrative claims and electronic health records, has been limited by the lack of such standards.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To establish a reference set of test cases that contain both positive and negative controls, which can serve the basis for methodological research in evaluating methods performance in identifying drug safety issues.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">Systematic literature review and natural language processing of structured product labeling was performed to identify evidence to support the classification of drugs as either positive controls or negative controls for four outcomes: acute liver injury, acute kidney injury, acute myocardial infarction, and upper gastrointestinal bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three-hundred and ninety-nine test cases comprised of 165 positive controls and 234 negative controls were identified across the four outcomes. The majority of positive controls for acute kidney injury and upper gastrointestinal bleeding were supported by randomized clinical trial evidence, while the majority of positive controls for acute liver injury and acute myocardial infarction were only supported based on published case reports. Literature estimates for the positive controls shows substantial variability that limits the ability to establish a reference set with known effect sizes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A reference set of test cases can be established to facilitate methodological research in drug safety. Creating a sufficient sample of drug-outcome pairs with binary classification of having no effect (negative controls) or having an increased effect (positive controls) is possible and can enable estimation of predictive accuracy through discrimination. Since the magnitude of the positive effects cannot be reliably obtained and the quality of evidence may vary across outcomes, assumptions are required to use the test cases in real data for purposes of measuring bias, mean squared error, or coverage probability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, 1125 Trenton-Harbourton Road, Room K30205, PO Box 200, Titusville, NJ, 08560, USA, ryan@omop.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Welebob</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Valentine</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0097-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gastroenterology. 2007 Feb;132(2):498-506</Citation><ArticleIdList><ArticleId IdType="pubmed">17258728</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2004;27(6):411-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15144234</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2006 Jul;27(14):1657-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16731535</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2004;27(10):735-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15350157</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2007 Jun 15;25(12):1401-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17539979</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2008 Jan 1;27(1):31-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17919277</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S95-106</Citation><ArticleIdList><ArticleId IdType="pubmed">24166227</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2005 Apr 23;330(7497):932</Citation><ArticleIdList><ArticleId IdType="pubmed">15746106</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):294-301</Citation><ArticleIdList><ArticleId IdType="pubmed">23042584</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 2010 Aug;66(8):831-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20473658</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2009;32(6):509-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19459718</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Nephrol. 2009;29(6):633-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19155617</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2010 Jun;69(6):689-700</Citation><ArticleIdList><ArticleId IdType="pubmed">20565461</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):328-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18188866</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2003 Jan 13;163(1):59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12523917</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):611-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22315152</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2008 Aug 28;337:a1069</Citation><ArticleIdList><ArticleId IdType="pubmed">18755768</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc R Soc Med. 1965 May;58:295-300</Citation><ArticleIdList><ArticleId IdType="pubmed">14283879</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2006 May;54(5):1378-89</Citation><ArticleIdList><ArticleId IdType="pubmed">16645966</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S59-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S159-69</Citation><ArticleIdList><ArticleId IdType="pubmed">24166232</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1999 Dec;48(6):847-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10594489</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2009 Nov 27;23(18):2425-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19617813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1993 Oct 1;119(7 Pt 1):576-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8363168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2005 Apr 5;142(7):481-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15809459</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Sci. 1990 Apr;299(4):222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2321664</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2000 Dec;23(6):533-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11144660</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2008;31(2):159-68</Citation><ArticleIdList><ArticleId IdType="pubmed">18217791</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2007 Mar;46(3):435-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17255138</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2011 May 23;171(10):944-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21606101</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2000 Mar 1;151(5):488-96</Citation><ArticleIdList><ArticleId IdType="pubmed">10707917</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 2007 Apr;63(4):403-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17347805</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2010 Jul 26;170(14):1191-1201</Citation><ArticleIdList><ArticleId IdType="pubmed">20656674</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2004 Jul;58(1):71-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15206996</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Gastroenterol Hepatol. 2003 Feb;15(2):173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12560762</ArticleId></ArticleIdList></Reference><Reference><Citation>Contraception. 2003 Jul;68(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12878281</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):292-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20945505</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol Ther. 2008 Dec;13(4):252-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18787084</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S27-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24166221</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2009 Jun;104(6):1475-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19491861</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Jul;65(7):795-803</Citation><ArticleIdList><ArticleId IdType="pubmed">18606952</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2012 Jun;91(6):1010-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>AMIA Annu Symp Proc. 2010 Nov 13;2010:177-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21346964</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 2008 Dec;121(12):1092-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19028206</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Oct;50(10):890-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S83-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24166226</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 2005 Mar;45(3):531-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15754275</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2006 Apr 1;23(7):937-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16573796</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2002 Feb;53(2):173-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11851641</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2003 Nov 1;158(9):915-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14585769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2010 Nov 2;153(9):600-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2006 Nov 1;164(9):881-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17005625</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2005 Dec 3;331(7528):1310-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16322018</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11059479</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2001 Sep;12(5):570-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11505178</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2009 Jul;20(4):512-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S107-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24166228</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2010 Jun;62(6):1592-601</Citation><ArticleIdList><ArticleId IdType="pubmed">20178131</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">24166225</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2006 Dec;55(12):1731-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16687434</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2008 Jul;66(1):76-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18460039</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Aug;36(8):651-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23670723</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2005 Aug 1;41(3):301-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16007524</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1176-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Jan;36(1):13-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23315292</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Clin Pharmacol. 2001;1:1</Citation><ArticleIdList><ArticleId IdType="pubmed">11228592</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S123-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19637402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2005 Nov;32(11):2212-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16265705</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1999 Oct 23;319(7217):1106-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10531103</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1016-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19718696</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S195-204</Citation><ArticleIdList><ArticleId IdType="pubmed">24166235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166223</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Managing data quality for a drug safety surveillance system.</ArticleTitle><Pagination><StartPage>S49</StartPage><EndPage>S58</EndPage><MedlinePgn>S49-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0098-7</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study is to present a data quality assurance program for disparate data sources loaded into a Common Data Model, highlight data quality issues identified and resolutions implemented.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Observational Medical Outcomes Partnership is conducting methodological research to develop a system to monitor drug safety. Standard processes and tools are needed to ensure continuous data quality across a network of disparate databases, and to ensure that procedures used to extract-transform-load (ETL) processes maintain data integrity. Currently, there is no consensus or standard approach to evaluate the quality of the source data, or ETL procedures.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We propose a framework for a comprehensive process to ensure data quality throughout the steps used to process and analyze the data. The approach used to manage data anomalies includes: (1) characterization of data sources; (2) detection of data anomalies; (3) determining the cause of data anomalies; and (4) remediation.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Data anomalies included incomplete raw dataset: no race or year of birth recorded. Implausible data: year of birth exceeding current year, observation period end date precedes start date, suspicious data frequencies and proportions outside normal range. Examples of errors found in the ETL process were zip codes incorrectly loaded, drug quantities rounded, drug exposure length incorrectly calculated, and condition length incorrectly programmed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Complete and reliable observational data are difficult to obtain, data quality assurance processes need to be continuous as data is regularly updated; consequently, processes to assess data quality should be ongoing and transparent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>College of Pharmacy, University of Florida, Gainesville, FL, USA, Hartzema@ufl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Welebob</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>J Marc</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001330" MajorTopicYN="N">Electronic Data Processing</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166223</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0098-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):393-401</Citation><ArticleIdList><ArticleId IdType="pubmed">17066486</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin J Am Soc Nephrol. 2006 Jan;1(1):43-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17699189</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Jul;50 Suppl:S21-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22692254</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2002 Aug;144(2):290-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12177647</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2007 Oct;21(10):1733-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17285379</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Gen Pract. 2010 Mar;60(572):e128-36</Citation><ArticleIdList><ArticleId IdType="pubmed">20202356</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 1996 Oct;25(5):948-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8921479</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):842-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18498081</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2003 May;23(5):686-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12741446</ArticleId></ArticleIdList></Reference><Reference><Citation>Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):311-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16611207</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Health Serv Res. 2006 Dec 15;6:161</Citation><ArticleIdList><ArticleId IdType="pubmed">17173686</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1998 May;45(5):419-25</Citation><ArticleIdList><ArticleId IdType="pubmed">9643612</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2010 Nov-Dec;17(6):652-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Obstet Gynaecol. 2008 Oct;48(5):481-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19032664</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 2008 Jun;51(6):1624-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18413488</ArticleId></ArticleIdList></Reference><Reference><Citation>J Asthma. 1997;34(4):273-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9250251</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2007 Dec;45(12):1216-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18007173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):611-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22315152</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2005 May;43(5):480-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15838413</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Nephrol. 2006 Jun;17(6):1688-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16641149</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):596-603</Citation><ArticleIdList><ArticleId IdType="pubmed">20140892</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Jul;50 Suppl:S60-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2008 Jun;61(6):561-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18471660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2010 Nov 2;153(9):600-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):555-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19844945</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2005 Feb;43(2):182-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15655432</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2010 Jan;69(1):4-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20078607</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2009 Nov 10;28(25):3124-38</Citation><ArticleIdList><ArticleId IdType="pubmed">19691034</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2007 Feb 15;57(1):103-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17266097</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2007 Nov;102(11):2437-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17662100</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):389-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11802582</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166224</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.</ArticleTitle><Pagination><StartPage>S59</StartPage><EndPage>S72</EndPage><MedlinePgn>S59-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0099-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Observational healthcare data offer the potential to enable identification of risks of medical products, but appropriate methodology has not yet been defined. The new user cohort method, which compares the post-exposure rate among the target drug to a referent comparator group, is the prevailing approach for many pharmacoepidemiology evaluations and has been proposed as a promising approach for risk identification but its performance in this context has not been fully assessed.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the performance of the new user cohort method as a tool for risk identification in observational healthcare data.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">The method was applied to 399 drug-outcome scenarios (165 positive controls and 234 negative controls across 4 health outcomes of interest) in 5 real observational databases (4 administrative claims and 1 electronic health record) and in 6 simulated datasets with no effect and injected relative risks of 1.25, 1.5, 2, 4, and 10, respectively.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Method performance was evaluated through Area Under ROC Curve (AUC), bias, and coverage probability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The new user cohort method achieved modest predictive accuracy across the outcomes and databases under study, with the top-performing analysis near AUC &gt;0.70 in most scenarios. The performance of the method was particularly sensitive to the choice of comparator population. For almost all drug-outcome pairs there was a large difference, either positive or negative, between the true effect size and the estimate produced by the method, although this error was near zero on average. Simulation studies showed that in the majority of cases, the true effect estimate was not within the 95 % confidence interval produced by the method.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The new user cohort method can contribute useful information toward a risk identification system, but should not be considered definitive evidence given the degree of error observed within the effect estimates. Careful consideration of the comparator selection and appropriate calibration of the effect estimates is required in order to properly interpret study findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, NJ, USA, ryan@omop.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zorych</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="Y">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0099-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmacoepidemiol Drug Saf. 1998 Jul;7(4):275-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15073990</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8410092</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 1986 Sep;15(3):413-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3771081</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 1996 Jul;7(4):335-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8793355</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2007 Oct;45(10 Supl 2):S131-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17909372</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):858-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20681003</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S143-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1176-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Nov;50(11):948-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23047784</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2008 Feb 15;167(4):492-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18056625</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23023988</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2011 Dec 1;174(11):1213-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22025356</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2005 Oct 27;353(17):1773-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16169887</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2006 Jun 15;163(12):1149-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16624967</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:41-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22262592</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2006 Feb 1;163(3):262-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16371515</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2011 Jun 15;173(12):1404-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21602301</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:32-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22262591</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 2006 Jul;60(7):578-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16790829</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2009 Jul;20(4):488-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19525685</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2012 May 1;35(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">22489640</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:282-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22262618</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 2002 Apr;31(2):422-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11980807</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2010 May;21(3):383-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1994 Feb;47(2):183-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8113827</ArticleId></ArticleIdList></Reference><Reference><Citation>Prostate Cancer Prostatic Dis. 2004;7(2):132-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15007379</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Public Health. 2000;21:121-45</Citation><ArticleIdList><ArticleId IdType="pubmed">10884949</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S15-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24166220</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2014 Jan 30;33(2):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Res Methodol. 2005 Sep 13;5:28</Citation><ArticleIdList><ArticleId IdType="pubmed">16159397</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:138-47</Citation><ArticleIdList><ArticleId IdType="pubmed">22552989</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2003 Nov 1;158(9):915-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14585769</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11059479</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2009 Jul;20(4):512-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2010 Oct 1;172(7):843-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20716704</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2000 Dec 13;284(22):2912-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11147989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166225</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical performance of the case-control method: lessons for developing a risk identification and analysis system.</ArticleTitle><Pagination><StartPage>S73</StartPage><EndPage>S82</EndPage><MedlinePgn>S73-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0105-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Considerable attention now focuses on the use of large-scale observational healthcare data for understanding drug safety. In this context, analysts utilize a variety of statistical and epidemiological approaches such as case-control, cohort, and self-controlled methods. The operating characteristics of these methods are poorly understood.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Establish the operating characteristics of the case-control method for large scale observational analysis in drug safety.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">We empirically evaluated the case-control approach in 5 real observational healthcare databases and 6 simulated datasets. We retrospectively studied the predictive accuracy of the method when applied to a collection of 165 positive controls and 234 negative controls across 4 outcomes: acute liver injury, acute myocardial infarction, acute kidney injury, and upper gastrointestinal bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In our experiment, the case-control method provided weak discrimination between positive and negative controls. Furthermore, the method yielded positively biased estimates and confidence intervals that had poor coverage properties.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For the four outcomes we examined, the case-control method may not be the method of choice for estimating potentially harmful effects of drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, 1255 Amsterdam Avenue, New York, NY, 10027, USA, david.madigan@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="Y">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166225</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0105-z</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166226</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system.</ArticleTitle><Pagination><StartPage>S83</StartPage><EndPage>S93</EndPage><MedlinePgn>S83-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0100-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The self-controlled case series (SCCS) offers potential as an statistical method for risk identification involving medical products from large-scale observational healthcare data. However, analytic design choices remain in encoding the longitudinal health records into the SCCS framework and its risk identification performance across real-world databases is unknown.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the performance of SCCS and its design choices as a tool for risk identification in observational healthcare data.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">We examined the risk identification performance of SCCS across five design choices using 399 drug-health outcome pairs in five real observational databases (four administrative claims and one electronic health records). In these databases, the pairs involve 165 positive controls and 234 negative controls. We also consider several synthetic databases with known relative risks between drug-outcome pairs.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">We evaluate risk identification performance through estimating the area under the receiver-operator characteristics curve (AUC) and bias and coverage probability in the synthetic examples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The SCCS achieves strong predictive performance. Twelve of the twenty health outcome-database scenarios return AUCs &gt;0.75 across all drugs. Including all adverse events instead of just the first per patient and applying a multivariate adjustment for concomitant drug use are the most important design choices. However, the SCCS as applied here returns relative risk point-estimates biased towards the null value of 1 with low coverage probability.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The SCCS recently extended to apply a multivariate adjustment for concomitant drug use offers promise as a statistical tool for risk identification in large-scale observational healthcare databases. Poor estimator calibration dampens enthusiasm, but on-going work should correct this short-coming.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA, msuchard@ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorych</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Shawn E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166226</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0100-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166227</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system.</ArticleTitle><Pagination><StartPage>S95</StartPage><EndPage>S106</EndPage><MedlinePgn>S95-106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0101-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Observational healthcare data offer the potential to enable identification of risks of medical products, but appropriate methodology has not yet been defined. The self-controlled cohort method, which compares the post-exposure outcome rate with the pre-exposure rate among an exposed cohort, has been proposed as a potential approach for risk identification but its performance has not been fully assessed.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the performance of the self-controlled cohort method as a tool for risk identification in observational healthcare data.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">The method was applied to 399 drug-outcome scenarios (165 positive controls and 234 negative controls across 4 health outcomes of interest) in 5 real observational databases (4 administrative claims and 1 electronic health record) and in 6 simulated datasets with no effect and injected relative risks of 1.25, 1.5, 2, 4, and 10, respectively.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Method performance was evaluated through area under ROC curve (AUC), bias, and coverage probability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The self-controlled cohort design achieved strong predictive accuracy across the outcomes and databases under study, with the top-performing settings exceeding AUC &gt;0.76 in all scenarios. However, the estimates generated were observed to be highly biased with low coverage probability.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">If the objective for a risk identification system is one of discrimination, the self-controlled cohort method shows promise as a potential tool for risk identification. However, if a system is intended to generate effect estimates to quantify the magnitude of potential risks, the self-controlled cohort method may not be suitable, and requires substantial calibration to be properly interpreted under nominal properties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, 1125 Trenton-Harbourton Road, Room K30205, PO Box 200, Titusville, NJ, 08560, USA, ryan@omop.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="Y">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166227</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0101-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2008 Feb 15;167(4):492-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18056625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1993 Oct 1;119(7 Pt 1):576-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8363168</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2003 Jun 30;22(12):2071-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12802823</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2011 Feb 22;183(3):E173-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21220436</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2011;62:1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20809798</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2014 Jan 30;33(2):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11059479</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S143-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1176-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166228</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system.</ArticleTitle><Pagination><StartPage>S107</StartPage><EndPage>S121</EndPage><MedlinePgn>S107-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0095-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Observational healthcare data offer the potential to identify adverse drug reactions that may be missed by spontaneous reporting. The self-controlled cohort analysis within the Temporal Pattern Discovery framework compares the observed-to-expected ratio of medical outcomes during post-exposure surveillance periods with those during a set of distinct pre-exposure control periods in the same patients. It utilizes an external control group to account for systematic differences between the different time periods, thus combining within- and between-patient confounder adjustment in a single measure.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the performance of the calibrated self-controlled cohort analysis within Temporal Pattern Discovery as a tool for risk identification in observational healthcare data.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">Different implementations of the calibrated self-controlled cohort analysis were applied to 399 drug-outcome pairs (165 positive and 234 negative test cases across 4 health outcomes of interest) in 5 real observational databases (four with administrative claims and one with electronic health records).</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Performance was evaluated on real data through sensitivity/specificity, the area under receiver operator characteristics curve (AUC), and bias.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The calibrated self-controlled cohort analysis achieved good predictive accuracy across the outcomes and databases under study. The optimal design based on this reference set uses a 360 days surveillance period and a single control period 180 days prior to new prescriptions. It achieved an average AUC of 0.75 and AUC &gt;0.70 in all but one scenario. A design with three separate control periods performed better for the electronic health records database and for acute renal failure across all data sets. The estimates for negative test cases were generally unbiased, but a minor negative bias of up to 0.2 on the RR-scale was observed with the configurations using multiple control periods, for acute liver injury and upper gastrointestinal bleeding.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The calibrated self-controlled cohort analysis within Temporal Pattern Discovery shows promise as a tool for risk identification; it performs well at discriminating positive from negative test cases. The optimal parameter configuration may vary with the data set and medical outcome of interest.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nor&#xe9;n</LastName><ForeName>G Niklas</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, niklas.noren@who-umc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergvall</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Juhlin</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="N">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="Y">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166228</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0095-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):670-2; author reply 673-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22678687</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2011 Feb 22;183(3):E173-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21220436</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2013 Feb;22(1):39-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21878461</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2011;62:1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20809798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1990 Jul 21;336(8708):156-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1973481</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2013 Feb;22(1):57-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21705438</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1996 Jun 1;143(11):1165-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8633607</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2000 Jun;22(6):415-23</Citation><ArticleIdList><ArticleId IdType="pubmed">10877036</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S95-106</Citation><ArticleIdList><ArticleId IdType="pubmed">24166227</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2013 Jun;93(6):539-46</Citation><ArticleIdList><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1991 Jan 15;133(2):144-53</Citation><ArticleIdList><ArticleId IdType="pubmed">1985444</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1988 Jul;26(1):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3203052</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology. 1983 Sep;148(3):839-43</Citation><ArticleIdList><ArticleId IdType="pubmed">6878708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1993 Oct 1;119(7 Pt 1):576-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8363168</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 1995 May;6(3):248-53</Citation><ArticleIdList><ArticleId IdType="pubmed">7619931</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 1996 Sep;7(5):478-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8862977</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Jan 27;338:b81</Citation><ArticleIdList><ArticleId IdType="pubmed">19174434</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166229</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Evaluation of disproportionality safety signaling applied to healthcare databases.</ArticleTitle><Pagination><StartPage>S123</StartPage><EndPage>S132</EndPage><MedlinePgn>S123-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0106-y</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the performance of a disproportionality design, commonly used for analysis of spontaneous reports data such as the FDA Adverse Event Reporting System database, as a potential analytical method for an adverse drug reaction risk identification system using healthcare data.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">We tested the disproportionality design in 5 real observational healthcare databases and 6 simulated datasets, retrospectively studying the predictive accuracy of the method when applied to a collection of 165 positive controls and 234 negative controls across 4 outcomes: acute liver injury, acute myocardial infarction, acute kidney injury, and upper gastrointestinal bleeding.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">We estimate how well the method can be expected to identify true effects and discriminate from false findings and explore the statistical properties of the estimates the design generates. The primary measure was the area under the curve (AUC) of the receiver operating characteristic (ROC) curve.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For each combination of 4 outcomes and 5 databases, 48 versions of disproportionality analysis (DPA) were carried out and the AUC computed. The majority of the AUC values were in the range of 0.35 &lt; AUC &lt; 0.6, which is considered to be poor predictive accuracy, since the value AUC = 0.5 would be expected from mere random assignment. Several DPA versions achieved AUC of about 0.7 for the outcome Acute Renal Failure within the GE database. The overall highest DPA version across all 20 outcome-database combinations was the Bayesian Information Component method with no stratification by age and gender, using first occurrence of outcome and with assumed time-at-risk equal to duration of exposure + 30 d, but none were uniformly optimal. The relative risk estimates for the negative control drug-event combinations were very often biased either upward or downward by a factor of 2 or more. Coverage probabilities of confidence intervals from all methods were far below nominal.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The disproportionality methods that we evaluated did not discriminate true positives from true negatives using healthcare data as they seem to do using spontaneous report data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DuMouchel</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Oracle Health Sciences, Burlington, Massachusetts, USA, bill.dumouchel@oracle.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166229</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0106-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Natl Cancer Inst. 1959 Apr;22(4):719-48</Citation><ArticleIdList><ArticleId IdType="pubmed">13655060</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2013 Feb;22(1):39-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21878461</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):483-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 1998 Jun;54(4):315-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2004;27(10):735-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15350157</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11059479</ArticleId></ArticleIdList></Reference><Reference><Citation>Invest Radiol. 2006 Aug;41(8):651-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16829749</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2013 Jun;93(6):539-46</Citation><ArticleIdList><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2006;29(10):875-87</Citation><ArticleIdList><ArticleId IdType="pubmed">16970511</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2007 Aug;82(2):157-66</Citation><ArticleIdList><ArticleId IdType="pubmed">17538548</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166223</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2004 Jul;26(7):1092-1104</Citation><ArticleIdList><ArticleId IdType="pubmed">15336474</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2013 Feb;22(1):57-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21705438</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Oct;50(10):890-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Saf. 2005 Sep;4(5):929-48</Citation><ArticleIdList><ArticleId IdType="pubmed">16111454</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2003 Sep;12(6):517-21</Citation><ArticleIdList><ArticleId IdType="pubmed">14513665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2008 Jan-Mar;20(1):21-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18297583</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2002;25(6):381-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12071774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166230</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system.</ArticleTitle><Pagination><StartPage>S133</StartPage><EndPage>S142</EndPage><MedlinePgn>S133-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0107-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The availability of large-scale observational healthcare data allows for the active monitoring of safety of drugs, but research is needed to determine which statistical methods are best suited for this task. Recently, the Longitudinal Gamma Poisson Shrinker (LGPS) and Longitudinal Evaluation of Observational Profiles of Adverse events Related to Drugs (LEOPARD) methods were developed specifically for this task. LGPS applies Bayesian shrinkage to an estimated incidence rate ratio, and LEOPARD aims to detect and discard associations due to protopathic bias. The operating characteristics of these methods still need to be determined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Establish the operating characteristics of LGPS and LEOPARD for large scale observational analysis in drug safety.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">We empirically evaluated LGPS and LEOPARD in five real observational healthcare databases and six simulated datasets. We retrospectively studied the predictive accuracy of the methods when applied to a collection of 165 positive control and 234 negative control drug-outcome pairs across four outcomes: acute liver injury, acute myocardial infarction, acute kidney injury, and upper gastrointestinal bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In contrast to earlier findings, we found that LGPS and LEOPARD provide weak discrimination between positive and negative controls, although the use of LEOPARD does lead to higher performance in this respect. Furthermore, the methods produce biased estimates and confidence intervals that have poor coverage properties.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For the four outcomes we examined, LGPS and LEOPARD may not be the designs of choice for risk identification.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands, m.schuemie@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166230</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0107-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stat Med. 1989 Dec;8(12):1421-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2616932</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):292-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20945505</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Oct;50(10):890-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2012 Jan 18;1:CD008922</Citation><ArticleIdList><ArticleId IdType="pubmed">22258993</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Jan;36(1):13-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23315292</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2005 Nov;32(11):2212-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16265705</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1999 Sep;17(9):2971-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10561376</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 1998 Jul;19(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9673854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 2003 Jan;18(1):57-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12534765</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2006 May 9;113(18):2173-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16684873</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2011;62:1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20809798</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11059479</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2010 Jun;62(6):1592-601</Citation><ArticleIdList><ArticleId IdType="pubmed">20178131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166231</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>A comparison of the empirical performance of methods for a risk identification system.</ArticleTitle><Pagination><StartPage>S143</StartPage><EndPage>S158</EndPage><MedlinePgn>S143-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0108-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Observational healthcare data offer the potential to enable identification of risks of medical products, and the medical literature is replete with analyses that aim to accomplish this objective. A number of established analytic methods dominate the literature but their operating characteristics in real-world settings remain unknown.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To compare the performance of seven methods (new user cohort, case control, self-controlled case series, self-controlled cohort, disproportionality analysis, temporal pattern discovery, and longitudinal gamma poisson shrinker) as tools for risk identification in observational healthcare data.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">The experiment applied each method to 399 drug-outcome scenarios (165 positive controls and 234 negative controls across 4 health outcomes of interest) in 5 real observational databases (4 administrative claims and 1 electronic health record).</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Method performance was evaluated through Area Under the receiver operator characteristics Curve (AUC), bias, mean square error, and confidence interval coverage probability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Multiple methods offer strong predictive accuracy, with AUC &gt; 0.70 achievable for all outcomes and databases with more than one analytical approach. Self-controlled methods (self-controlled case series, temporal pattern discovery, self-controlled cohort) had higher predictive accuracy than cohort and case-control methods across all databases and outcomes. Methods differed in the expected value and variance of the error distribution. All methods had lower coverage probability than the expected nominal properties.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Observational healthcare data can inform risk identification of medical product effects on acute liver injury, acute myocardial infarction, acute renal failure and gastrointestinal bleeding. However, effect estimates from all methods require calibration to address inconsistency in method operating characteristics. Further empirical evaluation is required to gauge the generalizability of these findings to other databases and outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, 1125 Trenton-Harbourton Road, Room K30205, PO Box 200, Titusville, NJ, 08560, USA, ryan@omop.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>J Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>DuMouchel</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0108-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2007 Sep 05;2(9):e840</Citation><ArticleIdList><ArticleId IdType="pubmed">17786211</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2007 Dec;16(12):1275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17955500</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S59-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2012 Apr;65(4):384-93</Citation><ArticleIdList><ArticleId IdType="pubmed">22197519</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Jun 14;356(24):2457-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17517853</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):17-29</Citation><ArticleIdList><ArticleId IdType="pubmed">12616844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2005 Feb 5-11;365(9458):475-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15705456</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S83-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24166226</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2014 Jan 30;33(2):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 2012 Apr;41(2):393-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22493323</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2010 Mar;33(3):526-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20009093</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 1996 May;7(3):231-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8728434</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1991 Jan 15;133(2):144-53</Citation><ArticleIdList><ArticleId IdType="pubmed">1985444</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2005 Aug;2(8):e124</Citation><ArticleIdList><ArticleId IdType="pubmed">16060722</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2010 Jul 28;304(4):411-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20584880</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2008 Jun;17(6):601-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18383442</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2003 Jul 1;158(1):77-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12835289</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:32-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22262591</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2006 Aug;59(8):808-18</Citation><ArticleIdList><ArticleId IdType="pubmed">16828674</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:50-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22262593</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2005 Aug 1;22(3):175-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16091054</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Oct;50(10):890-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):858-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20681003</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Res Methodol. 2013 Jun 24;13:82</Citation><ArticleIdList><ArticleId IdType="pubmed">23800078</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2004 Jun 19;328(7454):1490</Citation><ArticleIdList><ArticleId IdType="pubmed">15205295</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528</Citation><ArticleIdList><ArticleId IdType="pubmed">11087881</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S107-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24166228</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">24166225</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2008 Aug;98(8):1366-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18556607</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S95-106</Citation><ArticleIdList><ArticleId IdType="pubmed">24166227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1176-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Jan;36(1):13-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23315292</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S123-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2005 Mar 17;352(11):1092-102</Citation><ArticleIdList><ArticleId IdType="pubmed">15713943</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166232</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.</ArticleTitle><Pagination><StartPage>S159</StartPage><EndPage>S169</EndPage><MedlinePgn>S159-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0109-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Observational Medical Outcomes Partnership (OMOP) has just completed a large scale empirical evaluation of statistical methods and analysis choices for risks identification in longitudinal observational healthcare data. This experiment drew data from four large US health insurance claims databases and one US electronic health record (EHR) database, but it is unclear to what extend the findings of this study apply to other data sources.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To replicate the OMOP experiment in six European EHR databases.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">Six databases of the EU-ADR (Exploring and Understanding Adverse Drug Reactions) database network participated in this study: Aarhus (Denmark), ARS (Italy), HealthSearch (Italy), IPCI (the Netherlands), Pedianet (Italy), and Pharmo (the Netherlands). All methods in the OMOP experiment were applied to a collection of 165 positive and 234 negative control drug-outcome pairs across four outcomes: acute liver injury, acute myocardial infarction, acute kidney injury, and upper gastrointestinal bleeding. Area under the receiver operator characteristics curve (AUC) was computed per database and for a combination of all six databases using meta-analysis for random effects. We provide expected values of estimation error as well, based on negative controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Similarly to the US experiment, high predictive accuracy was found (AUC &gt;0.8) for some analyses. Self-controlled designs, such as self-controlled case series, IC temporal pattern discovery and self-controlled cohort achieved higher performance than other methods, both in terms of predictive accuracy and observed bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The major findings of the recent OMOP experiment were also observed in the European databases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands, m.schuemie@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gini</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Coloma</LastName><ForeName>Preciosa M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Straatman</LastName><ForeName>Huub</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Herings</LastName><ForeName>Ron M C</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Innocenti</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mazzaglia</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Picelli</LastName><ForeName>Gino</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>van der Lei</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sturkenboom</LastName><ForeName>Miriam C J M</ForeName><Initials>MC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166232</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0109-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S59-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2013 Jan 1;20(1):184-92</Citation><ArticleIdList><ArticleId IdType="pubmed">22955495</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166223</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S83-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24166226</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Inform. 2012 Aug;45(4):689-96</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S181-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24166234</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S143-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S95-106</Citation><ArticleIdList><ArticleId IdType="pubmed">24166227</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1988 Feb 11;318(6):352-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3123929</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S123-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S133-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24166230</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Oct;50(10):890-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11059479</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S107-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24166228</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">24166225</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166233</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Evaluating performance of risk identification methods through a large-scale simulation of observational data.</ArticleTitle><Pagination><StartPage>S171</StartPage><EndPage>S180</EndPage><MedlinePgn>S171-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0110-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There has been only limited evaluation of statistical methods for identifying safety risks of drug exposure in observational healthcare data. Simulations can support empirical evaluation, but have not been shown to adequately model the real-world phenomena that challenge observational analyses.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To design and evaluate a probabilistic framework (OSIM2) for generating simulated observational healthcare data, and to use this data for evaluating the performance of methods in identifying associations between drug exposure and health outcomes of interest.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">Seven observational designs, including case-control, cohort, self-controlled case series, and self-controlled cohort design were applied to 399 drug-outcome scenarios in 6 simulated datasets with no effect and injected relative risks of 1.25, 1.5, 2, 4, and 10, respectively.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Longitudinal data for 10 million simulated patients were generated using a model derived from an administrative claims database, with associated demographics, periods of drug exposure derived from pharmacy dispensings, and medical conditions derived from diagnoses on medical claims.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Simulation validation was performed through descriptive comparison with real source data. Method performance was evaluated using Area Under ROC Curve (AUC), bias, and mean squared error.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">OSIM2 replicates prevalence and types of confounding observed in real claims data. When simulated data are injected with relative risks (RR) &#x2265; 2, all designs have good predictive accuracy (AUC &gt; 0.90), but when RR &lt; 2, no methods achieve 100 % predictions. Each method exhibits a different bias profile, which changes with the effect size.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">OSIM2 can support methodological research. Results from simulation suggest method operating characteristics are far from nominal properties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, 1125 Trenton-Harbourton Road, Room K30205, PO Box 200, Titusville, NJ, 08560, USA, ryan@omop.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166233</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0110-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2011 Dec 1;174(11):1213-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22025356</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2012 Oct;50(10):890-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S123-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>AMIA Annu Symp Proc. 2011;2011:1176-85</Citation><ArticleIdList><ArticleId IdType="pubmed">22195178</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2007 Sep 15;166(6):646-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17615092</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2008 Jun;17(6):546-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18311848</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Mar 3;281(9):841-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10071007</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S59-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S83-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24166226</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2012 Nov 15;176(10):938-48</Citation><ArticleIdList><ArticleId IdType="pubmed">23100247</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S107-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24166228</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">24166225</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166234</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.</ArticleTitle><Pagination><StartPage>S181</StartPage><EndPage>S193</EndPage><MedlinePgn>S181-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0111-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A systematic risk identification system has the potential to test marketed drugs for important Health Outcomes of Interest or HOI. For each HOI, multiple definitions are used in the literature, and some of them are validated for certain databases. However, little is known about the effect of different definitions on the ability of methods to estimate their association with medical products.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Alternative definitions of HOI were studied for their effect on the performance of analytical methods in observational outcome studies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A set of alternative definitions for three HOI were defined based on literature review and clinical diagnosis guidelines: acute kidney injury, acute liver injury and acute myocardial infarction. The definitions varied by the choice of diagnostic codes and the inclusion of procedure codes and lab values. They were then used to empirically study an array of analytical methods with various analytical choices in four observational healthcare databases. The methods were executed against predefined drug-HOI pairs to generate an effect estimate and standard error for each pair. These test cases included positive controls (active ingredients with evidence to suspect a positive association with the outcome) and negative controls (active ingredients with no evidence to expect an effect on the outcome). Three different performance metrics where used: (i) Area Under the Receiver Operator Characteristics (ROC) curve (AUC) as a measure of a method's ability to distinguish between positive and negative test cases, (ii) Measure of bias by estimation of distribution of observed effect estimates for the negative test pairs where the true effect can be assumed to be one (no relative risk), and (iii) Minimal Detectable Relative Risk (MDRR) as a measure of whether there is sufficient power to generate effect estimates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the three outcomes studied, different definitions of outcomes show comparable ability to differentiate true from false control cases (AUC) and a similar bias estimation. However, broader definitions generating larger outcome cohorts allowed more drugs to be studied with sufficient statistical power.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Broader definitions are preferred since they allow studying drugs with lower prevalence than the more precise or narrow definitions while showing comparable performance characteristics in differentiation of signal vs. no signal as well as effect size estimation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>AstraZeneca PLC, 35 Gatehouse Drive, Waltham, MA, 02451, USA, reich@omop.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166234</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0111-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1977 Jun;33(2):414-8</Citation><ArticleIdList><ArticleId IdType="pubmed">884199</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2001 Aug 22-29;286(8):954-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11509060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2010 Nov 2;153(9):600-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11059479</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Aug;36(8):651-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23670723</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S143-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nephrol. 2009 May-Jun;22(3):295-305</Citation><ArticleIdList><ArticleId IdType="pubmed">19557705</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S195-204</Citation><ArticleIdList><ArticleId IdType="pubmed">24166235</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 1997 Sep;6(5):313-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15073765</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1993 Jun 1;137(11):1251-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8322765</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephron Clin Pract. 2008;109(4):c182-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18802365</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:82-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22262596</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1977 May;105(5):488-95</Citation><ArticleIdList><ArticleId IdType="pubmed">871121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24166235</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.</ArticleTitle><Pagination><StartPage>S195</StartPage><EndPage>S204</EndPage><MedlinePgn>S195-204</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-013-0112-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A systematic risk identification system has the potential to study all marketed drugs. However, the rates of drug exposure and outcome occurrences in observational databases, the database size and the desired risk detection threshold determine the power and therefore limit the feasibility of the application of appropriate analytical methods. Drugs vary dramatically for these parameters because of their prevalence of indication, cost, time on the market, payer formularies, market pressures and clinical guidelines.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Evaluate (i) the feasibility of a risk identification system based on commercially available observational databases, (ii) the range of drugs that can be studied for certain outcomes, (iii) the influence of underpowered drug-outcome pairs on the performance of analytical methods estimating the strength of their association and (iv) the time required from the introduction of a new drug to accumulate sufficient data for signal detection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As part of the Observational Medical Outcomes Partnership experiment, we used data from commercially available observational databases and calculated the minimal detectable relative risk of all pairs of marketed drugs and eight health outcomes of interest. We then studied an array of analytical methods for their ability to distinguish between pre-determined positive and negative drug-outcome test pairs. The positive controls contained active ingredients with evidence of a positive association with the outcome, and the negative controls had no such evidence. As a performance measure we used the area under the receiver operator characteristics curve (AUC). We compared the AUC of methods using all test pairs or only pairs sufficiently powered for detection of a relative risk of 1.25. Finally, we studied all drugs introduced to the market in 2003-2008 and determined the time required to achieve the same minimal detectable relative risk threshold.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The performance of methods improved after restricting them to fully powered drug-outcome pairs. The availability of drug-outcome pairs with sufficient power to detect a relative risk of 1.25 varies enormously among outcomes. Depending on the market uptake, drugs can generate relevant signals in the first month after approval, or never reach sufficient power.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The incidence of drugs and important outcomes determines sample size and method performance in estimating drug-outcome associations. Careful consideration is therefore necessary to choose databases and outcome definitions, particularly for newly introduced drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>AstraZeneca PLC, 35 Gatehouse Drive, Waltham, MA, 02451, USA, reich@omop.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24166235</ArticleId><ArticleId IdType="doi">10.1007/s40264-013-0112-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1987 Aug;126(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 2012 Feb;68(2):123-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21808989</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):611-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22315152</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Mar 3;281(9):841-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10071007</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1983 Jun;39(2):499-503</Citation><ArticleIdList><ArticleId IdType="pubmed">6354290</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1995 Jul 14;269(5221):164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7618077</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 2009 Feb;122(2):114-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19185083</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 2000 Oct-Dec;20(4):468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11059479</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S181-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24166234</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S143-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 May 22;363(9422):1728-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15158638</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2006 Aug 15;25(15):2618-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16372391</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1981 Nov;114(5):725-34</Citation><ArticleIdList><ArticleId IdType="pubmed">7030065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24235108</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-2208</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>IEEE journal of biomedical and health informatics</Title><ISOAbbreviation>IEEE J Biomed Health Inform</ISOAbbreviation></Journal><ArticleTitle>Adverse drug effect detection.</ArticleTitle><Pagination><StartPage>305</StartPage><EndPage>311</EndPage><MedlinePgn>305-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1109/TITB.2012.2227272</ELocationID><Abstract><AbstractText>Large collections of electronic patient records provide abundant but under-explored information on the real-world use of medicines. Although they are maintained for patient administration, they provide a broad range of clinical information for data analysis. One growing interest is drug safety signal detection from these longitudinal observational data. In this paper, we proposed two novel algorithms-a likelihood ratio model and a Bayesian network model-for adverse drug effect discovery. Although the performance of these two algorithms is comparable to the state-of-the-art algorithm, Bayesian confidence propagation neural network, the combination of three works better due to their diversity in solutions. Since the actual adverse drug effects on a given dataset cannot be absolutely determined, we make use of the simulated observational medical outcomes partnership (OMOP) dataset constructed with the predefined adverse drug effects to evaluate our methods. Experimental results show the usefulness of the proposed pattern discovery method on the simulated OMOP dataset by improving the standard baseline algorithm-chi-square-by 23.83%.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lian Duan</LastName><ForeName>Lian</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Khoshneshin</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Street</LastName><ForeName>W Nick</ForeName><Initials>WN</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mei</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>IEEE J Biomed Health Inform</MedlineTA><NlmUniqueID>101604520</NlmUniqueID><ISSNLinking>2168-2194</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="Y">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016571" MajorTopicYN="Y">Neural Networks, Computer</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24235108</ArticleId><ArticleId IdType="doi">10.1109/TITB.2012.2227272</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">24448022</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2163-8306</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>9</Issue><PubDate><Year>2013</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>CPT: pharmacometrics &amp; systems pharmacology</Title><ISOAbbreviation>CPT Pharmacometrics Syst Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Medication-wide association studies.</ArticleTitle><Pagination><StartPage>e76</StartPage><MedlinePgn>e76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/psp.2013.52</ELocationID><Abstract><AbstractText>Undiscovered side effects of drugs can have a profound effect on the health of the nation, and electronic health-care databases offer opportunities to speed up the discovery of these side effects. We applied a "medication-wide association study" approach that combined multivariate analysis with exploratory visualization to study four health outcomes of interest in an administrative claims database of 46 million patients and a clinical database of 11 million patients. The technique had good predictive value, but there was no threshold high enough to eliminate false-positive findings. The visualization not only highlighted the class effects that strengthened the review of specific products but also underscored the challenges in confounding. These findings suggest that observational databases are useful for identifying potential associations that warrant further consideration but are unlikely to provide definitive evidence of causal effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>P B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>P E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>1] Janssen Research and Development, Titusville, New Jersey, USA [2] Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CPT Pharmacometrics Syst Pharmacol</MedlineTA><NlmUniqueID>101580011</NlmUniqueID><ISSNLinking>2163-8306</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24448022</ArticleId><ArticleId IdType="pmc">PMC4026636</ArticleId><ArticleId IdType="doi">10.1038/psp.2013.52</ArticleId><ArticleId IdType="pii">psp201352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blumenthal D., Tavenner M. The &#x201c;meaningful use&#x201d; regulation for electronic health records. N. Engl. J. Med. 2010;363:501&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">20647183</ArticleId></ArticleIdList></Reference><Reference><Citation>Access to CMS Data &amp; Application.
&lt;
http://www.cms.gov/Research-Statistics-Data-and-Systems/CMS-Information-Technology/AccesstoDataApplication/index.html
&gt;
Accessed 20 January 2013.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). Adverse Event Reporting System (AERS).
&lt;
http://www.fda.gov/cder/aers
&gt;
Accessed 20 January 2013.</Citation></Reference><Reference><Citation>Friedman C.P., Wong A.K., Blumenthal D. Achieving a nationwide learning health system. Sci. Transl. Med. 2010;2:57cm29.</Citation><ArticleIdList><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. The importance of pharmacovigilance&#x2014;safety monitoring of medicinal products. World Health Organization; Geneva; 
. &lt;
http://apps.who.int/medicinedocs/en/d/Js4893e/
&gt;
2002. Accessed 20 January 2013.</Citation></Reference><Reference><Citation>Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">9555760</ArticleId></ArticleIdList></Reference><Reference><Citation>Classen D.C., Pestotnik S.L., Evans R.S., Lloyd J.F., Burke J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">9002492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S.R. Adverse drug event monitoring at the Food and Drug Administration. J. Gen. Intern. Med. 2003;18:57&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1494803</ArticleId><ArticleId IdType="pubmed">12534765</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins D., et al. GRADE Working Group Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC428525</ArticleId><ArticleId IdType="pubmed">15205295</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin J.A., Glasser S.C., Ellenberg S.S. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am. J. Public Health. 2008;98:1366&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2446471</ArticleId><ArticleId IdType="pubmed">18556607</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller P.C., Evans S.J. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol. Drug Saf. 2003;12:17&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">12616844</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., DuMouchel W., Shah N.H., Madigan D., Ryan P., Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Ther. 2012;91:1010&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.M. Confounding by indication. Epidemiology. 1996;7:335&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">8793355</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41&#x2013;55.</Citation></Reference><Reference><Citation>Wang X., Hripcsak G, Friedman C. Characterizing environmental and phenotypic associations using information theory and electronic health records. BMC Bioinformatics. 2009;10 suppl. 9:S13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745684</ArticleId><ArticleId IdType="pubmed">19761567</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Stang P.E., et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann. Intern. Med. 2010;153:600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P.B., Madigan D., Stang P.E., Overhage J.M., Racoosin J.A., Hartzema A.G. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat. Med. 2012;31:4401&#x2013;4415.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Arellano F.M. The withdrawal of rofecoxib. Pharmacoepidemiol. Drug Saf. 2005;14:213&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">15724267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lependu P., Iyer S.V., Fairon C., Shah N.H. Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. J. Biomed. Semantics. 2012;3 suppl. 1:S5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337270</ArticleId><ArticleId IdType="pubmed">22541596</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownstein J.S., Sordo M., Kohane I.S., Mandl K.D. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE. 2007;2:e840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950690</ArticleId><ArticleId IdType="pubmed">17786211</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J.S., et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol. Drug Saf. 2007;16:1275&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pubmed">17955500</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M.J., et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med. Care. 2012;50:890&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram M.A., et al. Genomewide association studies of stroke. N. Engl. J. Med. 2009;360:1718&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768348</ArticleId><ArticleId IdType="pubmed">19369658</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny J.C., et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010;26:1205&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859132</ArticleId><ArticleId IdType="pubmed">20335276</ArticleId></ArticleIdList></Reference><Reference><Citation>International Classification of Diseases, 9th Revision, Clinical Modification.
&lt;
http://www.cdc.gov/nchs/icd/icd9cm.htm
&gt;
Accessed 21 January 2013.</Citation></Reference><Reference><Citation>WHO Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical classification system: structure and principles.
&lt;
http://www.whocc.no/atc/structure_and_principles/
&gt;
Accessed 21 January 2013.</Citation></Reference><Reference><Citation>Food and Drug Administration Amendments Act of 2007. Public Law 110&#x2013;85, 21 STAT. 823. 2007.</Citation></Reference><Reference><Citation>Robb M.A., et al. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol. Drug Saf. 2012;21 suppl. 1:9&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262587</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweder T, Spjotvoll E. Plots of P-values to evaluate many tests simultaneously. Biometrika. 1982;69:493&#x2013;502.</Citation></Reference><Reference><Citation>LePendu P., et al. Pharmacovigilance using clinical notes. Clin. Pharmacol. Ther. 2013;93:547&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3846296</ArticleId><ArticleId IdType="pubmed">23571773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., DuMouchel W., LePendu P., Bauer-Mehren A., Ryan P., Shah N.H. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin. Pharmacol. Ther. 2013;93:539&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857139</ArticleId><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti N.P., Ye P.P., Daneshjou R., Altman R.B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 2012;4:125ra31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382018</ArticleId><ArticleId IdType="pubmed">22422992</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti N.P., Fernald G.H., Altman R.B. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J. Am. Med. Inform. Assoc. 2012;19:79&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240755</ArticleId><ArticleId IdType="pubmed">21676938</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J.D., et al. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput. Biol. 2012;8:e1002614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415435</ArticleId><ArticleId IdType="pubmed">22912565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill A.B. The environment and disease: association or causation. Proc. R. Soc. Med. 1965;58:295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1898525</ArticleId><ArticleId IdType="pubmed">14283879</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership, Health Outcomes of Interest Library.
&lt;
http://omop.org/HOI
&gt;
Accessed 24 July 2013.</Citation></Reference><Reference><Citation>Tisdale J., Miller D.Drug-Induced Diseases: Prevention, Detection, and Management2nd edn. (Bethesda, MD: American Society of Health-System Pharmacists; 2010</Citation></Reference><Reference><Citation>Whitaker H.J., Hocine M.N., Farrington C.P. The methodology of self-controlled case series studies. Stat. Methods Med. Res. 2009;18:7&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">18562396</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker H.J., Farrington C.P., Spiessens B., Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat. Med. 2006;25:1768&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pubmed">16220518</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D., Ryan P., Simpson S., Zorych I.Bayesian methods in pharmacovigilance. Bayesian Statistics 9.eds.Bernardo J.M.et al) (Oxford, UK Oxford University Press; 2011</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24551366</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2013</Volume><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Desiderata for healthcare integrated data repositories based on architectural comparison of three public repositories.</ArticleTitle><Pagination><StartPage>648</StartPage><EndPage>656</EndPage><MedlinePgn>648-56</MedlinePgn></Pagination><Abstract><AbstractText>Integrated data repositories (IDRs) are indispensable tools for numerous biomedical research studies. We compare three large IDRs (Informatics for Integrating Biology and the Bedside (i2b2), HMO Research Network's Virtual Data Warehouse (VDW) and Observational Medical Outcomes Partnership (OMOP) repository) in order to identify common architectural features that enable efficient storage and organization of large amounts of clinical data. We define three high-level classes of underlying data storage models and we analyze each repository using this classification. We look at how a set of sample facts is represented in each repository and conclude with a list of desiderata for IDRs that deal with the information storage model, terminology model, data integration and value-sets management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory for Informatics Development, NIH Clinical Center, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimino</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Laboratory for Informatics Development, NIH Clinical Center, Bethesda, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018511" MajorTopicYN="Y">Systems Integration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24551366</ArticleId><ArticleId IdType="pmc">PMC3900207</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mackenzie SL, Wyatt MC, Schuff R, Tenenbaum JD, Anderson N. Practices and perspectives on building integrated data repositories: results from a 2010 CTSA survey. J Am Med Inform Assoc. 2012 Jun 1;19(e1):e119&#x2013;e24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392848</ArticleId><ArticleId IdType="pubmed">22437072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimino JJ. Desiderata for controlled medical vocabularies in the twenty-first century. Methods Inf Med. 1998 Nov;37(4&#x2013;5):394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415631</ArticleId><ArticleId IdType="pubmed">9865037</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff SM, Rocha RA, Bray BE, Warner HR, Haug PJ. An event model of medical information representation. J Am Med Inform Assoc. 1995 Mar-Apr;2(2):116&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC116245</ArticleId><ArticleId IdType="pubmed">7743315</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Morgan MM, Barnett GO, Chueh HC. Optimizing healthcare research data warehouse design through past COSTAR query analysis. Proc AMIA Symp. 1999:892&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2232518</ArticleId><ArticleId IdType="pubmed">10566489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni PM. Metadata-driven software systems in biomedicine. New York: Springer; 2011.</Citation></Reference><Reference><Citation>Gilchrist J, Frize M, Ennett CM, Bariciak E. Performance Evaluation of Various Storage Formats for Clinical Data Repositories. Instrumentation and Measurement, IEEE Transactions on. 2011;60(10):3244&#x2013;52.</Citation></Reference><Reference><Citation>Sittig DF, Hazlehurst BL, Brown J, Murphy S, Rosenman M, Tarczy-Hornoch P, et al. A survey of informatics platforms that enable distributed comparative effectiveness research using multi-institutional heterogenous clinical data. Med Care. 2012 Jul;50(Suppl):S49&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415281</ArticleId><ArticleId IdType="pubmed">22692259</ArticleId></ArticleIdList></Reference><Reference><Citation>Marenco L, Tosches N, Crasto C, Shepherd G, Miller PL, Nadkarni PM. Achieving evolvable Web-database bioscience applications using the EAV/CR framework: recent advances. J Am Med Inform Assoc. 2003 Sep-Oct;10(5):444&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC212781</ArticleId><ArticleId IdType="pubmed">12807806</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Mendis M, Hackett K, Kuttan R, Pan W, Phillips LC, et al. Architecture of the open-source clinical research chart from Informatics for Integrating Biology and the Bedside. AMIA Annu Symp Proc. 2007:548&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655844</ArticleId><ArticleId IdType="pubmed">18693896</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohane IS, Churchill SE, Murphy SN. A translational engine at the national scale: informatics for integrating biology and the bedside. J Am Med Inform Assoc. 2012 Mar-Apr;19(2):181&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277623</ArticleId><ArticleId IdType="pubmed">22081225</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornbrook MC, Hart G, Ellis JL, Bachman DJ, Ansell G, Greene SM, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr. 2005;(35):12&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287881</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapter 4: Virtual Data Warehouse, Collaboration toolkit. Available from: http://www.hmoresearchnetwork.org/resources/toolkit/HMORN_CollaborationToolkit.pdf#4.</Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 2;153(9):600&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace WD, Cifuentes M, Valuck RJ, Staton EW, Brandt EC, West DR. An electronic practice-based network for observational comparative effectiveness research. Ann Intern Med. 2009 Sep 1;151(5):338&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638402</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser V, Rasmussen LV, Oberg R, Starren JB. Implementation of workflow engine technology to deliver basic clinical decision support functionality. BMC Med Res Methodol. 2011;11:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079703</ArticleId><ArticleId IdType="pubmed">21477364</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimino JJ, Ayres EJ. The clinical research data repository of the US National Institutes of Health. Stud Health Technol Inform. 2010;160(Pt 2):1299&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3408090</ArticleId><ArticleId IdType="pubmed">20841894</ArticleId></ArticleIdList></Reference><Reference><Citation>Chute CG, Beck SA, Fisk TB, Mohr DN. The Enterprise Data Trust at Mayo Clinic: a semantically integrated warehouse of biomedical data. J Am Med Inform Assoc. 2010 Mar-Apr;17(2):131&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000789</ArticleId><ArticleId IdType="pubmed">20190054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe HJ, Ferris TA, Hernandez PM, Weber SC. STRIDE--An integrated standards-based translational research informatics platform. AMIA Annu Symp Proc; 2009; 2009. pp. 391&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815452</ArticleId><ArticleId IdType="pubmed">20351886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox AB, Vawdrey DK, Chen YH, Forman B, Hripcsak G. The evolving use of a clinical data repository: facilitating data access within an electronic medical record. AMIA Annu Symp Proc; 2009; 2009. pp. 701&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815410</ArticleId><ArticleId IdType="pubmed">20351944</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath MM, Winfield S, Evans S, Slopek S, Shang H, Ferranti J. The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement. Journal of biomedical informatics. 2011 Apr;44(2):266&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063322</ArticleId><ArticleId IdType="pubmed">21130181</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Integrated Data Repositories   Available from:  http://clinfowiki.org/wiki/index.php/CIDR.</Citation></Reference><Reference><Citation>Baorto D, Li L, Cimino JJ. Practical experience with the maintenance and auditing of a large medical ontology. Journal of biomedical informatics. 2009 Jun;42(3):494&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508433</ArticleId><ArticleId IdType="pubmed">19285569</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton PD, Narus SP, Huff SM, Pryor TA, Haug PJ, Larkin T, et al. Building a comprehensive clinical information system from components. The approach at Intermountain Health Care. Methods Inf Med. 2003;42(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12695790</ArticleId></ArticleIdList></Reference><Reference><Citation>Natter MD, Quan J, Ortiz DM, Bousvaros A, Ilowite NT, Inman CJ, et al. An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc. 2012 Jun 25;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555330</ArticleId><ArticleId IdType="pubmed">22733975</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman D, Field T, Bredfeldt C, Hornbrook M, Bauck A, Tavel H, et al. PS2-51: Utilization Quality Assurance: Are We Better Yet? Clin Med Res. 2012 Aug;10(3):195&#x2013;6.</Citation></Reference><Reference><Citation>Fernandes L, Brandt M, Fletcher D, Grant K, Hatton L, Postal S, et al. Building an enterprise master person index. J AHIMA. 2004 Jan;75(1):56A&#x2013;D.</Citation><ArticleIdList><ArticleId IdType="pubmed">14748232</ArticleId></ArticleIdList></Reference><Reference><Citation>Waitman LR, Warren JJ, Manos EL, Connolly DW. Expressing observations from electronic medical record flowsheets in an i2b2 based clinical data repository to support research and quality improvement. AMIA Annu Symp Proc; 2011; 2011. pp. 1454&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243191</ArticleId><ArticleId IdType="pubmed">22195209</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson N, Abend A, Mandel A, Geraghty E, Gabriel D, Wynden R, et al. Implementation of a deidentified federated data network for population-based cohort discovery. J Am Med Inform Assoc. 2012 Jun 1;19(e1):e60&#x2013;e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392860</ArticleId><ArticleId IdType="pubmed">21873473</ArticleId></ArticleIdList></Reference><Reference><Citation>Integrating R efficiently to allow secure, interactive analysis within a clinical data warehouse, Use R! Conference Proceedings, 2012. Available from: http://biostat.mc.vanderbilt.edu/wiki/pub/Main/UseR-2012/141-Connolly.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25083251</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2042-0986</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Therapeutic advances in drug safety</Title><ISOAbbreviation>Ther Adv Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies.</ArticleTitle><Pagination><StartPage>53</StartPage><EndPage>62</EndPage><MedlinePgn>53-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/2042098613477445</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clinical studies that use observational databases, such as administrative claims and electronic health records, to evaluate the effects of medical products have become commonplace. These studies begin by selecting a particular study design, such as a case control, cohort, or self-controlled design, and different authors can and do choose different designs for the same clinical question. Furthermore, published papers invariably report the study design but do not discuss the rationale for the specific choice. Studies of the same clinical question with different designs, however, can generate different results, sometimes with strikingly different implications. Even within a specific study design, authors make many different analytic choices and these too can profoundly impact results. In this paper, we systematically study heterogeneity due to the type of study design and due to analytic choices within study design.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">We conducted our analysis in 10 observational healthcare databases but mostly present our results in the context of the GE Centricity EMR database, an electronic health record database containing data for 11.2 million lives. We considered the impact of three different study design choices on estimates of associations between bisphosphonates and four particular health outcomes for which there is no evidence of an association. We show that applying alternative study designs can yield discrepant results, in terms of direction and significance of association. We also highlight that while traditional univariate sensitivity analysis may not show substantial variation, systematic assessment of all analytical choices within a study design can yield inconsistent results ranging from statistically significant decreased risk to statistically significant increased risk. Our findings show that clinical studies using observational databases can be sensitive both to study design choices and to specific analytic choices within study design.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">More attention is needed to consider how design choices may be impacting results and, when possible, investigators should examine a wide array of possible choices to confirm that significant findings are consistently identified.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Professor and Chair, Department of Statistics, Columbia University, 1255 Amsterdam Ave., New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD and Janssen Research and Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD and Department of Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Drug Saf</MedlineTA><NlmUniqueID>101549074</NlmUniqueID><ISSNLinking>2042-0986</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">analysis</Keyword><Keyword MajorTopicYN="N">health outcomes</Keyword><Keyword MajorTopicYN="N">healthcare database</Keyword><Keyword MajorTopicYN="N">study design</Keyword></KeywordList><CoiStatement><b>Conflict of interest statement:</b> Drs Ryan, Stang, and Berlin are employees of Johnson &amp; Johnson, and Dr Ryan is a past employee of GlaxoSmithKline.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25083251</ArticleId><ArticleId IdType="pmc">PMC4110833</ArticleId><ArticleId IdType="doi">10.1177/2042098613477445</ArticleId><ArticleId IdType="pii">10.1177_2042098613477445</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brixner D., Said Q., Kirkness C., Oberg B., Ben-Joseph R., Oderda G. (2007) Assessment of cardiometabolic risk factors in a national primary care electronic health record database. Value Health 10: S29&#x2013;S36</Citation></Reference><Reference><Citation>Cardwell C., Abnet C., Cantwell M., Murray L. (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304: 657&#x2013;663</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513370</ArticleId><ArticleId IdType="pubmed">20699457</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford A., Cote C., Couto J., Daskiran M., Gunnarsson C., Haas K., et al. (2010) Comparison of GE centricity electronic medical record database and national ambulatory medical care survey findings on the prevalence of major conditions in the United States. Popul Health Manag 13: 139&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pubmed">20568974</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries F., De Vries C., Cooper C., Leufkens B., Van Staa T. (2006) Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the general practice research database. Int J Epidemiol 35: 1301&#x2013;1308</Citation><ArticleIdList><ArticleId IdType="pubmed">17053011</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon W., Solomon D. (2011) Bisphosphonates and esophageal cancer &#x2013; a pathway through the confusion. Nat Rev Rheumatol 7: 369&#x2013;372</Citation><ArticleIdList><ArticleId IdType="pubmed">21537362</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne J., Fireman B., Ryan P., Maclure M., Gerhard T., Toh S., et al. (2012) Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf 21(Suppl. 1): 32&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">22262591</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill J., Chen Y. (2008) Quality of lipid management in outpatient care: a national study using electronic health records. Am J Med Qual 23: 375&#x2013;381</Citation><ArticleIdList><ArticleId IdType="pubmed">18820142</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J., Czanner G., Reeves G., Watson J., Wise L., Beral V. (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case&#x2013;control analysis within a UK primary care cohort. BMJ 341: c4444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933354</ArticleId><ArticleId IdType="pubmed">20813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S. (2005) Multiple-bias modelling for analysis of observational data. J R Stat Soc A 168: 267&#x2013;306</Citation></Reference><Reference><Citation>Grosso A., Douglas I., Hingorani A., Macallister R., Smeeth L. (2009) Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 4: e4720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648983</ArticleId><ArticleId IdType="pubmed">19266096</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Diaz S., Varas-Lorenzo C., Garcia Rodriguez L. (2006) Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98: 266&#x2013;274</Citation><ArticleIdList><ArticleId IdType="pubmed">16611201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis J. (2005) Why most published research findings are false. PLoS Med 2: e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182327</ArticleId><ArticleId IdType="pubmed">16060722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lash T., Fox M., Fink A. (2009) Applying Quantitative Bias Analysis to Epidemiologic Data. New York: Springer</Citation></Reference><Reference><Citation>Loke Y., Kwok C., Singh S. (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342: d1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230110</ArticleId><ArticleId IdType="pubmed">21415101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayes L., Horwitz R., Feinstein A. (1988) A collection of 56 topics with contradictory results in case&#x2013;control research. Int J Epidemiol 17: 680&#x2013;685</Citation><ArticleIdList><ArticleId IdType="pubmed">3272133</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier C., Schlienger R., Kraenzlin M., Schlegel B., Jick H. (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283: 3205&#x2013;3210</Citation><ArticleIdList><ArticleId IdType="pubmed">10866867</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage J., Ryan P., Reich C., Hartzema A., Stang P. (2011) Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 19: 54&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrio M., Waller P., Shakir S. (2007) An analysis of the exclusion criteria used in observational pharmacoepidemiological studies. Pharmacoepidemiol Drug Saf 16: 329&#x2013;336</Citation><ArticleIdList><ArticleId IdType="pubmed">16741894</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C., Ryan P., Stang P., Rocca M. (2012) Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform 45: 689&#x2013;696</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P., Madigan D., Stang P., Overhage J., Racoosin J., Hartzema A. (2012) Empirical assessment of analytic methods for risk identification in observational healthcare data: results from the experiments of the observational medical outcomes partnership. Stat Med 31: 4401&#x2013;4415</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S., Rassen J., Glynn R., Avorn J., Mogun H., Brookhart M. (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20: 512&#x2013;522</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith G., Ebrahim S. (2001) Epidemiology &#x2013; is it time to call it a day? Int J Epidemiol 30: 1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pubmed">11171840</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang P., Ryan P., Dusetzina S., Hartzema A., Reich C., Overhage J., et al. (2011) Health outcomes of interest in observational data: issues in identifying definitions in the literature. Health Outcomes Res Med 3: e37&#x2013;e44</Citation></Reference><Reference><Citation>Stang P., Ryan P., Racoosin J., Overhage J., Hartzema A., Reich C., et al. (2010) Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med 153: 600&#x2013;606</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenland K., Greenland S. (2004) Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. Am J Epidemiol 160: 384&#x2013;392</Citation><ArticleIdList><ArticleId IdType="pubmed">15286024</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifiro G., Pariente A., Coloma P., Kors J., Polimeni G., Miremont-Salame G., et al. (2009) Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf 18: 1176&#x2013;1184</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Staa T., Wegman S., de Vries F., Leufkens B., Cooper C. (2001) Use of statins and risk of fractures. JAMA 285: 1850&#x2013;1855</Citation><ArticleIdList><ArticleId IdType="pubmed">11308398</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E., Altman D., Egger M., Pocock S., Gotzsche P., Vandenbroucke J., et al. (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61: 344&#x2013;349</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker H. (2008) The self controlled case series method. BMJ 337: a1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">18755768</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25328363</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1049-3301</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>ACM transactions on modeling and computer simulation : a publication of the Association for Computing Machinery</Title><ISOAbbreviation>ACM Trans Model Comput Simul</ISOAbbreviation></Journal><ArticleTitle>Massive parallelization of serial inference algorithms for a complex generalized linear model.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1145/2414416.2414791</ELocationID><Abstract><AbstractText>Following a series of high-profile drug safety disasters in recent years, many countries are redoubling their efforts to ensure the safety of licensed medical products. Large-scale observational databases such as claims databases or electronic health record systems are attracting particular attention in this regard, but present significant methodological and computational concerns. In this paper we show how high-performance statistical computation, including graphics processing units, relatively inexpensive highly parallel computing devices, can enable complex methods in large databases. We focus on optimization and massive parallelization of cyclic coordinate descent approaches to fit a conditioned generalized linear model involving tens of millions of observations and thousands of predictors in a Bayesian context. We find orders-of-magnitude improvement in overall run-time. Coordinate descent approaches are ubiquitous in high-dimensional statistics and the algorithms we propose open up exciting new methodological possibilities with the potential to significantly improve drug safety.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biomathematics University of California, Los Angeles, CA, USA ; Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA ; Department of Biostatistics, UCLA School of Public Health, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Shawn E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorych</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Pharmaceutical Research and Development Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM086887</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG006139</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACM Trans Model Comput Simul</MedlineTA><NlmUniqueID>101613245</NlmUniqueID><ISSNLinking>1049-3301</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25328363</ArticleId><ArticleId IdType="mid">NIHMS607868</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baskaran M, Bordawekar R. Optimizing sparse matrix-vector multiplication on GPUs. IBM research report RC24704. 2009.</Citation></Reference><Reference><Citation>Bell N, Garland M. Efficient sparse matrix-vector multiplication in CUDA. Proc. ACM/IEEE Conf. Supercomputing (SC), Portland; OR, USA. New York: ACM; 2009.</Citation></Reference><Reference><Citation>Chatterjee A, Lahiri S. Bootstrapping lasso estimators. Journal of the American Statistical Association. 2011;106:608&#x2013;625.</Citation></Reference><Reference><Citation>Coplan P, Noel R, Levitan B, Ferguson J, Mussen F. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit&#x2013;risk balance of medicines. Clinical Pharmacology &amp; Therapeutics. 2011;89:312&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">21160469</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis J, Cheng H, Delzell E, Fram D, Kilgore M, Saag K, Yun H, Du-Mouchel W. Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Medical care. 2008;46:969&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694945</ArticleId><ArticleId IdType="pubmed">18725852</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis J, Jr, Schnabel R. A view of unconstrained optimization. Handbooks in operations research and management science. 1989;1:1&#x2013;72.</Citation></Reference><Reference><Citation>d&#x2019;Esopo D. A convex programming procedure. Naval Research Logistics Quarterly. 1959;6:33&#x2013;42.</Citation></Reference><Reference><Citation>Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science. 1986;1:54&#x2013;75.</Citation></Reference><Reference><Citation>Farrington C. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51:228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">7766778</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk M, Westreich D, Wiesen C, St&#xfc;rmer T, Brookhart M, Davidian M. Doubly robust estimation of causal effects. American journal of epidemiology. 2011;173:761&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070495</ArticleId><ArticleId IdType="pubmed">21385832</ArticleId></ArticleIdList></Reference><Reference><Citation>Genkin A, Lewis D, Madigan D. Large-scale Bayesian logistic regression for text categorization. Technometrics. 2007;49:291&#x2013;304.</Citation></Reference><Reference><Citation>Harris M. Optimizing parallel reduction in CUDA. 2010. nVidia, online.</Citation></Reference><Reference><Citation>Jin H, Chen J, He H, Williams G, Kelman C, O&#x2019;Keefe C. Mining unexpected temporal associations: Applications in detecting adverse drug reactions. Information Technology in Biomedicine, IEEE Transactions on. 2008;12:488&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">18632329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulldorff M, Davis R, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Sequential Analysis. 2011;30:58&#x2013;78.</Citation></Reference><Reference><Citation>Kyung M, Gill J, Ghosh M, Casella G. Penalized regression, standard errors, and Bayesian lassos. Bayesian Analysis. 2010;5:369&#x2013;412.</Citation></Reference><Reference><Citation>Lange K. A gradient algorithm locally equivalent to the EM algorithm. Journal of the Royal Statistical Society, Series B. 1995;57:425&#x2013;437.</Citation></Reference><Reference><Citation>Lee A, Yau C, Giles M, Doucet A, Holmes C. On the utility of graphics cards to perform massively parallel simulation of advanced Monte Carlo methods. Journal of Computational and Graphical Statistics. 2010;19:769&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191530</ArticleId><ArticleId IdType="pubmed">22003276</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L. A conditional sequential sampling procedure for drug safety surveillance. Statistics in medicine. 2009;28:3124&#x2013;3138.</Citation><ArticleIdList><ArticleId IdType="pubmed">19691034</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan P, Simpson S, Zorych I. Bayesian methods in pharmacovigilance. In: Bernardo J, Bayarri M, Berger J, Dawid A, Heckerman D, Smith A, West M, editors. Bayesian Statistics 9. Oxford University Press; Oxford, UK: 2011. pp. 421&#x2013;438.</Citation></Reference><Reference><Citation>Nelder J, Wedderburn R. Generalized linear models. Journal of the Royal Statistical Society. Series A (General) 1972;135:370&#x2013;384.</Citation></Reference><Reference><Citation>Nor&#xe9;n G, Bate A, Hopstadius J, Star K, Edwards I. Temporal pattern discovery for trends and transient effects: its application to patient records. Proceeding of the 14th ACM SIGKDD international conference on Knowledge discovery and data mining; ACM, New York. 2008. pp. 963&#x2013;971.</Citation></Reference><Reference><Citation>Park M, Hastie T. L1-regularization path algorithm for generalized linear models. (Series B).Journal of the Royal Statistical Society. 2007;69:659.</Citation></Reference><Reference><Citation>Ryan P, Suchard M, Madigan D. Learning from epidemiology: a framework for interpreting large-scale observational database studies Under review. 2012.</Citation></Reference><Reference><Citation>Schneeweiss S, Rassen J, Glynn R, Avorn J, Mogun H, Brookhart M. Epidemiology. Vol. 20. Cambridge, Mass; 2009. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data; pp. 512&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Silberstein M, Schuster A, Geiger D, Patney A, Owens J. Efficient computation of sum-products on GPUs through software-managed cache. Proceedings of the 22nd Annual International Conference on Supercomputing; ACM, New York. 2008. pp. 309&#x2013;318.</Citation></Reference><Reference><Citation>Simpson S. Ph.D. thesis. COLUMBIA UNIVERSITY; 2011. Self-controlled methods for postmarketing drug safety surveillance in large-scale longitudinal data.</Citation></Reference><Reference><Citation>Stang P, Ryan P, Racoosin J, Overhage J, Hartzema A, Reich C, Welebob E, Scarnecchia T, Woodcock J. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Annals of internal medicine. 2010;153:600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M, Rambaut A. Many-core algorithms for statistical phylogenetics. Bioinformatics. 2009;25:1370&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682525</ArticleId><ArticleId IdType="pubmed">19369496</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M, Wang Q, Chan C, Frelinger J, Cron A, West M. Understanding GPU programming for statistical computation: Studies in massively parallel massive mixtures. Journal of Computational and Graphical Statistics. 2010;19:419&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945379</ArticleId><ArticleId IdType="pubmed">20877443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibbits M, Haran M, Liechty J. Parallel multivariate slice sampling. Statistics and Computing. 2011;21:415&#x2013;430.</Citation></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society, Series B. 1996;58:267&#x2013;268.</Citation></Reference><Reference><Citation>Veldhuizen T. Expression templates. C++ Report. 1995;7:26&#x2013;31.</Citation></Reference><Reference><Citation>Warga J. Minimizing certain convex functions. Journal of the Society for Industrial and Applied Mathematics. 1963;11:588&#x2013;593.</Citation></Reference><Reference><Citation>Wilkinson D. Parallel Bayesian computation. In: Kontoghiorghes E, editor. Handbook of Parallel Computing and Statistics. Chapman &amp; Hall/CRC; New York: 2006. pp. 481&#x2013;512.</Citation></Reference><Reference><Citation>Wu T, Chen Y, Hastie T, Sobel E, Lange K. Genome-wide association analysis by lasso penalized logistic regression. Bioinformatics. 2009;25:714&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732298</ArticleId><ArticleId IdType="pubmed">19176549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Lange K. Coordinate descent algorithms for lasso penalized regression. The Annals of Applied Statistics. 2008;2:224&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212875</ArticleId><ArticleId IdType="pubmed">22081779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Oles F. Text categorization based on regularized linear classification methods. Information Retrieval. 2001;4:5&#x2013;31.</Citation></Reference><Reference><Citation>Zhou H, Lange K, Suchard M. Graphics processing units and high-dimensional optimization. Statistical Science. 2010;25:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155776</ArticleId><ArticleId IdType="pubmed">21847315</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23900808</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0258</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Statistics in medicine</Title><ISOAbbreviation>Stat Med</ISOAbbreviation></Journal><ArticleTitle>Interpreting observational studies: why empirical calibration is needed to correct p-values.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>218</EndPage><MedlinePgn>209-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/sim.5925</ELocationID><Abstract><AbstractText>Often the literature makes assertions of medical product effects on the basis of ' p&#x2009;&lt;&#x2009;0.05'. The underlying premise is that at this threshold, there is only a 5% probability that the observed effect would be seen by chance when in reality there is no effect. In observational studies, much more than in randomized trials, bias and confounding may undermine this premise. To test this premise, we selected three exemplar drug safety studies from literature, representing a case-control, a cohort, and a self-controlled case series design. We attempted to replicate these studies as best we could for the drugs studied in the original articles. Next, we applied the same three designs to sets of negative controls: drugs that are not believed to cause the outcome of interest. We observed how often p&#x2009;&lt;&#x2009;0.05 when the null hypothesis is true, and we fitted distributions to the effect estimates. Using these distributions, we compute calibrated p-values that reflect the probability of observing the effect estimate under the null hypothesis, taking both random and systematic error into account. An automated analysis of scientific literature was performed to evaluate the potential impact of such a calibration. Our experiment provides evidence that the majority of observational studies would declare statistical significance when no effect is present. Empirical calibration was found to reduce spurious results to the desired 5% level. Applying these adjustments to literature suggests that at least 54% of findings with p&#x2009;&lt;&#x2009;0.05 are not actually statistically significant and should be reevaluated.</AbstractText><CopyrightInformation>&#xa9; 2013 The Authors. Statistics in Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands; Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>DuMouchel</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Med</MedlineTA><NlmUniqueID>8215016</NlmUniqueID><ISSNLinking>0277-6715</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>V83O1VOZ8L</RegistryNumber><NameOfSubstance UI="D007538">Isoniazid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="Y">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="Y">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007538" MajorTopicYN="N">Isoniazid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">calibration</Keyword><Keyword MajorTopicYN="N">hypothesis testing</Keyword><Keyword MajorTopicYN="N">negative controls</Keyword><Keyword MajorTopicYN="N">observational studies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23900808</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="doi">10.1002/sim.5925</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mayes LC, Horwitz RI, Feinstein AR. A collection of 56 topics with contradictory results in case-control research. International Journal of Epidemiology. 1988;17:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">3272133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology. 2011;22:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">21490505</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933354</ArticleId><ArticleId IdType="pubmed">20813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. Journal of the American Medical Association. 2010;304:657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513370</ArticleId><ArticleId IdType="pubmed">20699457</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JP. Why most published research findings are false. PLoS Medicine. 2005;2:e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182327</ArticleId><ArticleId IdType="pubmed">16060722</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology. 1996;143:1165&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">8633607</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41&#x2013;55.</Citation></Reference><Reference><Citation>Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. Canadian Medical Association Journal. 2011;183:E173&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042475</ArticleId><ArticleId IdType="pubmed">21220436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJ, Whitaker HJ, Farrington CP, Card TR, West J. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding. Alimentary Pharmacology &amp; Therapeutics. 2005;22:175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">16091054</ArticleId></ArticleIdList></Reference><Reference><Citation>McAfee AT, Ming EE, Seeger JD, Quinn SG, Ng EW, Danielson JD, Cutone JA, Fox JC, Walker AM. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiology and Drug Safety. 2006;15:444&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">16761308</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology. 2002;122:1822&#x2013;1828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12055590</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. American Journal of Gastroenterology. 2007;102:2437&#x2013;2443.</Citation><ArticleIdList><ArticleId IdType="pubmed">17662100</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, Everhart JE, Moseley RH, Terrault N, Ackerson L, Selby JV. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Archives of Internal Medicine. 2003;163:728&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639207</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham NS, Cohen DC, Rivers B, Richardson P. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Alimentary Pharmacology &amp; Therapeutics. 2006;24:299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16842456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper GS, Chak A, Lloyd LE, Yurchick PJ, Harper DL, Rosenthal GE. The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage. Gastrointestinal Endoscopy. 2000;51:423&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744813</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade SE, Gurwitz JH, Chan KA, Donahue JG, Beck A, Boles M, Buist DS, Goodman M, LaCroix AZ, Levin TR, Platt R. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. Journal of Clinical Epidemiology. 2002;55:310&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">11864803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisdale JE, Miller DA. Drug-Induced Diseases. Prevention, Detection, and Management, Bethesda, MD: American Society of Health-System Pharmacists; 2010.</Citation></Reference><Reference><Citation>Gustafson P, McCandless LC. Probabilistic approaches to better quantifying the results of epidemiologic studies. International Journal of Environmental Research and Public Health. 2010;7:1520&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872335</ArticleId><ArticleId IdType="pubmed">20617044</ArticleId></ArticleIdList></Reference><Reference><Citation>Efron B. Large-scale simultaneous hypothesis testing: the choice of a null hypothesis. Journal of the American Statistical Association. 2004;99:96&#x2013;104.</Citation></Reference><Reference><Citation>Langaas M, Lindqvist BH, Ferkingstad E. Estimating the proportion of true null hypotheses, with application to DNA microarray data. Journal of the Royal Statistical Society Series B. 2005;67:555&#x2013;572.</Citation></Reference><Reference><Citation>Strimmer K. A unified approach to false discovery rate estimation. BMC Bioinformatics. 2008;9:303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2475539</ArticleId><ArticleId IdType="pubmed">18613966</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">24068252</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-4357</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Biostatistics (Oxford, England)</Title><ISOAbbreviation>Biostatistics</ISOAbbreviation></Journal><ArticleTitle>Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature.</ArticleTitle><Pagination><StartPage>36</StartPage><EndPage>45</EndPage><MedlinePgn>36-9; discussion 39-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/biostatistics/kxt037</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD 20814, USAJanssen Research and Development LLC, Titusville, NJ 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Shahn</LastName><ForeName>Zach</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biostatistics</MedlineTA><NlmUniqueID>100897327</NlmUniqueID><ISSNLinking>1465-4644</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Biostatistics. 2014 Jan;15(1):1-12. doi: 10.1093/biostatistics/kxt007.</RefSource><PMID Version="1">24068246</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="Y">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005189" MajorTopicYN="Y">False Positive Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011642" MajorTopicYN="N">Publications</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24068252</ArticleId><ArticleId IdType="pmc">PMC3862211</ArticleId><ArticleId IdType="doi">10.1093/biostatistics/kxt037</ArticleId><ArticleId IdType="pii">kxt037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farrington C. P. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51(1):228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">7766778</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrington C. P., Nash J., Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology. 1996;143(11):1165&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">8633607</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S., Rassen J. A., Glynn R. J., Avorn J., Mogun H., Brookhart M. A. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Ryan P. B., Dumouchel W., Suchard M. A., Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Statistics in Medicine. 2013.  . http://onlinelibrary.wiley.com/doi/10.1002/sim.5925/abstract;jsessionid=600EF19932F674BCC9E2DEBF20110E76.d03t01 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24526267</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Exposure to oral fluoroquinolones and the risk of retinal detachment: retrospective analyses of two large healthcare databases.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>182</EndPage><MedlinePgn>171-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-014-0138-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A recent Canadian case-control study reported a 4.5-fold increased risk of retinal detachment (RD) during oral fluoroquinolone use. Of the fluoroquinolone-exposed cases, 83 % were exposed to ciprofloxacin. We sought to replicate this finding, and assess whether it applied to all fluoroquinolones.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In two large US healthcare databases, we performed three case-control analyses: one replicating the recent study; one addressing additional potential confounders; and one that increased sample size by dropping the Canadian study's requirement for a prior ophthalmologist visit. We also performed a self-controlled case-series (SCCS) analysis in which each subject served as his or her own comparator.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the replication case-control analyses, the adjusted odds ratios (ORs) for any exposure to fluoroquinolones or ciprofloxacin were approximately 1.2 in both databases, and were statistically significant, and the ORs for current exposure were modestly above 1 in one database, modestly below 1 in the other, and not statistically significant. In the other case-control analyses, the ORs were close to 1. In a post hoc age-stratified case-control analysis, we observed an association of RD with fluoroquinolone exposure among older subjects in one of the two databases. All estimates from the SCCS analyses were below 1.2 and none was statistically significant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present study does not confirm the recent Canadian study's finding of a strong relationship between RD and current exposure to fluoroquinolones. Instead, it found a modest association between RD and current or any exposure to fluoroquinolones in the case-control analyses, and no association in the SCCS analyses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fife</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutical Research and Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA, dfife@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Vivienne</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Levy-Clarke</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024841" MajorTopicYN="N">Fluoroquinolones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012163" MajorTopicYN="N">Retinal Detachment</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24526267</ArticleId><ArticleId IdType="pmc">PMC3936132</ArticleId><ArticleId IdType="doi">10.1007/s40264-014-0138-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307:1414&#x2013;1419. doi: 10.1001/jama.2012.383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.383</ArticleId><ArticleId IdType="pubmed">22474205</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternak B, Svanstrom H, Melbye M, Hviid A. Association between oral fluoroquinolone use and retinal detachment. JAMA. 2013;310:2184&#x2013;2190. doi: 10.1001/jama.2013.280500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.280500</ArticleId><ArticleId IdType="pubmed">24281462</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan P. What can we really learn from observational studies? The need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research. Epidemiology. 2011;22:629&#x2013;631. doi: 10.1097/EDE.0b013e318228ca1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e318228ca1d</ArticleId><ArticleId IdType="pubmed">21811110</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178:645&#x2013;651. doi: 10.1093/aje/kwt010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt010</ArticleId><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126:356&#x2013;358. doi: 10.1093/aje/126.2.356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/126.2.356</ArticleId><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz SG, Flynn HW, Jr, Mieler WF. Update on retinal detachment surgery. Curr Opin Ophthalmol. 2013;24:255&#x2013;261. doi: 10.1097/ICU.0b013e32835f8e6b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICU.0b013e32835f8e6b</ArticleId><ArticleId IdType="pubmed">23429600</ArticleId></ArticleIdList></Reference><Reference><Citation>Han DP, Szabo A. Flashes, floaters, and oral fluoroquinolones. Arch Ophthalmol. Epub 2012 Sep 1:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183446</ArticleId><ArticleId IdType="pubmed">23307216</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24635221</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2014</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2796</ISSN><JournalIssue CitedMedium="Internet"><Volume>275</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of internal medicine</Title><ISOAbbreviation>J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?</ArticleTitle><Pagination><StartPage>551</StartPage><EndPage>561</EndPage><MedlinePgn>551-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.12159</ELocationID><Abstract><AbstractText>A growing number of international initiatives (e.g. EU-ADR, Sentinel, OMOP, PROTECT and VAESCO) are based on the combined use of multiple healthcare databases for the conduct of active surveillance studies in the area of drug and vaccine safety. The motivation behind combining multiple healthcare databases is the earlier detection and validation, and hence earlier management, of potential safety issues. Overall, the combination of multiple healthcare databases increases statistical sample size and heterogeneity of exposure for postmarketing drug and vaccine safety surveillance, despite posing several technical challenges. Healthcare databases generally differ by underlying healthcare systems, type of information collected, drug/vaccine and medical event coding systems and language. Therefore, harmonization of medical data extraction through homogeneous coding algorithms across highly different databases is necessary. Although no standard procedure is currently available to achieve this, several approaches have been developed in recent projects. Another main challenge involves choosing the work models for data management and analyses whilst respecting country-specific regulations in terms of data privacy and anonymization. Dedicated software (e.g. Jerboa) has been produced to deal with privacy issues by sharing only anonymized and aggregated data using a common data model. Finally, storage and safe access to the data from different databases requires the development of a proper remote research environment. The aim of this review is to provide a summary of the potential, disadvantages, methodological issues and possible solutions concerning the conduct of postmarketing multidatabase drug and vaccine safety studies, as demonstrated by several international initiatives.</AbstractText><CopyrightInformation>&#xa9; 2014 The Association for the Publication of the Journal of Internal Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trifir&#xf2;</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coloma</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Romio</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mosseveld</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Weibel</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bonhoeffer</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>van der Lei</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sturkenboom</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intern Med</MedlineTA><NlmUniqueID>8904841</NlmUniqueID><ISSNLinking>0954-6820</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020380" MajorTopicYN="N">Needs Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">claims database</Keyword><Keyword MajorTopicYN="N">drug monitoring</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">postmarketing</Keyword><Keyword MajorTopicYN="N">product surveillance</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24635221</ArticleId><ArticleId IdType="doi">10.1111/joim.12159</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24713590</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Toward enhanced pharmacovigilance using patient-generated data on the internet.</ArticleTitle><Pagination><StartPage>239</StartPage><EndPage>246</EndPage><MedlinePgn>239-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/clpt.2014.77</ELocationID><Abstract><AbstractText>The promise of augmenting pharmacovigilance with patient-generated data drawn from the Internet was called out by a scientific committee charged with conducting a review of the current and planned pharmacovigilance practices of the US Food and Drug Administration (FDA). To this end, we present a study on harnessing behavioral data drawn from Internet search logs to detect adverse drug reactions (ADRs). By analyzing search queries collected from 80 million consenting users and by using a widely recognized benchmark of ADRs, we found that the performance of ADR detection via search logs is comparable and complementary to detection based on the FDA's adverse event reporting system (AERS). We show that by jointly leveraging data from the AERS and search logs, the accuracy of ADR detection can be improved by 19% relative to the use of each data source independently. The results suggest that leveraging nontraditional sources such as online search logs could supplement existing pharmacovigilance approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>White</LastName><ForeName>R W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Microsoft Research, Redmond, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harpaz</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>N H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuMouchel</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>1] Oracle Health Sciences, Burlington, Massachusetts, USA [2] Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horvitz</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Microsoft Research, Redmond, Washington, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM101430</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG004028</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54-HG004028</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM101430-01A1</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Pharmacol Ther. 2014 Aug;96(2):149-50. doi: 10.1038/clpt.2014.115.</RefSource><PMID Version="1">25056395</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="N">Data Mining</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="N">Internet</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>R.W.W. and E.H. are employed by Microsoft Research. W.D. is employed by Oracle. R.H. was a visiting researcher at Microsoft Research while conducting portions of this research. N.H.S. declared no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24713590</ArticleId><ArticleId IdType="mid">NIHMS596702</ArticleId><ArticleId IdType="pmc">PMC4111778</ArticleId><ArticleId IdType="doi">10.1038/clpt.2014.77</ArticleId><ArticleId IdType="pii">clpt201477</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lazarou, J., Pomeranz, B.H. &amp; Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200&#x2013;1205 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9555760</ArticleId></ArticleIdList></Reference><Reference><Citation>Classen, D.C., Pestotnik, S.L., Evans, R.S., Lloyd, J.F. &amp; Burke, J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301&#x2013;306 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9002492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad, S.R. Adverse drug event monitoring at the Food and Drug Administration. J. Gen. Intern. Med. 18, 57&#x2013;60 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1494803</ArticleId><ArticleId IdType="pubmed">12534765</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz, R., DuMouchel, W., Shah, N.H., Madigan, D., Ryan, P. &amp; Friedman, C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Ther. 91, 1010&#x2013;1021 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P. &amp; Shah, N.H. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin. Pharmacol. Ther. 93, 539&#x2013;546 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857139</ArticleId><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt, R., Wilson, M., Chan, K.A., Benner, J.S., Marchibroda, J. &amp; McClellan, M. The new Sentinel network &#x2014; improving the evidence of medical-product safety. New Eng J Med. 361, 645&#x2013;647 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19635947</ArticleId></ArticleIdList></Reference><Reference><Citation>Avorn, J. &amp; Schneeweiss, S. Managing drug-risk information &#x2014; what to do with all those new numbers. New Eng J Med. 361, 647&#x2013;649 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19635948</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang, P.E. et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann. Intern. Med. 153, 600&#x2013;606 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>McClellan, M. Drug safety reform at the FDA&#x2014;pendulum swing or systematic improvement? N. Engl. J. Med. 356, 1700&#x2013;1702 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17435081</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma, P.M. et al.; EU-ADR Consortium. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol. Drug Saf. 20, 1&#x2013;11 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Science Board Subcommittee: Review of the FDA/CDER Pharmacovigilance Program (Prepared for the FDA Science Board May 2011). &lt;http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ScienceBoardtotheFoodandDrugAdministration/UCM276888.pdf&gt;. Accessed November 2013.</Citation></Reference><Reference><Citation>Leaman, R., Wojtulewicz, L., Sullivan, R., Skariah, A., Yang, J. &amp; Gonzalez, G. Towards Internet-age pharmacovigilance: extracting adverse drug reactions from user posts in health-related social networks. In Proceedings of the 2010 Workshop on Biomedical Natural Language Processing, Uppsala, Sweden, 15 July 2010, 117&#x2013;125.</Citation></Reference><Reference><Citation>Wicks, P., Vaughan, T.E., Massagli, M.P. &amp; Heywood, J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat. Biotechnol. 29, 411&#x2013;414 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21516084</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). Use of the Internet for Health Information: United States, 2009. &lt;http://www.cdc.gov/nchs/data/databriefs/db66.htm&gt;. Accessed November 2013.</Citation></Reference><Reference><Citation>Pew Research Center. Pew Internet &amp; American Life Project: Health Online 2013. &lt;http://www.pewinternet.org/~/media/Files/Reports/2013/Pew%20Internet%20Health%20Online%20report.pdf&gt;. Accessed November 2013.</Citation></Reference><Reference><Citation>Ginsberg, J., Mohebbi, M.H., Patel, R.S., Brammer, L., Smolinski, M.S. &amp; Brilliant, L. Detecting influenza epidemics using search engine query data. Nature 457, 1012&#x2013;1014 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19020500</ArticleId></ArticleIdList></Reference><Reference><Citation>White, R.W., Tatonetti, N.P., Shah, N.H., Altman, R.B. &amp; Horvitz, E. Web-scale pharmacovigilance: listening to signals from the crowd. J. Am. Med. Inform. Assoc. 20, 404&#x2013;408 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628066</ArticleId><ArticleId IdType="pubmed">23467469</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis, T.A., Lavori, P.W., Bailar, J.C. 3rd &amp; Polansky, M. Crossover and self-controlled designs in clinical research. N. Engl. J. Med. 310, 24&#x2013;31 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6689736</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership (OMOP). &lt;http://omop.org/&gt;. Accessed November 2013.</Citation></Reference><Reference><Citation>Trifir&#xf2;, G. et al.; EU-ADR group. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol. Drug Saf. 18, 1176&#x2013;1184 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel, W. &amp; Pregibon, D. Empirical bayes screening for multi-item associations. Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, San Francisco, CA, 26-29 August 2001, 67&#x2013;76.</Citation></Reference><Reference><Citation>Szarfman, A., Machado, S.G. &amp; O&#x2019;Neill, R.T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA&#x2019;s spontaneous reports database. Drug Saf. 25, 381&#x2013;392 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12071774</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez, Y., Hidalgo, A., Maignen, F. &amp; Slattery, J. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 33, 475&#x2013;487 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20486730</ArticleId></ArticleIdList></Reference><Reference><Citation>Almenoff, J.S., LaCroix, K.K., Yuen, N.A., Fram, D. &amp; DuMouchel, W. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf. 29, 875&#x2013;887 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16970511</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin, C. et al. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker. Pharmacoepidemiol. Drug Saf. 21, 622&#x2013;630 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21994119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan, P.B., Madigan, D., Stang, P.E., Marc, O.J., Racoosin, J.A. &amp; Hartzema, A.G. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat. Med. 31, 4401&#x2013;4415 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg, A.M., Reisinger, S.J., Pearson, R.K., O&#x2019;Hara, D.J. &amp; Hall, K. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Inf. J. 41, 633&#x2013;643 (2007).</Citation></Reference><Reference><Citation>Harpaz, R., DuMouchel, W., LePendu, P. &amp; Shah, N.H. Empirical Bayes model to combine signals of adverse drug reactions. Proceedings of 2013 ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD&#x2019;13), Chicago, IL, 11-14 August.</Citation></Reference><Reference><Citation>Harpaz, R. et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J. Am. Med. Inform. Assoc. 20, 413&#x2013;419 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>LePendu, P. et al. Pharmacovigilance using clinical notes. Clin. Pharmacol. Ther. 93, 547&#x2013;555 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3846296</ArticleId><ArticleId IdType="pubmed">23571773</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty, K.D. &amp; Dalal, S.R. Using information mining of the medical literature to improve drug safety. J. Am. Med. Inform. Assoc. 18, 668&#x2013;674 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168306</ArticleId><ArticleId IdType="pubmed">21546507</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouliot, Y., Chiang, A.P. &amp; Butte, A.J. Predicting adverse drug reactions using publicly available PubChem BioAssay data. Clin. Pharmacol. Ther. 90, 90&#x2013;99 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464971</ArticleId><ArticleId IdType="pubmed">21613989</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar, S., Harpaz, R., Chase, H.S., Costanzi, S., Rabadan, R. &amp; Friedman, C. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J. Am. Med. Inform. Assoc. 18 (suppl. 1), i73&#x2013;i80 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241177</ArticleId><ArticleId IdType="pubmed">21946238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan, P.B., Schuemie, M.J., Welebob, E., Duke, J., Valentine, S. &amp; Hartzema, A.G. Defining a reference set to support methodological research in drug safety. Drug Saf. 36 (suppl. 1), S33&#x2013;S47 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan, P.B. et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 36 (suppl. 1), S143&#x2013;S158 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Caster, O., Nor&#xe9;n, G.N., Madigan, D. &amp; Bate, A. Large-scale regression-based pattern discovery: the example of screening the WHO global drug safety database. Stat. Anal. Data Min. 3, 197&#x2013;208 (2010).</Citation></Reference><Reference><Citation>Cami, A., Arnold, A., Manzi, S. &amp; Reis, B. Predicting adverse drug events using pharmacological network models. Science Translational Med. 3, 114ra127 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22190238</ArticleId></ArticleIdList></Reference><Reference><Citation>Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT). &lt;http://www.ihtsdo.org/snomed-ct/&gt;. Accessed November 2013.</Citation></Reference><Reference><Citation>RxNorm. &lt;http://www.nlm.nih.gov/research/umls/rxnorm/&gt;. Accessed November 2013.</Citation></Reference><Reference><Citation>Whetzel, P.L. et al. BioPortal: enhanced functionality via new Web services from the National Center for Biomedical Ontology to access and use ontologies in software applications. Nucleic Acids Res. 39, W541&#x2013;W545 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125807</ArticleId><ArticleId IdType="pubmed">21672956</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeferman, D. &amp; Berger, A. Agglomerative clustering of a search engine query log. Proceedings of the Sixth ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, Boston, Massachusetts, 20 August 2000.</Citation></Reference><Reference><Citation>Graham, P.L., Mengersen, K. &amp; Morton, A.P. Confidence limits for the ratio of two rates based on likelihood scores: non-iterative method. Stat. Med. 22, 2071&#x2013;2083 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12802823</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin, X. et al. pROC: an open-source package for R and S plus to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24780722</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>pSCANNER: patient-centered Scalable National Network for Effectiveness Research.</ArticleTitle><Pagination><StartPage>621</StartPage><EndPage>626</EndPage><MedlinePgn>621-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/amiajnl-2014-002751</ELocationID><Abstract><AbstractText>This article describes the patient-centered Scalable National Network for Effectiveness Research (pSCANNER), which is part of the recently formed PCORnet, a national network composed of learning healthcare systems and patient-powered research networks funded by the Patient Centered Outcomes Research Institute (PCORI). It is designed to be a stakeholder-governed federated network that uses a distributed architecture to integrate data from three existing networks covering over 21 million patients in all 50 states: (1) VA Informatics and Computing Infrastructure (VINCI), with data from Veteran Health Administration's 151 inpatient and 909 ambulatory care and community-based outpatient clinics; (2) the University of California Research exchange (UC-ReX) network, with data from UC Davis, Irvine, Los Angeles, San Francisco, and San Diego; and (3) SCANNER, a consortium of UCSD, Tennessee VA, and three federally qualified health systems in the Los Angeles area supplemented with claims and health information exchange data, led by the University of Southern California. Initial use cases will focus on three conditions: (1) congestive heart failure; (2) Kawasaki disease; (3) obesity. Stakeholders, such as patients, clinicians, and health service researchers, will be engaged to prioritize research questions to be answered through the network. We will use a privacy-preserving distributed computation model with synchronous and asynchronous modes. The distributed system will be based on a common data model that allows the construction and evaluation of distributed multivariate models for a variety of statistical analyses.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ohno-Machado</LastName><ForeName>Lucila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine and Clinical Translational Research Institute, University of California San Diego, La Jolla, California, USA Division of Health Services Research &amp; Development, Veterans Affairs, San Diego Healthcare System, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agha</LastName><ForeName>Zia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Health Services Research &amp; Development, Veterans Affairs, San Diego Healthcare System, La Jolla, California, USA Division of Internal Medicine, Department of Medicine, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Douglas S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA Department of Health, RAND Corporation, Santa Monica, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahm</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Health Information Technology Department, Institute for Clinical and Translational Science, University of California Irvine, Orange, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Michele E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine and Clinical Translational Research Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doctor</LastName><ForeName>Jason N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Davera</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Health and Technology, University of California Davis, Davis, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahlon</LastName><ForeName>Maninder K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine &amp; Clinical and Translational Science Institute, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Katherine K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Betty Irene Moore School of Nursing, University of California Davis, Davis, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogarth</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Internal Medicine, University of California Davis, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Research &amp; Development Service, Tennessee Valley Healthcare System, Veterans Health Administration, Nashville, Tennessee, USA Division of General Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Health, RAND Corporation, Santa Monica, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nebeker</LastName><ForeName>Jonathan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure (VINCI) and Geriatric Research Education and Clinical Center (GRECC), Veterans Health Administration, Salt Lake City, Utah, USA Department of Medicine, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>pSCANNER team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1TR000124</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HL108460</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR000002</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HS019913</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC4 AG039115</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54HL108460</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000124</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RC4AG039115-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HS019913</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR000153</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000153</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR000004</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000002</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000100</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000004</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR000100</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002864</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002747</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002758</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002764</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002744</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002746</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002743</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002827</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002740</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002727</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002745</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002759</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002756</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003195" MajorTopicYN="Y">Computer Communication Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003219" MajorTopicYN="N">Confidentiality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="Y">Patient-Centered Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014493" MajorTopicYN="N">United States Department of Veterans Affairs</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical data research network</Keyword><Keyword MajorTopicYN="N">comparative effectiveness research</Keyword><Keyword MajorTopicYN="N">distributed analysis</Keyword><Keyword MajorTopicYN="N">patient-centered research</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Resnic</LastName><ForeName>Frederic</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khodyakov</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armstead</LastName><ForeName>Lattice</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagler</LastName><ForeName>Travis</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morley</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phillips</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heber</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Zhaoping</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ong</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Ayan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zachariah</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jane C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniels</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doan</LastName><ForeName>Son</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farcas</LastName><ForeName>Claudiu</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germann-Kurtz</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiaoqian</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyeon-Eui</ForeName><Initials>HE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Paulina</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taras</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremoulet</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Shuang</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Wenhong</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizk-Jackson</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Arcy</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kesselman</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knight</LastName><ForeName>Tara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlman</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidenreich</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rifkin</LastName><ForeName>Dena</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stepnowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zamora</LastName><ForeName>Tania</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Lewis J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scehnet</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sauer</LastName><ForeName>Brian C</ForeName><Initials>BC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Facelli</LastName><ForeName>Julio C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gouripeddi</LastName><ForeName>Ram K</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denton</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>FitzHenry</LastName><ForeName>Fern</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fly</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messina</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minter</LastName><ForeName>Freneka</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nookala</LastName><ForeName>Lalit</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Heidi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Speroff</LastName><ForeName>Theodore</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Westerman</LastName><ForeName>Dax</ForeName><Initials>D</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24780722</ArticleId><ArticleId IdType="pmc">PMC4078293</ArticleId><ArticleId IdType="doi">10.1136/amiajnl-2014-002751</ArticleId><ArticleId IdType="pii">amiajnl-2014-002751</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Observational Medical Outcomes Partnership: Common Data Model Specifications Version 4.0. 2012</Citation></Reference><Reference><Citation>Kohane IS, Churchill SE, Murphy SN. A translational engine at the national scale: informatics for integrating biology and the bedside. J Am Med Inform Assoc 2012;19:181&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277623</ArticleId><ArticleId IdType="pubmed">22081225</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Sarwate AD, Ohno-Machado L. Privacy technology to support data sharing for comparative effectiveness research: a systematic review. Med Care 2013;51(8 Suppl 3):S58&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728160</ArticleId><ArticleId IdType="pubmed">23774511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KK, McGraw D, Mamo L, et al. Development of a privacy and security policy framework for a multistate comparative effectiveness research network. Med Care 2013;51(8 Suppl 3):S66&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pubmed">23774516</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling LM, Kwan BM, Drolshagen CT, et al. 
Scalable Architecture for Federated Translational Inquiries Network (SAFTINet) Technology Infrastructure for a Distributed Data Network. eGEMs
2013;1. http://dx.doi.org/10.13063/2327-9214.1027%5Bpublished Online First: Epub Date</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1027%5Bpublished</ArticleId><ArticleId IdType="pmc">PMC4371513</ArticleId><ArticleId IdType="pubmed">25848567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamo LA, Browe DK, Logan HM, et al. Patient Informed Governance of Distributed Research Networks: Results and Discussion from Six Patient Focus Groups. Washington, DC: American Medical Informatics Association Annual Symposium, 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900224</ArticleId><ArticleId IdType="pubmed">24551383</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533&#x2013;44</Citation><ArticleIdList><ArticleId IdType="pubmed">15302199</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalkey N, Helmer O. An experimental application of the Delphi method to use of experts. Manag Sci 1963;9:428&#x2013;76</Citation></Reference><Reference><Citation>Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast 1999;15:353&#x2013;75</Citation></Reference><Reference><Citation>Dalal S, Khodyakov D, Srinivasan R, et al. ExpertLens: a system for eliciting opinions from a large pool of non-collocated experts with diverse knowledge. Technol Forecast Soc Change 2011;78:1426&#x2013;44</Citation></Reference><Reference><Citation>Khodyakov D, Hempel S, Rubenstein L, et al. Conducting online expert panels: a feasibility and experimental replicability study. BMC Med Res Methodol 2011;11:174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3313865</ArticleId><ArticleId IdType="pubmed">22196011</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeker D, Skeels C, Pearlman L, et al. A System and User Interface for Standardized Preparation of Analytic Data Sets. Bethesda, MD: Observational Medical Outcomes Partnership Annual Symposium, 2013</Citation></Reference><Reference><Citation>Ogunyemi OI, Meeker D, Kim HE, et al. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Med Care 2013;51(8 Suppl 3):S45&#x2013;52</Citation><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012;19: 54&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, et al. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform 2012;45:689&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med 2012;31:4401&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Brown J, Dahm L, et al. Pains and palliation in distributed research networks: lessons from the field AMIA summit on clinical research informatics. American Medical Informatics Association, 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845789</ArticleId><ArticleId IdType="pubmed">24303246</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeker D, Hussey S, Shetty K, et al. Project Report: Integration of Structured Evidence and Data into eMeasure Development, Office of the National Coordinator for Health Information Technology: Office Of the National Coordinator, 2013</Citation></Reference><Reference><Citation>Meeker D, Pearlman L, Doctor JN. Data quality in multisite research networks. Baltimore, MD: AcademyHealth Annual Research Meeting, 2013</Citation></Reference><Reference><Citation>Kim KK, Browe DK, Logan HC, et al. Data governance requirements for distributed clinical research networks: triangulating perspectives of diverse stakeholders. J Am Med Inform Assoc 2014;21:714&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078279</ArticleId><ArticleId IdType="pubmed">24302285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado L, Alipahan N, Day ME, et al. 
Comprehensive Inventory of Research Networks: Clinical Data Research Networks, Patient-Powered Research Networks, and Patient Registries. 2013. 
http://www.pcori.org/assets/2013/06/PCORI-Comprehensive-Inventory-Research-Networks-061213.pdf</Citation></Reference><Reference><Citation>Wu Y, Jiang X, Kim J, et al. Grid Binary LOgistic REgression (GLORE): building shared models without sharing data. J Am Med Inform Assoc 2012;19:758&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422844</ArticleId><ArticleId IdType="pubmed">22511014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Jiang X, Ohno-Machado L. Preserving Institutional Privacy in Distributed binary Logistic Regression. AMIA Annu Symp Proc 2012;2012:1450&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540539</ArticleId><ArticleId IdType="pubmed">23304425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado L. To share or not to share: that is not the question. Sci Transl Med 2012;4:165cm15</Citation><ArticleIdList><ArticleId IdType="pubmed">23253606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Jiang X, Wu Y, et al. EXpectation Propagation LOgistic REgRession (EXPLORER): distributed privacy-preserving online model learning. J Biomed Inform 2013;46:480&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676314</ArticleId><ArticleId IdType="pubmed">23562651</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheny ME, Morrow DA, Ohno-Machado L, et al. Validation of an automated safety surveillance system with prospective, randomized trial data. Med Decis Making 2009;29:247&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743924</ArticleId><ArticleId IdType="pubmed">19015285</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheny ME, Normand SL, Gross TP, et al. Evaluation of an automated safety surveillance system using risk adjusted sequential probability ratio testing. BMC Med Inform Decis Mak 2011;11:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262755</ArticleId><ArticleId IdType="pubmed">22168892</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnic FS, Gross TP, Marinac-Dabic D, et al. Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA 2010;304:2019&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5130290</ArticleId><ArticleId IdType="pubmed">21063011</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W, Li P, Wang S, et al. WebGLORE: a web service for Grid LOgistic REgression. Bioinformatics 2013;29:3238&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842761</ArticleId><ArticleId IdType="pubmed">24072732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner J, Xiong L, Xiao Y, et al. SHARE: system design and case studies for statistical health information release. J Am Med Inform Assoc 2013;20:109&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555328</ArticleId><ArticleId IdType="pubmed">23059729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed N, Jiang X, Chen R, et al. Privacy-preserving heterogeneous health data sharing. J Am Med Inform Assoc 2013;20:462&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628047</ArticleId><ArticleId IdType="pubmed">23242630</ArticleId></ArticleIdList></Reference><Reference><Citation>Que J, Jiang X, Ohno-Machado L. A collaborative framework for Distributed Privacy-Preserving Support Vector Machine learning. AMIA Annu Symp Proc 2012;2012:1350&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540462</ArticleId><ArticleId IdType="pubmed">23304414</ArticleId></ArticleIdList></Reference><Reference><Citation>Pautasso C, Zimmerman O, Leymann F. RESTful web services vs. &#x201c;big&#x201d; web services: making the right architectural decision. 17th international conference on World Wide Web, New York, NY, 2008</Citation></Reference><Reference><Citation>Serme G, de Oliveira AS, Massiera J, et al. Enabling message security for RESTful services. Web Services (ICWS), 2012 IEEE 19th International Conference on; 24&#x2013;29 June 2012; Honolulu, HI, 2012</Citation></Reference><Reference><Citation>Boxwala AA, Kim J, Grillo JM, et al. Using statistical and machine learning to help institutions detect suspicious access to electronic health records. J Am Med Inform Assoc 2011;18:498&#x2013;505</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128412</ArticleId><ArticleId IdType="pubmed">21672912</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Gainer V, Mendis M, et al. Strategies for maintaining patient privacy in i2b2. J Am Med Inform Assoc 2011;18(Suppl 1):i103&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241166</ArticleId><ArticleId IdType="pubmed">21984588</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24821737</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>PEDSnet: a National Pediatric Learning Health System.</ArticleTitle><Pagination><StartPage>602</StartPage><EndPage>606</EndPage><MedlinePgn>602-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/amiajnl-2014-002743</ELocationID><Abstract><AbstractText>A learning health system (LHS) integrates research done in routine care settings, structured data capture during every encounter, and quality improvement processes to rapidly implement advances in new knowledge, all with active and meaningful patient participation. While disease-specific pediatric LHSs have shown tremendous impact on improved clinical outcomes, a national digital architecture to rapidly implement LHSs across multiple pediatric conditions does not exist. PEDSnet is a clinical data research network that provides the infrastructure to support a national pediatric LHS. A consortium consisting of PEDSnet, which includes eight academic medical centers, two existing disease-specific pediatric networks, and two national data partners form the initial partners in the National Pediatric Learning Health System (NPLHS). PEDSnet is implementing a flexible dual data architecture that incorporates two widely used data models and national terminology standards to support multi-institutional data integration, cohort discovery, and advanced analytics that enable rapid learning.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margolis</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>L Charles</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsolo</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Beccaro</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Seattle Children's Hospital, Seattle, Washington, USA Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finkelstein</LastName><ForeName>Jonathan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of General Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milov</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Nemours Children's Hospital and the College of Medicine, University of Central Florida, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieland</LastName><ForeName>Veronica J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children's Hospital and Departments of Pediatrics and Statistics, The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Bryan A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Feliciano B</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital Colorado, University of Colorado and the Colorado Clinical and Translational Sciences Institute, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01HS019912</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HS019912</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HS022974</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01HS022974</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001082</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002864</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002747</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002758</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002764</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002744</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002746</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002827</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002740</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002727</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002751</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002745</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002759</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/amiajnl-2014-002756</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003195" MajorTopicYN="Y">Computer Communication Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="N">Information Dissemination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="N">Medical Record Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="Y">Patient-Centered Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010372" MajorTopicYN="Y">Pediatrics</DescriptorName><QualifierName UI="Q000193" MajorTopicYN="N">education</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="N">Vocabulary, Controlled</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">comparative effectivness research</Keyword><Keyword MajorTopicYN="N">data sharing</Keyword><Keyword MajorTopicYN="N">distributed databases</Keyword><Keyword MajorTopicYN="N">hypoplastic left heart syndrome</Keyword><Keyword MajorTopicYN="N">inflammatory bowel diseases</Keyword><Keyword MajorTopicYN="N">obesity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24821737</ArticleId><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="doi">10.1136/amiajnl-2014-002743</ArticleId><ArticleId IdType="pii">amiajnl-2014-002743</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van der Lee JH, Mokkink LB, Grootenhuis MA, et al. Definitions and measurement of chronic health conditions in childhood: a systematic review. JAMA 2007;297:2741&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">17595275</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon TD, Berry J, Feudtner C, et al. Children with complex chronic conditions in inpatient hospital settings in the United States. Pediatrics 2010;126:647&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962571</ArticleId><ArticleId IdType="pubmed">20855394</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, Kuo DZ, Agrawal R, et al. Children with medical complexity: an emerging population for clinical and research initiatives. Pediatrics 2011;127:529&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387912</ArticleId><ArticleId IdType="pubmed">21339266</ArticleId></ArticleIdList></Reference><Reference><Citation>Etheredge LM. A rapid-learning health system. Health Aff (Millwood) 2007;26:w107&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">17259191</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen L, Aisner D, McGinnis JM.
The learning healthcare system: workshop summary (IOM roundtable on evidence-based medicine). National Academies Press, 2007. 
http://books.google.com/books?hl=en&amp;lr=&amp;id=VWmjvCZOFjoC&amp;oi=fnd&amp;pg=PP1&amp;dq=olsen+aisner+mcginnis+the+learning+healthcare+system&amp;ots=0SX5y0LPkw&amp;sig=TVY43GfL_PfesNz_uZsqs9gTL4Y (accessed 29 Aug 2013)</Citation><ArticleIdList><ArticleId IdType="pubmed">21452449</ArticleId></ArticleIdList></Reference><Reference><Citation>Slutsky JR. Moving closer to a rapid-learning health care system. Health Aff (Millwood) 2007;26:w122&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pubmed">17259193</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CP, Wong AK, Blumenthal D. Achieving a nationwide learning health system. Sci Transl Med 2010;2:57cm29</Citation><ArticleIdList><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>Seid M, Margolis PA, Opipari-Arrigan L. Engagement, peer production, and the learning healthcare system. JAMA Pediatr 2014;168:201&#x2013;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918091</ArticleId><ArticleId IdType="pubmed">24446048</ArticleId></ArticleIdList></Reference><Reference><Citation>Crandall W, Kappelman MD, Colletti RB, et al. ImproveCareNow: the development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis 2011;17:450&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">20602466</ArticleId></ArticleIdList></Reference><Reference><Citation>Crandall WV, Margolis PA, Kappelman MD, et al. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics 2012;129:e1030&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3313634</ArticleId><ArticleId IdType="pubmed">22412030</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolis PA, Peterson LE, Seid M. Collaborative Chronic Care Networks (C3Ns) to transform chronic illness care. Pediatrics 2013;131(Suppl 4):S219&#x2013;223</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075135</ArticleId><ArticleId IdType="pubmed">23729764</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis JM. Engineering the learning healthcare system. Eng Syst Healthc Deliv 2010;153:145</Citation><ArticleIdList><ArticleId IdType="pubmed">20543243</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman C, McGinnis JM. Digital infrastructure for the learning health system: the foundation for continuous improvement in health and health care: workshop series summary. National Academies Press, 2011</Citation><ArticleIdList><ArticleId IdType="pubmed">22379651</ArticleId></ArticleIdList></Reference><Reference><Citation>Selby JV, Lipstein SH. PCORI at 3 years&#x2014;progress, lessons, and plans. N Engl J Med 2014;370:592&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">24521104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kugler JD, Beekman RH, III, Rosenthal GL, et al. Development of a pediatric cardiology quality improvement collaborative: from inception to implementation. From the Joint Council on Congenital Heart Disease Quality Improvement Task Force. Congenit Heart Dis 2009;4:318&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">19740186</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). J Am Med Inform Assoc 2010;17:124&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010;153:600&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner SP. Ontologies and semantic data integration. Drug Discov Today 2005;10:1001&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">16023059</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Gennari JH, Fridsma DB. User-centered semantic harmonization: a case study. J Biomed Inform 2007;40:353&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pubmed">17452021</ArticleId></ArticleIdList></Reference><Reference><Citation>Timm J, Renly S, Farkash A. Large scale healthcare data integration and analysis using the semantic web. Stud Health TechnolInform 2011;169:729&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">21893843</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine,. Data harmonization for patient-centered clinical research&#x2014;a workshop. Washington, DC: Institute of Medicine, 2013. 
http://www.iom.edu/Activities/Quality/VSRT/~/media/Files/Activity%20Files/Quality/VSRT/Data-Harmonization/VSRT-WIB-DataHarmonization.pdf (accessed 29 Jan 2014)</Citation></Reference><Reference><Citation>Office of the National Coordinator. Meaningful Use Stage 2.
2013. 
http://www.healthit.gov/policy-researchers-implementers/meaningful-use-stage-2 (accessed 15 Feb 2014)</Citation></Reference><Reference><Citation>Meaningful Use Regulations. http://www.healthit.gov/policy-researchers-implementers/meaningful-use-regulations (accessed 12 Feb 2014)</Citation></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services. EHR Incentive Programs: Stage 2
2013. 
http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Stage_2.html (accessed 15 Feb 2014)</Citation><ArticleIdList><ArticleId IdType="pubmed">26110197</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O, Nguyen D, Chiang P, et al. The NLM value set authority center. Stud Health Technol Inform 2013;192:1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300102</ArticleId><ArticleId IdType="pubmed">23920998</ArticleId></ArticleIdList></Reference><Reference><Citation>National Library of Medicine. Common Data Element (CDE) Resource Portal. Common Data Element (CDE) Resource Portal, 2013. 
http://www.nlm.nih.gov/cde/ (accessed 16 Feb 2014)</Citation><ArticleIdList><ArticleId IdType="pubmed">28792816</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Bailey LC, Forrest CB, et al. Building a common pediatric research terminology for accelerating child health research. Pediatrics 2014;133:516&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934328</ArticleId><ArticleId IdType="pubmed">24534404</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB. Digitization of patient-reported outcomes. Value Health 2013;16:459&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">23796279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett AV, Jensen RE, Basch E. Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 2012;62:337&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">22811342</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow RE, Kaplan RM, Ockene JK, et al. Patient-reported measures of psychosocial issues and health behavior should be added to electronic health records. Health Aff (Millwood) 2012;31:497&#x2013;504</Citation><ArticleIdList><ArticleId IdType="pubmed">22392660</ArticleId></ArticleIdList></Reference><Reference><Citation>Estabrooks PA, Boyle M, Emmons KM, et al. Harmonized patient-reported data elements in the electronic health record: supporting meaningful use by primary care action on health behaviors and key psychosocial factors. J Am Med Inform Assoc 2012;19:575&#x2013;82</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384114</ArticleId><ArticleId IdType="pubmed">22511015</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)&#x2014;a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick JE, Morgan DeWitt E, Rothrock N, et al. 
Advances in Patient Reported Outcomes: The NIH PROMIS Measures. eGEMs (Generating Evidence &amp; Methods to improve patient outcomes);1. doi:http://dx.doi.org/10.13063/2327-9214.1015. http://repository.academyhealth.org/egems/vol1/iss1/12</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1015</ArticleId><ArticleId IdType="pmc">PMC4371419</ArticleId><ArticleId IdType="pubmed">25848562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24985530</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>567</EndPage><MedlinePgn>557-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-014-0189-0</ELocationID><Abstract><AbstractText>The entire drug safety enterprise has a need to search, retrieve, evaluate, and synthesize scientific evidence more efficiently. This discovery and synthesis process would be greatly accelerated through access to a common framework that brings all relevant information sources together within a standardized structure. This presents an opportunity to establish an open-source community effort to develop a global knowledge base, one that brings together and standardizes all available information for all drugs and all health outcomes of interest (HOIs) from all electronic sources pertinent to drug safety. To make this vision a reality, we have established a workgroup within the Observational Health Data Sciences and Informatics (OHDSI, http://ohdsi.org) collaborative. The workgroup's mission is to develop an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. The knowledge base will make it simpler for practitioners to access, retrieve, and synthesize evidence so that they can reach a rigorous and accurate assessment of causal relationships between a given drug and HOI. Development of the knowledge base will proceed with the measureable goal of supporting an efficient and thorough evidence-based assessment of the effects of 1,000 active ingredients across 100 HOIs. This non-trivial task will result in a high-quality and generally applicable drug safety knowledge base. It will also yield a reference standard of drug-HOI pairs that will enable more advanced methodological research that empirically evaluates the performance of drug safety analysis methods.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh, PA, USA, rdb20@pitt.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Nor&#xe9;n</LastName><ForeName>G Niklas</ForeName><Initials>GN</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Trifir&#xf2;</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Harpaz</LastName><ForeName>Rave</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>J Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Khayter</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Dumontier</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM011838</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01LM011838-01</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AG044433</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG044433</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D062313" MajorTopicYN="N">Databases, Pharmaceutical</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24985530</ArticleId><ArticleId IdType="pmc">PMC4134480</ArticleId><ArticleId IdType="doi">10.1007/s40264-014-0189-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bush V. As we may think. The Atlantic. July 1945.</Citation></Reference><Reference><Citation>Yu AC. Methods in biomedical ontology. J Biomed Inform. 2006;39(3):252&#x2013;266. doi: 10.1016/j.jbi.2005.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2005.11.006</ArticleId><ArticleId IdType="pubmed">16387553</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall MS, Boyce R, Deus HF, Zhao J, Willighagen EL, Samwald M, et al. Emerging practices for mapping and linking life sciences data using RDF&#x2014;a case series. Web Semant Sci Serv Agents World Wide Web. 2012;14:2&#x2013;13. doi: 10.1016/j.websem.2012.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.websem.2012.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacunski A, Tatonetti NP. Connecting the dots: applications of network medicine in pharmacology and disease. Clin Pharmacol Therap. 2013;94(6):659&#x2013;669. doi: 10.1038/clpt.2013.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.168</ArticleId><ArticleId IdType="pubmed">23995266</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeleswarapu S, Rao A, Joseph T, Saipradeep VG, Srinivasan R. A pipeline to extract drug-adverse event pairs from multiple data sources. BMC Med Inform Decis Mak. 2014;14(1):13. doi: 10.1186/1472-6947-14-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-14-13</ArticleId><ArticleId IdType="pmc">PMC3936866</ArticleId><ArticleId IdType="pubmed">24559132</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel W, Ryan PB, Schuemie MJ, Madigan D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf. 2013;36(Suppl 1):S123&#x2013;S132. doi: 10.1007/s40264-013-0106-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0106-y</ArticleId><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S73&#x2013;S82. doi: 10.1007/s40264-013-0105-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0105-z</ArticleId><ArticleId IdType="pubmed">24166225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401&#x2013;4415. doi: 10.1002/sim.5620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5620</ArticleId><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 2013;36(Suppl 1):S171&#x2013;S180. doi: 10.1007/s40264-013-0110-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0110-2</ArticleId><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S59&#x2013;S72. doi: 10.1007/s40264-013-0099-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0099-6</ArticleId><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S95&#x2013;S106. doi: 10.1007/s40264-013-0101-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0101-3</ArticleId><ArticleId IdType="pubmed">24166227</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(Suppl 1):S143&#x2013;S158. doi: 10.1007/s40264-013-0108-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0108-9</ArticleId><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Madigan D, Ryan PB. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S133&#x2013;S142. doi: 10.1007/s40264-013-0107-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0107-x</ArticleId><ArticleId IdType="pubmed">24166230</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S83&#x2013;S93. doi: 10.1007/s40264-013-0100-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0100-4</ArticleId><ArticleId IdType="pubmed">24166226</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifiro G, Matthews JN, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50(10):890&#x2013;897. doi: 10.1097/MLR.0b013e31825f63bf.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e31825f63bf</ArticleId><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Gini R, Coloma PM, Straatman H, Herings RM, Pedersen L, et al. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Saf. 2013;36(Suppl 1):S159&#x2013;S169. doi: 10.1007/s40264-013-0109-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0109-8</ArticleId><ArticleId IdType="pubmed">24166232</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 2010;33(6):475&#x2013;487. doi: 10.2165/11534410-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11534410-000000000-00000</ArticleId><ArticleId IdType="pubmed">20486730</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31. doi: 10.1126/scitranslmed.3003377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003377</ArticleId><ArticleId IdType="pmc">PMC3382018</ArticleId><ArticleId IdType="pubmed">22422992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg AM, Hauben M, Pearson RK, O&#x2019;Hara DJ, Reisinger SJ, Goldsmith DI, et al. An evaluation of three signal-detection algorithms using a highly inclusive reference event database. Drug Saf. 2009;32(6):509&#x2013;525. doi: 10.2165/00002018-200932060-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200932060-00007</ArticleId><ArticleId IdType="pubmed">19459718</ArticleId></ArticleIdList></Reference><Reference><Citation>Nor&#xe9;n GN, Bergvall T, Ryan PB, Juhlin K, Schuemie MJ, Madigan D. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S107&#x2013;S121. doi: 10.1007/s40264-013-0095-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0095-x</ArticleId><ArticleId IdType="pubmed">24166228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33&#x2013;S47. doi: 10.1007/s40264-013-0097-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0097-8</ArticleId><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36(1):13&#x2013;23. doi: 10.1007/s40264-012-0002-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-012-0002-x</ArticleId><ArticleId IdType="pubmed">23315292</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6&#xa0;years. J Am Med Inform Assoc. 2011;18(4):441&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D, de Keizer N, Lau F, Cornet R. Literature review of SNOMED CT use. JAMIA. 2014;21(e1):e11&#x2013;e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957381</ArticleId><ArticleId IdType="pubmed">23828173</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Defalco FJ, Ryan PB, Soledad Cepeda M. Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Methodol. 2013;13(1):58&#x2013;67. doi: 10.1007/s10742-012-0102-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10742-012-0102-1</ArticleId><ArticleId IdType="pmc">PMC3566397</ArticleId><ArticleId IdType="pubmed">23396660</ArticleId></ArticleIdList></Reference><Reference><Citation>Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(1):D1091&#x2013;D1097. doi: 10.1093/nar/gkt1068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1068</ArticleId><ArticleId IdType="pmc">PMC3965102</ArticleId><ArticleId IdType="pubmed">24203711</ArticleId></ArticleIdList></Reference><Reference><Citation>Schriml LM, Arze C, Nadendla S, Chang YW, Mazaitis M, Felix V, et al. Disease ontology: a backbone for disease semantic integration. Nucleic Acids Res. 2012;40(Database issue):D940&#x2013;D946. doi: 10.1093/nar/gkr972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr972</ArticleId><ArticleId IdType="pmc">PMC3245088</ArticleId><ArticleId IdType="pubmed">22080554</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database&#x2014;update and key issues. N Engl J Med. 2011;364(9):852&#x2013;860. doi: 10.1056/NEJMsa1012065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa1012065</ArticleId><ArticleId IdType="pmc">PMC3066456</ArticleId><ArticleId IdType="pubmed">21366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J, Friedlin J, Ryan P. A quantitative analysis of adverse events and &#x201c;overwarning&#x201d; in drug labeling. Arch Intern Med. 2011;171(10):944&#x2013;946. doi: 10.1001/archinternmed.2011.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2011.182</ArticleId><ArticleId IdType="pubmed">21606101</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Friedlin J. ADESSA: a real-time decision support service for delivery of semantically coded adverse drug event data. AMIA Annu Symp Proc. 2010;2010:177&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041415</ArticleId><ArticleId IdType="pubmed">21346964</ArticleId></ArticleIdList></Reference><Reference><Citation>Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21&#x2013;37. doi: 10.2165/00002018-200831010-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200831010-00003</ArticleId><ArticleId IdType="pubmed">18095744</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Therap. 1977;21(3):247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">837643</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L. Adverse drug reactions&#x2014;a matter of opinion. Clin Pharmacol Therap. 1976;19(5 Pt 1):489&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">1277705</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh Y, Li SC. A new algorithm to identify the causality of adverse drug reactions. Drug Saf. 2005;28(12):1159&#x2013;1161. doi: 10.2165/00002018-200528120-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200528120-00010</ArticleId><ArticleId IdType="pubmed">16329718</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug-reactions. Clin Pharmacol Therap. 1981;30(2):239&#x2013;245. doi: 10.1038/clpt.1981.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.1981.154</ArticleId><ArticleId IdType="pubmed">7249508</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh Y, Yap CW, Li SC. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system. Int J Med Inform. 2008;77(6):421&#x2013;430. doi: 10.1016/j.ijmedinf.2007.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2007.08.010</ArticleId><ArticleId IdType="pubmed">17921048</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Therap. 1995;58(6):692&#x2013;698. doi: 10.1016/0009-9236(95)90026-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0009-9236(95)90026-8</ArticleId><ArticleId IdType="pubmed">8529335</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Han X, Wang ZP, Subhadarshini A, Karnik SD, Li XC. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. Plos Comput Biol. 2012;8(8):e1002614. doi: 10.1371/journal.pcbi.1002614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002614</ArticleId><ArticleId IdType="pmc">PMC3415435</ArticleId><ArticleId IdType="pubmed">22912565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cami A, Arnold A, Manzi S, Reis B. Predicting adverse drug events using pharmacological network models. Sci Transl Med. 2011;3(114):114ra127. doi: 10.1126/scitranslmed.3002774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002774</ArticleId><ArticleId IdType="pubmed">22190238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cami A, Manzi S, Arnold A, Reis BY. Pharmacointeraction network models predict unknown drug&#x2013;drug interactions. Plos One. 2013;8(4):e61468. doi: 10.1371/journal.pone.0061468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0061468</ArticleId><ArticleId IdType="pmc">PMC3631217</ArticleId><ArticleId IdType="pubmed">23620757</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng FX, Li WH, Wang XC, Zhou YD, Wu ZR, Shen J, et al. Adverse drug events: database construction and in silico prediction. J Chem Inf Model. 2013;53(4):744&#x2013;752. doi: 10.1021/ci4000079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci4000079</ArticleId><ArticleId IdType="pubmed">23521697</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Therap. 2012;91(6):1010&#x2013;1021. doi: 10.1038/clpt.2012.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.50</ArticleId><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Juhlin K, Ye X, Star K, Nor&#xe9;n GN. Outlier removal to uncover patterns in adverse drug reaction surveillance&#x2014;a simple unmasking strategy. Pharmacoepidemiol Drug Saf. 2013;22(10):1119&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">23832706</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi G, Star K, Nor&#xe9;n GN, Hagg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One. 2013;8(7):e68938. doi: 10.1371/journal.pone.0068938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068938</ArticleId><ArticleId IdType="pmc">PMC3711907</ArticleId><ArticleId IdType="pubmed">23869234</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf. 2013;22(3):294&#x2013;301. doi: 10.1002/pds.3351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3351</ArticleId><ArticleId IdType="pubmed">23042584</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25187016</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model.</ArticleTitle><Pagination><StartPage>945</StartPage><EndPage>959</EndPage><MedlinePgn>945-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-014-0214-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The unique structure and coding of the Clinical Practice Research Datalink (CPRD) presents challenges for epidemiologic analysis and for comparisons with other databases. To address this limitation we sought to transform CPRD into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An extraction, transformation and loading process was developed, which detailed source code mappings, Read code domain classification, an imputation algorithm for drug duration and special handling of lifestyle/clinical data. Completeness and accuracy of the above elements were assessed. A final validation exercise involved replication of a published case-control study that examined use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of first-time acute myocardial infarction (AMI) in raw CPRD data and the CPRD CDM.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">All elements of the CPRD CDM transformation were assessed to be of high quality. 99.9&#xa0;% of database condition records and 89.7&#xa0;% of database drug records were mapped (majority unmapped drugs were devices and over-the-counter products); 3.1&#xa0;% of duration imputations were deemed possibly erroneous and prevalences for selected conditions and drugs across CPRD raw and CDM data were equivalent. Results between the replication raw data and CDM study agreed for conditions, demographics and lifestyle data with slight NSAID exposure data loss owing to unmapped drugs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CPRD can be accurately transformed into the OMOP CDM with acceptable information loss across drugs, conditions and observations. We determined that for a particular use, case CDM structure was adequate and mappings could be improved but did not substantially change the results of our analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matcho</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 920 US Route 202, Raritan, NJ, 08869, USA, AMatcho@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fife</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Drug Saf. 2014 Nov;37(11):893-6. doi: 10.1007/s40264-014-0221-4.</RefSource><PMID Version="1">25187018</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25187016</ArticleId><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="doi">10.1007/s40264-014-0214-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the general practice research database and linked cancer registries. Pharmacoepidemiol Drug Saf. 2013;22(2):168&#x2013;175. doi: 10.1002/pds.3374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3374</ArticleId><ArticleId IdType="pubmed">23239282</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4&#x2013;14. doi: 10.1111/j.1365-2125.2009.03537.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2009.03537.x</ArticleId><ArticleId IdType="pmc">PMC2805870</ArticleId><ArticleId IdType="pubmed">20078607</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686&#x2013;689. doi: 10.1592/phco.23.5.686.32205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1592/phco.23.5.686.32205</ArticleId><ArticleId IdType="pubmed">12741446</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600&#x2013;606. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational medical outcomes partnership common data model specifications version 4.0. In: Implementation common data model CDM specifications V4.0. Reagan-Udall Foundation. 2012. http://omop.org/CDM. Accessed November 28 2013.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36(2):119&#x2013;134. doi: 10.1007/s40264-012-0009-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-012-0009-3</ArticleId><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol. 2002;54(3):327&#x2013;332. doi: 10.1046/j.1365-2125.2002.01637.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.2002.01637.x</ArticleId><ArticleId IdType="pmc">PMC1874430</ArticleId><ArticleId IdType="pubmed">12236854</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia Rodriguez LA, Perez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419&#x2013;425. doi: 10.1046/j.1365-2125.1998.00701.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.1998.00701.x</ArticleId><ArticleId IdType="pmc">PMC1873548</ArticleId><ArticleId IdType="pubmed">9643612</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A. OMOP CDM v4.0 CPRD ETL version 8. In: Implementation common data model CPRD by Janssen research and development. Reagan-Udall Foundation. 2013. http://omop.org/CDM. Accessed Nov 28 2013.</Citation></Reference><Reference><Citation>Reich CRP, Torok D, Vereshagin S, Khayter M, Welebob E. Standard vocabularies in observational data analysis version 4.0. In: Implementation vocabularies standard vocabulary specification. 2012. http://omop.org/CDM. Accessed Nov 28 2012.</Citation></Reference><Reference><Citation>Ryan PB. Establishing a drug era persistence window for active surveillance. In: White papers. 2010. http://omop.org/OMOPWhitePapers. Accessed Apr 4 2014.</Citation></Reference><Reference><Citation>Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case&#x2013;control method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S73&#x2013;S82. doi: 10.1007/s40264-013-0105-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0105-z</ArticleId><ArticleId IdType="pubmed">24166225</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25187018</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Converting to a common data model: what is lost in translation? : Commentary on "fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model".</ArticleTitle><Pagination><StartPage>893</StartPage><EndPage>896</EndPage><MedlinePgn>893-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-014-0221-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands, p.rijnbeek@erasmusmc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Drug Saf. 2014 Dec;37(12):1073</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Drug Saf. 2014 Nov;37(11):945-59. doi: 10.1007/s40264-014-0214-3.</RefSource><PMID Version="1">25187016</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25187018</ArticleId><ArticleId IdType="doi">10.1007/s40264-014-0221-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>BMC Med Inform Decis Mak. 2013 Mar 02;13:30</Citation><ArticleIdList><ArticleId IdType="pubmed">23452306</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Inf Med. 1999 Dec;38(4-5):339-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10805025</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2013 Aug;51(8 Suppl 3):S45-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intern Med. 2014 Jun;275(6):551-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24635221</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2014 Nov;37(11):945-59</Citation><ArticleIdList><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Feb;36(2):119-34</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Aug 13;361(7):645-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19635947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25250527</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2163-8306</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>CPT: pharmacometrics &amp; systems pharmacology</Title><ISOAbbreviation>CPT Pharmacometrics Syst Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Similarity-based modeling applied to signal detection in pharmacovigilance.</ArticleTitle><Pagination><StartPage>e137</StartPage><MedlinePgn>e137</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/psp.2014.35</ELocationID><Abstract><AbstractText>One of the main objectives in pharmacovigilance is the detection of adverse drug events (ADEs) through mining of healthcare databases, such as electronic health records or administrative claims data. Although different approaches have been shown to be of great value, research is still focusing on the enhancement of signal detection to gain efficiency in further assessment and follow-up. We applied similarity-based modeling techniques, using 2D and 3D molecular structure, ADE, target, and ATC (anatomical therapeutic chemical) similarity measures, to the candidate associations selected previously in a medication-wide association study for four ADE outcomes. Our results showed an improvement in the precision when we ranked the subset of ADE candidates using similarity scorings. This method is simple, useful to strengthen or prioritize signals generated from healthcare databases, and facilitates ADE detection through the identification of the most similar drugs for which ADE information is available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vilar</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Department of Biomedical Informatics, Columbia University, New York, New York, USA [2] Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>P B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>1] Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA [2] Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1] Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA [2] Department of Statistics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>P E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>1] Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA [2] Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>1] Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA [2] Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] Department of Biomedical Informatics, Columbia University, New York, New York, USA [2] Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>N P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>1] Department of Biomedical Informatics, Columbia University, New York, New York, USA [2] Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA [3] Department of Systems Biology, Columbia University Medical Center, New York, New York, USA [4] Department of Medicine, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Department of Biomedical Informatics, Columbia University, New York, New York, USA [2] Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM008635</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM010016</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CPT Pharmacometrics Syst Pharmacol</MedlineTA><NlmUniqueID>101580011</NlmUniqueID><ISSNLinking>2163-8306</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25250527</ArticleId><ArticleId IdType="pmc">PMC4211266</ArticleId><ArticleId IdType="doi">10.1038/psp.2014.35</ArticleId><ArticleId IdType="pii">psp201435</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak G., Albers D.J. Next-generation phenotyping of electronic health records. J. Am. Med. Inform. Assoc. 2013;20:117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>The Truven MarketScan Commercial Claims and Encounters (CCAE) 
. &lt;
http://www.truvenhealth.com/
&gt;.
Accessed 1 September 2013.</Citation></Reference><Reference><Citation>FDA U.S. Food and Drug Administration FDA Adverse Event Reporting System (FAERS). &lt;
. &lt;
http://www.fda.gov/cder/aers/default.htm
&gt;.
Accessed 1 September 2013.</Citation></Reference><Reference><Citation>Wang X., Hripcsak G., Markatou M., Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J. Am. Med. Inform. Assoc. 2009;16:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732239</ArticleId><ArticleId IdType="pubmed">19261932</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben M., Madigan D., Gerrits C.M., Walsh L., Van Puijenbroek E.P. The role of data mining in pharmacovigilance. Expert Opin. Drug Saf. 2005;4:929&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111454</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig P.K. Advancing the science of pharmacovigilance. Clin. Pharmacol. Ther. 2013;93:474&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">23689213</ArticleId></ArticleIdList></Reference><Reference><Citation>Almenoff J.S., Pattishall E.N., Gibbs T.G., DuMouchel W., Evans S.J., Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther. 2007;82:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">17538548</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., DuMouchel W., LePendu P., Bauer-Mehren A., Ryan P., Shah N.H. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin. Pharmacol. Ther. 2013;93:539&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857139</ArticleId><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek E.P., Egberts A.C., Heerdink E.R., Leufkens H.G. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. 2000;56:733&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">11214785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben M., Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov. Today. 2009;14:343&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">19187799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P.B., et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36 suppl. 1:S143&#x2013;S158.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P.B., Madigan D., Stang P.E., Overhage J.M., Racoosin J.A., Hartzema A.G. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat. Med. 2012;31:4401&#x2013;4415.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P.B., Schuemie M.J. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 2013;36 suppl. 1:S171&#x2013;S180.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M.J., Madigan D., Ryan P.B. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36 suppl. 1:S133&#x2013;S142.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166230</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel W., Ryan P.B., Schuemie M.J., Madigan D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf. 2013;36 suppl. 1:S123&#x2013;S132.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P.B., Schuemie M.J., Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36 suppl. 1:S95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166227</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes A.B., Hawson A., Liu F., Friedman C., Khiabanian H., Rabadan R. Discovering disease associations by integrating electronic clinical data and medical literature. PLoS One. 2011;6:e21132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121722</ArticleId><ArticleId IdType="pubmed">21731656</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese J.A., et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010;116:2127&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951857</ArticleId><ArticleId IdType="pubmed">20530792</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R., et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J. Am. Med. Inform. Assoc. 2013;20:413&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P.B., Madigan D., Stang P.E., Schuemie M.J., Hripcsak G. Medication-wide association studies. CPT Pharmacometrics Syst. Pharmacol. 2013;2:e76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026636</ArticleId><ArticleId IdType="pubmed">24448022</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S., Harpaz R., Santana L., Uriarte E., Friedman C. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS One. 2012;7:e41471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3404072</ArticleId><ArticleId IdType="pubmed">22911794</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S., Harpaz R., Chase H.S., Costanzi S., Rabadan R., Friedman C. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J. Am. Med. Inform. Assoc. 2011;18 suppl. 1:i73&#x2013;i80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241177</ArticleId><ArticleId IdType="pubmed">21946238</ArticleId></ArticleIdList></Reference><Reference><Citation>LiverTox. Clinical and Research Information on Drug-Induced Liver Injury 
. &lt;
http://livertox.nih.gov/
&gt;.
Accessed 15 November 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">31643176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacre S., Medghalchi M., Gregory B., Brennan F., Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 2010;62:683&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">20131240</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade C., Sandarsh S., Chethan K.B., Nagesh K.S. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J. Clin. Psychiatry. 2010;71:1565&#x2013;1575.</Citation><ArticleIdList><ArticleId IdType="pubmed">21190637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellemkjaer L., et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br. J. Clin. Pharmacol. 2002;53:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1874281</ArticleId><ArticleId IdType="pubmed">11851641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace J.L. How do NSAIDs cause ulcer disease. Baillieres. Best Pract. Res. Clin. Gastroenterol. 2000;14:147&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">10749095</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer A.I. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J. Clin. Pharmacol. 1995;35:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">7608308</ArticleId></ArticleIdList></Reference><Reference><Citation>DrugBank database, version 3.0 
. &lt;
http://www.drugbank.ca/
&gt;.
Accessed 1 September 2013.</Citation></Reference><Reference><Citation>Van Solingen R.M., et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am. J. Med. 2001;111:285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566459</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugdex &#xae; System (Micromedex Healthcare Series) Greenwood Village, CO; Thomson Reuters (Healthcare) Inc.; 2011.</Citation></Reference><Reference><Citation>Tu X., et al. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. J. Am. Soc. Nephrol. 2008;19:77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2391039</ArticleId><ArticleId IdType="pubmed">18045851</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallurupalli N.G., Goldhaber S.Z. Gastrointestinal complications of dual antiplatelet therapy. Circulation. 2006;113:e655&#x2013;e658.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567572</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyboom R.H., Egberts A.C., Edwards I.R., Hekster Y.A., de Koning F.H., Gribnau F.W. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16:355&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">9241490</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton E.E., et al. PubChem3D: a new resource for scientists. J. Cheminform. 2011;3:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269824</ArticleId><ArticleId IdType="pubmed">21933373</ArticleId></ArticleIdList></Reference><Reference><Citation>The PubChem Project 
. &lt;
http://pubchem.ncbi.nlm.nih.gov/
&gt;.
Accessed 1 September 2013.</Citation></Reference><Reference><Citation>Suchard M.A., Zorych I., Simpson S.E., Schuemie M.J., Ryan P.B., Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36 suppl. 1:S83&#x2013;S93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166226</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson S.E., Madigan D., Zorych I., Schuemie M.J., Ryan P.B., Suchard M.A. Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics. 2013;69:893&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117144</ArticleId></ArticleIdList></Reference><Reference><Citation>Durant J.L., Leland B.A., Henry D.R., Nourse J.G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 2002;42:1273&#x2013;1280.</Citation><ArticleIdList><ArticleId IdType="pubmed">12444722</ArticleId></ArticleIdList></Reference><Reference><Citation>Daylight, Chemical Information Systems, Inc. 
&lt;
http://www.daylight.com/dayhtml/doc/theory/theory.finger.html
&gt;.
Accessed 1 December 2011.</Citation></Reference><Reference><Citation>Vilar S., Harpaz R., Uriarte E., Santana L., Rabadan R., Friedman C. Drug-drug interaction through molecular structure similarity analysis. J. Am. Med. Inform. Assoc. 2012;19:1066&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534468</ArticleId><ArticleId IdType="pubmed">22647690</ArticleId></ArticleIdList></Reference><Reference><Citation>LigPrep, version 2.5. Schr&#xf6;dinger, LLC, New York, USA 
. &lt;
http://www.schrodinger.com/
&gt; (
2011. Accessed 1 October 2013.</Citation></Reference><Reference><Citation>Kaminski G.A., Friesner R.A., Tirado-Rives J., Jorgensen W.L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B. 2001;105:6474&#x2013;6487.</Citation></Reference><Reference><Citation>MacroModel, version 9.9. Schr&#xf6;dinger, LLC, New York, NY 
. &lt;
http://www.schrodinger.com/
&gt; (
2011. Accessed 1 October 2013.</Citation></Reference><Reference><Citation>Phase, version 3.3. Schr&#xf6;dinger, LLC, New York, USA 
. &lt;
http://www.schrodinger.com/
&gt; (
2011. Accessed 1 October 2013).</Citation></Reference><Reference><Citation>SIDER Side Effect Resource 
. &lt;
http://sideeffects.embl.de/
&gt;.
Accessed 15 May 2013.</Citation></Reference><Reference><Citation>WHO Collaborating Centre for Drug Statistics Methodology (WHOCC) 
. &lt;
http://www.whocc.no
&gt;.
Accessed 15 October 2013.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25848597</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2327-9214</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>EGEMS (Washington, DC)</Title><ISOAbbreviation>EGEMS (Wash DC)</ISOAbbreviation></Journal><ArticleTitle>Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model.</ArticleTitle><Pagination><StartPage>1110</StartPage><MedlinePgn>1110</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1110</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.13063/2327-9214.1110</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) has been implemented on various claims and electronic health record (EHR) databases, but has not been applied to a hospital transactional database. This study addresses the implementation of the OMOP CDM on the U.S. Premier Hospital database.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We designed and implemented an extract, transform, load (ETL) process to convert the Premier hospital database into the OMOP CDM. Standard charge codes in Premier were mapped between the OMOP version 4.0 Vocabulary and standard charge descriptions. Visit logic was added to impute the visit dates. We tested the conversion by replicating a published study using the raw and transformed databases. The Premier hospital database was compared to a claims database, in regard to prevalence of disease.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The data transformed into the CDM resulted in 1% of the data being discarded due to data errors in the raw data. A total of 91.4% of Premier standard charge codes were mapped successfully to a standard vocabulary. The results of the replication study resulted in a similar distribution of patient characteristics. The comparison to the claims data yields notable similarities and differences amongst conditions represented in both databases.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The transformation of the Premier database into the OMOP CDM version 4.0 adds value in conducting analyses due to successful mapping of the drugs and procedures. The addition of visit logic gives ordinality to drugs and procedures that wasn't present prior to the transformation. Comparing conditions in Premier against a claims database can provide an understanding about Premier's potential use in pharmacoepidemiology studies that are traditionally conducted via claims databases.</AbstractText><AbstractText Label="CONCLUSION AND NEXT STEPS" NlmCategory="UNASSIGNED">The conversion of the Premier database into the OMOP CDM 4.0 was completed successfully. The next steps include refinement of vocabularies and mappings and continual maintenance of the transformed CDM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EGEMS (Wash DC)</MedlineTA><NlmUniqueID>101629606</NlmUniqueID><ISSNLinking>2327-9214</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25848597</ArticleId><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="doi">10.13063/2327-9214.1110</ArticleId><ArticleId IdType="pii">egems1110</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. The New England journal of medicine. 2000 Jun 22;342(25):1878&#x2013;86. PubMed PMID: 10861324. Epub 2000/06/22. eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861324</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. Journal of the American Medical Informatics Association : JAMIA. 2012 Jan-Feb;19(1):54&#x2013;60. PubMed PMID: 22037893. Pubmed Central PMCID: PMC3240764. Epub 2011/11/01. eng.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. Journal of biomedical informatics. 2012 Aug;45(4):689&#x2013;96. PubMed PMID: 22683994. Epub 2012/06/12. eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Choi B-J, Hong E-K, Kim S-K, Lee D. A Taxonomy of Dirty Data. Data Mining and Knowledge Discovery. 2003;7(1):81&#x2013;99. 2003/01/01; English.</Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Annals of internal medicine. 2010 Nov 2;153(9):600&#x2013;6. PubMed PMID: 21041580. Epub 2010/11/03. eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug safety : an international journal of medical toxicology and drug experience. 2013 Feb;36(2):119&#x2013;34. PubMed PMID: 23329543. Epub 2013/01/19. eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Foundation RU. Observational Medical Outcomes Partnership [cited 2013]  Available from:  http://omop.org/.</Citation></Reference><Reference><Citation>Premier Research Services . Premier Perspective Database. Charlotte, N.C.: 2013.</Citation></Reference><Reference><Citation>Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. The New England journal of medicine. 2005 Jul 28;353(4):349&#x2013;61. PubMed PMID: 16049209. Epub 2005/07/29. eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">16049209</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R. 2012. OMOP Common Data Model (CDM V4.0) ETL Mapping Specification Premier.</Citation></Reference><Reference><Citation>Lasky T, Ernst FR, Greenspan J, Wang S, Gonzalez L. Estimating pediatric inpatient medication use in the United States. Pharmacoepidemiology and drug safety. 2011 Jan;20(1):76&#x2013;82. PubMed PMID: 21182155. Epub 2010/12/25. eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">21182155</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E. 2012. MQ. OMOP Common Data Model (CDM V4.0) ETL Mapping Specification Optum Clinformatics.</Citation></Reference><Reference><Citation>Oderda GM, Gan TJ, Johnson BH, Robinson SB. Effect of opioid-related adverse events on outcomes in selected surgical patients. Journal of pain &amp; palliative care pharmacotherapy. 2013 Mar;27(1):62&#x2013;70. PubMed PMID: 23302094. Epub 2013/01/11. eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">23302094</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA : the journal of the American Medical Association. 2010 May 26;303(20):2035&#x2013;42. PubMed PMID: 20501925. Epub 2010/05/27. eng.</Citation><ArticleIdList><ArticleId IdType="pubmed">20501925</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25848603</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2327-9214</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>2</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>EGEMS (Washington, DC)</Title><ISOAbbreviation>EGEMS (Wash DC)</ISOAbbreviation></Journal><ArticleTitle>The DARTNet Institute: Seeking a Sustainable Support Mechanism for Electronic Data Enabled Research Networks.</ArticleTitle><Pagination><StartPage>1063</StartPage><MedlinePgn>1063</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1063</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.13063/2327-9214.1063</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Clinical data research networks require large investments in infrastructure support to maintain their abilities to extract, transform, and load data from varied data sources, expand electronic data sources and develop learning communities.</AbstractText><AbstractText Label="CASE DESCRIPTION" NlmCategory="METHODS">This paper outlines a sustainable business model of ongoing infrastructure support for clinical data research activities. The DARTNet Institute is a not-for-profit 501(c)(3) organization that serves as a support entity for multiple practice-based research networks. Several clinical data research networks working closely with a professional society began collaborating to support shared goals in 2008. This loose affiliation called itself the "DARTNet Collaborative." In 2011, the DARTNet Institute incorporated as an independent, not-for-profit entity. The business structure allows DARTNet to advocate for all partners without operating its own practice-based research network, serve as a legal voice for activities that overlap multiple partners, share personnel resources through service contracts between partners, and purchase low-cost (nonprofit rate) software.</AbstractText><AbstractText Label="MAJOR THEMES" NlmCategory="UNASSIGNED">DARTNet's business model relies upon four diverse sources of revenue: (1) DARTNet licenses and provides access to a propriety software system that extracts, transforms, and loads data from all major electronic health records (EHRs) utilized in the United States, and which also provides clinical decision support for research studies; (2) DARTNet operates a recognized, national professional-society-quality improvement registry that enables organizations to fulfill Meaningful Use 2 criteria; (3) DARTNet provides access to data for research activities that are funded by direct research dollars, provided at prices that generate excess revenue; and (4) DARTNet provides access to large primary care datasets for observational studies and pregrant analyses such as for sample size development. The ability of the system to support pragmatic trials will be described.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The DARTNet model facilitates the use of direct grant dollars to generate revenue to support the overall enterprise through a purchased services arrangement. Other services provided through subcontracting provide facilities and administration fees as well as direct dollars to support the system. The flexibility of the business model overcomes the complicated financial arrangements and governance requirements of many professional associations and academic medical centers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pace</LastName><ForeName>Wilson D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Chester H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>University at Buffalo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Turner</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Rockhurst University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>American Academy of Family Physicians.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HS022956</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EGEMS (Wash DC)</MedlineTA><NlmUniqueID>101629606</NlmUniqueID><ISSNLinking>2327-9214</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Sustainability</Keyword><Keyword MajorTopicYN="N">research networks</Keyword><Keyword MajorTopicYN="N">shared resources</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25848603</ArticleId><ArticleId IdType="pmc">PMC4371434</ArticleId><ArticleId IdType="doi">10.13063/2327-9214.1063</ArticleId><ArticleId IdType="pii">egems1063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anonymous. Spontaneous abortion in primary care. A report from ASPN. Journal of the American Board of Family Practice. 1988;1(1):15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">3414385</ArticleId></ArticleIdList></Reference><Reference><Citation>Malloy MH, Onstad L, Wright E. The effect of cesarean delivery on birth outcome in very low birth weight infants. National Institute of Child Health and Human Development Neonatal Research Network. Obstetrics and gynecology. 1991;77(4):498&#x2013;503. Epub 1991/04/01.</Citation><ArticleIdList><ArticleId IdType="pubmed">2002969</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality (AHRQ)  AHRQ Support for Primary Care Practice-Based Research Networks (PBRNs)  [updated 12/2012; cited 2014 February 28]; Available from:  http://www.ahrq.gov/research/pbrn/pbrnfact.htm.</Citation></Reference><Reference><Citation>Ettinger DS, Stanley KE, Nystrom JS. Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study. Cancer treatment reports. 1980;64(10&#x2013;11):1017&#x2013;21. Epub 1980/10/01.</Citation><ArticleIdList><ArticleId IdType="pubmed">6970075</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabana MD, Kunselman SJ, Nyenhuis SM, Wechsler ME. Researching asthma across the ages: insights from the National Heart, Lung, and Blood Institute&#x2019;s Asthma Network. The Journal of allergy and clinical immunology. 2014;133(1):27&#x2013;33. Epub 2013/12/29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901784</ArticleId><ArticleId IdType="pubmed">24369796</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutner JS, Main DS, Westfall JM, Pace W. The practice-based research network as a model for end-of-life care research: challenges and opportunities. Cancer Control. 2005;12(3):186&#x2013;95. Epub 2005/08/03.</Citation><ArticleIdList><ArticleId IdType="pubmed">16062166</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt TM, Elston-Lafata J, Tolsma D, Greene SM. The role of research in integrated healthcare systems: the HMO Research Network. The American journal of managed care. 2004;10(9):643&#x2013;8. Epub 2004/11/02.</Citation><ArticleIdList><ArticleId IdType="pubmed">15515997</ArticleId></ArticleIdList></Reference><Reference><Citation>Green LA, White LL, Barry HC, Nease DEJ, Hudson BL. Infrastructure requirements for practice-based research networks. Annals of family medicine. 2005;3(Suppl 1):S5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1466956</ArticleId><ArticleId IdType="pubmed">15928219</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009;62(5):499&#x2013;505. Epub 2009/04/08.</Citation><ArticleIdList><ArticleId IdType="pubmed">19348976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwarenstein M, Treweek S. What kind of randomized trials do we need? J Clin Epidemiol. 2009;62(5):461&#x2013;3. Epub 2009/04/08.</Citation><ArticleIdList><ArticleId IdType="pubmed">19348970</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow RE, Vinson C, Chambers D, Khoury MJ, Kaplan RM, Hunter C. National Institutes of Health Approaches to Dissemination and Implementation Science: Current and Future Directions. American Journal of Public Health. 2012 Jul;102(7):1274&#x2013;81. May 17 [epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478005</ArticleId><ArticleId IdType="pubmed">22594758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobb r, Colditz GA. Implementation science and its application to population health. Annu Rev Public Health. 2013;34:235&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901430</ArticleId><ArticleId IdType="pubmed">23297655</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner HI, Glasgow RE, Vinson CA, Chambers D, Brown-son RC, Green LW, et al. The U.S. training institute for dissemination and implementation research in health. Implementation science : IS. 2013;8(1):12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564839</ArticleId><ArticleId IdType="pubmed">23347882</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin BA, Brownson RC, Haire-Joshu D, Kreuter MW, Weaver NL. A glossary for dissemination and implementation research in health. J Public Health Manag Pract. 2008;14(2):117&#x2013;23. Epub 2008/02/22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18287916</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299(2):211&#x2013;3. Epub 2008/01/10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18182604</ArticleId></ArticleIdList></Reference><Reference><Citation>Improved Clinical Effectiveness through Behavioural Research Group (ICEBeRG) Designing theoretically-informed implementation interventions. Implement Sci. 2006;1:4. Epub 2006/05/26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1436012</ArticleId><ArticleId IdType="pubmed">16722571</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson KA, Fontaine P, Speedie S. The Electronic Primary Care Research Network (ePCRN): a new era in practice-based research. [erratum appears in J Am Board Fam Med. 2006 May&#x2013;Jun;19(3):329] Journal of the American Board of Family Medicine: JABFM. 2006;19(1):93&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16492011</ArticleId></ArticleIdList></Reference><Reference><Citation>Binns HJ, Lanier D, Pace WD, Galliher JM, Ganiats TG, Grey M, et al. Describing primary care encounters: the Primary Care Network Survey and the National Ambulatory Medical Care Survey. Annals of family medicine. 2007;5(1):39&#x2013;47. Epub 2007/01/31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783926</ArticleId><ArticleId IdType="pubmed">17261863</ArticleId></ArticleIdList></Reference><Reference><Citation>Green LA. Prescription for health: Round 1 initial results. Annals of family medicine. 2005;3(Supplement 2):S2&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1466972</ArticleId><ArticleId IdType="pubmed">16049076</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership  Common Data Model and Standard Vocabularies (Version 4)  Available from:  http://omop.fnih.org/CDMvocabV4.</Citation></Reference><Reference><Citation>Schilling LM, Kwan BM, Drolshagen CT, Hosokawa PW, Brandt E, Pace WD, et al. Scalable Architecture for Federated Translational Inquiries Network (SAFTINet) Technology Infrastructure for a Distributed Data Network. eGEMs (Generating Evidence &amp; Methods to improve patient outcomes) 2013;1(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371513</ArticleId><ArticleId IdType="pubmed">25848567</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) Journal of the American Medical Informatics Association : JAMIA. 2010;17(2):124&#x2013;30. Epub 2010/03/02.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardee R. Questions and answers about the Virtual Data Warehouse: An introduction for New HMORN site staff.  [cited 2014 March 3]; Available from:  http://www.hmoresearchnetwork.org/en/Tools%20&amp;%20Materials/VDW/HMORN_VDW-Questions-and-Answers.pdf.</Citation></Reference><Reference><Citation>Clinical Data Interchange Standards Consortium.  [cited 2014 March 3]; Available from:  www.cdisc.org/.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership  2013.  [cited 2013 June 10]; Available from:  http://omop.org/.</Citation></Reference><Reference><Citation>SCAlable National Network for Effectiveness Research (SCANNER)  2013.  [updated 12/2013; cited 2014 March 3]; Available from:  http://scanner.ucsd.edu/.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership. Vocabularies  2014.  [cited 2014 July 2]; Available from:  http://omop.org/Vocabularies.</Citation></Reference><Reference><Citation>Libby AM, Pace W, Bryan C, Anderson HO, Ellis SL, Allen RR, et al. Comparative effectiveness research in DARTNet primary care practices: point of care data collection on hypoglycemia and over-the-counter and herbal use among patients diagnosed with diabetes. Medical care. 2010;48(6 Suppl):S39&#x2013;44. Epub 2010/05/18.</Citation><ArticleIdList><ArticleId IdType="pubmed">20473193</ArticleId></ArticleIdList></Reference><Reference><Citation>Valuck RJ, Anderson HO, Libby AM, Brandt E, Bryan C, Allen RR, et al. Enhancing electronic health record measurement of depression severity and suicide ideation: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. Journal of the American Board of Family Medicine : JABFM. 2012;25(5):582&#x2013;93. Epub 2012/09/08.</Citation><ArticleIdList><ArticleId IdType="pubmed">22956694</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt E, Fernald DH, Parnes B, Pace WD, West DR. An Electronic Card Study of Treatment Strategies for Community-Acquired Methicilin- Resistant Staphylococcus Aureus (CA-MRSA) Advances in the Prevention and Control of Healthcare-Associated Infections. In Press.</Citation></Reference><Reference><Citation>Parnes B, Fernald D, Coombs L, Dealleaume L, Brandt E, Webster B, et al. Improving the management of skin and soft tissue infections in primary care: a report from State Networks of Colorado Ambulatory Practices and Partners (SNOCAP-USA) and the Distributed Ambulatory Research in Therapeutics Network (DARTNet) Journal of the American Board of Family Medicine : JABFM. 2011;24(5):534&#x2013;42. Epub 2011/09/09.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900436</ArticleId></ArticleIdList></Reference><Reference><Citation>Westfall JM, Zittleman L, Staton EW, Parnes B, Smith PC, Niebauer L, et al. Card Studies for Observational Research in Practice. Annals of family medicine. 2011;9(1):63&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3022048</ArticleId><ArticleId IdType="pubmed">21242563</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins TC, Irwin A, Coombs L, DeAlleaume L, Ross SE, Rozwadowski J, et al. Effects of Clinical Pathways for Common Outpatient Infections on Antibiotic Prescribing. The American journal of medicine. 2013;126(4):327&#x2013;35.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3666348</ArticleId><ArticleId IdType="pubmed">23507206</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox CH, Vest BM, Kahn LS, Dickinson LM, Fang H, Pace W, et al. Improving evidence-based primary care for chronic kidney disease: study protocol for a cluster randomized control trial for translating evidence into practice (TRANSLATE CKD) Implementation science : IS. 2013;8:88. Epub Aug. 8, 2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751479</ArticleId><ArticleId IdType="pubmed">23927603</ArticleId></ArticleIdList></Reference><Reference><Citation>National Kidney Foundation. Guidelines and Commentaries  2014.  [cited 2014 April 17]; Available from:  http://www.kidney.org/professionals/kdoqi/guidelines_commentaries.cfm.</Citation></Reference><Reference><Citation>Galliher JM, Manning BK, Petterson SM, Dickinson LM, Brandt EC, Staton EW, et al. Do Professional Development Programs for Maintenance of Certification (MOC) Affect Quality of Patient Care? Journal of the American Board of Family Medicine : JABFM. 2014;27(1):19&#x2013;25. Epub 2014/01/07.</Citation><ArticleIdList><ArticleId IdType="pubmed">24390882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hissett J, Folks B, Coombs L, LeBlanc W, Pace WD. Effects of Changing Guidelines on Prescribing Aspirin for Primary Prevention of Cardiovascular Events. The Journal of the American Board of Family Medicine. 2014;27(1):78&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24390889</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace WD, Graham D, Emsermann CD, Karty A. Regional Variations in the Use of Testing Modalities for Cardiovascular Disease. North American Primary Care Research Group Annual Meeting; Banff, Alberta Canada. 2011.</Citation></Reference><Reference><Citation>DARTNet Institute  DARTNet website.  [Web site] [cited 2013 September 11]; Available from:  http://www.dartnet.info/.</Citation></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services  Meaningful Use Stage 2. 2013.  [updated 12/06/2013; cited 2014 February 28]; Available from:  http://cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Stage_2.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26052957</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-2887</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Research synthesis methods</Title><ISOAbbreviation>Res Synth Methods</ISOAbbreviation></Journal><ArticleTitle>Exploration of heterogeneity in distributed research network drug safety analyses.</ArticleTitle><Pagination><StartPage>352</StartPage><EndPage>370</EndPage><MedlinePgn>352-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jrsm.1121</ELocationID><Abstract><AbstractText>Distributed data networks representing large diverse populations are an expanding focus of drug safety research. However, interpreting results is difficult when treatment effect estimates vary across datasets (i.e., heterogeneity). In a previous study, risk estimates were generated for selected drugs and potential adverse outcomes. Analyses were replicated across eight distributed data sources using an identical analytic structure. To evaluate heterogeneity of risk estimates across data sources, the estimates were combined with summary-level data characterizing the population of each data source. Meta-analysis, meta-regression, and plots of the influence on overall results versus contribution to heterogeneity were examined and used to illustrate an approach to heterogeneity assessment. Heterogeneity, as measured by the I-squared statistic, was high with variability across outcomes. Plots of the relationship between influence on overall results and contribution to heterogeneity suggest that certain datasets and characteristics were influential but there was variability dependent on the drug and outcome being assessed. Exploratory meta-regression identified many possible influential factors, but may be subject to ecological bias and false positive conclusions. Distributed data network drug safety analyses can produce heterogeneous risk estimates that may not be easily explained. Approaches illustrated here can be useful for research that is subject to similar problems with heterogeneity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, College of Science and Math, Auburn University, Auburn, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Analytics Department, Janssen Research and Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonawane</LastName><ForeName>Kalyani</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teeter</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westrich</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Pharmaceutical Council (NPC), Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>National Pharmaceutical Council (NPC), Washington, DC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Res Synth Methods</MedlineTA><NlmUniqueID>101543738</NlmUniqueID><ISSNLinking>1759-2879</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="Y">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="N">Medical Record Linkage</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="Y">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">distributed data</Keyword><Keyword MajorTopicYN="N">drug safety</Keyword><Keyword MajorTopicYN="N">heterogeneity</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">meta-regression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26052957</ArticleId><ArticleId IdType="doi">10.1002/jrsm.1121</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25670757</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Feasibility and utility of applications of the common data model to multiple, disparate observational health databases.</ArticleTitle><Pagination><StartPage>553</StartPage><EndPage>564</EndPage><MedlinePgn>553-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocu023</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the utility of applying the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) across multiple observational databases within an organization and to apply standardized analytics tools for conducting observational research.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Six deidentified patient-level datasets were transformed to the OMOP CDM. We evaluated the extent of information loss that occurred through the standardization process. We developed a standardized analytic tool to replicate the cohort construction process from a published epidemiology protocol and applied the analysis to all 6 databases to assess time-to-execution and comparability of results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Transformation to the CDM resulted in minimal information loss across all 6 databases. Patients and observations excluded were due to identified data quality issues in the source system, 96% to 99% of condition records and 90% to 99% of drug records were successfully mapped into the CDM using the standard vocabulary. The full cohort replication and descriptive baseline summary was executed for 2 cohorts in 6 databases in less than 1 hour.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The standardization process improved data quality, increased efficiency, and facilitated cross-database comparisons to support a more systematic approach to observational research. Comparisons across data sources showed consistency in the impact of inclusion criteria, using the protocol and identified differences in patient characteristics and coding practices across databases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Standardizing data structure (through a CDM), content (through a standard vocabulary with source code mappings), and analytics can enable an institution to apply a network-based approach to observational research across multiple, disparate observational health databases.</AbstractText><CopyrightInformation>&#xa9; The Author 2015. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA evoss3@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matcho</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qianli</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knoll</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Londhe</LastName><ForeName>Ajit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Informatics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Vivienne</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="Y">Health Services Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="Y">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">controlled health services research</Keyword><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">factual vocabulary</Keyword><Keyword MajorTopicYN="N">medical informatics observational study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25670757</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pii">ocu023</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862718</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart MA, St&#xfc;rmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(6):S114&#x2013;S120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024462</ArticleId><ArticleId IdType="pubmed">20473199</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Stang PE, Berlin JA, et al. A systematic statistical approach to evaluating evidence from observational studies. Ann Rev Stat Appl. 2014;1(1):11&#x2013;39.</Citation></Reference><Reference><Citation>Psaty BM, Furberg CD. COX-2 inhibitors&#x2013;lessons in drug safety. N Engl J Med. 2005;352 (11):1133&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713946</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger SJ, Ryan PB, O&#x2019;Hara DJ, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. JAMIA 2010;17 (6):652&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000752</ArticleId><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Council. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: The National Academies Press; 2007.</Citation></Reference><Reference><Citation>Food and Drug Administration Amendments Act of 2007. US Government Printing Office Website. http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/html/PLAW-110publ85.htm. Accessed June 12, 2014. </Citation></Reference><Reference><Citation>FDA&#x2019;s Sentinel Initiative. US Food and Drug Administration Website. http://www.fda.gov/safety/FDAsSentinelInitiative/ucm2007250.htm. Accessed June 12, 2014. </Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership (OMOP). Observational Medical Outcomes Partnership Website. http://omop.org. Accessed June 12, 2014.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI) Website. http://www.ohdsi.org. Accessed June 12, 2014. </Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Safety. 2011;20(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>EU-ADR. EU-Adverse Drug Reactions Website. http://www.euadr-project.org. Accessed June 12, 2014.</Citation></Reference><Reference><Citation>OMOP Common Data Model (CDM). Observational Medical Outcomes Partnership Website. http://omop.org/CDM. Accessed June 13, 2014. </Citation></Reference><Reference><Citation>OMOP Vocabularies.
Observational Medical Outcomes Partnership Website. http://omop.org/Vocabularies. Accessed June 13, 2014. </Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010; 153(9):600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. JAMIA. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care. 2012;50 Suppl:S60-S67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M. Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies. Ther Adv Drug Safety. 2013;4(2):53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110833</ArticleId><ArticleId IdType="pubmed">25083251</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunyemi OI, Meeker D, Kim HE, Ashish N, Farzaneh S, Boxwala A. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Med Care. 2013;51(8 Suppl 3):S45-S52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401&#x2013;4415.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Stang PE, Overhage JM, et al. A comparison of the empirical performance of methods for a risk identification system . Drug Safety. 2013;36(Suppl 1):S143&#x2013;S158.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012;45(4):689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>WhiteRabbit [computer application]. GitHub Website. https://github.com/OHDSI/WhiteRabbit. Accessed June 13, 2014
</Citation></Reference><Reference><Citation>Matcho A.
OMOP Common Data Model (CDM, Version 4.0): Clinical Practice Research Datalink (CPRD) Mapping Specification. Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014; 
http://75.101.131.161/download/loadfile.php?docname=CPRD%20ETL. Accessed June 23, 2014. </Citation></Reference><Reference><Citation>Makadia R.
OMOP Common Data Model (CDM, Version 4.0): ETL Mapping Specification Premier. Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014; 
http://75.101.131.161/download/loadfile.php?docname=Premier%20ETL. Accessed June 23, 2014.</Citation></Reference><Reference><Citation>Ma Q, Voss E.
Janssen Research &amp; Development, Pharmaceutical Companies of Johnson &amp; Johnson Common Data Model (CDM, Version 4.0) ETL Mapping Specification for Optum
Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014; 
http://75.101.131.161/download/loadfile.php?docname=OPTUM%20ETL. Accessed June 23, 2014.</Citation></Reference><Reference><Citation>Ma Q, Voss E.
Johnson &amp; Johnson Common Data Model (CDM, Version 4.0) ETL Mapping Specification for TRUVEN (CCAE and MDCR). Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014; 
http://75.101.131.161/download/loadfile.php?docname=CCAE%2FMDCR%20SAS%20ETL%20by%20Janssen. Accessed June 23, 2014.</Citation></Reference><Reference><Citation>Ma Q, Voss E.
Johnson &amp; Johnson Common Data Model (CDM, Version, 4.0) ETL Mapping Specification for TRUVEN (MDCD). Washington, DC: Reagan-Udall Foundation for the FDA; Year of Publication: 2014; 
http://75.101.131.161/download/loadfile.php?docname=MDCD%20SAS%20ETL%20by%20Janssen. Accessed June 23, 2014.</Citation></Reference><Reference><Citation>Ryan C, Joshua JG, Jennifer N, et al. ; US Food and Drug Administration. Mini-Sentinel Surveillance Plan: Mini-Sentinel prospective routine observational monitoring program tools (prompt): rivaroxaban surveillance. http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_PROMPT_Rivaroxaban-Surveillance-Plan.pdf. Accessed June 23, 2014.</Citation></Reference><Reference><Citation>Matcho A, Ryan PB, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP Common Data Model. Drug Safety. 2014;37(11):945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan P. Transforming the Premier Perspective hospital database into the OMOP Common Data Model. eGEMs (Generating Evidence &amp; Methods to improve patient outcomes). 2014;2(1)Article 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Schuemie MJ; Observation Medical Outcomes Partnership. Seasonality in acute liver Injury in healthcare claims data. http://omop.org/sites/default/files/34_Weinstein_ALI%20seasonality.pdf. Accessed June 23, 2014.</Citation></Reference><Reference><Citation>Fife D, Zhu V, Voss E, Levy-Clarke G, Ryan P. Exposure to oral fluoroquinolones and the risk of retinal detachment: retrospective analyses of two large healthcare databases. Drug Safety. 2014;37(3):171&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3936132</ArticleId><ArticleId IdType="pubmed">24526267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain. 2013;14(10):1227&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">23850177</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll CA, DeFalco FJ, Ryan PB; Observation Medical Outcomes Partnership. Applications of the OMOP Common Data Model for clinical trial feasibility assessment. http://omop.org/sites/default/files/04_Knoll_OMOP%20DM%20for%20Clincial%20Trial%20Feasibility%20Assessment.pdf. Accessed June 23, 2014. </Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25730525</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5857</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>International clinical psychopharmacology</Title><ISOAbbreviation>Int Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.</ArticleTitle><Pagination><StartPage>151</StartPage><EndPage>157</EndPage><MedlinePgn>151-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YIC.0000000000000068</ELocationID><Abstract><AbstractText>This report examines relapse risk following a switch from risperidone long-acting injectable (RLAI) to another long-acting injectable antipsychotic [paliperidone palmitate (PP)] versus a switch to oral antipsychotics (APs). Truven Health's MarketScan Multistate Medicaid Database compared relapses following switches from RLAI. New user cohorts for these two groups were created on the basis of first incidence of exposure to the 'switched to' drug. Groups were balanced using 1:1 propensity score matching. Time-to-event analysis assessed schizophrenia-related hospital/emergency department visits. A total of 188 patients switched from RLAI to PP, and 131 patients switched from RLAI to oral AP. Propensity score-matched cohort included 109 patients who switched to PP and 109 patients who switched to an oral AP. Patients who switched from RLAI to PP had fewer events (26 vs. 32), longer time to an event (mean 70 vs. 47 days), and lower risk of relapse (hazard ratio, 0.54; 95% confidence interval, 0.32-0.92; P=0.024) compared with those who switched from RLAI to oral AP. Switching from RLAI to PP may be associated with a lower risk for relapse and longer duration of therapy compared with switching to oral AP. Given the limitations of observational studies, these results should be confirmed by other prospective evaluations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>aJanssen Research &amp; Development, LLC bJanssen Scientific Affairs, LLC, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Hough</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Alphs</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Clin Psychopharmacol</MedlineTA><NlmUniqueID>8609061</NlmUniqueID><ISSNLinking>0268-1315</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>R8P8USM8FR</RegistryNumber><NameOfSubstance UI="D000068882">Paliperidone Palmitate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="Y">Insurance Claim Review</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008484" MajorTopicYN="Y">Medicaid</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068882" MajorTopicYN="N">Paliperidone Palmitate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25730525</ArticleId><ArticleId IdType="pmc">PMC4383368</ArticleId><ArticleId IdType="doi">10.1097/YIC.0000000000000068</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association (1997). Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 154:1&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9090368</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. (2011). Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Defalco FJ, Ryan PB, Soledad Cepeda M. (2013). Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Methodol 13:58&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566397</ArticleId><ArticleId IdType="pubmed">23396660</ArticleId></ArticleIdList></Reference><Reference><Citation>Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. (2009). Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry 9:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2749836</ArticleId><ArticleId IdType="pubmed">19725969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusar-Poli P, Kempton MJ, Rosenheck RA. (2013). Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 28:57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">23165366</ArticleId></ArticleIdList></Reference><Reference><Citation>Genkin A, Lewis DD, Madigan D. (2007). Large-scale Bayesian logistic regression for text categorization. Technometrics 49:291&#x2013;304.</Citation></Reference><Reference><Citation>Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D. (2010). Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, et al. (2013). Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74:568&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">23842008</ArticleId></ArticleIdList></Reference><Reference><Citation>Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L. (2010). A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont) 7:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010966</ArticleId><ArticleId IdType="pubmed">21191530</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholl D, Akhras KS, Diels J, Schadrack J. (2010). Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 26:943&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">20163295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ. (2010). Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry 10:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955631</ArticleId><ArticleId IdType="pubmed">20920179</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership (OMOP) (2014). Vocabularies. Version 4. Observational Medical Outcomes Partnership. Available at: http://omop.org/Vocabularies. [Accessed 16 September 2014].</Citation></Reference><Reference><Citation>Olivares JM, Rodriguez-Martinez A, Bur&#xf3;n JA, Alonso-Escolano D, Rodriguez-Morales A, e-STAR Study Group (2008). Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 6:41&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18774869</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS, e-STAR Study Group (2009a). Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 25:2197&#x2013;2206.</Citation><ArticleIdList><ArticleId IdType="pubmed">19604073</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. (2009b). Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24:287&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">19195847</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. (2012). Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. (2012). Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform 45:689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika 70:41&#x2013;55.</Citation></Reference><Reference><Citation>Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. (2011a). Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 364:842&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">21366475</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, et al. (2011b). Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clin Trials 8:196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">21270143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB. (2010). Establishing a drug era persistence window for active surveillance. Observational Medical Outcomes Partnership. Available at: http://omop.org/sites/default/files/OMOP-Establishing%20a%20Drug%20Era%20Persistence%20Window%20for%20Active%20Surveillance-Jan%202010.pdf. [Accessed 16 September 2014.].</Citation></Reference><Reference><Citation>Schooler NR. (2003). Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry Suppl 16:14&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">14680414</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiden PJ. (2006). Switching in the era of atypical antipsychotics. An updated review. Postgrad Med Spec No:27&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17128659</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiden PJ, Olfson M. (1995). Cost of relapse in schizophrenia. Schizophr Bull 21:419&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">7481573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. (2005). The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66:1122&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16187769</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25848530</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2041-1480</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Journal of biomedical semantics</Title><ISOAbbreviation>J Biomed Semantics</ISOAbbreviation></Journal><ArticleTitle>Development and validation of a classification approach for extracting severity automatically from electronic health records.</ArticleTitle><Pagination><StartPage>14</StartPage><MedlinePgn>14</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13326-015-0010-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Electronic Health Records (EHRs) contain a wealth of information useful for studying clinical phenotype-genotype relationships. Severity is important for distinguishing among phenotypes; however other severity indices classify patient-level severity (e.g., mild vs. acute dermatitis) rather than phenotype-level severity (e.g., acne vs. myocardial infarction). Phenotype-level severity is independent of the individual patient's state and is relative to other phenotypes. Further, phenotype-level severity does not change based on the individual patient. For example, acne is mild at the phenotype-level and relative to other phenotypes. Therefore, a given patient may have a severe form of acne (this is the patient-level severity), but this does not effect its overall designation as a mild phenotype at the phenotype-level.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We present a method for classifying severity at the phenotype-level that uses the Systemized Nomenclature of Medicine - Clinical Terms. Our method is called the Classification Approach for Extracting Severity Automatically from Electronic Health Records (CAESAR). CAESAR combines multiple severity measures - number of comorbidities, medications, procedures, cost, treatment time, and a proportional index term. CAESAR employs a random forest algorithm and these severity measures to discriminate between severe and mild phenotypes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using a random forest algorithm and these severity measures as input, CAESAR differentiates between severe and mild phenotypes (sensitivity&#x2009;=&#x2009;91.67, specificity&#x2009;=&#x2009;77.78) when compared to a manually evaluated reference standard (k&#x2009;=&#x2009;0.716).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CAESAR enables researchers to measure phenotype severity from EHRs to identify phenotypes that are important for comparative effectiveness research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Mary Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY USA ; Observational Health Data Sciences and Informatics (OHDSI), Columbia University, 622 West 168th Street, PH-20, New York, NY USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY USA ; Observational Health Data Sciences and Informatics (OHDSI), Columbia University, 622 West 168th Street, PH-20, New York, NY USA ; Department of Systems Biology, Columbia University, New York, NY USA ; Department of Medicine, Columbia University, New York, NY USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY USA ; Observational Health Data Sciences and Informatics (OHDSI), Columbia University, 622 West 168th Street, PH-20, New York, NY USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Semantics</MedlineTA><NlmUniqueID>101531992</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data mining</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">Health status indicators</Keyword><Keyword MajorTopicYN="N">Outcome assessment (Health Care)</Keyword><Keyword MajorTopicYN="N">Phenotype</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25848530</ArticleId><ArticleId IdType="pmc">PMC4386082</ArticleId><ArticleId IdType="doi">10.1186/s13326-015-0010-8</ArticleId><ArticleId IdType="pii">10</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;151:203&#x2013;205. doi: 10.7326/0003-4819-151-3-200908040-00125.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-3-200908040-00125</ArticleId><ArticleId IdType="pubmed">19567618</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153:600&#x2013;606. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho AN, Pacheco JA, Peissig PL, Rasmussen L, Newton KM, Weston N, et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med. 2011;3:79re71. doi: 10.1126/scitranslmed.3001807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001807</ArticleId><ArticleId IdType="pmc">PMC3690272</ArticleId><ArticleId IdType="pubmed">21508311</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene&#x2013;disease associations. Bioinformatics. 2010;26:1205&#x2013;1210. doi: 10.1093/bioinformatics/btq126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq126</ArticleId><ArticleId IdType="pmc">PMC2859132</ArticleId><ArticleId IdType="pubmed">20335276</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Hripcsak G, Shen Y, Chung WK, Weng C. Defining a comprehensive verotype using electronic health records for personalized medicine. J Am Med Inform Assoc. 2013;20:e232&#x2013;e238. doi: 10.1136/amiajnl-2013-001932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-001932</ArticleId><ArticleId IdType="pmc">PMC3861934</ArticleId><ArticleId IdType="pubmed">24001516</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc. 2013;20:144&#x2013;151. doi: 10.1136/amiajnl-2011-000681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000681</ArticleId><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton GB. Bias associated with mining electronic health records. J Biomed Discov Collab. 2011;6:48. doi: 10.5210/disco.v6i0.3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.5210/disco.v6i0.3581</ArticleId><ArticleId IdType="pmc">PMC3149555</ArticleId><ArticleId IdType="pubmed">21647858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. Correlating electronic health record concepts with healthcare process events. J Am Med Inform Assoc. 2013;20:e311&#x2013;e318. doi: 10.1136/amiajnl-2013-001922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-001922</ArticleId><ArticleId IdType="pmc">PMC3861922</ArticleId><ArticleId IdType="pubmed">23975625</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson PN, K&#xf6;hler S, Bauer S, Seelow D, Horn D, Mundlos S. The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet. 2008;83:610&#x2013;615. doi: 10.1016/j.ajhg.2008.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.09.017</ArticleId><ArticleId IdType="pmc">PMC2668030</ArticleId><ArticleId IdType="pubmed">18950739</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkin PL, Brown SH, Husser CS, Bauer BA, Wahner-Roedler D, Rosenbloom ST, et al. Mayo Clinic Proceedings. North America: Elsevier; 2006. Evaluation of the content coverage of SNOMED CT: ability of SNOMED clinical terms to represent clinical problem lists; pp. 741&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16770974</ArticleId></ArticleIdList></Reference><Reference><Citation>Stearns MQ, Price C, Spackman KA, Wang AY. Proceedings of the AMIA Symposium. Ann Arbor: American Medical Informatics Association; 2001. SNOMED clinical terms: overview of the development process and project status; p. 662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243297</ArticleId><ArticleId IdType="pubmed">11825268</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JR, Payne TH. A comparison of four schemes for codification of problem lists. Proc Annu Symp Comput Appl Med Care. 1994;201:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2247911</ArticleId><ArticleId IdType="pubmed">7949920</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NH. Mining the ultimate phenome repository. Nat Biotechnol. 2013;31:1095&#x2013;1097. doi: 10.1038/nbt.2757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2757</ArticleId><ArticleId IdType="pmc">PMC4036679</ArticleId><ArticleId IdType="pubmed">24316646</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J, Wintfeld N, Sharkey P, Passman LJ. THe importance of severity of illness in assessing hospital mortality. JAMA. 1990;263:241&#x2013;246. doi: 10.1001/jama.1990.03440020075036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1990.03440020075036</ArticleId><ArticleId IdType="pubmed">2403601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206&#x2013;212. doi: 10.1067/S0190-9622(03)00910-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/S0190-9622(03)00910-1</ArticleId><ArticleId IdType="pubmed">12894066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastien CH, Valli&#xe8;res A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297&#x2013;307. doi: 10.1016/S1389-9457(00)00065-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1389-9457(00)00065-4</ArticleId><ArticleId IdType="pubmed">11438246</ArticleId></ArticleIdList></Reference><Reference><Citation>McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199&#x2013;213. doi: 10.1016/0740-5472(92)90062-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0740-5472(92)90062-S</ArticleId><ArticleId IdType="pubmed">1334156</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thorson AG, et al. Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence. Dis Colon Rectum. 1999;42:1525&#x2013;1531. doi: 10.1007/BF02236199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02236199</ArticleId><ArticleId IdType="pubmed">10613469</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn SD, Horn RA. Reliability and validity of the severity of illness index. Med Care. 1986;24:159&#x2013;178. doi: 10.1097/00005650-198602000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-198602000-00007</ArticleId><ArticleId IdType="pubmed">3080648</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser V, Cimino JJ. Don&#x2019;t take your EHR to heaven, donate it to science: legal and research policies for EHR post mortem. J Am Med Inform Assoc. 2014;21:8&#x2013;12. doi: 10.1136/amiajnl-2013-002061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-002061</ArticleId><ArticleId IdType="pmc">PMC3912713</ArticleId><ArticleId IdType="pubmed">23966483</ArticleId></ArticleIdList></Reference><Reference><Citation>Perotte A, Hripcsak G. Temporal properties of diagnosis code time series in aggregate. IEEE J Biomed Health Inform. 2013;17:477&#x2013;483. doi: 10.1109/JBHI.2013.2244610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JBHI.2013.2244610</ArticleId><ArticleId IdType="pmc">PMC4030411</ArticleId><ArticleId IdType="pubmed">24235118</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitch R, Walsh C, Hripcsak G, Tatonetti NP. Prediction of Biomedical Events via Time Intervals Mining. NYC, USA: ACM KDD Workshop on Connected Health in Big Data Era; 2014.</Citation></Reference><Reference><Citation>Moskovitch R, Shahar Y. Classification-driven temporal discretization of multivariate time series. Data Min Knowl Disc. 2014;1:43.</Citation></Reference><Reference><Citation>Moskovitch R, Shahar Y. Fast time intervals mining using the transitivity of temporal relations. Knowl Inf Syst. 2013;1:28.</Citation></Reference><Reference><Citation>Averill RF, McGuire TE, Manning BE, Fowler DA, Horn SD, Dickson PS, et al. A study of the relationship between severity of illness and hospital cost in New Jersey hospitals. Health Serv Res. 1992;27:587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069899</ArticleId><ArticleId IdType="pubmed">1464535</ArticleId></ArticleIdList></Reference><Reference><Citation>CMS. License for Use of Current Procedural Terminology, Four. http://www.cms.gov/apps/ama/license.asp?file=/physicianfeesched/downloads/cpepfiles022306.zip 2004, Accessed 25 April 2014.</Citation></Reference><Reference><Citation>Hyv&#xe4;rinen A, Oja E. Independent component analysis: algorithms and applications. Neural Netw. 2000;13:411&#x2013;430. doi: 10.1016/S0893-6080(00)00026-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0893-6080(00)00026-5</ArticleId><ArticleId IdType="pubmed">10946390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records. J Am Med Inform Assoc. 2013;20:117&#x2013;121. doi: 10.1136/amiajnl-2012-001145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-001145</ArticleId><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932;140. http://www.worldcat.org/title/technique-for-the-measurement-of-attitudes/oclc/812060.</Citation></Reference><Reference><Citation>Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70:213&#x2013;220. doi: 10.1037/h0026256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/h0026256</ArticleId><ArticleId IdType="pubmed">19673146</ArticleId></ArticleIdList></Reference><Reference><Citation>Revelle W. Package &#x2018;psych&#x2019;: Procedures for Psychological, Psychometric, and Personality Research (Version 1.4.4) [software]. 2014. Available from http://cran.r-project.org/web/packages/psych/psych.pdf.</Citation></Reference><Reference><Citation>Fleiss J. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76:378&#x2013;382. doi: 10.1037/h0031619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/h0031619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamer M, Lemon J, Fellows I, Sing P. Package irr: Various Coefficients of Interrater Reliability and Agreement (Version 0.84) [software]. 2013. Available from http://cran.r-project.org/web/packages/irr/irr.pdf.</Citation></Reference><Reference><Citation>Liaw A, Wiener M. Classification and Regression by randomForest. R news. 2002;2:18&#x2013;22.</Citation></Reference><Reference><Citation>Breiman L, Cutler A, Liaw A, Wiener M. Package &#x2018;randomForest&#x2019;: Breiman and Cutler&#x2019;s random forests for classification and regression (Version 4.6-7) [software]. 2012. Available from: http://cran.r-project.org/web/packages/randomForest/randomForest.pdf.</Citation></Reference><Reference><Citation>Westreich D. Berkson&#x2019;s bias, selection bias, and missing data. Epidemiology (Cambridge, Mass) 2012;23:159. doi: 10.1097/EDE.0b013e31823b6296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e31823b6296</ArticleId><ArticleId IdType="pmc">PMC3237868</ArticleId><ArticleId IdType="pubmed">22081062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinetti ME, Studenski SA. Comparative Effectiveness Research and Patients with Multiple Chronic Conditions. N Engl J Med. 2011;364(26):2478&#x2013;2481. doi: 10.1056/NEJMp1100535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1100535</ArticleId><ArticleId IdType="pubmed">21696327</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissim N, Boland MR, Moskovitch R, Tatonetti NP, Elovici Y, Shahar Y, et al. An Active Learning Enhancement for Conditions Severity Classification. NYC, USA: ACM KDD on Workshop on Connected Health at Big Data Era; 2014.</Citation></Reference><Reference><Citation>Housman TS, Feldman SR, Williford PM, Fleischer AB, Jr, Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425&#x2013;429. doi: 10.1067/mjd.2003.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mjd.2003.186</ArticleId><ArticleId IdType="pubmed">12637924</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rocco M, Giona F, Carubbi F, Linari S, Minichilli F, Brady RO, et al. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica. 2008;93:1211&#x2013;1218. doi: 10.3324/haematol.12379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.12379</ArticleId><ArticleId IdType="pubmed">18603565</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes AB, Hawson A, Liu F, Friedman C, Khiabanian H, Rabadan R. Discovering disease associations by integrating electronic clinical data and medical literature. PLoS One. 2011;6:e21132. doi: 10.1371/journal.pone.0021132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021132</ArticleId><ArticleId IdType="pmc">PMC3121722</ArticleId><ArticleId IdType="pubmed">21731656</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Schuemie MJ, Hripcsak G. Medication-wide association studies. Pharmacometr Syst Pharmacol. 2013;2:e76. doi: 10.1038/psp.2013.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/psp.2013.52</ArticleId><ArticleId IdType="pmc">PMC4026636</ArticleId><ArticleId IdType="pubmed">24448022</ArticleId></ArticleIdList></Reference><Reference><Citation>Dligach D, Bethard S, Becker L, Miller T, Savova GK. Discovering body site and severity modifiers in clinical texts. J Am Med Inform Assoc. 2014;21(3):448&#x2013;454. doi: 10.1136/amiajnl-2013-001766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-001766</ArticleId><ArticleId IdType="pmc">PMC3994852</ArticleId><ArticleId IdType="pubmed">24091648</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25887092</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2015</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>The impact of standardizing the definition of visits on the consistency of multi-database observational health research.</ArticleTitle><Pagination><StartPage>13</StartPage><MedlinePgn>13</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-015-0001-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Use of administrative claims from multiple sources for research purposes is challenged by the lack of consistency in the structure of the underlying data and definition of data across claims data providers. This paper evaluates the impact of applying a standardized revenue code-based logic for defining inpatient encounters across two different claims databases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We selected members who had complete enrollment in 2012 from the Truven MarketScan Commercial Claims and Encounters (CCAE) and the Optum Clinformatics (Optum) databases. The overall prevalence of inpatient conditions in the raw data was compared to that in the common data model (CDM) with the standardized visit definition applied.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In CCAE, 87.18% of claims from 2012 that were classified as part of inpatient visits in the raw data were also classified as part of inpatient visits after the data were standardized to CDM, and this overlap was consistent from 2006 to 2011. In contrast, Optum had 83.18% concordance in classification of 2012 claims from inpatient encounters before and after standardization, but the consistency varied over time. The re-classification of inpatient encounters substantially impacted the observed prevalence of medical conditions occurring in the inpatient setting and the consistency in prevalence estimates between the databases. On average, before standardization, each condition in Optum was 12% more prevalent than that same condition in CCAE; after standardization, the prevalence of conditions had a mean difference of only 1% between databases. Amongst 7,039 conditions reviewed, the difference in the prevalence of 67% of conditions in these two databases was reduced after standardization.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In an effort to improve consistency in research results across database one should review sources of database heterogeneity, such as the way data holders process raw claims data. Our study showed that applying the Observational Medical Outcomes Partnership (OMOP) CDM with a standardized approach for defining inpatient visits during the extract, transfer, and load process can decrease the heterogeneity observed in disease prevalence estimates across two different claims data sources.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, 920 Route 202, Raritan, NJ, 08869, USA. evoss3@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qianli</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, 920 Route 202, Raritan, NJ, 08869, USA. qma3@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, 920 Route 202, Raritan, NJ, 08869, USA. pryan4@its.jnj.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="N">Insurance Claim Review</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009819" MajorTopicYN="N">Office Visits</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25887092</ArticleId><ArticleId IdType="pmc">PMC4369827</ArticleId><ArticleId IdType="doi">10.1186/s12874-015-0001-6</ArticleId><ArticleId IdType="pii">10.1186/s12874-015-0001-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323&#x2013;37. doi: 10.1016/j.jclinepi.2004.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2004.10.012</ArticleId><ArticleId IdType="pubmed">15862718</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart MA, St&#xfc;rmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(6):S114&#x2013;20. doi: 10.1097/MLR.0b013e3181dbebe3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3181dbebe3</ArticleId><ArticleId IdType="pmc">PMC4024462</ArticleId><ArticleId IdType="pubmed">20473199</ArticleId></ArticleIdList></Reference><Reference><Citation>2012 Truven Health MarketScan&#xae; commercial claims and encounters data dictionary medicare supplemental and coordination of benefits. Truven Health Analytics. 2013.</Citation></Reference><Reference><Citation>Nasim NG. Optum Clinformatics Data Mart (CDM) data dictionary. Optum; 2012.</Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Overhage JM, Schuemie MJ, Hartzema AG, Welebob E. Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey. Drug Saf. 2013;36(Suppl 1):S15&#x2013;25. doi: 10.1007/s40264-013-0103-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0103-1</ArticleId><ArticleId IdType="pubmed">24166220</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367555</ArticleId></ArticleIdList></Reference><Reference><Citation>Mini-sentinel systematic reviews of validated methods for identifying health outcomes using administrative data: analysis of evidence gaps and lessons learned report. [http://www.mini-sentinel.org/work_products/HealthOutcomes/Mini-Sentinel-HOI-Evidence-Review-Gap-Analysis-Report.pdf]</Citation><ArticleIdList><ArticleId IdType="pubmed">22262596</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the mini-sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):23&#x2013;31. doi: 10.1002/pds.2336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2336</ArticleId><ArticleId IdType="pubmed">22262590</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). [http://omop.org/CDM]</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20(1):1&#x2013;11. doi: 10.1002/pds.2053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2053</ArticleId><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>The National patient-centered clinical research network (PCORnet). [http://pcornet.org/]</Citation></Reference><Reference><Citation>Vogt TM, Elston-Lafata J, Tolsma D, Greene SM. The role of research in integrated healthcare systems: the HMO research network. Am J Manag Care. 2004;10(9):643&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15515997</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600&#x2013;6. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Scerbo M, Dickstein C, Wilson A. Health care data and SAS. Cary, NC: SAS Institute Inc.; 2001.</Citation></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012;45(4):689&#x2013;96. doi: 10.1016/j.jbi.2012.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>A unified approach to measuring the effect size between two groups using SAS&#xae; (Paper 335&#x2013;2012). [http://support.sas.com/resources/papers/proceedings12/335-2012.pdf]</Citation></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645&#x2013;51. doi: 10.1093/aje/kwt010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt010</ArticleId><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Truven Health MarketScan&#xae; Research Databases. Commercial claims and encounters medicare supplemental user guide, data year 2012 edition. Truven Health Analytics Inc.; 2013.</Citation></Reference><Reference><Citation>Janssen research &amp; development, pharmaceutical companies of Johnson &amp; Johnson common data model (CDM v4.0) ETL mapping specification for Optum. [http://omop.org/CDM]</Citation></Reference><Reference><Citation>Janssen research &amp; development, pharmaceutical companies of Johnson &amp; Johnson common data model (CDM v4.0) ETL mapping specification for Truven (CCAE and MDCR). [http://omop.org/CDM]</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25992385</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2327-9214</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>EGEMS (Washington, DC)</Title><ISOAbbreviation>EGEMS (Wash DC)</ISOAbbreviation></Journal><ArticleTitle>Transparent reporting of data quality in distributed data networks.</ArticleTitle><Pagination><StartPage>1052</StartPage><MedlinePgn>1052</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1052</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.13063/2327-9214.1052</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Poor data quality can be a serious threat to the validity and generalizability of clinical research findings. The growing availability of electronic administrative and clinical data is accompanied by a growing concern about the quality of these data for observational research and other analytic purposes. Currently, there are no widely accepted guidelines for reporting quality results that would enable investigators and consumers to independently determine if a data source is fit for use to support analytic inferences and reliable evidence generation.</AbstractText><AbstractText Label="MODEL AND METHODS" NlmCategory="UNASSIGNED">We developed a conceptual model that captures the flow of data from data originator across successive data stewards and finally to the data consumer. This "data lifecycle" model illustrates how data quality issues can result in data being returned back to previous data custodians. We highlight the potential risks of poor data quality on clinical practice and research results. Because of the need to ensure transparent reporting of a data quality issues, we created a unifying data-quality reporting framework and a complementary set of 20 data-quality reporting recommendations for studies that use observational clinical and administrative data for secondary data analysis. We obtained stakeholder input on the perceived value of each recommendation by soliciting public comments via two face-to-face meetings of informatics and comparative-effectiveness investigators, through multiple public webinars targeted to the health services research community, and with an open access online wiki.</AbstractText><AbstractText Label="RECOMMENDATIONS" NlmCategory="CONCLUSIONS">Our recommendations propose reporting on both general and analysis-specific data quality features. The goals of these recommendations are to improve the reporting of data quality measures for studies that use observational clinical and administrative data, to ensure transparency and consistency in computing data quality measures, and to facilitate best practices and trust in the new clinical discoveries based on secondary use of observational data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>University of Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Harvard Pilgrim Health Care Institute ; Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Alein T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Health System.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Bruce N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Hoag Memorial Hospital Presbyterian.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Southern California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>University of Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiskopf</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Oregon Health Sciences University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Maine Medical Center Research Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zozus</LastName><ForeName>Meredith Nahm</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Duke University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HS019908</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U13 HS019564</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000154</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EGEMS (Wash DC)</MedlineTA><NlmUniqueID>101629606</NlmUniqueID><ISSNLinking>2327-9214</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Informatics</Keyword><Keyword MajorTopicYN="N">comparative effectiveness</Keyword><Keyword MajorTopicYN="N">data use and quality</Keyword><Keyword MajorTopicYN="N">observational data</Keyword><Keyword MajorTopicYN="N">research networks</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25992385</ArticleId><ArticleId IdType="pmc">PMC4434997</ArticleId><ArticleId IdType="doi">10.13063/2327-9214.1052</ArticleId><ArticleId IdType="pii">egems1052</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lopez MH, Holve E, Sarkar IN, Segal C. Building the informatics infrastructure for Comparative Effectiveness Research (CER): A review of the literature. Med Care. 2012 Jul;50(Suppl):S38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692258</ArticleId></ArticleIdList></Reference><Reference><Citation>Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA J Am Med Assoc. 2012;307(15):1583&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22511682</ArticleId></ArticleIdList></Reference><Reference><Citation>Clancy C, Collins FS. Patient-Centered Outcomes Research Institute: the intersection of science and health care. Sci Transl Med. 2010;2(37):37cm18&#x2013;37cm18.</Citation><ArticleIdList><ArticleId IdType="pubmed">20574065</ArticleId></ArticleIdList></Reference><Reference><Citation>Washington AE, Lipstein SH.The Patient-Centered Outcomes Research Institute&#x2014;promoting better information, decisions, and health N Engl J Med [Internet] 2011[cited 2013 Aug 29];365(15). Available from: http://www.nejm.org/doi/full/10.1056/nejmp1109407</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmp1109407</ArticleId><ArticleId IdType="pubmed">21992473</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine (US) Committee on Improving the Patient Record. In: Dick RS, Steen EB, editors. The computer-based patient record: An essential technology for health care. revised edition. Washington, D.C: National Academy Press; 1997. p. xii.p. 190.</Citation><ArticleIdList><ArticleId IdType="pubmed">25121222</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran C, Bloomrosen M, Hammond WE, Labkoff S, Markel-Fox S, Tang PC, et al. Toward a National Framework for the Secondary Use of Health Data: An American Medical Informatics Association White Paper. J Am Med Inf Assoc. 2007 Jan 1;14(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329823</ArticleId><ArticleId IdType="pubmed">17077452</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MG, Embi PJ. Toward Reuse of Clinical Data for Research and Quality Improvement: The End of the Beginning? Ann Intern Med. 2009;151(5):359&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638404</ArticleId></ArticleIdList></Reference><Reference><Citation>Borycki EM, Newsham D, Bates DW. eHealth in North America. Yearb Med Inform. 2013;8(1):103&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23974555</ArticleId></ArticleIdList></Reference><Reference><Citation>Holve E, Segal C, Hamilton Lopez M. Opportunities and challenges for Comparative Effectiveness Research (CER) with electronic clinical data: A perspective from the EDM forum. Med Care. 2012 Jul;50(Suppl):S11&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692252</ArticleId></ArticleIdList></Reference><Reference><Citation>Embi PJ, Payne PRO. Evidence Generating Medicine: Redefining the Research-Practice Relationship to Complete the Evidence Cycle. Med Care. 2013 Aug;51:S87&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23793052</ArticleId></ArticleIdList></Reference><Reference><Citation>Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing Reports of Bleeding. N Engl J Med. 2013;368(14):1272&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484796</ArticleId></ArticleIdList></Reference><Reference><Citation>Concato J, Shah N, Horwitz R. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000 Jun 22;342(25):1887&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1557642</ArticleId><ArticleId IdType="pubmed">10861325</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloomrosen M, Detmer D. Advancing the Framework: Use of Health Data - A Report of a Working Conference of the American Medical Informatics Association. J Amer Med Inf Assoc. 2008 Dec;15(6):715&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585531</ArticleId><ArticleId IdType="pubmed">18755988</ArticleId></ArticleIdList></Reference><Reference><Citation>Velentgas P, Dreyer NA, Nourjah P, Smith SR, Tourchia M.  Developing a protocol of observational comparative effectiveness research: A user&#x2019;s guide [Internet] Rockville, MD: 2013.  Report No.: AHRQ Publication 12(13)-EHC099. Available from:  www.effectivehealthcare.ahrq.gov/Methods-OCER.cfm.</Citation><ArticleIdList><ArticleId IdType="pubmed">23469377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics. 1997 Jun;99:765&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9164767</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornbrook MC, Hart G, Ellis JL, Bachman DJ, Ansell G, Greene SM, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr. 2005:12&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287881</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace WD, Cifuentes M, Valuck RJ, Staton EW, Brandt EC, West DR. An electronic practice-based network for observational comparative effectiveness research. Ann Intern Med. 2009 Sep 1;151(5):338&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638402</ArticleId></ArticleIdList></Reference><Reference><Citation>Maro JC, Platt R, Holmes JH, Strom BL, Hennessy S, Lazarus R, et al. Design of a national distributed health data network. Ann Intern Med. 2009 Sep 1;151(5):341&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638403</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, et al. The U.S. Food and Drug Administration&#x2019;s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012 Jan;21(Suppl 1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262586</ArticleId></ArticleIdList></Reference><Reference><Citation>Holve E, Segal C, Lopez MH, Rein A, Johnson BH. The Electronic Data Methods (EDM) Forum for Comparative Effectiveness Research (CER) Med Care. 2012 Jul;50(Suppl):S7&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross TR, Ng D, Brown JS, Pardee R, Hornbrook MC, Hart G, et al.  The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. EGEMs Gener Evid Methods Improve Patient Outcomes [Internet] 2014. Mar 24,  [cited 2014 Apr 16];2(1). Available from:  http://repository.academyhealth.org/egems/vol2/iss1/2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371424</ArticleId><ArticleId IdType="pubmed">25848584</ArticleId></ArticleIdList></Reference><Reference><Citation> RFA-RM-13-012: NIH Health Care Systems Research Collaboratory - Demonstration Projects for Pragmatic Clinical Trials Focusing on Multiple Chronic Conditions (UH2/UH3) [Internet]. [cited 2013 Dec 9]. Available from:  http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-13-012.html.</Citation></Reference><Reference><Citation>Blumenthal D, Tavenner M. The &#x201c;Meaningful Use&#x201d; Regulation for Electronic Health Records. N Engl J Med. 2010;363(6):501&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20647183</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal D. Launching HITECH. N Engl J Med. 2010 Feb 4;362:382&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20042745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez MH, Holve E, Rein A, Winkler J. Involving Patients and Consumers in Research: New Opportunities for Meaningful Engagement in Research and Quality Improvement. 2012.  Available from:  http://repository.academyhealth.org/edm_briefs/2/</Citation></Reference><Reference><Citation>Bates DW, Bitton A. The future of health information technology in the patient-centered medical home. Health Aff (Millwood) 2010;29(4):614&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20368590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralston JD, Coleman K, Reid RJ, Handley MR, Larson EB. Patient experience should be part of meaningful-use criteria. Health Aff (Millwood) 2010;29(4):607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">20368589</ArticleId></ArticleIdList></Reference><Reference><Citation>Etheredge LM. A rapid-learning health system. Health Aff Proj Hope. 2007 Apr;26(2):w107&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">17259191</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen L, Aisner D, McGinnis JM, editors. Roundtable on Evidence-Based Medicine. The Learning Healthcare System: Workshop Summary (IOM Roundtable on Evidence-Based Medicine) 2007.  Available from:  http://www.nap.edu/openbook.php?record_id=11903.</Citation><ArticleIdList><ArticleId IdType="pubmed">21452449</ArticleId></ArticleIdList></Reference><Reference><Citation>Abernethy AP, Etheredge LM, Ganz PA, Wallace P, German RR, Neti C, et al. Rapid-Learning System for Cancer Care. J Clin Oncol. 2010 Jun 28;28(27):4268&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953977</ArticleId><ArticleId IdType="pubmed">20585094</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CP, Wong AK, Blumenthal D. Achieving a nationwide learning health system. Sci Transl Med. 2010 Nov 10;2:57cm29.</Citation><ArticleIdList><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman C, McGinnis JM. Digital Infrastructure for the Learning Health System: The Foundation for Continuous Improvement in Health and Health Care: Workshop Series Summary. National Academies Press; 2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">22379651</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System--a national resource for evidence development. N Engl J Med. 2011 Feb 10;364(6):498&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21226658</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronsky D, Haug PJ. Assessing the quality of clinical data in a computer-based record for calculating the pneumonia severity index. J Am Med Inform Assoc JAMIA. 2000 Feb;7(1):55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61455</ArticleId><ArticleId IdType="pubmed">10641963</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts DGT, De Keizer NF, Scheffer G-J. Defining and improving data quality in medical registries: a literature review, case study, and generic framework. J Am Med Inform Assoc JAMIA. 2002 Dec;9(6):600&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC349377</ArticleId><ArticleId IdType="pubmed">12386111</ArticleId></ArticleIdList></Reference><Reference><Citation>Botsis T, Hartvigsen G, Chen F, Weng C. Secondary use of EHR: Data quality issues and informatics opportunities. AMIA Summits Transl Sci Proc. 2010;2010:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041534</ArticleId><ArticleId IdType="pubmed">21347133</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian Institute for Health Information  . The CIHI data quality framework [Internet] Ottawa, Ont.: CIHI; 2009.  Available from:  http://www.cihi.ca/CIHI-ext-portal/pdf/internet/DATA_QUALITY_FRAMEWORK_2009_EN.</Citation></Reference><Reference><Citation>Hersh WR, Weiner MG, Embi PJ, Logan JR, Payne PRO, Bernstam EV, et al. Caveats for the Use of Operational Electronic Health Record Data in Comparative Effectiveness Research. Med Care. 2013 Aug;51:S30&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748381</ArticleId><ArticleId IdType="pubmed">23774517</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Kahn M, Toh S. Data quality assessment for comparative effectiveness research in distributed data networks. Med Care. 2013;51:S22&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306391</ArticleId><ArticleId IdType="pubmed">23793049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartzema AG, Reich CG, Ryan PB, Stang PE, Madigan D, Welebob E, et al. Managing data quality for a drug safety surveillance system. Drug Saf Int J Med Toxicol Drug Exp. 2013 Oct;36(Suppl 1):49&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166223</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Green S, Collaboration C.  Cochrane handbook for systematic reviews of interventions [Internet] Wiley Online Library; 2008.  [cited 2013 Aug 29]. Available from:  http://www.cochrane.org.</Citation></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008 Apr;61(4):344&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Simera I, Altman DG, Moher D, Schulz KF, Hoey J. Guidelines for reporting health research: the EQUATOR network&#x2019;s survey of guideline authors. PLoS Med. 2008 Jun 24;5(6):e139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443184</ArticleId><ArticleId IdType="pubmed">18578566</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira P, Rodrigues F, Henriques PR. A Formal Definition of Data Quality Problems. IQ [Internet] 2005.  [cited 2013 Jul 4]. Available from:  http://mitiq.mit.edu/ICIQ/Documents/IQ%20Conference%202005/Papers/AFormalDefinitionofDQProblems.pdf.</Citation></Reference><Reference><Citation>Kim W, Choi B-J, Hong E-K, Kim S-K, Lee D. A taxonomy of dirty data. Data Min Knowl Discov. 2003;7(1):81&#x2013;99.</Citation></Reference><Reference><Citation>Wand Y, Wang R. Anchoring data quality dimensions in ontological foundations. Comm ACM. 1996;39:86&#x2013;95.</Citation></Reference><Reference><Citation>Sanna F. Discovering Data Quality [Internet] 2006.  Available from:  http://www.dmreview.com/portals/portalarticle.cfm?articleId=1056199&amp;topicId=230005.</Citation></Reference><Reference><Citation>Chapman AD.  Principles of Data Quality V1.0. Report for the Global Biodiversity Information Facility [Internet] GBIF Secretariat; 2005.  Available from:  http://www.gbif.org/orc/?doc_id=1229.</Citation></Reference><Reference><Citation>Wang R, Strong D. Beyond accuracy: What data quality means to data consumers. J Manag Inf Syst. 1996;12:5&#x2013;34.</Citation></Reference><Reference><Citation>Batini C. Data Quality: Concepts, Methodologies and Techniques. Berlin: Springer; 2006. p. 262.</Citation></Reference><Reference><Citation>Redman TC. Data Quality: The Field Guide. Boston: Digital Press; 2001. p. 241.</Citation></Reference><Reference><Citation>Redman TC. Data quality for the information age. Boston: Artech House; 1996. p. 303.</Citation></Reference><Reference><Citation>Winkler WE. Methods for evaluating and creating data quality. Inf Syst. 2004 Oct;29(7):531&#x2013;50.</Citation></Reference><Reference><Citation>Kahn MG, Raebel MA, Glanz JM, Riedlinger K, Steiner JF. A pragmatic framework for single-site and multisite data quality assessment in electronic health record-based clinical research. Med Care. 2012 Jul;50(Suppl):S21&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833692</ArticleId><ArticleId IdType="pubmed">22692254</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc. 2013 Jan 1;20:144&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahm M. Clinical Research Informatics. London: Springer-Verlag; 2012. Data quality in clinical research; pp. 175&#x2013;201.</Citation></Reference><Reference><Citation>Liaw ST, Rahimi A, Ray P, Taggart J, Dennis S, de Lusignan S, et al. Towards an ontology for data quality in integrated chronic disease management: A realist review of the literature. Int J Med Inf. 2013 Jan;82(1):10&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23122633</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of the National Coordinator  . Report to Congress: Update on the adoption of health information technology and related efforts to facilitate the electronic use and exchange of health information [Internet] Office of the National Coordinator for Health Information Technology; 2014. Oct, p. 54. [cited 2013 Dec 2] Available from:  http://www.healthit.gov/sites/default/files/rtc_adoption_and_exchange9302014.pdf.</Citation></Reference><Reference><Citation>Curry Joel. The Data Advantage: How accuracy creates opportunity. A Experian QAS 2013 Research Report [Internet] 2013.  [cited 2013 Dec 2]. Available from:  http://www.experian.co.uk/assets/marketing-services/white-papers/wp-qas-the-data-advantage.pdf.</Citation></Reference><Reference><Citation>Loshin D. The Practitioner&#x2019;s Guide to Data Quality Improvement. Morgan Kaufmann; 2010. p. 432.</Citation></Reference><Reference><Citation>Kohn LT, Corrigan JM, Donaldson MS. To err is human: Building a safer health system [Internet] Washington D.C: National Academy Press; 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">25077248</ArticleId></ArticleIdList></Reference><Reference><Citation>Riain C, Helfert M. An evaluation of data quality related problems patterns in healthcare information systems. In: Isaias P, Nunes M, dos Reis A, editors. IADIS virtual multi conference on computer science and information systems. 2005.</Citation></Reference><Reference><Citation>Brennan PF, Stead WW. Assessing data quality: from concordance, through correctness and completeness, to valid manipulatable representations. J Am Med Inf Assoc. 2000 Jan;7:106&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61460</ArticleId><ArticleId IdType="pubmed">10641968</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahm ML, Pieper CF, Cunningham MM. Quantifying data quality for clinical trials using electronic data capture. PloS One. 2008;3(8):e3049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2516178</ArticleId><ArticleId IdType="pubmed">18725958</ArticleId></ArticleIdList></Reference><Reference><Citation>Baigent C, Harrell FE, Buyse M, Emberson JR, Altman DG. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials Lond Engl. 2008;5(1):49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18283080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton G. Bias associated with mining electronic health records. J Biomed Discov Collab. 2011;6:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149555</ArticleId><ArticleId IdType="pubmed">21647858</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Lash TL. Bias Analysis Modern epidemiology. Philadelphia: Wolters Kluwer/Lippincott Williams &amp; Wilkins; 2008.</Citation></Reference><Reference><Citation>Davis JR, Institute of Medicine (US)   Roundtable on Research and Development of Drugs Biologics and Medical Devices Assuring data quality and validity in clinical trials for regulatory decision making : workshop report [Internet] Washington, DC: National Academy Press; 1999. p. xii.p. 76. Available from:  http://books.nap.edu/catalog/9623.html.</Citation><ArticleIdList><ArticleId IdType="pubmed">25077226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gassman JJ, Owen WW, Kuntz TE, Martin JP, Amoroso WP. Data quality assurance, monitoring, and reporting. Control Clin Trials. 1995 Apr;16(2 Suppl):104S&#x2013;136S.</Citation><ArticleIdList><ArticleId IdType="pubmed">7789140</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieneisen ML, Zhang M. A Comprehensive Survey of Retracted Articles from the Scholarly Literature. PLoS ONE. 2012 Oct 24;7(10):e44118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480361</ArticleId><ArticleId IdType="pubmed">23115617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mini-Sentinel Coordinating Center  Mini-Sentinel Standard Operating Procedure: Data Quality Checking and Profiling. 20.  Available from:  http://www.mini-sentinel.org/work_products/About_Us/Mini-Sentinel_SOP_Data-Quality-Checking-and-Profiling.pdf.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership  OSCAR - Observational Source Characteristics Analysis Report (OSCAR) Design Specification and Feasibility Assessment [Internet] 2011.  [cited 2013 Apr 1]. Available from:  http://omop.fnih.org/OSCAR.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership  Generalized Review of OSCAR Unified Checking [Internet] 2011.  [cited 2013 Apr 1]. Available from:  http://omop.fnih.org/GROUCH.</Citation></Reference><Reference><Citation>Maydanchik A. Data quality assessment. Bradley Beach, NJ: Technics Publications; 2007. p. xiv.p. 321.</Citation></Reference><Reference><Citation>Magnusson D, Bergman LR. European Network on Longitudinal Studies on Individual Development Data quality in longitudinal research. Cambridge [England] ; New York: Cambridge University Press; 1990. p. xii.p. 285.</Citation></Reference><Reference><Citation>Singh S. Evaluation of data quality. [London, England]: International Statistical Institute by Oxford University Press; 1987. pp. 618&#x2013;643.</Citation></Reference><Reference><Citation>Sadiq S, editor. Handbook of Data Quality. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013.</Citation></Reference><Reference><Citation>Creswell JW. Qualitative, Quantitative, and Mixed Methods Approaches (Crewell, Research Design: Qualitative, Quantitative, and Mixed Methods Approaches) 4th edition. Fourth Edition. Thousand Oaks, California: SAGE Publications, Inc; 2013. p. 273.</Citation></Reference><Reference><Citation>ISO . ISO/IEC 11179 - Information technology &#x2014; Metadata registries (MDR) &#x2014; Part 3: Registry metamodel and basic attributes. International Standard Organization; 2013.</Citation></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care. 2012 Jul;50(Suppl):S60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26041386</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Birth month affects lifetime disease risk: a phenome-wide method.</ArticleTitle><Pagination><StartPage>1042</StartPage><EndPage>1053</EndPage><MedlinePgn>1042-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocv046</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">An individual's birth month has a significant impact on the diseases they develop during their lifetime. Previous studies reveal relationships between birth month and several diseases including atherothrombosis, asthma, attention deficit hyperactivity disorder, and myopia, leaving most diseases completely unexplored. This retrospective population study systematically explores the relationship between seasonal affects at birth and lifetime disease risk for 1688 conditions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed a hypothesis-free method that minimizes publication and disease selection biases by systematically investigating disease-birth month patterns across all conditions. Our dataset includes 1 749 400 individuals with records at New York-Presbyterian/Columbia University Medical Center born between 1900 and 2000 inclusive. We modeled associations between birth month and 1688 diseases using logistic regression. Significance was tested using a chi-squared test with multiplicity correction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found 55 diseases that were significantly dependent on birth month. Of these 19 were previously reported in the literature (P&#x2009;&lt;&#x2009;.001), 20 were for conditions with close relationships to those reported, and 16 were previously unreported. We found distinct incidence patterns across disease categories.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lifetime disease risk is affected by birth month. Seasonally dependent early developmental mechanisms may play a role in increasing lifetime risk of disease.</AbstractText><CopyrightInformation>&#xa9; The Author 2015. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Mary Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahn</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Statistics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI) Department of Statistics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics Observational Health Data Sciences and Informatics (OHDSI) Department of Systems Biology Department of Medicine, Columbia University, New York, NY, USA nick.tatonetti@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="N">Data Mining</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004194" MajorTopicYN="Y">Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011297" MajorTopicYN="N">Prenatal Exposure Delayed Effects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">embryonic and fetal development</Keyword><Keyword MajorTopicYN="N">maternal exposure</Keyword><Keyword MajorTopicYN="N">personalized medicine</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">prenatal nutritional physiological phenomena</Keyword><Keyword MajorTopicYN="N">seasons</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26041386</ArticleId><ArticleId IdType="pmc">PMC4986668</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocv046</ArticleId><ArticleId IdType="pii">ocv046</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hippocrates, Adams Ft. On Airs, Waters, and Places. http://classics.mit.edu/Hippocrates/airwatpl.mb.txt. 460BCE. Accessed August 7, 2014.</Citation></Reference><Reference><Citation>McGrath JJ, Eyles DW, Pedersen CB, et al. Neonatal vitamin d status and risk of schizophrenia: A population-based case-control study. Arch General Psychiatr. 2010;67(9):889&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">20819982</ArticleId></ArticleIdList></Reference><Reference><Citation>Halldner L, Tillander A, Lundholm C, et al. Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports. J Child Psychol Psychiatr. 2014;55(8):897&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">24673585</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC. Timing of birth and risk of multiple sclerosis: population based study. BMJ. 2005;330(7483):120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544426</ArticleId><ArticleId IdType="pubmed">15585537</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber S, Didham R, Fieder M. Month of birth and offspring count of women: data from the Southern hemisphere. Hum Reprod. 2008;23(5):1187&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981771</ArticleId><ArticleId IdType="pubmed">18326861</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber S, Fieder M. Strong association between birth month and reproductive performance of Vietnamese women. Am J Hum Biol. 2009;21(1):25&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072539</ArticleId><ArticleId IdType="pubmed">18561148</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber S, Fieder M. Perinatal winter conditions affect later reproductive performance in Romanian women: intra and intergenerational effects. Am J Hum Biol. 2011;23(4):546&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">21630366</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber S, Fieder M, Wallner B, Moser G, Arnold W. Brief communication: birth month influences reproductive performance in contemporary women. Hum Reprod. 2004;19(5):1081&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">15121731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemkes A. The impact of maternal birth month on reproductive performance: controlling for socio-demographic confounders. J Biosoc Sci. 2010;42(2):177&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">20018119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn HS, Morgan TM, Case LD, et al. Association of type 1 diabetes with month of birth among US youth the SEARCH for Diabetes in Youth Study. Diabetes Care. 2009;32(11):2010&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768213</ArticleId><ArticleId IdType="pubmed">19675199</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G, Chaplin G, Morahan JM, et al. Month of birth, vitamin D and risk of immune mediated disease: a case control study. BMC Med. 2012;10(1):69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3395583</ArticleId><ArticleId IdType="pubmed">22764877</ArticleId></ArticleIdList></Reference><Reference><Citation>Doblhammer G, Vaupel JW. Lifespan depends on month of birth. Proc Natl Acad Sci. 2001;98(5):2934&#x2013;2939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30243</ArticleId><ArticleId IdType="pubmed">11226344</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsgaard J, Dahl R. Sensitivity to house dust mite and grass pollen in adults. Influence of the month of birth. Clin Allergy. 1983;13(6):529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">6640888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahn U, Lau S, Bergmann R, et al. Indoor allergen exposure is a risk factor for sensitization during the first three years of life. J Allergy Clin Immunol. 1997;99(6, Part 1):763&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">9215243</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G, Watson CT, Meier UC, Ebers GC, Giovannoni G, Ramagopalan SV. Month of birth and thymic output. JAMA Neurol. 2013;70(4):527&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">23568650</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha AK. Meaningful use of electronic health records: the road ahead. JAMA. 2010;304(15):1709&#x2013;1710.</Citation><ArticleIdList><ArticleId IdType="pubmed">20959581</ArticleId></ArticleIdList></Reference><Reference><Citation>Roque FS, Jensen PB, Schmock H, et al. Using electronic patient records to discover disease correlations and stratify patient cohorts. PLoS Comput Biol. 2011;7(8):e1002141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3161904</ArticleId><ArticleId IdType="pubmed">21901084</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13(6):395&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">22549152</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Hripcsak G, Shen Y, Chung WK, Weng C. Defining a comprehensive verotype using electronic health records for personalized medicine. JAMIA. 2013;20(e2):e232&#x2013;e238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861934</ArticleId><ArticleId IdType="pubmed">24001516</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. JAMIA. 2013;20(1):144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton G. Bias associated with mining electronic health records. J Biomed Discov Collab. 2011;6:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149555</ArticleId><ArticleId IdType="pubmed">21647858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. Correlating electronic health record concepts with healthcare process events. JAMIA. 2013;20(e2):e311&#x2013;e318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861922</ArticleId><ArticleId IdType="pubmed">23975625</ArticleId></ArticleIdList></Reference><Reference><Citation>Loukides G, Gkoulalas-Divanis A, Malin B. Anonymization of electronic medical records for validating genome-wide association studies. Proc Natl Acad Sci. 2010;107(17):7898&#x2013;7903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867915</ArticleId><ArticleId IdType="pubmed">20385806</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkin PL, Brown SH, Husser CS, et al. Evaluation of the Content Coverage of SNOMED CT: ability of SNOMED Clinical Terms to Represent Clinical Problem Lists. Mayo Clinic Proc. 2006;81(6):741&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16770974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton GB. Using discordance to improve classification in narrative clinical databases: an application to community-acquired pneumonia. Comput Biol Med. 2007;37(3):296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16620802</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. 1997;315:640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127436</ArticleId><ArticleId IdType="pubmed">9310565</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990;263(10):1385&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">2406472</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13(6):395&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">22549152</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Hripcsak G, Albers DJ, et al. Discovering medical conditions associated with periodontitis using linked electronic health records. J Clin Periodontol. 2013;40(5):474&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690348</ArticleId><ArticleId IdType="pubmed">23495669</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Ritchie MD, Basford MA, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010;26(9):1205&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859132</ArticleId><ArticleId IdType="pubmed">20335276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohane IS. Using electronic health records to drive discovery in disease genomics. Nat Rev Genet. 2011;12(6):417&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">21587298</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford DC, Crosslin DR, Tromp G, et al. eMERGEing progress in genomics&#x2014;the first seven years. Front Genet. 2014;5:184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060012</ArticleId><ArticleId IdType="pubmed">24987407</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Hripcsak G, Markatou M, Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. JAMIA. 2009;16(3):328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732239</ArticleId><ArticleId IdType="pubmed">19261932</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerian K, Varn D, Vaidya S, Ena L, Chase H, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Therap. 2012;92(2):228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685297</ArticleId><ArticleId IdType="pubmed">22713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes AB, Hawson A, Liu F, Friedman C, Khiabanian H, Rabadan R. Discovering disease associations by integrating electronic clinical data and medical literature. PloS ONE. 2011;6(6):e21132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121722</ArticleId><ArticleId IdType="pubmed">21731656</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi-Velez F, Ge Y, Kohane I. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics. 2014;133(1):e54&#x2013;e63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3876178</ArticleId><ArticleId IdType="pubmed">24323995</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed RD, Khiabanian H, Rabadan R. Data-driven discovery of seasonally linked diseases from an Electronic Health Records system. BMC Bioinformatics. 2014;15 (Suppl 6):S3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158606</ArticleId><ArticleId IdType="pubmed">25078762</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen HA, Blau H, Hoshen M, Batat E, Balicer RD. Seasonality of asthma: a retrospective population study. Pediatrics. 2014;133(4):e923&#x2013;e932.</Citation><ArticleIdList><ArticleId IdType="pubmed">24616356</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph C. Seasonality of asthma: a retrospective population study. Pediatrics. 2014;134 (Suppl 3):S165&#x2013;S166.</Citation><ArticleIdList><ArticleId IdType="pubmed">25363962</ArticleId></ArticleIdList></Reference><Reference><Citation>Easterbrook PJ, Gopalan R, Berlin JA, Matthews DR. Publication bias in clinical research. The Lancet. 1991;337(8746):867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">1672966</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawdrey DK, Hripcsak G. Publication bias in clinical trials of electronic health records. J Biomed Inform. 2013;46(1):139&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662474</ArticleId><ArticleId IdType="pubmed">22975314</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. JAMIA. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JR, Payne TH. A comparison of four schemes for codification of problem lists. Proceedings / the Annual Symposium on Computer Application [sic] in Medical Care Symposium on Computer Applications in Medical Care. 1994:201&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2247911</ArticleId><ArticleId IdType="pubmed">7949920</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolis R, Derr L, Dunn M, et al. The National Institutes of Health's Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data. JAMIA. 2014;21(6):957&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215061</ArticleId><ArticleId IdType="pubmed">25008006</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Vital Stats Beyond 20/20. National Vital Statistics System US Department of Health and Human Services. 2014. http://205.207.175.93/Vitalstats/Common/Login/Login.aspx. Accessed July 1, 2014.</Citation></Reference><Reference><Citation>Duncan J, Narus SP, Clyde S, Eilbeck K, Thornton S, Staes C. Birth of identity: understanding changes to birth certificates and their value for identity resolution. JAMIA. 2015;22:e120&#x2013;e129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25080533</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Average sunshine in Skagen, Denmark. World Weather and Climate Information. 2014. http://www.weather-and-climate.com/average-monthly-hours-Sunshine,skagen,Denmark. Accessed August 8, 2014.</Citation></Reference><Reference><Citation>Average sunshine in New York, United States of America. World Weather and Climate Information. 2014. http://www.weather-and-climate.com/average-monthly-hours-Sunshine,New-York,United-States-of-America. Accessed August 8, 2014.</Citation></Reference><Reference><Citation>Mandel Y, Grotto I, El-Yaniv R, et al. Season of birth, natural light, and myopia. Ophthalmology. 2008;115(4):686&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698195</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;berg N. Birth season variation in asthma and allergic rhinitis. Clin Exp Allergy. 1989;19(6):643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">2598104</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita Y, Tilly JL. Oocyte apoptosis: like sand through an hourglass. Dev Biol. 1999;213(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">10452843</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker T. A quantitative and cytological study of germ cells in human ovaries. Proc R Soc Lond. 1963;158(972):417&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">14070052</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilly JL, Niikura Y, Rueda BR. The current status of evidence for and against postnatal oogenesis in mammals: a case of ovarian optimism versus pessimism? Biol Reprod. 2009;80(1):2&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804806</ArticleId><ArticleId IdType="pubmed">18753611</ArticleId></ArticleIdList></Reference><Reference><Citation>Burne THJ, F&#xe9;ron F, Brown J, Eyles DW, McGrath JJ, Mackay-Sim A. Combined prenatal and chronic postnatal vitamin D deficiency in rats impairs prepulse inhibition of acoustic startle. Physiol Behav. 2004;81(4):651&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">15178159</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker A, Eyles DW, McGrath JJ, Grecksch G. Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats. Behav Brain Res. 2005;161(2):306&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumder B, Almond D, Park K, Crimmins EM, Finch CE. Lingering prenatal effects of the 1918 influenza pandemic on cardiovascular disease. J Dev Origins Health Dis. 2010;1(1):26&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826837</ArticleId><ArticleId IdType="pubmed">20198106</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282(21):2012&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591383</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson-Hughes B, Dallal GE, Krall EA, Harris S, Sokoll LJ, Falconer G. Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Ann Int Med. 1991;115(7):505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">1883119</ArticleId></ArticleIdList></Reference><Reference><Citation>Halicioglu O, Sutcuoglu S, Koc F, Yildiz O, Akman SA, Aksit S. Vitamin D status of exclusively breastfed 4-month-old infants supplemented during different seasons. Pediatrics. 2012;130(4):e921&#x2013;e927.</Citation><ArticleIdList><ArticleId IdType="pubmed">23008460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Smith JR, Philipp BL, Chen TC, Mathieu J, Holick MF. Vitamin D deficiency in a healthy group of mothers and newborn infants. Clin Pediatr. 2007;46(1):42&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17164508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiencyan important, common, and easily treatable cardiovascular risk factor? J Am College Cardiol. 2008;52(24):1949&#x2013;1956.</Citation><ArticleIdList><ArticleId IdType="pubmed">19055985</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726624</ArticleId><ArticleId IdType="pubmed">18180395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease. Circ Heart Fail. 2014;7(5):732&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">25104043</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis JP, von Muhlen D, Miller ER, 3rd, Michos ED, Appel LJ. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics. 2009;124(3):e371&#x2013;e379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222068</ArticleId><ArticleId IdType="pubmed">19661053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics. 2009;124(3):e362&#x2013;e370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749840</ArticleId><ArticleId IdType="pubmed">19661054</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenquist JN, Lehrer SF, O&#x2019;Malley AJ, Zaslavsky AM, Smoller JW, Christakis NA. Cohort of birth modifies the association between FTO genotype and BMI. Proc Natl Acad Sci. 2015;112(2):354&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299180</ArticleId><ArticleId IdType="pubmed">25548176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records. 2013;20(1):117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Rusanov A, Weng C. Sick patients have more data: the non-random completeness of electronic health records. AMIA Annual Symposium Proceedings; 2013 American Medical Informatics Association; 2013: 1472-1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900159</ArticleId><ArticleId IdType="pubmed">24551421</ArticleId></ArticleIdList></Reference><Reference><Citation>Flamand C, Fabregue M, Bringay S, et al. Mining local climate data to assess spatiotemporal dengue fever epidemic patterns in French Guiana. JAMIA. 2014;21(e2):e232&#x2013;e240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4173173</ArticleId><ArticleId IdType="pubmed">24549761</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26055920</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.</ArticleTitle><Pagination><StartPage>749</StartPage><EndPage>765</EndPage><MedlinePgn>749-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-015-0297-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">An often key component to coordinating surveillance activities across distributed networks is the design and implementation of a common data model (CDM). The purpose of this study was to evaluate two drug safety surveillance CDMs from an ecosystem perspective to better understand how differences in CDMs and analytic tools affect usability and interpretation of results.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Humana claims data from 2007 to 2012 were mapped to Observational Medical Outcomes Partnership (OMOP) and Mini-Sentinel CDMs. Data were described and compared at the patient level by source code and mapped concepts. Study cohort construction and effect estimates were also compared using two different analytical methods--one based on a new user design implementing a high-dimensional propensity score (HDPS) algorithm and the other based on univariate self-controlled case series (SCCS) design--across six established positive drug-outcome pairs to learn how differences in CDMs and analytics influence steps in the database analytic process and results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Claims data for approximately 7.7 million Humana health plan members were transformed into the two CDMs. Three health outcome cohorts and two drug cohorts showed differences in cohort size and constituency between Mini-Sentinel and OMOP CDMs, which was a result of multiple factors. Overall, the implementation of the HDPS procedure on Mini-Sentinel CDM detected more known positive associations than that on OMOP CDM. The SCCS method results were comparable on both CDMs. Differences in the implementation of the HDPS procedure between the two CDMs were identified; analytic model and risk period specification had a significant impact on the performance of the HDPS procedure on OMOP CDM.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Differences were observed between OMOP and Mini-Sentinel CDMs. The analysis of both CDMs at the data model level indicated that such conceptual differences had only a slight but not significant impact on identifying known safety associations. Our results show that differences at the ecosystem level of analyses across the CDMs can lead to strikingly different risk estimations, but this can be primarily attributed to the choices of analytic approach and their implementation in the community-developed analytic tools. The opportunities of using CDMs are clear, but our study shows the need for judicious comparison of analyses across the CDMs. Our work emphasizes the need for ongoing efforts to ensure sustainable transparent platforms to maintain and develop CDMs and associated tools for effective safety surveillance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yihua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Comprehensive Health Insights, Humana Inc., 515 W. Market St., Louisville, KY, 40202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Suehs</LastName><ForeName>Brandon T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Hartzema</LastName><ForeName>Abraham G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Moride</LastName><ForeName>Yola</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sauer</LastName><ForeName>Brian C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Moll</LastName><ForeName>Keran</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pasquale</LastName><ForeName>Margaret K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Vinit P</ForeName><Initials>VP</Initials></Author><Author ValidYN="Y"><LastName>Bate</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Drug Saf. 2015 Aug;38(8):683-6. doi: 10.1007/s40264-015-0313-9.</RefSource><PMID Version="1">26088718</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Drug Saf. 2015 Aug;38(8):767-8. doi: 10.1007/s40264-015-0322-8.</RefSource><PMID Version="1">26136091</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018571" MajorTopicYN="Y">Sentinel Surveillance</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26055920</ArticleId><ArticleId IdType="doi">10.1007/s40264-015-0297-5</ArticleId><ArticleId IdType="pii">10.1007/s40264-015-0297-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Epidemiology. 2012 Mar;23(2):238-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22266893</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Jan;36(1):13-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23315292</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Clin Pract Rheumatol. 2007 Dec;3(12):725-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18037932</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:18-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22262589</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S195-204</Citation><ArticleIdList><ArticleId IdType="pubmed">24166235</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Feb 10;364(6):498-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21226658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1036-45</Citation><ArticleIdList><ArticleId IdType="pubmed">23922322</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2009 Feb;18(1):7-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18562396</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:240-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22262612</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:23-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22262590</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Feb;36(2):119-34</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2010 Jun;48(6 Suppl):S45-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20473204</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2009 Jul;20(4):512-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):714-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21638520</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):861-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23801638</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2010 Nov 2;153(9):600-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S59-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26068584</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling.</ArticleTitle><Pagination><StartPage>e0129974</StartPage><MedlinePgn>e0129974</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0129974</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0129974</ELocationID><Abstract><AbstractText>Identification of Drug-Drug Interactions (DDIs) is a significant challenge during drug development and clinical practice. DDIs are responsible for many adverse drug effects (ADEs), decreasing patient quality of life and causing higher care expenses. DDIs are not systematically evaluated in pre-clinical or clinical trials and so the FDA U. S. Food and Drug Administration relies on post-marketing surveillance to monitor patient safety. However, existing pharmacovigilance algorithms show poor performance for detecting DDIs exhibiting prohibitively high false positive rates. Alternatively, methods based on chemical structure and pharmacological similarity have shown promise in adverse drug event detection. We hypothesize that the use of chemical biology data in a post hoc analysis of pharmacovigilance results will significantly improve the detection of dangerous interactions. Our model integrates a reference standard of DDIs known to cause arrhythmias with drug similarity data. To compare similarity between drugs we used chemical structure (both 2D and 3D molecular structure), adverse drug side effects, chemogenomic targets, drug indication classes, and known drug-drug interactions. We evaluated the method on external reference standards. Our results showed an enhancement of sensitivity, specificity and precision in different top positions with the use of similarity measures to rank the candidates extracted from pharmacovigilance data. For the top 100 DDI candidates, similarity-based modeling yielded close to twofold precision enhancement compared to the proportional reporting ratio (PRR). Moreover, the method helps in the DDI decision making through the identification of the DDI in the reference standard that generated the candidate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vilar</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States of America; Department of Systems Biology, Columbia University, New York, NY, United States of America; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorberbaum</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States of America; Department of Systems Biology, Columbia University, New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States of America; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States of America; Department of Systems Biology, Columbia University, New York, NY, United States of America; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America; Department of Medicine, Columbia University, New York, NY, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM082797</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="Y">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26068584</ArticleId><ArticleId IdType="pmc">PMC4466327</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0129974</ArticleId><ArticleId IdType="pii">PONE-D-15-04363</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tatonetti NP, Fernald GH, Altman RB. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc. 2012;19(1):79&#x2013;85. 10.1136/amiajnl-2011-000214</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000214</ArticleId><ArticleId IdType="pmc">PMC3240755</ArticleId><ArticleId IdType="pubmed">21676938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirmohamed M. Ml O: Drug Interactions of Clinical Importance. London: Chapman &amp; Hall; 1998.</Citation></Reference><Reference><Citation>Percha B, Altman RB. Informatics confronts drug-drug interactions. Trends Pharmacol Sci. 2013;34(3):178&#x2013;84. 10.1016/j.tips.2013.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2013.01.006</ArticleId><ArticleId IdType="pmc">PMC3808975</ArticleId><ArticleId IdType="pubmed">23414686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice PJ, Perry RJ, Afzal Z, Stockley IH. Antibacterial prescribing and warfarin: a review. Br Dent J. 2003;194(8):411&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12778089</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna G, Ma L, Prasad P, Moton A, Martinho M, O'Mara E. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol. 2012;8(1):1&#x2013;10. 10.1517/17425255.2012.639360</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425255.2012.639360</ArticleId><ArticleId IdType="pubmed">22176629</ArticleId></ArticleIdList></Reference><Reference><Citation>Korhonen LE, Rahnasto M, Mahonen NJ, Wittekindt C, Poso A, Juvonen RO, et al. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005;48(11):3808&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">15916432</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahnasto M, Raunio H, Poso A, Wittekindt C, Juvonen RO. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J Med Chem. 2005;48(2):440&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15658857</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap CW, Chen YZ. Prediction of cytochrome p450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J Chem Inf Model. 2005;45(4):982&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16045292</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A, Masimirembwa CM. Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol. 2001;59(4):909&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259637</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rienzo F, Fanelli F, Menziani MC, De Benedetti PG. Theoretical investigation of substrate specificity for cytochromes p450 IA2, p450 IID6 and p450 IIIA4. J Comput Aided Mol Des. 2000;14(1):93&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702928</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S, Harpaz R, Uriarte E, Santana L, Rabadan R, Friedman C. Drug-drug interaction through molecular structure similarity analysis. J Am Med Inform Assoc. 2012;19(6):1066&#x2013;74. 10.1136/amiajnl-2012-000935</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000935</ArticleId><ArticleId IdType="pmc">PMC3534468</ArticleId><ArticleId IdType="pubmed">22647690</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S, Uriarte E, Santana L, Tatonetti NP, Friedman C. Detection of drug-drug interactions by modeling interaction profile fingerprints. PLOS ONE. 2013;8(3):e58321 10.1371/journal.pone.0058321</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0058321</ArticleId><ArticleId IdType="pmc">PMC3592896</ArticleId><ArticleId IdType="pubmed">23520498</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb A, Stein GY, Oron Y, Ruppin E, Sharan R. INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol Syst Biol. 2012;8:592 10.1038/msb.2012.26</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/msb.2012.26</ArticleId><ArticleId IdType="pmc">PMC3421442</ArticleId><ArticleId IdType="pubmed">22806140</ArticleId></ArticleIdList></Reference><Reference><Citation>Tari L, Anwar S, Liang S, Cai J, Baral C. Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics. 2010;26(18):i547&#x2013;i53. 10.1093/bioinformatics/btq382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq382</ArticleId><ArticleId IdType="pmc">PMC2935409</ArticleId><ArticleId IdType="pubmed">20823320</ArticleId></ArticleIdList></Reference><Reference><Citation>Percha B, Garten Y, Altman RB. Discovery and explanation of drug-drug interactions via text mining. Pac Symp Biocomput. 2012. 2012:410&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345566</ArticleId><ArticleId IdType="pubmed">22174296</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). Available: http://www.fda.gov/cder/aers/default.htm. Accessed 01 Apr 2014.</Citation></Reference><Reference><Citation>Harpaz R, Chase HS, Friedman C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics. 2010;11(Suppl 9):S7 10.1186/1471-2105-11-S9-S7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-11-S9-S7</ArticleId><ArticleId IdType="pmc">PMC2967748</ArticleId><ArticleId IdType="pubmed">21044365</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-Driven Prediction of Drug Effects and Interactions. Sci Transl Med. 2012;4(125): 125ra31 10.1126/scitranslmed.3003377</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003377</ArticleId><ArticleId IdType="pmc">PMC3382018</ArticleId><ArticleId IdType="pubmed">22422992</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S, Harpaz R, Chase HS, Costanzi S, Rabadan R, Friedman C. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inf Assoc. 2011;18:I73&#x2013;I80. 10.1136/amiajnl-2011-000417</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000417</ArticleId><ArticleId IdType="pmc">PMC3241177</ArticleId><ArticleId IdType="pubmed">21946238</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S, Harpaz R, Santana L, Uriarte E, Friedman C. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS One. 2012;7(7):e41471 10.1371/journal.pone.0041471</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041471</ArticleId><ArticleId IdType="pmc">PMC3404072</ArticleId><ArticleId IdType="pubmed">22911794</ArticleId></ArticleIdList></Reference><Reference><Citation>DrugBank database, version 3.0. Accessed: http://www.drugbank.ca. Accessed 15 Apr 2011.</Citation></Reference><Reference><Citation>Olvey EL, Clauschee S, Malone DC. Comparison of Critical Drug-Drug Interaction Listings: The Department of Veterans Affairs Medical System and Standard Reference Compendia. Clin Pharmacol Ther. 2010;87(1):48&#x2013;51. 10.1038/clpt.2009.198</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2009.198</ArticleId><ArticleId IdType="pubmed">19890252</ArticleId></ArticleIdList></Reference><Reference><Citation>Durant JL, Leland BA, Henry DR, Nourse JG. Reoptimization of MDL keys for use in drug discovery. J Chem Inf Comput Sci. 2002;42(6):1273&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12444722</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;dinger package, version 9.2, Schr&#xf6;dinger, LLC, New York, USA, 2011. Available: http://www.schrodinger.com (Accessed 15 Oct 2013).</Citation></Reference><Reference><Citation>Vilar S, Uriarte E, Santana L, Friedman C, Tatonetti NP. State of the art and development of a drug-drug interaction large scale predictor based on 3D pharmacophoric similarity. Curr Drug Metab. 2014;15(5):490&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">25431152</ArticleId></ArticleIdList></Reference><Reference><Citation>SIDER Side Effect Resource. Accessed: http://sideeffects.embl.de. Accessed 01 May 2013.</Citation></Reference><Reference><Citation>WHO Collaborating Centre for Drug Statistics Methodology (WHOCC). Available: http://www.whocc.no. Accessed 01 Jun 2014.</Citation></Reference><Reference><Citation>Vilar S, Uriarte E, Santana L, Lorberbaum T, Hripcsak G, Friedman C, et al. Similarity-based modeling in large-scale prediction of drug-drug interactions. Nat Protoc. 2014;9(9):2147&#x2013;2163. 10.1038/nprot.2014.151</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2014.151</ArticleId><ArticleId IdType="pmc">PMC4422192</ArticleId><ArticleId IdType="pubmed">25122524</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugdex System (Micromedex Healthcare Series). Greenwood Village, CO: Thomson Reuters (Healthcare) Inc., 2011. Available: http://www.micromedexsolutions.com. Accessed 01 Mar 2014.</Citation></Reference><Reference><Citation>Drug Information Online, Drugs.com database. Available: http://www.drugs.com (Accessed 01 Mar 2014).</Citation></Reference><Reference><Citation>The Truven MarketScan Commercial Claims and Encounters (CCAE). Available: http://www.truvenhealth.com. Accessed 01 Jun 2014.</Citation></Reference><Reference><Citation>Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23(7):881&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885102</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Zhao Z. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. J Am Med Inform Assoc. 2014;21(e2):e278&#x2013;86. 10.1136/amiajnl-2013-002512</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-002512</ArticleId><ArticleId IdType="pmc">PMC4173180</ArticleId><ArticleId IdType="pubmed">24644270</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S, Ryan PB, Madigan D, Stang PE, Schuemie MJ, Friedman C, et al. Similarity-based modeling applied to signal detection in pharmacovigilance. CPT Pharmacometrics Syst Pharmacol. 2014;3:e137 10.1038/psp.2014.35</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/psp.2014.35</ArticleId><ArticleId IdType="pmc">PMC4211266</ArticleId><ArticleId IdType="pubmed">25250527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26092163</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1437-1588</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz</Title><ISOAbbreviation>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</ISOAbbreviation></Journal><ArticleTitle>[Benefits of large healthcare databases for drug risk research].</ArticleTitle><Pagination><StartPage>829</StartPage><EndPage>837</EndPage><MedlinePgn>829-837</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00103-015-2185-7</ELocationID><Abstract><AbstractText>Large electronic healthcare databases have become an important worldwide data resource for drug safety research after approval. Signal generation methods and drug safety studies based on these data facilitate the prospective monitoring of drug safety after approval, as has been recently required by EU law and the German Medicines Act. Despite its large size, a single healthcare database may include insufficient patients for the study of a very small number of drug-exposed patients or the investigation of very rare drug risks. For that reason, in the United States, efforts have been made to work on models that provide the linkage of data from different electronic healthcare databases for monitoring the safety of medicines after authorization in (i) the Sentinel Initiative and (ii) the Observational Medical Outcomes Partnership (OMOP). In July 2014, the pilot project Mini-Sentinel included a total of 178&#xa0;million people from 18 different US databases. The merging of the data is based on a distributed data network with a common data model. In the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) there has been no comparable merging of data from different databases; however, first experiences have been gained in various EU drug safety projects. In Germany, the data of the statutory health insurance providers constitute the most important resource for establishing a large healthcare database. Their use for this purpose has so far been severely restricted by the Code of Social Law (Section 75, Book 10). Therefore, a reform of this section is absolutely necessary.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garbe</LastName><ForeName>Edeltraut</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Leibniz-Institut f&#xfc;r Pr&#xe4;ventionsforschung und Epidemiologie - BIPS, Achterstra&#xdf;e 30, 28359, Bremen, Deutschland. garbe@uni-bremen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wissenschaftsschwerpunkt "Gesundheitswissenschaften", Universit&#xe4;t Bremen, Bremen, Deutschland. garbe@uni-bremen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pigeot</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Leibniz-Institut f&#xfc;r Pr&#xe4;ventionsforschung und Epidemiologie - BIPS, Achterstra&#xdf;e 30, 28359, Bremen, Deutschland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Statistik, Fachbereich Mathematik und Informatik, Universit&#xe4;t Bremen, Bremen, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Der Nutzen gro&#xdf;er Gesundheitsdatenbanken f&#xfc;r die Arzneimittelrisikoforschung.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</MedlineTA><NlmUniqueID>101181368</NlmUniqueID><ISSNLinking>1436-9990</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="N">Data Mining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="N">Health Services Research</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="N">Medical Record Linkage</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071220" MajorTopicYN="N">Pharmaceutical Research</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26092163</ArticleId><ArticleId IdType="doi">10.1007/s00103-015-2185-7</ArticleId><ArticleId IdType="pii">10.1007/s00103-015-2185-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26116429</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>A supervised adverse drug reaction signalling framework imitating Bradford Hill's causality considerations.</ArticleTitle><Pagination><StartPage>356</StartPage><EndPage>368</EndPage><MedlinePgn>356-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2015.06.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(15)00121-5</ELocationID><Abstract><AbstractText>Big longitudinal observational medical data potentially hold a wealth of information and have been recognised as potential sources for gaining new drug safety knowledge. Unfortunately there are many complexities and underlying issues when analysing longitudinal observational data. Due to these complexities, existing methods for large-scale detection of negative side effects using observational data all tend to have issues distinguishing between association and causality. New methods that can better discriminate causal and non-causal relationships need to be developed to fully utilise the data. In this paper we propose using a set of causality considerations developed by the epidemiologist Bradford Hill as a basis for engineering features that enable the application of supervised learning for the problem of detecting negative side effects. The Bradford Hill considerations look at various perspectives of a drug and outcome relationship to determine whether it shows causal traits. We taught a classifier to find patterns within these perspectives and it learned to discriminate between association and causality. The novelty of this research is the combination of supervised learning and Bradford Hill's causality considerations to automate the Bradford Hill's causality assessment. We evaluated the framework on a drug safety gold standard known as the observational medical outcomes partnership's non-specified association reference set. The methodology obtained excellent discrimination ability with area under the curves ranging between 0.792 and 0.940 (existing method optimal: 0.73) and a mean average precision of 0.640 (existing method optimal: 0.141). The proposed features can be calculated efficiently and be readily updated, making the framework suitable for big observational data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>School of Computer Science, University of Nottingham, NG8 1BB, UK. Electronic address: jenna.reps@nottingham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garibaldi</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>School of Computer Science, University of Nottingham, NG8 1BB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aickelin</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>School of Computer Science, University of Nottingham, NG8 1BB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>Jack E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Public Health, University of Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubbard</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Public Health, University of Nottingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004813" MajorTopicYN="N">Epidemiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Big data</Keyword><Keyword MajorTopicYN="N">Causal effects</Keyword><Keyword MajorTopicYN="N">Longitudinal observational data</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword><Keyword MajorTopicYN="N">Signal detection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26116429</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2015.06.011</ArticleId><ArticleId IdType="pii">S1532-0464(15)00121-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26153397</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions.</ArticleTitle><Pagination><StartPage>895</StartPage><EndPage>908</EndPage><MedlinePgn>895-908</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-015-0314-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Observational healthcare data contain information useful for hastening detection of adverse drug reactions (ADRs) that may be missed by using data in spontaneous reporting systems (SRSs) alone. There are only several papers describing methods that integrate evidence from healthcare databases and SRSs. We propose a methodology that combines ADR signals from these two sources.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to investigate whether the proposed method would result in more accurate ADR detection than methods using SRSs or healthcare data alone.</AbstractText><AbstractText Label="RESEARCH DESIGN" NlmCategory="METHODS">We applied the method to four clinically serious ADRs, and evaluated it using three experiments that involve combining an SRS with a single facility small-scale electronic health record (EHR), a larger scale network-based EHR, and a much larger scale healthcare claims database. The evaluation used a reference standard comprising 165 positive and 234 negative drug-ADR pairs.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Area under the receiver operator characteristics curve (AUC) was computed to measure performance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no improvement in the AUC when the SRS and small-scale HER were combined. The AUC of the combined SRS and large-scale EHR was 0.82 whereas it was 0.76 for each of the individual systems. Similarly, the AUC of the combined SRS and claims system was 0.82 whereas it was 0.76 and 0.78, respectively, for the individual systems.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The proposed method resulted in a significant improvement in the accuracy of ADR detection when the resources used for combining had sufficient amounts of data, demonstrating that the method could integrate evidence from multiple sources and serve as a tool in actual pharmacovigilance practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, 622 W. 168th Street, Presbyterian Building 20th Floor, New York, NY, 10032, USA. yl2565@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, 622 W. 168th Street, Presbyterian Building 20th Floor, New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Columbia University, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, 622 W. 168th Street, Presbyterian Building 20th Floor, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM010016</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Drug Saf. 2015 Oct;38(10):847-8. doi: 10.1007/s40264-015-0342-4.</RefSource><PMID Version="1">26323240</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26153397</ArticleId><ArticleId IdType="pmc">PMC4579260</ArticleId><ArticleId IdType="doi">10.1007/s40264-015-0314-8</ArticleId><ArticleId IdType="pii">10.1007/s40264-015-0314-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. JAMA. 1995;274(1):29&#x2013;34. doi: 10.1001/jama.1995.03530010043033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1995.03530010043033</ArticleId><ArticleId IdType="pubmed">7791255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Washington, DC: 1996) 2001;41(2):192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11297331</ArticleId></ArticleIdList></Reference><Reference><Citation>Classen DC, Pestonik SL, Scott Evans R, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. Obstet Gynecol Surv. 1997;52(5):291. doi: 10.1097/00006254-199705000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006254-199705000-00016</ArticleId><ArticleId IdType="pubmed">9002492</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98(8):1366&#x2013;1371. doi: 10.2105/AJPH.2007.124537.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2007.124537</ArticleId><ArticleId IdType="pmc">PMC2446471</ArticleId><ArticleId IdType="pubmed">18556607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003;18(1):57&#x2013;60. doi: 10.1046/j.1525-1497.2003.20130.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2003.20130.x</ArticleId><ArticleId IdType="pmc">PMC1494803</ArticleId><ArticleId IdType="pubmed">12534765</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19(1):1&#x2013;10. doi: 10.2165/00002018-199819010-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-199819010-00001</ArticleId><ArticleId IdType="pubmed">9673854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427&#x2013;436. doi: 10.1002/pds.1742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1742</ArticleId><ArticleId IdType="pubmed">19358225</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, DuMouchel W, Shah N, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010&#x2013;1021. doi: 10.1038/clpt.2012.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.50</ArticleId><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis. 1994;18(6):946&#x2013;950. doi: 10.1093/clinids/18.6.946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/18.6.946</ArticleId><ArticleId IdType="pubmed">8086558</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LM. Under-reporting of adverse drug reactions estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(6):483&#x2013;488. doi: 10.1007/s002280050498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002280050498</ArticleId><ArticleId IdType="pubmed">9776440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Guerrero J, Colditz GA, Karlson EW, Hunter DJ, Speizer FE, Liang MH. Silicone breast implants and the risk of connective-tissue diseases and symptoms. N Engl J Med. 1995;332(25):1666&#x2013;1670. doi: 10.1056/NEJM199506223322502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199506223322502</ArticleId><ArticleId IdType="pubmed">7760867</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberth JM, Kline KN, Moskowitz DA, Montealegre JR, Scheurer ME. The role of media and the internet on vaccine adverse event reporting: a case study of human papillomavirus vaccination. J Adolesc Health. 2014;54(3):289&#x2013;295. doi: 10.1016/j.jadohealth.2013.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jadohealth.2013.09.005</ArticleId><ArticleId IdType="pmc">PMC3943880</ArticleId><ArticleId IdType="pubmed">24257032</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Schuemie MJ, Trifir&#xf2; G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. Pharmacoepidemiol Drug Saf. 2011;20(1):1&#x2013;11. doi: 10.1002/pds.2053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2053</ArticleId><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Hripcsak G, Markatou M, Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J Am Med Inform Assoc. 2009;16(3):328&#x2013;337. doi: 10.1197/jamia.M3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M3028</ArticleId><ArticleId IdType="pmc">PMC2732239</ArticleId><ArticleId IdType="pubmed">19261932</ArticleId></ArticleIdList></Reference><Reference><Citation>LePendu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Podchiyska T, et al. Pharmacovigilance using clinical notes. Clin Pharmacol Ther. 2013;93(6):547&#x2013;555. doi: 10.1038/clpt.2013.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.47</ArticleId><ArticleId IdType="pmc">PMC3846296</ArticleId><ArticleId IdType="pubmed">23571773</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Patadia VK, Schuemie MJ, Coloma P, Herings R, van der Lei J, Straus S, et al. Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. Int J Clin Pharm. 2015;37(1):94&#x2013;104. doi: 10.1007/s11096-014-0044-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-014-0044-5</ArticleId><ArticleId IdType="pubmed">25488315</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network&#x2014;improving the evidence of medical-product safety. N Engl J Med. 2009;361(7):645&#x2013;647. doi: 10.1056/NEJMp0905338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp0905338</ArticleId><ArticleId IdType="pubmed">19635947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(1):143&#x2013;158. doi: 10.1007/s40264-013-0108-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0108-9</ArticleId><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE. Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401&#x2013;4415. doi: 10.1002/sim.5620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5620</ArticleId><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifir&#xf2; G, Matthews JN, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50(10):890&#x2013;897. doi: 10.1097/MLR.0b013e31825f63bf.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e31825f63bf</ArticleId><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti N, Denny J, Murphy S, Fernald G, Krishnan G, Castro V, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther. 2011;90(1):133&#x2013;142. doi: 10.1038/clpt.2011.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.83</ArticleId><ArticleId IdType="pmc">PMC3216673</ArticleId><ArticleId IdType="pubmed">21613990</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Han X, Wang Z, Subhadarshini A, Karnik SD, Li X, et al. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol. 2012;8(8):e1002614. doi: 10.1371/journal.pcbi.1002614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002614</ArticleId><ArticleId IdType="pmc">PMC3415435</ArticleId><ArticleId IdType="pubmed">22912565</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S, Ryan P, Madigan D, Stang P, Schuemie M, Friedman C, et al. Similarity-based modeling applied to signal detection in pharmacovigilance. CPT Pharmacometrics Syst Pharmacol. 2014;3(9):e137. doi: 10.1038/psp.2014.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/psp.2014.35</ArticleId><ArticleId IdType="pmc">PMC4211266</ArticleId><ArticleId IdType="pubmed">25250527</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, DuMouchel W, LePendu P, Shah NH. Empirical bayes model to combine signals of adverse drug reactions. In: Proceedings of the 19th ACM SIGKDD international conference on Knowledge discovery and data mining. ACM; 2013. p. 1339&#x2013;47.</Citation></Reference><Reference><Citation>Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2015;22(1):179&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433365</ArticleId><ArticleId IdType="pubmed">25053577</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene&#x2013;disease associations. Bioinformatics. 2010;26(9):1205&#x2013;1210. doi: 10.1093/bioinformatics/btq126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq126</ArticleId><ArticleId IdType="pmc">PMC2859132</ArticleId><ArticleId IdType="pubmed">20335276</ArticleId></ArticleIdList></Reference><Reference><Citation>LePendu P, Iyer SV, Fairon C, Shah NH. Annotation analysis for testing drug safety signals using unstructured clinical notes. J Biomed Semantics. 2012;3(Suppl 1):S5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337270</ArticleId><ArticleId IdType="pubmed">22541596</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, Vilar S, DuMouchel W, Salmasian H, Haerian K, Shah NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20(3):413&#x2013;419. doi: 10.1136/amiajnl-2012-000930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000930</ArticleId><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerian K, Varn D, Vaidya S, Ena L, Chase H, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Ther. 2012;92(2):228&#x2013;234. doi: 10.1038/clpt.2012.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.54</ArticleId><ArticleId IdType="pmc">PMC3685297</ArticleId><ArticleId IdType="pubmed">22713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Salmasian H, Vilar S, Chase H, Friedman C, Wei Y. A method for controlling complex confounding effects in the detection of adverse drug reactions using electronic health records. J Am Med Inform Assoc. 2014;21(2):308&#x2013;314. doi: 10.1136/amiajnl-2013-001718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-001718</ArticleId><ArticleId IdType="pmc">PMC3932454</ArticleId><ArticleId IdType="pubmed">23907285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti NP, Fernald GH, Altman RB. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc. 2012;19(1):79&#x2013;85. doi: 10.1136/amiajnl-2011-000214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000214</ArticleId><ArticleId IdType="pmc">PMC3240755</ArticleId><ArticleId IdType="pubmed">21676938</ArticleId></ArticleIdList></Reference><Reference><Citation>Caster O, Nor&#xe9;n GN, Madigan D, Bate A. Large-scale regression-based pattern discovery: the example of screening the WHO global drug safety database. Stat Anal Data Min. 2010;3(4):197&#x2013;208.</Citation></Reference><Reference><Citation>Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539&#x2013;546. doi: 10.1038/clpt.2013.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.24</ArticleId><ArticleId IdType="pmc">PMC3857139</ArticleId><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifir&#xf2; G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salam&#xe9; G, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176&#x2013;1184. doi: 10.1002/pds.1836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1836</ArticleId><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Adverse Event Reporting System (FAERS). [cited]; Available from: http://www.fda.gov/cder/aers/default.htm.</Citation></Reference><Reference><Citation>Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 2008;36(suppl 1):D684&#x2013;D688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2238848</ArticleId><ArticleId IdType="pubmed">18084021</ArticleId></ArticleIdList></Reference><Reference><Citation>Medical Dictionary for Regulatory Activities (MedDRA&#xae;). [cited]; Available from: http://www.meddramsso.com.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(1):33&#x2013;47. doi: 10.1007/s40264-013-0097-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0097-8</ArticleId><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich CG, Ryan PB, Schuemie MJ. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf. 2013;36(1):181&#x2013;193. doi: 10.1007/s40264-013-0111-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0111-1</ArticleId><ArticleId IdType="pubmed">24166234</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloni A, Chernozhukov V, Wei Y. Honest confidence regions for a regression parameter in logistic regression with a large number of controls. 2013 (arXiv preprint arXiv:13043969).</Citation></Reference><Reference><Citation>Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839&#x2013;843. doi: 10.1148/radiology.148.3.6878708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.148.3.6878708</ArticleId><ArticleId IdType="pubmed">6878708</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 2011;12(1):77. doi: 10.1186/1471-2105-12-77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-77</ArticleId><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012;92(1):80&#x2013;86. doi: 10.1038/clpt.2011.369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.369</ArticleId><ArticleId IdType="pmc">PMC3947906</ArticleId><ArticleId IdType="pubmed">22588606</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (Cambridge, Mass) 2009;20(4):512. doi: 10.1097/EDE.0b013e3181a663cc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181a663cc</ArticleId><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401&#x2013;4415. doi: 10.1002/sim.5620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5620</ArticleId><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Nor&#xe9;n GN, Caster O, Juhlin K, Lindquist M. Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance. Drug Saf. 2014;37(9):655&#x2013;659. doi: 10.1007/s40264-014-0198-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0198-z</ArticleId><ArticleId IdType="pubmed">25005708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26262116</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>216</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers.</ArticleTitle><Pagination><StartPage>574</StartPage><EndPage>578</EndPage><MedlinePgn>574-8</MedlinePgn></Pagination><Abstract><AbstractText>The vision of creating accessible, reliable clinical evidence by accessing the clincial experience of hundreds of millions of patients across the globe is a reality. Observational Health Data Sciences and Informatics (OHDSI) has built on learnings from the Observational Medical Outcomes Partnership to turn methods research and insights into a suite of applications and exploration tools that move the field closer to the ultimate goal of generating evidence about all aspects of healthcare to serve the needs of patients, clinicians and all other decision-makers around the world.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Regenstrief Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, Stanford University, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>AstraZeneca PLC, Waltham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>NIH Clinical Center, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Dept. of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Dept. of Biomathematics &amp; Dept. of Human Genetics, David Geffen School of Medicine, Uni. of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ian Chi Kei</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Dept. of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lei</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Pharmacy and Medical Sciences, University of South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nor&#xe9;n</LastName><ForeName>G Niklas</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yu-Chuan</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>College of Medical Science and Technology (CoMST), Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="N">Health Services Research</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017146" MajorTopicYN="Y">Models, Organizational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="Y">Observational Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26262116</ArticleId><ArticleId IdType="mid">NIHMS771006</ArticleId><ArticleId IdType="pmc">PMC4815923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>OHDSI.  [Accessed 2014-12-07];  http://ohdsi.org/</Citation></Reference><Reference><Citation>OHDSI Vision.  [Accessed 2014-12-07];  http://ohdsi.org/who-we-are/mission-vision-values/</Citation></Reference><Reference><Citation> [Accessed 2014-12-07];OHDSI Values.   http://ohdsi.org/who-we-are/mission-vision-values/</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54&#x2013;60. Epub 2011 Oct 28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>IMEDS.  [Accessed 2014-12-07];  http://imeds.reaganudall.org/</Citation></Reference><Reference><Citation> [Accessed 2014-12-08];ACHILLES Repository.   http://github.com/ohdsi/achilles.</Citation></Reference><Reference><Citation> [Accessed 2014-12-08];ACHILLES Demonstration.   http://ohdsi.org/web/achilles/</Citation></Reference><Reference><Citation> [Accessed 2014-12-08];OHDSI Forums.   http://forums.ohdsi.org.</Citation></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, Suchard MA, DuMouchel W, Berlin JA. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013 Aug 15;178(4):645&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Schuemie MJ, Hripcsak G. Medication-wide association studies. CPT: Pharmacometrics &amp; Systems Pharmacology. 2013;2:e76. doi: 10.1038/psp.2013.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/psp.2013.52</ArticleId><ArticleId IdType="pmc">PMC4026636</ArticleId><ArticleId IdType="pubmed">24448022</ArticleId></ArticleIdList></Reference><Reference><Citation>Longhurst CA, Harrington RA, Shah NH. A &#x2018;green button&#x2019; for using aggregate patient data at the point of care. Health Aff (Millwood) 2014;33(7):1229&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006150</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein AR, Rubinstein JF, Ramshaw WA. Estimating prognosis with the aid of a conversational-mode computer program. Ann Intern Med. 1972;76(6):911&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">4554880</ArticleId></ArticleIdList></Reference><Reference><Citation> [Accessed 2014 12-08];PCORnet: the national patient-centered clinical research network.   http://www.pcornet.org.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26306268</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2153-4063</ISSN><JournalIssue CitedMedium="Print"><Volume>2015</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science</Title><ISOAbbreviation>AMIA Jt Summits Transl Sci Proc</ISOAbbreviation></Journal><ArticleTitle>Are All Vaccines Created Equal? Using Electronic Health Records to Discover Vaccines Associated With Clinician-Coded Adverse Events.</ArticleTitle><Pagination><StartPage>196</StartPage><EndPage>200</EndPage><MedlinePgn>196-200</MedlinePgn></Pagination><Abstract><AbstractText>Adverse drug events (ADEs) are responsible for unnecessary patient deaths making them a major public health issue. Literature estimates 1% of ADEs recorded in Electronic Health Records (EHRs) are reported to federal databases making EHRs a vital source of ADE-related information. Using Columbia University Medical Center (CUMC)'s EHRs, we developed an algorithm to mine for vaccine-related ADEs occurring within 3 months of vaccination. In phase one, we measured the association between vaccinated patients with an ADE (cases) against those vaccinated without an ADE. To adjust for healthcare-process effects, phase two compared cases against those who returned to CUMC within 3 months without an ADE. We report 7 results passing multiplicity correction after demographic confounder adjustment. We observed an association, having some literature support, between swine flu vaccination and ADEs (H1N1v-like, OR=9.469, p&lt;0.001; H1N1/H3N2, OR=3.207, p&lt;0.001). Our algorithm could inform clinicians of the risks/benefits of vaccinations towards improving clinical care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Mary Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University ; Observational Health Data Sciences and Informatics, Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University ; Department of Medicine, Columbia University ; Department of Systems Biology, Columbia University ; Observational Health Data Sciences and Informatics, Columbia University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Jt Summits Transl Sci Proc</MedlineTA><NlmUniqueID>101539486</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26306268</ArticleId><ArticleId IdType="pmc">PMC4525221</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998;279(15):1200&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9555760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the united states, 1969&#x2013;2002: The importance of reporting suspected reactions. Archives of Internal Medicine. 2005;165(12):1363&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15983284</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore TJ, Cohen MR, Furberg CD. SErious adverse drug events reported to the food and drug administration, 1998&#x2013;2005. Archives of Internal Medicine. 2007;167(16):1752&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846394</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder JA, Haas JS, Iyer A, Labuzetta MA, Ibara M, Celeste M, et al. Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting. Pharmacoepidemiology and Drug Safety. 2010;19(12):1211&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21155192</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha AK. Meaningful use of electronic health records: the road ahead. JAMA. 2010;304(15):1709&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20959581</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Hripcsak G, Shen Y, Chung WK, Weng C. Defining a comprehensive verotype using electronic health records for personalized medicine. J Am Med Inform Assoc. 2013;20(e2):e232&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861934</ArticleId><ArticleId IdType="pubmed">24001516</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc. 2013;20(1):144&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton G. Bias associated with mining electronic health records. J Biomed Discov Collab. 2011;6:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149555</ArticleId><ArticleId IdType="pubmed">21647858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. Correlating electronic health record concepts with healthcare process events. J Am Med Inform Assoc. 2013;20(e2):e311&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861922</ArticleId><ArticleId IdType="pubmed">23975625</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkin PL, Brown SH, Husser CS, Bauer BA, Wahner-Roedler D, Rosenbloom ST, et al. Evaluation of the Content Coverage of SNOMED CT: Ability of SNOMED Clinical Terms to Represent Clinical Problem Lists. Mayo Clinic Proceedings. 2006;81(6):741&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16770974</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K, Hsieh A, Farzaneh S, Doan S, Kim H. Standardizing Phenotype Variables in the Database of Genotypes and phenotypes (dbGaP) based on Information Models. AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:110.</Citation><ArticleIdList><ArticleId IdType="pubmed">24303316</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilbeck K, Jacobs J, McGarvey S, Vinion C, Staes CJ, editors. Exploring the use of ontologies and automated reasoning to manage selection of reportable condition lab tests from LOINC. ICBO; 2013.</Citation></Reference><Reference><Citation>Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton GB. Using discordance to improve classification in narrative clinical databases: An application to community-acquired pneumonia. Computers in Biology and Medicine. 2007;37(3):296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16620802</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13(6):395&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">22549152</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Hripcsak G, Albers DJ, Wei Y, Wilcox AB, Wei J, et al. Discovering medical conditions associated with periodontitis using linked electronic health records. J Clin Periodontol. 2013;40(5):474&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690348</ArticleId><ArticleId IdType="pubmed">23495669</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010;26(9):1205&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859132</ArticleId><ArticleId IdType="pubmed">20335276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohane IS. Using electronic health records to drive discovery in disease genomics. Nat Rev Genet. 2011;12(6):417&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">21587298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Hripcsak G, Markatou M, Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J Am Med Inform Assoc. 2009;16(3):328&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732239</ArticleId><ArticleId IdType="pubmed">19261932</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerian K, Varn D, Vaidya S, Ena L, Chase H, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clinical Pharmacology &amp; Therapeutics. 2012;92(2):228&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685297</ArticleId><ArticleId IdType="pubmed">22713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Wu Y, Chen Y, Sun J, Zhao Z, Chen X-w, et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc. 2012;19(e1):e28&#x2013;e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392844</ArticleId><ArticleId IdType="pubmed">22718037</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Z, Zhang G, Xu R. Mining patterns of adverse events using aggregated clinical trial results. AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:112&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814483</ArticleId><ArticleId IdType="pubmed">24303317</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Tatonetti NP, Hripcsak G. Intelligent Systems for Molecular Biology Phenotype Day. Boston, MA: 2014. CAESAR: a Classification Approach for Extracting Severity Automatically from Electronic Health Records; pp. 1&#x2013;8. In Press.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Schuemie MJ, Hripcsak G. Medication-wide association studies. CPT: pharmacometrics &amp; systems pharmacology. 2013;2:e76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026636</ArticleId><ArticleId IdType="pubmed">24448022</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak J, Chute CG. Analyzing categorical information in two publicly available drug terminologies: RxNorm and NDF-RT. J Am Med Inform Assoc. 2010;17(4):432&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995643</ArticleId><ArticleId IdType="pubmed">20595311</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An Epidemiologic and Clinical Evaluation of Guillain-Barre Syndrome Reported in Association with the Administration of Swine Influenza Vaccines. American Journal of Epidemiology. 1984;119(6):841&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">6328974</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson TA, Doughty E, Kann MG. Towards Precision Medicine: Advances in Computational Approaches for the Analysis of Human Variants. Journal of Molecular Biology. 2013;425(21):4047&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807015</ArticleId><ArticleId IdType="pubmed">23962656</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifonov V, Khiabanian H, Rabadan R. Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus. New England Journal of Medicine. 2009;361(2):115&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474418</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009&#x2013;January 31, 2010. Vaccine. 2010;28(45):7248&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">20850534</ArticleId></ArticleIdList></Reference><Reference><Citation>Classen DC, Resar R, Griffin F, Federico F, Frankel T, Kimmel N, et al. &#x2018;Global Trigger Tool&#x2019; Shows That Adverse Events In Hospitals May Be Ten Times Greater Than Previously Measured. Health Affairs. 2011;30(4):581&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21471476</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26448797</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership.</ArticleTitle><Pagination><StartPage>536</StartPage><EndPage>547</EndPage><MedlinePgn>536-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4338/ACI-2014-12-CR-0121</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adoption of a common data model across health systems is a key infrastructure requirement to allow large scale distributed comparative effectiveness analyses. There are a growing number of common data models (CDM), such as Mini-Sentinel, and the Observational Medical Outcomes Partnership (OMOP) CDMs.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">In this case study, we describe the challenges and opportunities of a study specific use of the OMOP CDM by two health systems and describe three comparative effectiveness use cases developed from the CDM.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The project transformed two health system databases (using crosswalks provided) into the OMOP CDM. Cohorts were developed from the transformed CDMs for three comparative effectiveness use case examples. Administrative/billing, demographic, order history, medication, and laboratory were included in the CDM transformation and cohort development rules.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Record counts per person month are presented for the eligible cohorts, highlighting differences between the civilian and federal datasets, e.g. the federal data set had more outpatient visits per person month (6.44 vs. 2.05 per person month). The count of medications per person month reflected the fact that one system's medications were extracted from orders while the other system had pharmacy fills and medication administration records. The federal system also had a higher prevalence of the conditions in all three use cases. Both systems required manual coding of some types of data to convert to the CDM.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The data transformation to the CDM was time consuming and resources required were substantial, beyond requirements for collecting native source data. The need to manually code subsets of data limited the conversion. However, once the native data was converted to the CDM, both systems were then able to use the same queries to identify cohorts. Thus, the CDM minimized the effort to develop cohorts and analyze the results across the sites.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>FitzHenry</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center , Nashville, TN ; Department of Biomedical Informatics; Vanderbilt University, Nashville , TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnic</LastName><ForeName>F S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Brigham and Women's Hospital , Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbins</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Brigham and Women's Hospital , Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denton</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center , Nashville, TN ; Division of General Internal Medicine and Public Health, Vanderbilt University , Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nookala</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center , Nashville, TN ; Division of General Internal Medicine and Public Health, Vanderbilt University , Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Health, RAND Corporation, Santa Monica , CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno-Machado</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Biomedical Informatics, University of California , San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>M E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center , Nashville, TN ; Department of Biomedical Informatics; Vanderbilt University, Nashville , TN ; Division of General Internal Medicine and Public Health, Vanderbilt University , Nashville, TN ; Department of Biostatistics, Vanderbilt University , Nashville, TN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HS019913</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HL108460</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HS019913</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54HL108460</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D065709" MajorTopicYN="Y">Common Data Elements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057186" MajorTopicYN="Y">Comparative Effectiveness Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">big data</Keyword><Keyword MajorTopicYN="N">comparative effectiveness</Keyword></KeywordList><CoiStatement><b>Conflict of Interest</b>. The authors declare that they have no conflicts of interest in the research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26448797</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="doi">10.4338/ACI-2014-12-CR-0121</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mayer-Sch&#xf6;nberger V, Cukier K. Big Data: a revolution that will transform how we live, work, and think. New York: Houghton Mifflin Harcourt; 2013.</Citation></Reference><Reference><Citation>Toh S, Platt R. Is size the next big thing in epidemiology? Epidemiology 2013; 24(3): 349&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">23549179</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman C, Powers B, Sanders J. [Rapporteurs]. Roundtable on value and science-driven health care, medicine Io: Digital data improvement priorities for continuous learning in health and healthcare: Workshop summary. Washington, DC: National Academies Press; 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">24921117</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen LA, McGinnis JM. Redesigning the clinical effectiveness research paradigm: Innovation and practice-based approaches: Workshop summary. Edited by Medicine Io. Washington, DC: National Academies Press; 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">21210561</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifir&#xf2; G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salam&#xe9; G, Catania MA, Salvo F, David A, Moore N, Caputi AP, Sturkenboom M, Molokhia M, Hippisley-Cox J, Acedo CD, van der Lei J, Fourrier-Reglat A. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiology and Drug Safety 2009; 18(12): 1176&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">19757412</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. Journal of Clinical Epidemiology 2005; 58(4): 323&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862718</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects&#x2013;advantages and disadvantages. Nature Clinical Practice Rheumatology 2007; 3(12): 725&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">18037932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohr KN. Emerging methods in comparative effectiveness and safety: symposium overview and summary. Medical Care 2007; 45(10 Supl 2): S5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17909383</ArticleId></ArticleIdList></Reference><Reference><Citation>American Recovery and Reinvestment Act of 2009. In USA; 2009: 123.</Citation></Reference><Reference><Citation>Berger ML, Doban V. Big data, advanced analytics and the future of comparative effectiveness research. Journal of Comparative Effectiveness Research 2014; 3(2): 167&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">24645690</ArticleId></ArticleIdList></Reference><Reference><Citation>Herland M, Khoshgoftaar T, Wald R. A review of data mining using big data in health informatics. Journal Of Big Data 2014; 1(1): 2.</Citation></Reference><Reference><Citation>Van Poucke S, Thomeer M, Hadzic A. 2015, big data in healthcare: for whom the bell tolls? Critical Care 2015; 19(1): 171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382849</ArticleId><ArticleId IdType="pubmed">25886956</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams CP, Brantner VV. Estimating the cost of new drug development: Is it really $802 million? Health Affairs 2006; 25(2): 420&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">16522582</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration: The sentinel initiative, National strategy for monitoring medical product safety. In.; 2010.</Citation></Reference><Reference><Citation>Food and Drug Administration: FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa&#xae; (dabigatran etexilate mesylate). In: PRNewswire. New York, NY: PRNewswire; 2012.</Citation></Reference><Reference><Citation>Rijnbeek P. Converting to a common data model: what is lost in translation? : Commentary on &#x201e;fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model&#x201d;. [Erratum appears in Drug Saf. 2014; 37(12): 1073]. Drug Safety 2014; 37(11): 893&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">25187018</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic &amp; Clinical Pharmacology &amp; Toxicology 2006; 98(3): 266&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortier I, Doiron D, Burton P, Raina P. Invited commentary: consolidating data harmonization&#x2013;how to obtain quality and applicability? American Journal of Epidemiology 2011; 174(3): 261&#x2013;264; author reply 265&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">21749975</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero CL, Lee TH. Achieving meaningful use: a health system perspective. American Journal of Managed Care 2010; 16(12 Suppl HIT): SP9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">21314229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunyemi OI, Meeker D, Kim H-E, Ashish N, Farzaneh S, Boxwala A. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Medical Care 2013; 51(8 Suppl 3): S45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan P, Torok D, Vereshagin S, Khayter M, Welebob E. OMOP Implementation Specification Standard Vocabularies in Observational Data Analysis Version 4.0. In.: Foundation for the National Institutes of Health; 2012.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. Journal of the American Medical Informatics Association 2012; 19(1): 54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, Bate A. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Safety 2013, 36(2): 119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Safety 2014; 37(11): 945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFalco F, Ryan P, Soledad Cepeda M. Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Method 2013, 13(1): 58&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566397</ArticleId><ArticleId IdType="pubmed">23396660</ArticleId></ArticleIdList></Reference><Reference><Citation>Veterans Health Administration: Patient care data capture: VHA Directive. 2009&#x2013;002. In. Edited by Affairs USDoV. Washington, DC: Veterans Health Administration; 2009.</Citation></Reference><Reference><Citation>Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Archives of Internal Medicine 2000; 160(21): 3252&#x2013;3257.</Citation><ArticleIdList><ArticleId IdType="pubmed">11088086</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration: FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa. In. Silver Springs, MD: Drug Safety Communications; 2012.</Citation></Reference><Reference><Citation>Southworth MR, Reichman ME, Unger EF: Dabigatran and postmarketing reports of bleeding. New England Journal of Medicine 2013, 368(14): 1272&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484796</ArticleId></ArticleIdList></Reference><Reference><Citation>Avorn J. The promise of pharmacoepidemiology in helping clinicians assess drug risk. Circulation 2013; 128(7): 745&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">23940388</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabigatran (Pradaxa) warfarin &amp; GI bleed, intracerebral hemorrhage (Modular Program) [http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_Modular-Program-Report_MSY3_MPR41_Dabigatran-Warfarin-GIH-ICH_Part-1.pdf]</Citation></Reference><Reference><Citation>Psaty BM, Breckenridge AM. Mini-Sentinel and regulatory science-big data rendered fit and functional. New England Journal of Medicine 2014; 370(23): 2165&#x2013;2167.</Citation><ArticleIdList><ArticleId IdType="pubmed">24897081</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, Suchard MA, Dumouchel W, Berlin JA. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol 2013; 178(4): 645&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan-Sarrazin MS, Wakefield B, Rosenthal GE. Mortality of Department of Veterans Affairs Patients Undergoing Coronary Revascularization in Private Sector Hospitals. Health Services Research 2007; 42(5): 1802&#x2013;1821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2254571</ArticleId><ArticleId IdType="pubmed">17850521</ArticleId></ArticleIdList></Reference><Reference><Citation>Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA 2001; 285(18): 2370&#x2013;2375.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen KM, Foldspang A, Larsen ML, Gerdes LU, Rasmussen S, Faergeman O. Estimating the incidence of the acute coronary syndrome: data from a Danish cohort of 138290 persons. European Journal of Cardiovascular Prevention &amp; Rehabilitation 2007; 14(5): 608&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">17925618</ArticleId></ArticleIdList></Reference><Reference><Citation>White RH. The Epidemiology of Venous Thromboembolism. Circulation 2003; 107(23 suppl 1): I4&#x2013;I8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814979</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterberg L, Blaschke T. Adherence to Medication. New England Journal of Medicine 2005; 353(5): 487&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">16079372</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Doran J, Lobo B, Sullivan TM, Potts A, Feldott CC, Matheny ME, McCulloch G, Deppen S, Doulis J. Medication-error alerts for warfarin orders detected by a bar-code-assisted medication administration system. American Journal of Health-System Pharmacy 2011; 68(5): 434&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">21330686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Mahoney L, Shakurova A, Goss F, Chang F, Bates D, Rocha R. How many medication orders are entered through free-text in EHRs? A study on hypoglycemic agents. American Medical Informatics Association Annual Meeting; Chicago, IL: 2012: 1079&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540584</ArticleId><ArticleId IdType="pubmed">23304384</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Dietrich M, Littlejohn S, Gregory D, Matheny M, Ehrenfeld J, Wells N. Postoperative pain time from severe to mild: effect of frequent and multimodal interventions. American Pain Society National Meeting 2013; New Orleans, LA: 2013.</Citation></Reference><Reference><Citation>Cunningham PJ, Kohn L. Health plan switching: choice or circumstance? Health Affairs 2000; 19(3): 158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">10812794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavarreda SA, Gatchell M, Ponce N, Brown ER, Chia YJ. Switching health insurance and its effects on access to physician services. Medical Care 2008; 46(10): 1055&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">18815527</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed M. Why people change their health care providers. Data Bull (Cent Stud Health Syst Change) 2000; 16: 1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12577973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederle F, Parenti C. Prescription drug costs as a reason for changing physicians. Journal of General Internal Medicine 1994; 9(3): 162&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">8195915</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker J, Pan E, Johnston D, Adler-Milstein J, Bates DW, Middleton B. The value of health care information exchange and interoperability. Health Affairs 2005; Suppl Web Exclusives: W5&#x2013;10, W15&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado L, Agha Z, Bell DS, Dahm L, Day ME, Doctor JN, Gabriel D, Kahlon MK, Kim KK, Hogarth M, Matheny ME, Meeker D, Nebeker JR, pSCANNER team. pSCANNER: patient-centered scalable national network for effectiveness research. Journal of the American Medical Informatics Association 2014; 21(4): 621&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078293</ArticleId><ArticleId IdType="pubmed">24780722</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency: Guideline on good pharmacovigilance practices: Module VIII &#x2013; Post authorisation safety studies (Rev 1). In.; London, United Kingdom: European Medicines Agency; 2013.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26515501</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Semantic processing of EHR data for clinical research.</ArticleTitle><Pagination><StartPage>247</StartPage><EndPage>259</EndPage><MedlinePgn>247-259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2015.10.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(15)00231-2</ELocationID><Abstract><AbstractText>There is a growing need to semantically process and integrate clinical data from different sources for clinical research. This paper presents an approach to integrate EHRs from heterogeneous resources and generate integrated data in different data formats or semantics to support various clinical research applications. The proposed approach builds semantic data virtualization layers on top of data sources, which generate data in the requested semantics or formats on demand. This approach avoids upfront dumping to and synchronizing of the data with various representations. Data from different EHR systems are first mapped to RDF data with source semantics, and then converted to representations with harmonized domain semantics where domain ontologies and terminologies are used to improve reusability. It is also possible to further convert data to application semantics and store the converted results in clinical research databases, e.g. i2b2, OMOP, to support different clinical research settings. Semantic conversions between different representations are explicitly expressed using N3 rules and executed by an N3 Reasoner (EYE), which can also generate proofs of the conversion processes. The solution presented in this paper has been applied to real-world applications that process large scale EHR data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Advanced Clinical Applications Research Group, Agfa HealthCare, Moutstraat 100, 9000 Gent, Belgium. Electronic address: hong.sun@agfa.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depraetere</LastName><ForeName>Kristof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Advanced Clinical Applications Research Group, Agfa HealthCare, Moutstraat 100, 9000 Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Roo</LastName><ForeName>Jos</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Advanced Clinical Applications Research Group, Agfa HealthCare, Moutstraat 100, 9000 Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mels</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Advanced Clinical Applications Research Group, Agfa HealthCare, Moutstraat 100, 9000 Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vloed</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Advanced Clinical Applications Research Group, Agfa HealthCare, Moutstraat 100, 9000 Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Twagirumukiza</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Advanced Clinical Applications Research Group, Agfa HealthCare, Moutstraat 100, 9000 Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colaert</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Advanced Clinical Applications Research Group, Agfa HealthCare, Moutstraat 100, 9000 Gent, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="Y">Semantics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical research</Keyword><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">N3 rules</Keyword><Keyword MajorTopicYN="N">RESTful</Keyword><Keyword MajorTopicYN="N">Semantic interoperability</Keyword><Keyword MajorTopicYN="N">Semantic web stack</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26515501</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2015.10.009</ArticleId><ArticleId IdType="pii">S1532-0464(15)00231-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26958207</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2015</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Clinical Predictive Modeling Development and Deployment through FHIR Web Services.</ArticleTitle><Pagination><StartPage>717</StartPage><EndPage>726</EndPage><MedlinePgn>717-26</MedlinePgn></Pagination><Abstract><AbstractText>Clinical predictive modeling involves two challenging tasks: model development and model deployment. In this paper we demonstrate a software architecture for developing and deploying clinical predictive models using web services via the Health Level 7 (HL7) Fast Healthcare Interoperability Resources (FHIR) standard. The services enable model development using electronic health records (EHRs) stored in OMOP CDM databases and model deployment for scoring individual patients through FHIR resources. The MIMIC2 ICU dataset and a synthetic outpatient dataset were transformed into OMOP CDM databases for predictive model development. The resulting predictive models are deployed as FHIR resources, which receive requests of patient information, perform prediction against the deployed predictive model and respond with prediction scores. To assess the practicality of this approach we evaluated the response and prediction time of the FHIR modeling web services. We found the system to be reasonably fast with one second total response time per patient prediction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalilia</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Georgia Institute of Technology, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Myung</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Georgia Institute of Technology, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Georgia Institute of Technology, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyengar</LastName><ForeName>Sneha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Georgia Institute of Technology, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunstein</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Georgia Institute of Technology, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jimeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Georgia Institute of Technology, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066275" MajorTopicYN="N">Health Information Exchange</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="N">Health Information Interoperability</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057208" MajorTopicYN="N">Health Level Seven</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="N">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26958207</ArticleId><ArticleId IdType="pmc">PMC4765683</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brownson RC, Colditz GA, Proctor EK. Dissemination and implementation research in health: translating science to practice. Oxford University Press; 2012.</Citation></Reference><Reference><Citation>Dobbins M, Ciliska D, Cockerill R, Barnsley J, DiCenso A. A Framework for the Dissemination and Utilization of Research for Health-Care Policy and Practice. Worldviews Evid-Based Nurs Presents Arch Online J Knowl Synth Nurs. 2002;E9:149&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">12439759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, et al. Predicting changes in hypertension control using electronic health records from a chronic disease management program. J Am Med Inform Assoc JAMIA. 2013 doi: 10.1136/amiajnl-2013-002033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-002033</ArticleId><ArticleId IdType="pmc">PMC3932462</ArticleId><ArticleId IdType="pubmed">24045907</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow RE, Emmons KM, How Can, We Increase. Translation of Research into Practice? Types of Evidence Needed. Annu Rev Public Health. 2007;28:413&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">17150029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wehling M. Translational medicine: science or wishful thinking? J Transl Med. 2008;6:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442586</ArticleId><ArticleId IdType="pubmed">18559092</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;rig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nat Med. 2005;11:705&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">16015353</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto GE, Spertus JA. EPOCH ePRISM: A web-based translational framework for bridging outcomes research and clinical practice. Computers in Cardiology, 2007. 2007:205&#x2013;208. doi: 10.1109/CIC.2007.4745457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/CIC.2007.4745457</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellazzi R, Zupan B. Predictive data mining in clinical medicine: Current issues and guidelines. Int J Med Inf. 2008;77:81&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188928</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto GE, Jones P, Spertus JA. PRISM trade;: a Web-based framework for deploying predictive clinical models. Computers in Cardiology, 2004. 2004:193&#x2013;196. doi: 10.1109/CIC.2004.1442905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/CIC.2004.1442905</ArticleId></ArticleIdList></Reference><Reference><Citation>Velickovski F, et al. Clinical Decision Support Systems (CDSS) for preventive management of COPD patients. J Transl Med. 2014;12:S9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255917</ArticleId><ArticleId IdType="pubmed">25471545</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry S. The Rise and Fall of HL7. 2011.  at &lt; http://hl7-watch.blogspot.com/2011/03/rise-and-fall-of-hl7.html&gt;.</Citation></Reference><Reference><Citation>Bender D, Sartipi K. HL7 FHIR: An Agile and RESTful approach to healthcare information exchange. 2013 IEEE 26th International Symposium on Computer-Based Medical Systems (CBMS) 2013:326&#x2013;331. doi: 10.1109/CBMS.2013.6627810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/CBMS.2013.6627810</ArticleId></ArticleIdList></Reference><Reference><Citation>Miliard M, Epic Cerner. others join HL7 project. Healthcare IT News. 2014 at &lt; http://www.healthcareitnews.com/news/epic-cerner-others-join-hl7-project&gt;.</Citation></Reference><Reference><Citation>Open Epic.  at &lt; https://open.epic.com/Interface/FHIR&gt;.</Citation></Reference><Reference><Citation>Raths D. SMART on FHIR a Smoking Hot Topic at AMIA Meeting. Healthcare Informatics. 2014.  at &lt; http://www.healthcare-informatics.com/article/smart-fhir-smoking-hot-topic-amia-meeting&gt;.</Citation></Reference><Reference><Citation>Ryan PB, Griffin D, Reich C. 2009 Omop Common Data Model (Cdm) Specifications;</Citation></Reference><Reference><Citation>Zhou X, et al. An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance. Drug Saf. 2013;36:119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Letham B, Rudin C, McCormick TH, Madigan D. An Interpretable Stroke Prediction Model using Rules and Bayesian Analysis. 2013.  at &lt; http://dspace.mit.edu/handle/1721.1/82148&gt;.</Citation></Reference><Reference><Citation>Duke J, Zhang Z, Li X. Characterizing an optimal predictive modeling framework for prediction of adverse drug events. Stakehold Symp. 2014 at &lt; http://repository.academyhealth.org/symposia/june2014/panels/7&gt;.</Citation></Reference><Reference><Citation> HL7 FHIR Development Version. at &lt; http://www.hl7.org/implement/standards/FHIR-Develop/&gt;.</Citation></Reference><Reference><Citation>Pedregosa F, et al. Scikit-learn: Machine Learning in Python. J Mach Learn Res. 2011;12:2825&#x2013;2830.</Citation></Reference><Reference><Citation> HL7 Application Programming Interface. at &lt; http://jamesagnew.github.io/hapi-fhir/doc_rest_client.html&gt;.</Citation></Reference><Reference><Citation> Simple Cloud-based Load Testing. at &lt; https://loader.io/&gt;.</Citation></Reference><Reference><Citation> FHIR Resource Subscription. at &lt; http://hl7.org/fhir/2015May/subscription.html&gt;.</Citation></Reference><Reference><Citation>Shvachko K, Kuang H, Radia S, Chansler R. The Hadoop Distributed File System. 2010 IEEE 26th Symposium on Mass Storage Systems and Technologies (MSST) 2010:1&#x2013;10. doi: 10.1109/MSST.2010.5496972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MSST.2010.5496972</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaharia M, Chowdhury M, Franklin MJ, Shenker S, Stoica I. Spark: cluster computing with working sets; Proceedings of the 2nd USENIX conference on Hot topics in cloud computing; 2010. pp. 10&#x2013;10. at &lt; http://static.usenix.org/legacy/events/hotcloud10/tech/full_papers/Zaharia.pdf&gt;.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">24685766</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0334</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Statistical methods in medical research</Title><ISOAbbreviation>Stat Methods Med Res</ISOAbbreviation></Journal><ArticleTitle>Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series.</ArticleTitle><Pagination><StartPage>2577</StartPage><EndPage>2592</EndPage><MedlinePgn>2577-2592</MedlinePgn></Pagination><Abstract><AbstractText>Most approaches used in postmarketing drug safety monitoring, including spontaneous reporting and statistical risk identification using electronic health care records, are primarily suited to pick up only acute adverse drug effects. With the availability of increasingly larger electronic health record and administrative claims databases comes the opportunity to monitor for potential adverse effects that occur only after prolonged exposure to a drug, but analysis methods are lacking. We propose an adaptation of the self-controlled case series design that uses the notion of accumulated exposure to capture long-term effects of drugs and evaluate extensions to correct for age and recurrent events. Several variations of the approach are tested on simulated data and two large insurance claims databases. To evaluate performance a set of positive and negative control drug-event pairs was created by medical experts based on drug product labels and review of the literature. Performance on the real data was measured using the area under the receiver operator characteristics curve. The best performing method achieved an area under the receiver operator characteristics curve of 0.86 in the largest database using a spline model, adjustment for age, and ignoring recurrent events, but it appears this performance can only be achieved with very large data sets.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2014.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands m.schuemie@erasmusmc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trifir&#xf2;</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coloma</LastName><ForeName>Preciosa M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Methods Med Res</MedlineTA><NlmUniqueID>9212457</NlmUniqueID><ISSNLinking>0962-2802</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004348" MajorTopicYN="N">Drug Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007344" MajorTopicYN="N">Insurance Claim Reporting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007348" MajorTopicYN="N">Insurance, Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse drug reactions</Keyword><Keyword MajorTopicYN="N">claims databases</Keyword><Keyword MajorTopicYN="N">methods analysis</Keyword><Keyword MajorTopicYN="N">receiver operator characteristics curve</Keyword><Keyword MajorTopicYN="N">self-controlled case series</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24685766</ArticleId><ArticleId IdType="doi">10.1177/0962280214527531</ArticleId><ArticleId IdType="pii">0962280214527531</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26527579</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>A normalization method for combination of laboratory test results from different electronic healthcare databases in a distributed research network.</ArticleTitle><Pagination><StartPage>307</StartPage><EndPage>316</EndPage><MedlinePgn>307-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.3893</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Distributed research networks (DRNs) afford statistical power by integrating observational data from multiple partners for retrospective studies. However, laboratory test results across care sites are derived using different assays from varying patient populations, making it difficult to simply combine data for analysis. Additionally, existing normalization methods are not suitable for retrospective studies. We normalized laboratory results from different data sources by adjusting for heterogeneous clinico-epidemiologic characteristics of the data and called this the subgroup-adjusted normalization (SAN) method.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subgroup-adjusted normalization renders the means and standard deviations of distributions identical under population structure-adjusted conditions. To evaluate its performance, we compared SAN with existing methods for simulated and real datasets consisting of blood urea nitrogen, serum creatinine, hematocrit, hemoglobin, serum potassium, and total bilirubin. Various clinico-epidemiologic characteristics can be applied together in SAN. For simplicity of comparison, age and gender were used to adjust population heterogeneity in this study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In simulations, SAN had the lowest standardized difference in means (SDM) and Kolmogorov-Smirnov values for all tests (p&#x2009;&lt;&#x2009;0.05). In a real dataset, SAN had the lowest SDM and Kolmogorov-Smirnov values for blood urea nitrogen, hematocrit, hemoglobin, and serum potassium, and the lowest SDM for serum creatinine (p&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Subgroup-adjusted normalization performed better than normalization using other methods. The SAN method is applicable in a DRN environment and should facilitate analysis of data integrated across DRN partners for retrospective observational studies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Dukyong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ju Han</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Seoul National University Biomedical Informatics, Seoul National University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong Ki</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Man Young</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Mibyeong Research Center, Korea Institute of Oriental Medicine, Daejeon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Eun Kyoung</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Eun-Young</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Centre for u-Healthcare, Gachon University Gil Hospital, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Dong Kyun</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Centre for u-Healthcare, Gachon University Gil Hospital, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Soo Yeon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Dahye</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Yeonsoo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Medical Informatics, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002984" MajorTopicYN="N">Clinical Laboratory Information Systems</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057186" MajorTopicYN="N">Comparative Effectiveness Research</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="Y">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007755" MajorTopicYN="N">Laboratories, Hospital</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="N">Pharmacoepidemiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">distributed research networks</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">laboratory test</Keyword><Keyword MajorTopicYN="N">normalization</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26527579</ArticleId><ArticleId IdType="doi">10.1002/pds.3893</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26559926</PMID><DateCompleted><Year>2016</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1939-005X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Wiley interdisciplinary reviews. Systems biology and medicine</Title><ISOAbbreviation>Wiley Interdiscip Rev Syst Biol Med</ISOAbbreviation></Journal><ArticleTitle>Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.</ArticleTitle><Pagination><StartPage>104</StartPage><EndPage>122</EndPage><MedlinePgn>104-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/wsbm.1323</ELocationID><Abstract><AbstractText>Small molecules are indispensable to modern medical therapy. However, their use may lead to unintended, negative medical outcomes commonly referred to as adverse drug reactions (ADRs). These effects vary widely in mechanism, severity, and populations affected, making ADR prediction and identification important public health concerns. Current methods rely on clinical trials and postmarket surveillance programs to find novel ADRs; however, clinical trials are limited by small sample size, whereas postmarket surveillance methods may be biased and inherently leave patients at risk until sufficient clinical evidence has been gathered. Systems pharmacology, an emerging interdisciplinary field combining network and chemical biology, provides important tools to uncover and understand ADRs and may mitigate the drawbacks of traditional methods. In particular, network analysis allows researchers to integrate heterogeneous data sources and quantify the interactions between biological and chemical entities. Recent work in this area has combined chemical, biological, and large-scale observational health data to predict ADRs in both individual patients and global populations. In this review, we explore the rapid expansion of systems pharmacology in the study of ADRs. We enumerate the existing methods and strategies and illustrate progress in the field with a model framework that incorporates crucial data elements, such as diet and comorbidities, known to modulate ADR risk. Using this framework, we highlight avenues of research that may currently be underexplored, representing opportunities for future work.</AbstractText><CopyrightInformation>&#xa9; 2015 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Mary Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacunski</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Program in Cellular, Molecular and Biomedical Studies, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorberbaum</LastName><ForeName>Tal</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4772-7392</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Cellular Biophysics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moskovitch</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM082797</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM00707</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA209997</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Wiley Interdiscip Rev Syst Biol Med</MedlineTA><NlmUniqueID>101516550</NlmUniqueID><ISSNLinking>1939-005X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049490" MajorTopicYN="N">Systems Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26559926</ArticleId><ArticleId IdType="mid">NIHMS731462</ArticleId><ArticleId IdType="pmc">PMC4760887</ArticleId><ArticleId IdType="doi">10.1002/wsbm.1323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147:755&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056659</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker KN, Flynn EA, Pepper GA, Bates DW, Mikeal RL. Medication errors observed in 36 health care facilities. Arch Intern Med. 2002;162:1897&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196090</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi TK, et al. Adverse Drug Events in Ambulatory Care. N Engl J Med. 2003;348:1556&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700376</ArticleId></ArticleIdList></Reference><Reference><Citation>Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing Reports of Bleeding. N Engl J Med. 2013;368:1272&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484796</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul SM, Mytelka DS, Dunwiddie CT. How to improve R&amp;D productivity: the pharmaceutical industry's grand challenge. Nature reviews Drug &#x2026;. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20168317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286737</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacunski A, Tatonetti NP. Connecting the dots: applications of network medicine in pharmacology and disease. Clin Pharmacol Ther. 2013;94:659&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">23995266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature. 2008;455:1054&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">18948945</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger SI, Iyengar R. Role of systems pharmacology in understanding drug adverse events. WIREs Syst Biol Med. 2010;3:129&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057924</ArticleId><ArticleId IdType="pubmed">20803507</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschini A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research. 2012;41:D808&#x2013;D815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531103</ArticleId><ArticleId IdType="pubmed">23203871</ArticleId></ArticleIdList></Reference><Reference><Citation>Law V, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Research. 2013;42:D1091&#x2013;D1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965102</ArticleId><ArticleId IdType="pubmed">24203711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010;6:343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824526</ArticleId><ArticleId IdType="pubmed">20087340</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti NP, Liu T, Altman RB. Predicting drug side-effects by chemical systems biology. Genome Biology. 2009;10:238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768971</ArticleId><ArticleId IdType="pubmed">19723347</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty KD, Dalal SR. Using information mining of the medical literature to improve drug safety. Journal of the American Medical Informatics Association. 2011;18:668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168306</ArticleId><ArticleId IdType="pubmed">21546507</ArticleId></ArticleIdList></Reference><Reference><Citation>Leaman R, et al. Proceedings of the &#x2026;. Association for Computational Linguistics; 2010. Towards internet-age pharmacovigilance: extracting adverse drug reactions from user posts to health-related social networks; pp. 117&#x2013;125.</Citation></Reference><Reference><Citation>Moskovitch R, Walsh C, Hripsack G, Tatonetti N. Prediction of Biomedical Events via Time Intervals Mining. ACM KDD Workshop on Connected Health in Big Data Era. 2014</Citation></Reference><Reference><Citation>Moskovitch R, Shahar Y. Classification-driven temporal discretization of multivariate time series. Data Min Knowl Disc. 2014:1&#x2013;43. doi: 10.1007/s10618-014-0380-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10618-014-0380-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitch R, Shahar Y. Fast time intervals mining using the transitivity of temporal relations. Knowl Inf Syst. 2013;42:21&#x2013;48.</Citation></Reference><Reference><Citation>Sacchi L, Dagliati A, Bellazzi R. Analyzing complex patients' temporal histories: new frontiers in temporal data mining. Methods Mol Biol. 2015;1246:89&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417081</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, Chase HS, Friedman C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics. 2010;11 Suppl 9:S7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967748</ArticleId><ArticleId IdType="pubmed">21044365</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouane-Hacene M, Toussaint Y, Valtchev P. Mining safety signals in spontaneous reports database using concept analysis. Artificial Intelligence in &#x2026;. 2009</Citation></Reference><Reference><Citation>Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22:39&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">21878461</ArticleId></ArticleIdList></Reference><Reference><Citation>Overby CL, Hripcsak G, Shen Y. Estimating heritability of drug-induced liver injury from common variants and implications for future study designs. Sci Rep. 2014;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104390</ArticleId><ArticleId IdType="pubmed">25042059</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerian K, et al. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Ther. 2012;92:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685297</ArticleId><ArticleId IdType="pubmed">22713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Tatonetti NP. Are All Vaccines Created Equal? Using Electronic Health Records to Discover Vaccines Associated With Clinician-Coded Adverse Events. AMIA Summits on Translational Science Proceedings. 2015:196&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525221</ArticleId><ArticleId IdType="pubmed">26306268</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey CG, et al. Adverse Events Associated With Smallpox Vaccination in the United States, January-October 2003. JAMA. 2005;294:2734&#x2013;2743.</Citation><ArticleIdList><ArticleId IdType="pubmed">16333009</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRussa PS, et al. Understanding the Role of Human Variation in Vaccine Adverse Events: The Clinical Immunization Safety Assessment Network. PEDIATRICS. 2011;127:S65&#x2013;S73.</Citation><ArticleIdList><ArticleId IdType="pubmed">21502239</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Zhihui, Z GQ, X R. Mining Patterns of Adverse Events Using Aggregated Clinical Trial Results. AMIA Summits on Translational Science Proceedings. 2013;2013:112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814483</ArticleId><ArticleId IdType="pubmed">24303317</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Hripcsak G, Markatou M, Friedman C. Active Computerized Pharmacovigilance Using Natural Language Processing, Statistics, and Electronic Health Records: A Feasibility Study. Journal of the American Medical Informatics Association. 2009;16:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732239</ArticleId><ArticleId IdType="pubmed">19261932</ArticleId></ArticleIdList></Reference><Reference><Citation>Melton GB, Hripcsak G. Automated Detection of Adverse Events Using Natural Language Processing of Discharge Summaries. Journal of the American Medical Informatics Association. 2005;12:448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1174890</ArticleId><ArticleId IdType="pubmed">15802475</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson R, Jensen PB, Frankild S, Jensen LJ, Brunak S. Dictionary construction and identification of possible adverse drug events in Danish clinical narrative text. Journal of the American Medical Informatics Association. 2013;20:947&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756275</ArticleId><ArticleId IdType="pubmed">23703825</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91:1010&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Motsinger-Reif AA, et al. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 2013;23:383&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003940</ArticleId><ArticleId IdType="pubmed">20639796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. The American Journal of Geriatric Pharmacotherapy. 2008;5:345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">18179993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Vilar S, Tatonetti NP. High-throughput methods for combinatorial drug discovery. Science Translational Medicine. 2013;5:205rv1.</Citation><ArticleIdList><ArticleId IdType="pubmed">24089409</ArticleId></ArticleIdList></Reference><Reference><Citation>Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug Target Identification Using Side-Effect Similarity. Science. 2008;321:263&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">18621671</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser MJ, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">17287757</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser MJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784146</ArticleId><ArticleId IdType="pubmed">19881490</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanishi Y, Kotera M, Kanehisa M, Goto S. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics. 2010;26:i246&#x2013;i254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881361</ArticleId><ArticleId IdType="pubmed">20529913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Li S. PLOS ONE: Network-Based Relating Pharmacological and Genomic Spaces for Drug Target Identification. 2010;5:e11764.  journals.plos.org.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909904</ArticleId><ArticleId IdType="pubmed">20668676</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, et al. Predicting putative adverse drug reaction related proteins based on network topological properties. Analytical Methods. 2014;6:2692&#x2013;2698.</Citation></Reference><Reference><Citation>Huang LC, Wu X, Chen JY. Predicting adverse side effects of drugs. BMC Genomics. 2011;12:S11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3287493</ArticleId><ArticleId IdType="pubmed">22369493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn M, et al. Systematic identification of proteins that elicit drug side effects. Mol Syst Biol. 2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693830</ArticleId><ArticleId IdType="pubmed">23632385</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, et al. Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network. PLoS Comput Biol. 2013;9:e1002998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605053</ArticleId><ArticleId IdType="pubmed">23555229</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimer&#xe0; R, Sales-Pardo M. A network inference method for large-scale unsupervised identification of novel drug-drug interactions. PLoS Comput Biol. 2013;9:e1003374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3854677</ArticleId><ArticleId IdType="pubmed">24339767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobanoglu MC, Liu C, Hu F, Oltvai ZN, Bahar I. Predicting drug-target interactions using probabilistic matrix factorization. J Chem Inf Model. 2013;53:3399&#x2013;3409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871285</ArticleId><ArticleId IdType="pubmed">24289468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lounkine E, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012;486:361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383642</ArticleId><ArticleId IdType="pubmed">22722194</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiber J, et al. Mapping Adverse Drug Reactions in Chemical Space. J Med Chem. 2009;52:3103&#x2013;3107.</Citation><ArticleIdList><ArticleId IdType="pubmed">19378990</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran-Frigola M, Rossell D, Aloy P. A chemo-centric view of human health and disease. Nat Comms. 2014;5:5676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338530</ArticleId><ArticleId IdType="pubmed">25435099</ArticleId></ArticleIdList></Reference><Reference><Citation>Atias N, Sharan R. An Algorithmic Framework for Predicting Side Effects of Drugs. journal of computational Biology. 2011;18</Citation><ArticleIdList><ArticleId IdType="pubmed">21385029</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. Journal of the American Medical Informatics Association. 2012;19:e28&#x2013;e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392844</ArticleId><ArticleId IdType="pubmed">22718037</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LC, Wu X, Chen JY. Predicting adverse drug reaction profiles by integrating protein interaction networks with drug structures. Proteomics. 2013;13:313&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">23184540</ArticleId></ArticleIdList></Reference><Reference><Citation>LaBute MX, et al. Adverse drug reaction prediction using scores produced by large-scale drug-protein target docking on high-performance computing machines. PLoS ONE. 2014;9:e106298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4156361</ArticleId><ArticleId IdType="pubmed">25191698</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RD, et al. CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions. J Chem Inf Model. 2011;51:2115&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3186041</ArticleId><ArticleId IdType="pubmed">21809884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa SF, et al. Protein-ligand docking in the new millennium--a retrospective of 10 years in the field. Curr Med Chem. 2013;20:2296&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">23531220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohlhoff KJ, et al. Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways. Nat Chem. 2014;6:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923464</ArticleId><ArticleId IdType="pubmed">24345941</ArticleId></ArticleIdList></Reference><Reference><Citation>Stjernschantz E, Oostenbrink C. Improved ligand-protein binding affinity predictions using multiple binding modes. Biophys J. 2010;98:2682&#x2013;2691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877349</ArticleId><ArticleId IdType="pubmed">20513413</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell AJ, Lamb ML, Joseph-McCarthy D. Ensemble-based docking using biased molecular dynamics. J Chem Inf Model. 2014;54:2127&#x2013;2138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24881672</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiber J, et al. Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis. J Chem Inf Model. 2009;49:308&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">19434832</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallach I, Jaitly N, Lilien R. A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS ONE. 2010;5:e12063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925884</ArticleId><ArticleId IdType="pubmed">20808786</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Li J, Xie L, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol. 2009;5:e1000387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676506</ArticleId><ArticleId IdType="pubmed">19436720</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, et al. A sub-pathway-based approach for identifying drug response principal network. Bioinformatics. 2011;27:649&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">21186246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Lee KH, Song M, Lee D. Building the process-drug&#x2013;side effect network to discover the relationship between biological Processes and side effects. BMC Bioinformatics. 2011;12:S2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073182</ArticleId><ArticleId IdType="pubmed">21489221</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran-Frigola M, Aloy P. Analysis of Chemical and Biological Features Yields Mechanistic Insights into Drug Side Effects. Chemistry &amp; Biology. 2013;20:594&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">23601648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb A, Altman RB. Integrating systems biology sources illuminates drug action. Clin Pharmacol Ther. 2014;95:663&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029855</ArticleId><ArticleId IdType="pubmed">24577151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov SM, Lagunin AA, Pogodin PV, Filimonov DA, Poroikov VV. Identification of drug-induced myocardial infarction-related protein targets through the prediction of drug-target interactions and analysis of biological processes. Chem Res Toxicol. 2014;27:1263&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">24920530</ArticleId></ArticleIdList></Reference><Reference><Citation>Silberberg Y, Gottlieb A, Kupiec M, Ruppin E, Sharan R. Large-scale elucidation of drug response pathways in humans. journal of computational Biology. 2012;19:163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272249</ArticleId><ArticleId IdType="pubmed">22300318</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, Yan Y, Jiang Z. Drug-pathway interaction prediction via multiple feature fusion. Mol BioSyst. 2014;10:2907&#x2013;2913.</Citation><ArticleIdList><ArticleId IdType="pubmed">25122125</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani S, Pauwels E, Stoven V, Goto S, Yamanishi Y. Relating drug-protein interaction network with drug side effects. Bioinformatics. 2012;28:i522&#x2013;i528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3436810</ArticleId><ArticleId IdType="pubmed">22962476</ArticleId></ArticleIdList></Reference><Reference><Citation>Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest. 1988;82:1826&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC442760</ArticleId><ArticleId IdType="pubmed">3198757</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennis MA, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med. 1991;91:631&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">1750433</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000;356:1587&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pubmed">11075787</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassaneeyakul W, Tiamkao S, Jantararoungtong T. Association between HLA-B* 1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. &#x2026;. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20345939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung SI, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16:297&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16538176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozeki T, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20:1034&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">21149285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonjou C, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">18192896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonjou C, et al. A marker for Stevens-Johnson syndrome&#x2026;: ethnicity matters. The pharmacogenomics journal. 2006;6:265&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415921</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger SI, Ma'ayan A, Iyengar R. Systems pharmacology of arrhythmias. Science signaling. 2010;3:ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068558</ArticleId><ArticleId IdType="pubmed">20407125</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibney MJ, et al. Metabolomics in human nutrition: opportunities and challenges. Am J Clin Nutr. 2005;82:497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155259</ArticleId></ArticleIdList></Reference><Reference><Citation>Winnike JH, et al. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther. 2010;88:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182423</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham K, et al. Pharmacometabonomic characterization of xenobiotic and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response. J Proteome Res. 2012;11:4630&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pubmed">22873827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz EM, et al. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J Pharm Biomed Anal. 2004;36:841&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">15533678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Beger RD, Schnackenberg LK. Metabolomics as a tool for personalizing medicine: 2012 update. Personalized Medicine. 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">29758850</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson JK, Wilson ID. Understanding &#x2018;global&#x2019; systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2003</Citation><ArticleIdList><ArticleId IdType="pubmed">12904817</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther. 2013;94:574&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">23933971</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleil JD, Sheldon LS. Adapting concepts from systems biology to develop systems exposure event networks for exposure science research. Biomarkers. 2011;16:99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">21138393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourley M, Miller FW. Mechanisms of disease: Environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol. 2007;3:172&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis A, Yang X, Schadt E. Integrative genomics strategies to elucidate the complexity of drug response. Pharmacogenomics. 2011;12:1695&#x2013;1715.</Citation><ArticleIdList><ArticleId IdType="pubmed">22118053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, et al. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009;338:a2752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615549</ArticleId><ArticleId IdType="pubmed">19129307</ArticleId></ArticleIdList></Reference><Reference><Citation>Onder G, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA) J Am Geriatr Soc. 2002;50:1962&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473007</ArticleId></ArticleIdList></Reference><Reference><Citation>Boran ADW, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel. 2010;13:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068535</ArticleId><ArticleId IdType="pubmed">20443163</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer. 2008;8 Suppl 3:S114&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18777950</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan-Chiu E, Yothers G, Romond E. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant &#x2026;. Journal of Clinical &#x2026;. 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">16258083</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-Driven Prediction of Drug Effects and Interactions. Science Translational Medicine. 2012;4:125ra31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382018</ArticleId><ArticleId IdType="pubmed">22422992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">18936753</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, et al. Predicting drug-target interaction networks based on functional groups and biological features. PLoS ONE. 2010;5:e9603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836373</ArticleId><ArticleId IdType="pubmed">20300175</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner RM, Park BK, Pirmohamed M. Parsing interindividual drug variability: an emerging role for systems pharmacology. WIREs Syst Biol Med. 2015 doi: 10.1002/wsbm.1302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wsbm.1302</ArticleId><ArticleId IdType="pmc">PMC4696409</ArticleId><ArticleId IdType="pubmed">25950758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V, Sarkar IN. Leveraging concept-based approaches to identify potential phyto-therapies. Journal of Biomedical Informatics. 2013;46:602&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723125</ArticleId><ArticleId IdType="pubmed">23665360</ArticleId></ArticleIdList></Reference><Reference><Citation>Staniek A, et al. Natural products - modifying metabolite pathways in plants. Biotechnol J. 2013;8:1159&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">24092673</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas HM, Amouzadeh HR, Engwall MJ. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Expert Opin Drug Saf. 2013;12:91&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">23170873</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model. 2012;52:1757&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402020</ArticleId><ArticleId IdType="pubmed">22587354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser M, Wetzel S, Kumar K, Waldmann H. Biology-inspired synthesis of compound libraries. Cell Mol Life Sci. 2008;65:1186&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131879</ArticleId><ArticleId IdType="pubmed">18193390</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Y, et al. TMDB: a literature-curated database for small molecular compounds found from tea. BMC Plant Biol. 2014;14:243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172869</ArticleId><ArticleId IdType="pubmed">25224438</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland RH. Update on St. John's Wort. J Psychosoc Nurs Ment Health Serv. 2010;48:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">21053786</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol. 2004;44:559&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">15145962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Li Y, Chen X. Computational identification of bioactive natural products by structure activity relationship. J Mol Graph Model. 2010;29:38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">20488738</ArticleId></ArticleIdList></Reference><Reference><Citation>Cami A, Arnold A, Manzi S, Reis B. Predicting Adverse Drug Events Using Pharmacological Network Models. Science Translational Medicine. 2011;3:114ra127&#x2013;114ra127.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190238</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, et al. Systems pharmacology of adverse event mitigation by drug combinations. Science Translational Medicine. 2013;5:206ra140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963511</ArticleId><ArticleId IdType="pubmed">24107779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorberbaum T, et al. Systems Pharmacology Augments Drug Safety Surveillance. Clin Pharmacol Ther. 2014;97:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4325423</ArticleId><ArticleId IdType="pubmed">25670520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Schuemie MJ. Medication-Wide Association Studies. CPT: pharmacometrics &#x2026;. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026636</ArticleId><ArticleId IdType="pubmed">24448022</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins JR, Sanak M, Canto G, Blanca M, Cornejo-Garc&#xed;a JA. Unravelling adverse reactions to NSAIDs using systems biology. Trends in Pharmacological Sciences. 2015;36:172&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">25577398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang Q, et al. A systematic investigation of computation models for predicting Adverse Drug Reactions (ADRs) PLoS ONE. 2014;9:e105889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152017</ArticleId><ArticleId IdType="pubmed">25180585</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok J, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences. 2013;110:3507&#x2013;3512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587220</ArticleId><ArticleId IdType="pubmed">23401516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31:4401&#x2013;4415.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26879560</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).</ArticleTitle><Pagination><StartPage>421</StartPage><EndPage>432</EndPage><MedlinePgn>421-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-016-0392-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Pharmacovigilance includes analysis of large databases of information on drugs and events using algorithms that detect disproportional frequencies of associations. In order to test such algorithms, attempts have been made to provide canonical reference lists of so-called 'positive controls' and 'negative controls'. Reference sets with even modest levels of misclassification may result in under- or overstatement of the performance of algorithms.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">We sought to determine the extent to which 'negative control' drug-event pairs in the Observational Medical Outcomes Partnership (OMOP) database are misclassified</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched the medical literature for evidence of associations between drugs and events listed by OMOP as negative controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The criteria used in OMOP to classify positive and negative controls are asymmetric; drug-event associations published only as case series or case reports are classified as positive controls if they are cited in Drug-Induced Diseases by Tisdale and Miller, but as negative controls if case series or case reports exist but are not cited in Tisdale and Miller. Of 233 drug-event pairs classified in the 2013 version of OMOP as negative controls, 21 failed to meet pre-specified OMOP adjudication criteria; in another 19 cases we found case reports, case series, or observational evidence that the drug and event are associated. Overall, OMOP misclassified, or may have misclassified, 40 (17&#xa0;%) of all 'negative controls.'</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results from studies of the performance of signal-detection algorithms based on the OMOP gold standard should be viewed with circumspection, because imperfect gold standards may lead to under/overstatement of absolute and relative signal detection algorithm performance. Improvements to OMOP would include omitting misclassified drug-event pairs, assigning more specific event labels, and using more extensive sources of information.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hauben</LastName><ForeName>Manfred</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Clinical Pharmacology, New York University School of Medicine, New York, NY, USA. manfred.hauben@Pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronson</LastName><ForeName>Jeffrey K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferner</LastName><ForeName>Robin E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26879560</ArticleId><ArticleId IdType="doi">10.1007/s40264-016-0392-2</ArticleId><ArticleId IdType="pii">10.1007/s40264-016-0392-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Infect Dis. 2010 Feb 1;201(3):318-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20039804</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J. 1977 Oct 8;2(6092):935</Citation><ArticleIdList><ArticleId IdType="pubmed">912374</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pathol Lab Med. 2006 Jan;130(1):101-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16390223</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2011 Apr 11;171(7):703-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21482850</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2015 Jan;38(1):101-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25511911</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Mar 04;10(3):e0118432</Citation><ArticleIdList><ArticleId IdType="pubmed">25738806</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1954 Dec 16;251(25):995-9</Citation><ArticleIdList><ArticleId IdType="pubmed">13214376</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephrol Dial Transplant. 2007 Feb;22(2):621-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17121780</ArticleId></ArticleIdList></Reference><Reference><Citation>J Toxicol Clin Toxicol. 1983 Jun;20(4):361-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6655776</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephrol Dial Transplant. 2000 Nov;15(11):1877-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11071983</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S33-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Cardiol Angeiol (Paris). 2011 Jun;60(3):154-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21306702</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2005 Oct;60(4):448-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16187979</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Med Assoc J. 1955 Aug 1;73(3):192-7</Citation><ArticleIdList><ArticleId IdType="pubmed">13240579</ArticleId></ArticleIdList></Reference><Reference><Citation>J R Coll Gen Pract. 1984 Oct;34(267):575-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6333509</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2013 Jun;93(6):539-46</Citation><ArticleIdList><ArticleId IdType="pubmed">23571771</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Gastroenterol Hepatol. 2010 Oct;7(10):557-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20736921</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1967 Oct 16;202(3):204-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4293095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 2002 Nov;42(11 Suppl):64S-70S</Citation><ArticleIdList><ArticleId IdType="pubmed">12412838</ArticleId></ArticleIdList></Reference><Reference><Citation>Case Rep Med. 2011;2011:490310</Citation><ArticleIdList><ArticleId IdType="pubmed">22007234</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Gastroenterol Hepatol. 2011 Jun;9(6):517-523.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">21356330</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 1995 Feb;20(2):474-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7742464</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2014 Aug;96(2):239-46</Citation><ArticleIdList><ArticleId IdType="pubmed">24713590</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Pathol. 1990 Feb;93(2):252-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2405632</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicol Lett. 1998 Dec 28;102-103:653-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10022330</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1999 Oct 2;354(9185):1180-1</Citation><ArticleIdList><ArticleId IdType="pubmed">10513719</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1970 Sep 3;283(10 ):518-20</Citation><ArticleIdList><ArticleId IdType="pubmed">5434136</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2001 Jun 12;103(23):2805-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11401936</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2009 May 15;134(2):e45-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18378025</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Sci Law. 2012 Oct;52(4):229-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23155125</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Oncol. 2002;19(2):117-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12180480</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 1995 Nov-Dec;17(6):1110-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8750402</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2010 Jul 1;33(7):527-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20553054</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nephrol. 2000 Jul;54(1):78-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10939762</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2015 Jan;38(1):113-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25432779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 2002 Jul-Aug;36(7-8):1162-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12086547</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 1997;53(2):105-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9403280</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pathol. 1974 Aug;98 (2):114-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4366005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1976 Dec 11;2(7998):1297</Citation><ArticleIdList><ArticleId IdType="pubmed">63763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugeskr Laeger. 2011 Dec 12;173(50):3270-1</Citation><ArticleIdList><ArticleId IdType="pubmed">22153212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Adolesc Health Care. 1989 Jul;10(4):332-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2659563</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Health Syst Pharm. 2007 Jun 1;64(11):1174-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17519460</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2014 Nov;96(5):616-24</Citation><ArticleIdList><ArticleId IdType="pubmed">25062063</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 2009 Jul;27(7):1485-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19491706</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Sep 4;349(10):1006-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12954755</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Clin (Barc). 1987 Jan 17;88(2):80-1</Citation><ArticleIdList><ArticleId IdType="pubmed">3821266</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaldi Arch Chest Dis. 2003 Mar;60(1):92-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12827839</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2001 Jul 15;20(13):1987-2001</Citation><ArticleIdList><ArticleId IdType="pubmed">11427955</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Data. 2014 Nov 11;1:140043</Citation><ArticleIdList><ArticleId IdType="pubmed">25632348</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2005 Jan;98(1):169-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15676187</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Gastroenterol. 1987 Jun;9(3):350-2</Citation><ArticleIdList><ArticleId IdType="pubmed">3112214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1999 Oct 5;131(7):548</Citation><ArticleIdList><ArticleId IdType="pubmed">10507980</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 1995 Jan-Mar;15(1):44-57</Citation><ArticleIdList><ArticleId IdType="pubmed">7898298</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2006 Dec 16;333(7581):1267-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17170419</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2015 Jan;38(1):105-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25511912</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 2007 Jan;49(1):153-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17185156</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2015 Oct;38(10):895-908</Citation><ArticleIdList><ArticleId IdType="pubmed">26153397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ir J Med Sci. 2012 Dec;181(4):479-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22231902</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharm. 1982 Mar-Apr;1(2):179-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7185517</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Cardiol. 2011 Nov;7(6):805-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22050066</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 1991 Sep;100(3):863-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1909621</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2008 Jan;153(2):290-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17965744</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin J Am Soc Nephrol. 2008 Sep;3(5):1494-503</Citation><ArticleIdList><ArticleId IdType="pubmed">18596115</ArticleId></ArticleIdList></Reference><Reference><Citation>Dtsch Med Wochenschr. 2011 Aug;136(34-35):1720-2</Citation><ArticleIdList><ArticleId IdType="pubmed">21877303</ArticleId></ArticleIdList></Reference><Reference><Citation>Nefrologia. 2003 Jul-Aug;23(4):355-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14558336</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):245-53</Citation><ArticleIdList><ArticleId IdType="pubmed">21499115</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Toxicol. 1979 Apr;14 (4):433-8</Citation><ArticleIdList><ArticleId IdType="pubmed">466984</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2012 Dec 30;31(30):4401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zentralbl Allg Pathol. 1976;120(2):83-7</Citation><ArticleIdList><ArticleId IdType="pubmed">941543</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2015 Jan;38(1):115-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25432780</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1987 Jan;23(1):73-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3814464</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2000 May;45(4):394-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10813077</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephrol Dial Transplant. 2003 Oct;18(10 ):2202-3</Citation><ArticleIdList><ArticleId IdType="pubmed">13679508</ArticleId></ArticleIdList></Reference><Reference><Citation>Helv Med Acta. 1967 Dec;34(1):23-35</Citation><ArticleIdList><ArticleId IdType="pubmed">4873914</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephrol Dial Transplant. 1992;7(8):879-80</Citation><ArticleIdList><ArticleId IdType="pubmed">1325625</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 1985 Jul;6(7):637-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3876212</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med J. 1985 May;61(715):461-3</Citation><ArticleIdList><ArticleId IdType="pubmed">4022885</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Clin (Barc). 1985 Feb 9;84(5):208-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3920451</ArticleId></ArticleIdList></Reference><Reference><Citation>Dental Press J Orthod. 2014 Sep-Oct;19(5):27-30</Citation><ArticleIdList><ArticleId IdType="pubmed">25715714</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2007;30(8):645-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17696577</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26893951</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2093-3681</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Healthcare informatics research</Title><ISOAbbreviation>Healthc Inform Res</ISOAbbreviation></Journal><ArticleTitle>Conversion and Data Quality Assessment of Electronic Health Record Data at a Korean Tertiary Teaching Hospital to a Common Data Model for Distributed Network Research.</ArticleTitle><Pagination><StartPage>54</StartPage><EndPage>58</EndPage><MedlinePgn>54-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4258/hir.2016.22.1.54</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">A distributed research network (DRN) has the advantages of improved statistical power, and it can reveal more significant relationships by increasing sample size. However, differences in data structure constitute a major barrier to integrating data among DRN partners. We describe our experience converting Electronic Health Records (EHR) to the Observational Health Data Sciences and Informatics (OHDSI) Common Data Model (CDM).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We transformed the EHR of a hospital into Observational Medical Outcomes Partnership (OMOP) CDM ver. 4.0 used in OHDSI. All EHR codes were mapped and converted into the standard vocabulary of the CDM. All data required by the CDM were extracted, transformed, and loaded (ETL) into the CDM structure. To validate and improve the quality of the transformed dataset, the open-source data characterization program ACHILLES was run on the converted data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patient, drug, condition, procedure, and visit data from 2.07 million patients who visited the subject hospital from July 1994 to November 2014 were transformed into the CDM. The transformed dataset was named the AUSOM. ACHILLES revealed 36 errors and 13 warnings in the AUSOM. We reviewed and corrected 28 errors. The summarized results of the AUSOM processed with ACHILLES are available at http://ami.ajou.ac.kr:8080/.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We successfully converted our EHRs to a CDM and were able to participate as a data partner in an international DRN. Converting local records in this manner will provide various opportunities for researchers and data holders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Dukyong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.; Observational Health Data Sciences and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Eun Kyoung</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.; Department of Nursing Science, Dongyang University, Yeongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Man Young</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.; Mibyeong Research Center, Korea Institute of Oriental Medicine, Daejeon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Soo Yeon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.; Global Epidemiology, Janssen Research and Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.; Global Epidemiology, Janssen Research and Development LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Dahye</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hojun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.; Observational Health Data Sciences and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Healthc Inform Res</MedlineTA><NlmUniqueID>101534553</NlmUniqueID><ISSNLinking>2093-3681</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Coding</Keyword><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">Epidemiologic Methods</Keyword><Keyword MajorTopicYN="N">Observational Health Data Sciences and Informatics (OHDSI)</Keyword></KeywordList><CoiStatement><b>Conflict of Interest:</b> Patrick Ryan is an employee of Janssen Research and Development and a stockholder in Johnson &amp; Johnson. Martijn J. Schuemie is an employee of Janssen Research and Development LLC. However, Janssen Research and Development LLC had no influence on any aspect of this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26893951</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network: improving the evidence of medical-product safety. N Engl J Med. 2009;361(7):645&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635947</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. Analytic tools [Internet] [place unknown]: Observational Health Data Sciences and Informatics; c2015.  [cited at 2015 Dec 1].  Available from:  http://www.ohdsi.org/analytic-tools/</Citation></Reference><Reference><Citation>Mini-Sentinel project [Internet] [place unknown]: Mini-Sentinel Coordinating Center; c2014.  [cited at 2015 Dec 1].  Available from:  http://www.mini-sentinel.org/</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership. OMOP Common Data Model [Internet] [place unknown]: Observational Medical Outcomes Partnership; 2013.  [cited at 2015 Dec 1].  Available from:  http://omop.org/CDM.</Citation></Reference><Reference><Citation>Boyce RD, Ryan PB, Noren GN, Schuemie MJ, Reich C, Duke J, et al. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf. 2014;37(8):557&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134480</ArticleId><ArticleId IdType="pubmed">24985530</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Chang BC, Kang SW, Bae H, Park RW. Adoption of electronic health records in Korean tertiary teaching and general hospitals. Int J Med Inform. 2012;81:196&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">22206619</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd S. Debating the evidence: oral contraceptives containing drospirenone and risk of blood clots. Curr Drug Saf. 2011;6(3):132&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">22122386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart PB, Bolger AF, Papapanou PN, Osinbowale O, Trevisan M, Levison ME, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association? A scientific statement from the American Heart Association. Circulation. 2012;125(20):2520&#x2013;2544.</Citation><ArticleIdList><ArticleId IdType="pubmed">22514251</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010;48(6 Suppl):S45&#x2013;S51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20473204</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262590</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 2014;37(11):945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnbeek PR. Converting to a common data model: what is lost in translation? Commentary on "fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model". Drug Saf. 2014;37(11):893&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">25187018</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26970249</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0258</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>22</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Statistics in medicine</Title><ISOAbbreviation>Stat Med</ISOAbbreviation></Journal><ArticleTitle>Limitations of empirical calibration of p-values using observational data.</ArticleTitle><Pagination><StartPage>3869</StartPage><EndPage>3882</EndPage><MedlinePgn>3869-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/sim.6936</ELocationID><Abstract><AbstractText>Controversy over non-reproducible published research reporting a statistically significant result has produced substantial discussion in the literature. p-value calibration is a recently proposed procedure for adjusting p-values to account for both random and systematic errors that address one aspect of this problem. The method's validity rests on the key assumption that bias in an effect estimate is drawn from a normal distribution whose mean and variance can be correctly estimated. We investigated the method's control of type I and type II error rates using simulated and real-world data. Under mild violations of underlying assumptions, control of the type I error rate can be conservative, while under more extreme departures, it can be anti-conservative. The extent to which the assumption is violated in real-world data analyses is unknown. Barriers to testing the plausibility of the assumption using historical data are discussed. Our studies of the type II error rate using simulated and real-world electronic health care data demonstrated that calibrating p-values can substantially increase the type II error rate. The use of calibrated p-values may reduce the number of false-positive results, but there will be a commensurate drop in the ability to detect a true safety or efficacy signal. While p-value calibration can sometimes offer advantages in controlling the type I error rate, its adoption for routine use in studies of real-world health care datasets is premature. Separate characterizations of random and systematic errors provide a richer context for evaluating uncertainty surrounding effect estimates. Copyright &#xa9; 2016 John Wiley &amp; Sons, Ltd.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>Susan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0127-0099</Identifier><AffiliationInfo><Affiliation>Reagan-Udall Foundation for the Food and Drug Administration, Washington, DC, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchetgen Tchetgen</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departments of Biostatistics and Epidemiology, Harvard School of Public Health, Boston, MA, U.S.A.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI104459</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES020337</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Med</MedlineTA><NlmUniqueID>8215016</NlmUniqueID><ISSNLinking>0277-6715</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Stat Med. 2016 Sep 30;35(22):3883-8. doi: 10.1002/sim.6977.</RefSource><PMID Version="1">27592566</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stat Med. 2016 Sep 30;35(22):3889-91. doi: 10.1002/sim.6984.</RefSource><PMID Version="1">27592567</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="Y">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="N">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="Y">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">p-value</Keyword><Keyword MajorTopicYN="N">p-value calibration</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26970249</ArticleId><ArticleId IdType="mid">NIHMS766743</ArticleId><ArticleId IdType="pmc">PMC5012943</ArticleId><ArticleId IdType="doi">10.1002/sim.6936</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ioannidis J. Why most published research findings are false. PLoS Med. 2005;2:e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182327</ArticleId><ArticleId IdType="pubmed">16060722</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman SN. Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature. Biostatistics. 2013 kxt035.</Citation><ArticleIdList><ArticleId IdType="pubmed">24068250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager LR, Leek JT. An estimate of the science-wise false discovery rate and application to the top medical literature. Biostatistics. 2014;15(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24068246</ArticleId></ArticleIdList></Reference><Reference><Citation>Colquhoun D. An investigation of the false discovery rate and the misinterpretation of p-values. Royal Society open science. 2014;1(3):140 216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4448847</ArticleId><ArticleId IdType="pubmed">26064558</ArticleId></ArticleIdList></Reference><Reference><Citation>Head ML, Holman L, Lanfear R, Kahn AT, Jennions MD. The extent and consequences of p-hacking in science. PLoS Biol. 2015;13(3):e1002 106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359000</ArticleId><ArticleId IdType="pubmed">25768323</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Statistics in Medicine. 2014;33(2):209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP. Observational medical outcomes partnership research 2013.  [Accessed: 1/31/2016]; URL  http://omop.org/Research.</Citation></Reference><Reference><Citation>Mini-Sentinel Data Core.  [Accessed: 1/31/2016];MINI-SENTINEL DISTRIBUTED DATABASE YEAR 4 SUMMARY REPORT Version 1.1. 2014 Aug; URL  http://mini-sentinel.org/data_activities/distributed_db_and_data/default.aspxl.</Citation></Reference><Reference><Citation>OMOP. Observational medical outcomes partnership 2013.  [Accessed: 1/31/2016]; URL  http://omop.org.</Citation></Reference><Reference><Citation>Bross I. Misclassification in 2 &#xd7; 2 tables. Biometrics. 1954;10:478&#x2013;486.</Citation></Reference><Reference><Citation>Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman &amp; Hall/CRC; 1993.</Citation></Reference><Reference><Citation>Freedman DA. On the so-called Huber sandwich estimator and robust standard errors. The American Statistician. 2006;60(4):299&#x2013;302.</Citation></Reference><Reference><Citation>Tchetgen Tchetgen E. The control outcome calibration approach (COCA) for unobserved confounding. American Journal of Epidemiology. 2013;179:633&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3927977</ArticleId><ArticleId IdType="pubmed">24363326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. The use of negative controls to detect confounding and other sources of error in experimental and observational science. Epidemiology. 2010:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative exposure controls in epidemiologic studies. Epidemiology. 2012:351&#x2013;352.</Citation></Reference><Reference><Citation>Rotnitzky A, Scharfstein D, Su S, Robins J. Methods for conducting sensitivity analysis of trials with potentially nonignorable competing causes of censoring. Biometrics. 2001;57:103113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252584</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz I, van der Laan MJ. Sensitivity analysis for causal inference under unmeasured confounding and measurement error problems. International Journal of Biostatistics. 2013;9:149160.</Citation><ArticleIdList><ArticleId IdType="pubmed">24246288</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum P. Observational Studies. 2nd. New York: Springer; 2002.</Citation></Reference><Reference><Citation>Gagnon-Bartsch JA, Speed TP. Using control genes to correct for unwanted variation in microarray data. Biostatistics. 2012;13:539&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577104</ArticleId><ArticleId IdType="pubmed">22101192</ArticleId></ArticleIdList></Reference><Reference><Citation>Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nature Biotechnology. 2014;32:896&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404308</ArticleId><ArticleId IdType="pubmed">25150836</ArticleId></ArticleIdList></Reference><Reference><Citation>Neostigmine methylsulfate bloxiverz clinical review.  [Accessed: 09/02/2014];  http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM361414.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27014709</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2327-9214</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>EGEMS (Washington, DC)</Title><ISOAbbreviation>EGEMS (Wash DC)</ISOAbbreviation></Journal><ArticleTitle>Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies.</ArticleTitle><Pagination><StartPage>1189</StartPage><MedlinePgn>1189</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1189</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.13063/2327-9214.1189</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We see increased use of existing observational data in order to achieve fast and transparent production of empirical evidence in health care research. Multiple databases are often used to increase power, to assess rare exposures or outcomes, or to study diverse populations. For privacy and sociological reasons, original data on individual subjects can't be shared, requiring a distributed network approach where data processing is performed prior to data sharing.</AbstractText><AbstractText Label="CASE DESCRIPTIONS AND VARIATION AMONG SITES" NlmCategory="UNASSIGNED">We created a conceptual framework distinguishing three steps in local data processing: (1) data reorganization into a data structure common across the network; (2) derivation of study variables not present in original data; and (3) application of study design to transform longitudinal data into aggregated data sets for statistical analysis. We applied this framework to four case studies to identify similarities and differences in the United States and Europe: Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical Records and Biomedical Knowledge (EU-ADR), Observational Medical Outcomes Partnership (OMOP), the Food and Drug Administration's (FDA's) Mini-Sentinel, and the Italian network-the Integration of Content Management Information on the Territory of Patients with Complex Diseases or with Chronic Conditions (MATRICE).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">National networks (OMOP, Mini-Sentinel, MATRICE) all adopted shared procedures for local data reorganization. The multinational EU-ADR network needed locally defined procedures to reorganize its heterogeneous data into a common structure. Derivation of new data elements was centrally defined in all networks but the procedure was not shared in EU-ADR. Application of study design was a common and shared procedure in all the case studies. Computer procedures were embodied in different programming languages, including SAS, R, SQL, Java, and C++.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Using our conceptual framework we found several areas that would benefit from research to identify optimal standards for production of empirical knowledge from existing databases.an opportunity to advance evidence-based care management. In addition, formalized CM outcomes assessment methodologies will enable us to compare CM effectiveness across health delivery settings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gini</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Agenzia Regionale di Sanit&#xe0; della Toscana; Erasmus MC University Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Epidemiology; Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Epidemiology; Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vacchi</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Universit&#xe0; degli Studi di Milano, Dipartimento di Informatica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Consiglio Nazionale delle Ricerche, Istituto di Scienza e Tecnologie dell'Informazione.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cazzola</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Universit&#xe0; degli Studi di Milano, Dipartimento di Informatica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coloma</LastName><ForeName>Preciosa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Erasmus MC University Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berni</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Agenzia Regionale di Sanit&#xe0; della Toscana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diallo</LastName><ForeName>Gayo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Bordeaux, LESIM - ISPED.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Luis Oliveira University of Aveiro, DETI/IEETA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avillach</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trifir&#xf2;</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Erasmus MC University Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Erasmus MC University Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellentani</LastName><ForeName>Mariadonata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Agenzia Nazionale per i Servizi Sanitari Regionali.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Der Lei</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Erasmus MC University Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klazinga</LastName><ForeName>Niek</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University of Amsterdam, Academic Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturkenboom</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Erasmus MC University Medical Center.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EGEMS (Wash DC)</MedlineTA><NlmUniqueID>101629606</NlmUniqueID><ISSNLinking>2327-9214</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data management</Keyword><Keyword MajorTopicYN="N">Data reuse</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">Health Services Research</Keyword><Keyword MajorTopicYN="N">Pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">Research networks</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27014709</ArticleId><ArticleId IdType="pmc">PMC4780748</ArticleId><ArticleId IdType="doi">10.13063/2327-9214.1189</ArticleId><ArticleId IdType="pii">egems1189</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salmon D, Yih WK, Lee G, Rosofsky R, Brown J, Vannice K, et al. Success of program linking data sources to monitor H1N1 vaccine safety points to potential for even broader safety surveillance. Health Aff (Millwood) 2012 Nov;31(11):2518&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">23129683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Savitz DA. From &#x201c;Big Epidemiology&#x201d; to &#x201c;Colossal Epidemiology&#x201d;. Epidemiology. 2013 May;24(3):344&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23549177</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh S, Platt R. Is Size the Next Big Thing in Epidemiology? Epidemiology. 2013 May;24(3):349&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23549179</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifir&#xf2; G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, et al. Combining multiple healthcare databases for post-marketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014 Mar 1;</Citation><ArticleIdList><ArticleId IdType="pubmed">24635221</ArticleId></ArticleIdList></Reference><Reference><Citation>McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiology and Drug Safety. 2012 Jan;21:18&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262589</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010 Jun;48(6 Suppl):S45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20473204</ArticleId></ArticleIdList></Reference><Reference><Citation>Valkhoff VE, Coloma PM, Masclee GMC, Gini R, Innocenti F, Lapi F, et al. Validation study in four health-care databases: upper gastrointestinal bleeding misclassification affects precision but not magnitude of drug-related upper gastrointestinal bleeding risk. Journal of Clinical Epidemiology. 2014 Aug;67(8):921&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">24794575</ArticleId></ArticleIdList></Reference><Reference><Citation>Avillach P, Mougin F, Joubert M, Thiessard F, Pariente A, Dufour J-C, et al. A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European eu-ADR project. Stud Health Technol Inform. 2009;150:190&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19745295</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Schuemie MJ, Trifir&#xf2; G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiology and Drug Safety. 2012 Jan;21:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262586</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Feb 11;153(9):600&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Agenzia nazionale per i Servizi Sanitari Regionali  Programma Mattoni del SSN - Progetto MATRICE.   http://www.agenas.it/images/agenas/In%20primo%20piano/Matrice/Progetto_MATRICE_Scheda_informativa.pdf. Accessed September 2015[Italian]</Citation></Reference><Reference><Citation>Agenzia regionale di sanit&#xe0; della Toscana  Data integration for chronic diseases management in outpatient settings (MATRICE Project)   https://www.ars.toscana.it/en/project/chronic-diseases/2460-matrice-project.html. Accessed September 2015.</Citation></Reference><Reference><Citation>Cordis  Safety Of non-Steroidal anti-inflammatory drugs.   http://cordis.europa.eu/result/rcn/54210_en.html. Accessed September 2015.</Citation></Reference><Reference><Citation>Valkhoff VE, Schade R, &#x2019;t Jong GW, Romio S, Schuemie MJ, Arfe A, et al. Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues? BMC Pediatr. 2013;13:192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4225575</ArticleId><ArticleId IdType="pubmed">24252465</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine Adverse Event Surveillance &amp; Communication.   https://brightoncollaboration.org/vaesco.html. Accessed September 2015.</Citation></Reference><Reference><Citation>Cordis  Arrhythmogenic Potential of Drugs.   http://cordis.europa.eu/project/rcn/94061_en.html. Accessed September 2015.</Citation></Reference><Reference><Citation>Safety Evaluation of Adverse Reactions in Diabetes.   www.safeguard-diabetes.org. Accessed September 2015.</Citation></Reference><Reference><Citation>Avillach P, Joubert M, Thiessard F, Trifir&#xf2; G, Dufour J-C, Pariente A, et al. Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project. Stud Health Technol Inform. 2010;160(Pt 2):1085&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20841851</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Valkhoff VE, Mazzaglia G, Nielsson MS, Pedersen L, Molokhia M, et al. Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open. 2013 Jan;3(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686251</ArticleId><ArticleId IdType="pubmed">23794587</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Coloma PM, Straatman H, Herings RMC, Trifir&#xf2; G, Matthews JN, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012 Oct;50(10):890&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifir&#xf2; G, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, et al. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform. 2011;166:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">21685607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09</Citation><ArticleIdList><ArticleId IdType="pubmed">23246544</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Schuemie MJ, Trifir&#xf2; G, Furlong L, van Mulligen E, Bauer-Mehren A, et al. Drug-Induced Acute Myocardial Infarction: Identifying &#x2018;Prime Suspects&#x2019; from Electronic Healthcare Records-Based Surveillance System. PLoS ONE. 2013 Aug;8(8):e72148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756064</ArticleId><ArticleId IdType="pubmed">24015213</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ. 2011;343:d3908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134565</ArticleId><ArticleId IdType="pubmed">21750072</ArticleId></ArticleIdList></Reference><Reference><Citation>Romio S, Weibel D, Dieleman JP, Olberg HK, de Vries CS, Sammon C, et al. Guillain-Barr&#xe9; Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe. PLoS ONE. 2014 Jan 3;9(1):e82222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880265</ArticleId><ArticleId IdType="pubmed">24404128</ArticleId></ArticleIdList></Reference><Reference><Citation>Avillach P, Dufour J-C, Diallo G, Salvo F, Joubert M, Thiessard F, et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. J Am Med Inform Assoc. 2013 May;20(3):446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628051</ArticleId><ArticleId IdType="pubmed">23195749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer-Mehren A, van Mullingen EM, Avillach P, Carrascosa MDC, Garcia-Serna R, Pi&#xf1;ero J, et al. Automatic filtering and substantiation of drug safety signals. PLoS Comput Biol. 2012;8(4):e1002457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3320573</ArticleId><ArticleId IdType="pubmed">22496632</ArticleId></ArticleIdList></Reference><Reference><Citation>  http://www.imi.europa.eu/content/emif. Accessed September 2015.</Citation></Reference><Reference><Citation>Mini-Senetinel    www.mini-sentinel.org. Accessed September 2015.</Citation></Reference><Reference><Citation>Raebel MA, Penfold R, McMahon AW, Reichman M, Shetterly S, Goodrich G, et al. Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. Pediatrics. 2014;134(5):e1308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25287454</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnahan RM, Moores KG. Mini-Sentinel&#x2019;s systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned. Pharmacoepidemiology and Drug Safety. 2012 Jan;21:82&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262596</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutrona SL, Toh S, Iyer A, Foy S, Cavagnaro E, Forrow S, et al. Design for validation of acute myocardial infarction cases in Mini-Sentinel. Pharmacoepidemiology and Drug Safety. 2012 Jan;21:274&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679667</ArticleId><ArticleId IdType="pubmed">22262617</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, et al. Validation of acute myocardial infarction in the Food and Drug Administration&#x2019;s Mini-Sentinel program. Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):40&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601831</ArticleId><ArticleId IdType="pubmed">22745038</ArticleId></ArticleIdList></Reference><Reference><Citation>McClure DL, Raebel MA, Yih WK, Shoaibi A, Mullersman JE, Anderson-Smits C, et al. Mini-Sentinel methods: framework for assessment of positive results from signal refinement: FRAMEWORK FOR ASSESSMENT OF POSITIVE RESULTS FROM SIGNAL REFINEMENT. Pharmacoepidemiology and Drug Safety. 2014;23(1):3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24395545</ArticleId></ArticleIdList></Reference><Reference><Citation>Raebel MA, Haynes K, Woodworth TS, Saylor G, Cavagnaro E, Coughlin KO, et al. Electronic clinical laboratory test results data tables: lessons from Mini-Sentinel: THE MINI-SENTINEL LABORATORY RESULTS TABLE. Pharmacoepidemiology and Drug Safety. 2014;23(6):609&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">24677577</ArticleId></ArticleIdList></Reference><Reference><Citation>Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiology and Drug Safety. 2012 Jan;21:41&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012 Dec 30;31(30):4401&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012 Aug;45(4):689&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartzema AG, Reich CG, Ryan PB, Stang PE, Madigan D, Welebob E, et al. Managing Data Quality for a Drug Safety Surveillance System. Drug Safety. 2013 Oct 29;36(S1):49&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A Comparison of the Empirical Performance of Methods for a Risk Identification System. Drug Safety. 2013 Oct 29;36(S1):143&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics    ohdsi.org. Accessed September 2015.</Citation></Reference><Reference><Citation>Buja A, Gini R, Visca M, Damiani G, Federico B, Francesconi P, et al. Prevalence of chronic diseases by immigrant status and disparities in chronic disease management in immigrants: a population-based cohort study, Valore Project. BMC Public Health. 2013 May 24;13(1):504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673842</ArticleId><ArticleId IdType="pubmed">23706129</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja A, Damiani G, Gini R, Visca M, Federico B, Donato D, et al. Systematic Age-Related Differences in Chronic Disease Management in a Population-Based Cohort Study: A New Paradigm of Primary Care Is Required. PLoS ONE. 2014 Mar 14;9(3):e91340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3954692</ArticleId><ArticleId IdType="pubmed">24632818</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja A, Gini R, Visca M, Damiani G, Federico B, Donato D, et al. Need and disparities in primary care management of patients with diabetes. BMC Endocrine Disorders. 2014 Jul 10;14(1):56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107618</ArticleId><ArticleId IdType="pubmed">25011729</ArticleId></ArticleIdList></Reference><Reference><Citation>Visca M, Donatini A, Gini R, Federico B, Damiani G, Francesconi P, et al. Group versus single handed primary care: a performance evaluation of the care delivered to chronic patients by Italian GPs. Health Policy. 2013 Nov;113(1&#x2013;2):188&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">23800605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini R, Francesconi P, Mazzaglia G, Cricelli I, Pasqua A, Gallina P, et al. Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey. BMC Public Health. 2013 Jan 9;13(1):15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551838</ArticleId><ArticleId IdType="pubmed">23297821</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini R, Schuemie MJ, Lapi F, Cricelli I, Pasqua A, et al. Can Italian healthcare administrative databases be used to compare regions with respect to compliance with standards of care for chronic diseases? PLoS ONE. 2014 May;9(5):e95419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4015953</ArticleId><ArticleId IdType="pubmed">24816637</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali A, Calvanese D, De Giacomo G, Lenzerini M. Data integration under integrity constraints. Information Systems. 2004;29(2):147&#x2013;163.</Citation></Reference><Reference><Citation>Morley KI, Wallace J, Denaxas SC, Hunter RJ, Patel RS, Perel P, et al. Defining Disease Phenotypes Using National Linked Electronic Health Records: A Case Study of Atrial Fibrillation. PLoS ONE. 2014 Nov;9(11):e110900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4219705</ArticleId><ArticleId IdType="pubmed">25369203</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Kahn M, Toh S. Data quality assessment for comparative effectiveness research in distributed data networks. Med Care. 2013 Aug;51(8 Suppl 3):S22&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306391</ArticleId><ArticleId IdType="pubmed">23793049</ArticleId></ArticleIdList></Reference><Reference><Citation>  thematrix.isti.cnr.it. Accessed September 2015.</Citation></Reference><Reference><Citation>Avillach P, Coloma PM, Gini R, Schuemie M, Mougin F, Dufour J-C, et al. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc. 2012 Sep 6;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555316</ArticleId><ArticleId IdType="pubmed">22955495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzola W. Domain-Specific Languages in Few Steps: The Neverlang Approach. Proceedings of the 11th International Conference on Software Composition (SC&#x2019;12); Prague, Czech Republic. May&#x2013;June 2012; Springer; pp. 162&#x2013;177. LNCS 7306.</Citation></Reference><Reference><Citation>Cazzola W, Vacchi E. Neverlang 2: Componentised Language Development for the JVM. Proceedings of the 12th International Conference on Software Composition (SC&#x2019;13); Budapest, Hungary. June 2013; Springer; pp. 17&#x2013;32. LNCS 8088.</Citation></Reference><Reference><Citation>Adler-Milstein J, Ronchi E, Cohen GR, Winn LAP, Jha AK. Benchmarking health IT among OECD countries: better data for better policy. J Am Med Inform Assoc. 2014 Jan 1;21(1):111&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912720</ArticleId><ArticleId IdType="pubmed">23721983</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Gini R, Coloma PM, Straatman H, Herings RMC, Pedersen L, et al. Replication of the OMOP Experiment in Europe: Evaluating Methods for Risk Identification in Electronic Health Record Databases. Drug Safety. 2013 Oct;36(S1):159&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166232</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh SS, Gagne JJP, Rassen JAS, Fireman BH, Kulldorff M, Brown JS. Confounding Adjustment in Comparative Effectiveness Research Conducted Within Distributed Research Networks. Medical Care. 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">23752258</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh S, Reichman ME, Houstoun M, Ding X, Fireman BH, Gravel E, et al. Multivariable confounding adjustment in distributed data networks without sharing of patient-level data. Pharmacoepidemiol Drug Saf. 2013;22(11):1171&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23878013</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh SS, Shetterly SM, Powers JDM, Arterburn D. Privacy-preserving Analytic Methods for Multisite Comparative Effectiveness and Patient-centered Outcomes Research. Medical Care. 2014. 2014;52(7):664&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24926715</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA. With great data comes great responsibility: publishing comparative effectiveness research in EPIDEMIOLOGY. Epidemiology. 2011 May;22(3):290&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072432</ArticleId><ArticleId IdType="pubmed">21464646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen RA, Gray MD, Fox BI, Hollingsworth JC, Gao J, Zeng P. How Well Do Various Health Outcome Definitions Identify Appropriate Cases in Observational Studies? Drug Safety. 2013 Oct 29;36(S1):27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166221</ArticleId></ArticleIdList></Reference><Reference><Citation>Valkhoff VE, Coloma PM, Lapi F, Gini R, Nielsson MS, Mosseveld M, Molokhia M, Schuemie MJ, Sturkenboom MCJM, Trifir&#xf2; G. Positive predictive value for upper gastrointestinal bleeding in four health care databases using different coding systems in the EU-ADR project. Presented at the Digestive Disease Week; San Diego, California. May 19&#x2013;22 2012.</Citation></Reference><Reference><Citation>Reich CG, Ryan PB, Schuemie MJ. Alternative Outcome Definitions and Their Effect on the Performance of Methods for Observational Outcome Studies. Drug Safety. 2013 Ottobre;36(S1):181&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166234</ArticleId></ArticleIdList></Reference><Reference><Citation>Maro JC, Brown JS, Dal Pan GJ, Kulldorff M. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity. Pharmacoepidemiol Drug Saf. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181336</ArticleId><ArticleId IdType="pubmed">24700557</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Statistics in Medicine. 2013 Jul;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Popper K. Conjectures and refutations: the growth of scientific knowledge. Routledge; London: 1963.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27016383</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><PubDate><Year>2016</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Improving condition severity classification with an efficient active learning based framework.</ArticleTitle><Pagination><StartPage>44</StartPage><EndPage>54</EndPage><MedlinePgn>44-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2016.03.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(16)30007-7</ELocationID><Abstract><AbstractText>Classification of condition severity can be useful for discriminating among sets of conditions or phenotypes, for example when prioritizing patient care or for other healthcare purposes. Electronic Health Records (EHRs) represent a rich source of labeled information that can be harnessed for severity classification. The labeling of EHRs is expensive and in many cases requires employing professionals with high level of expertise. In this study, we demonstrate the use of Active Learning (AL) techniques to decrease expert labeling efforts. We employ three AL methods and demonstrate their ability to reduce labeling efforts while effectively discriminating condition severity. We incorporate three AL methods into a new framework based on the original CAESAR (Classification Approach for Extracting Severity Automatically from Electronic Health Records) framework to create the Active Learning Enhancement framework (CAESAR-ALE). We applied CAESAR-ALE to a dataset containing 516 conditions of varying severity levels that were manually labeled by seven experts. Our dataset, called the "CAESAR dataset," was created from the medical records of 1.9 million patients treated at Columbia University Medical Center (CUMC). All three AL methods decreased labelers' efforts compared to the learning methods applied by the original CAESER framework in which the classifier was trained on the entire set of conditions; depending on the AL strategy used in the current study, the reduction ranged from 48% to 64% that can result in significant savings, both in time and money. As for the PPV (precision) measure, CAESAR-ALE achieved more than 13% absolute improvement in the predictive capabilities of the framework when classifying conditions as severe. These results demonstrate the potential of AL methods to decrease the labeling efforts of medical experts, while increasing accuracy given the same (or even a smaller) number of acquired conditions. We also demonstrated that the methods included in the CAESAR-ALE framework (Exploitation and Combination_XA) are more robust to the use of human labelers with different levels of professional expertise.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nissim</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Malware Lab, Cyber Security Research Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Electronic address: nirni@post.bgu.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Mary Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA; Observational Health Data Sciences and Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Department of Medicine, Columbia University, New York, NY, USA; Observational Health Data Sciences and Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elovici</LastName><ForeName>Yuval</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA; Observational Health Data Sciences and Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahar</LastName><ForeName>Yuval</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moskovitch</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA; Department of Systems Biology, Columbia University, New York, NY, USA; Department of Medicine, Columbia University, New York, NY, USA; Observational Health Data Sciences and Informatics, Columbia University, New York, NY, USA. Electronic address: robert.moskovitch@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001331" MajorTopicYN="N">Automation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066289" MajorTopicYN="Y">Data Curation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018794" MajorTopicYN="Y">Problem-Based Learning</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Active learning</Keyword><Keyword MajorTopicYN="N">Condition</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">Phenotyping</Keyword><Keyword MajorTopicYN="N">Severity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27016383</ArticleId><ArticleId IdType="mid">NIHMS869287</ArticleId><ArticleId IdType="pmc">PMC5486916</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2016.03.016</ArticleId><ArticleId IdType="pii">S1532-0464(16)30007-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010 Nov 2;153(9):600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho AN, Pacheco JA, Peissig PL, et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci Translational Med. 2011 Apr 20;3(79):79re1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690272</ArticleId><ArticleId IdType="pubmed">21508311</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Ritchie MD, Basford MA, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene&#x2013;disease associations. Bioinformatics. 2010 May 1;26(9):1205&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859132</ArticleId><ArticleId IdType="pubmed">20335276</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Hripcsak G, Shen Y, Chung WK, Weng C. Defining a comprehensive verotype using electronic health records for personalized medicine. J Am Med Inform Assoc. 2013 Dec 1;20(e2):e232&#x2013;e238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861934</ArticleId><ArticleId IdType="pubmed">24001516</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc. 2013;20(1):144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton GB. Bias associated with mining electronic health records. J Biomed Discov Collab. 2011;6:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149555</ArticleId><ArticleId IdType="pubmed">21647858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. Correlating electronic health record concepts with healthcare process events. J Am Med Inform Assoc. 2013 Dec 1;20(e2):e311&#x2013;e318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861922</ArticleId><ArticleId IdType="pubmed">23975625</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">12894066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastien CH, Valli&#xe8;res A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438246</ArticleId></ArticleIdList></Reference><Reference><Citation>McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9(3):199&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">1334156</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood TH, Church JM, Fleshman JW, et al. Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence. Dis Colon Rectum. 1999;42(12):1525&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">10613469</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn SD, Horn RA. Reliability and validity of the severity of illness index. Med Care. 1986;24(2):159&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">3080648</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Tatonetti NP, Hripcsak G. CAESAR: a Classification Approach for Extracting Severity Automatically from Electronic Health Records. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4386082</ArticleId><ArticleId IdType="pubmed">25848530</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkin PL, Brown SH, Husser CS, et al. Evaluation of the content coverage of SNOMED CT: ability of SNOMED clinical terms to represent clinical problem lists, Mayo Clinic Proceedings, 2006, Elsevier. 2006:741&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16770974</ArticleId></ArticleIdList></Reference><Reference><Citation>Stearns MQ, Price C, Spackman KA, Wang AY. SNOMED clinical terms: overview of the development process and project status. Proceedings of the AMIA Symposium, 2001, American Medical Informatics Association. 2001:662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243297</ArticleId><ArticleId IdType="pubmed">11825268</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhanan G, Perl Y, Geller J. A survey of SNOMED CT direct users, 2010: impressions and preferences regarding content and quality. J Am Med Inform Assoc. 2011 Dec 1;18(Suppl 1):i36&#x2013;i44. 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241171</ArticleId><ArticleId IdType="pubmed">21836159</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitch R, Shahar Y. Vaidurya: a multiple-ontology, concept-based, context-sensitive clinical-guideline search engine. J Biomed Inform. 2009 Feb;42(1):11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721900</ArticleId></ArticleIdList></Reference><Reference><Citation>HCUP Chronic Condition Indicator for ICD-9-CM. Healthcare Cost and Utilization Project (HCUP) 2011  http://www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp&gt; accessed on February 25, 2014.</Citation></Reference><Reference><Citation>Hwang W, Weller W, Ireys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff. 2001 Nov 1;20(6):267&#x2013;278. 2001.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816667</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi M-j, Lee C-y, Wu S-c. The prevalence of chronic conditions and medical expenditures of the elderly by chronic condition indicator (CCI) Arch Gerontol Geriatr. 2011;52(3):284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">20452688</ArticleId></ArticleIdList></Reference><Reference><Citation>Perotte A, Pivovarov R, Natarajan K, Weiskopf N, Wood F, Elhadad N. Diagnosis code assignment: models and evaluation metrics. J Am Med Inform Assoc. 2014 Mar 1;21(2):231&#x2013;237. 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932472</ArticleId><ArticleId IdType="pubmed">24296907</ArticleId></ArticleIdList></Reference><Reference><Citation>Perotte A, Hripcsak G. Temporal properties of diagnosis code time series in aggregate. IEEE J Biomed Health Inform. 2013 Mar;17(2):477&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030411</ArticleId><ArticleId IdType="pubmed">24235118</ArticleId></ArticleIdList></Reference><Reference><Citation>Torii M, Wagholikar K, Liu H. Using machine learning for concept extraction on clinical documents from multiple data sources. J Am Med Inform Assoc. 2011 Jun27 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168314</ArticleId><ArticleId IdType="pubmed">21709161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AN, Lawley MJ, Hansen DP, et al. Symbolic rule-based classification of lung cancer stages from free-text pathology reports. J Am Med Inform Assoc. 2010 Jul 1;17(4):440&#x2013;445. 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995652</ArticleId><ArticleId IdType="pubmed">20595312</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissim N, Moskovitch R, Rokach L, Elovici Y. Novel active learning methods for enhanced PC malware detection in windows OS. Expert Syst Appl. 2014;41(13):5843&#x2013;5857. 10/1/</Citation></Reference><Reference><Citation>Nissim N, Moskovitch R, Rokach L, Elovici Y. Detecting unknown computer worm activity via support vector machines and active learning. Pattern Anal Appl. 2012;15:459&#x2013;475.</Citation></Reference><Reference><Citation>Nissim N, Cohen A, Glezer C, Elovici Y. Detection of malicious PDF files and directions for enhancements: a state-of-the art survey. Comput Secur. 2015;48:246&#x2013;266.</Citation></Reference><Reference><Citation>Angluin D. Queries and concept learning. Mach Learn. 1988;2:319&#x2013;342.</Citation></Reference><Reference><Citation>Lewis D, Gale W. A sequential algorithm for training text classifiers. Proceedings of the Seventeenth Annual International ACM-SIGIR Conference on Research and Development in Information Retrieval, Springer-Verlag. 1994:3&#x2013;12.</Citation></Reference><Reference><Citation>Liu Y. Active learning with support vector machine applied to gene expression data for cancer classification. J Chem Inf Comput Sci. 2004;44(6):1936&#x2013;1941.</Citation><ArticleIdList><ArticleId IdType="pubmed">15554662</ArticleId></ArticleIdList></Reference><Reference><Citation>Warmuth MK, Liao J, R&#xe4;tsch G, Mathieson M, Putta S, Lemmen C. Active learning with support vector machines in the drug discovery process. J Chem Inf Comput Sci. 2003;43(2):667&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">12653536</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa RL, Zeng-Treitler Q, Ngo LH, Goryachev S, Wiechmann EP. Active learning for clinical text classification: is it better than random sampling? J Am Med Inform Assoc. 2012  http://dx.doi.org/10.1136/amiajnl-2011-000648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000648</ArticleId><ArticleId IdType="pmc">PMC3422824</ArticleId><ArticleId IdType="pubmed">22707743</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen DH, Patrick JD. Supervised machine learning and active learning in classification of radiology reports. J Am Med Inform Assoc. 2014  http://dx.doi.org/10.1136/amiajnl-2013-002516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-002516</ArticleId><ArticleId IdType="pmc">PMC4147614</ArticleId><ArticleId IdType="pubmed">24853067</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Lin CJ. LIBSVM: a library for support vector machines. ACM Trans Intell Syst Technol (TIST) 2011;2(3):27.</Citation></Reference><Reference><Citation>Tong S, Koller D. Support vector machine active learning with applications to text classification. J Mach Learn Res. 2000&#x2013;2001;2:45&#x2013;66.</Citation></Reference><Reference><Citation>Ralf H, Graepel T, Campbell C. Bayes point machines. J Mach Learn Res. 2001;1:245&#x2013;279.</Citation></Reference><Reference><Citation>Nissim N, Moskovitch R, Rokach L, Elovici Y. Novel active learning methods for enhanced PC malware detection in windows OS. Expert Syst Appl. 2014;41(13)</Citation></Reference><Reference><Citation>Nissim N, Moskovitch R, Rokach L, Elovici Y. Detecting unknown computer worm activity via support vector machines and active learning. Pattern Anal Appl. 2012;15(4):459&#x2013;475.</Citation></Reference><Reference><Citation>Moskovitch R, Nissim N, Elovici Y. ACM SIGKDD Workshop in Privacy, Security and Trust in KDD. Las Vegas: 2008. Malicious code detection using active learning.</Citation></Reference><Reference><Citation>Moskovitch R, Stopel D, Feher C, Nissim N, Japkowicz N, Elovici Y. Unknown malcode detection and the imbalance problem. J Comput Virol. 2009;5(4)</Citation></Reference><Reference><Citation>Nissim N, Cohen A, Moskovitch R, et al. ALPD: active learning framework for enhancing the detection of malicious PDF files aimed at organizations, in. Proceedings of JISIC. 2014</Citation></Reference><Reference><Citation>Baram Y, El-Yaniv R, Luz K. Online choice of active learning algorithms. J Mach Learn Res. 2004;5:255&#x2013;291.</Citation></Reference><Reference><Citation>Herman R. 72 Statistics on Hourly Physician Compensation. 2013  http://www.beckershospitalreview.com/compensation-issues/72-statistics-on-hourly-physician-compensation.html accessed in January 2015.</Citation></Reference><Reference><Citation>Boland MR, Tatonetti NP. AMIA Summits on Translational Science Proceedings 2015. San Francisco, CA, USA: 2015. Are all vaccines created equal? Using electronic health records to discover vaccines associated with clinician-coded adverse events, in; pp. 196&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525221</ArticleId><ArticleId IdType="pubmed">26306268</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Tatonetti NP, Hripcsak G. Intelligent Systems for Molecular Biology Phenotype Day. Boston, MA: 2014. CAESAR: a classification approach for extracting severity automatically from electronic health records, in.</Citation></Reference><Reference><Citation>Vapnik V. Statistical Learning Theory. Springer; New York: 1998.</Citation></Reference><Reference><Citation>Boland MR, Tatonetti NP, Hripcsak G. Development and validation of a classification approach for extracting severity automatically from electronic health records. J Biomed Semantics. 2015;6(14)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4386082</ArticleId><ArticleId IdType="pubmed">25848530</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitch R, Cohen-Kashi S, Dror U, Levy I, Maimon A, Shahar Y. Multiple hierarchical classification of free-text clinical guidelines. Artif Intell Med. 2006;37:177&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">16730962</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissim N, Boland MR, Moskovitch R, Tatonetti NP, Elovici Y, Shahar Y, Hripcsak G. An active learning framework for efficient condition severity classification, in. Artificial Intelligence in Medicine (AIME-15), Springer International Publishing. 2015:13&#x2013;24.</Citation></Reference><Reference><Citation>Vapnik VN. Estimation of Dependences Based on Empirical Data. Vol. 41. Springer-Verlag; New York: 1982.</Citation></Reference><Reference><Citation>Joachims T. Making large scale SVM learning practical. 1999</Citation></Reference><Reference><Citation>Burges CJ. A tutorial on support vector machines for pattern recognition. Data Min Knowl Disc. 1998;2(2):121&#x2013;167.</Citation></Reference><Reference><Citation>Berthold Michael. The fog of data: data exploration in the life sciences. Invited Talk at 11th AIME Conference. 2007 In Artificial Intelligence in Medicine.</Citation></Reference><Reference><Citation>Cebron Nicolas, Berthold Michael R. Active learning for object classification: from exploration to exploitation. Data Min Knowl Discov. 2009 Jul 27;18(2):283&#x2013;299. 2008.</Citation></Reference><Reference><Citation>Moskovitch Robert, Hessing Alon, Shahar Yuval. Vaidurya &#x2013; a concept-based, context-sensitive search engine for clinical guidelines, MedInfo 2004. San Francisco, USA: 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15360791</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitch Robert, Martins Suzana, Behiri Eytan, Weiss Aviram, Shahar Yuval. A comparative evaluation of a full-text, concept based, and context sensitive search engine. J Am Med Inform Assoc. 2007;14:164&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213470</ArticleId><ArticleId IdType="pubmed">17213502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13(6)</Citation><ArticleIdList><ArticleId IdType="pubmed">22549152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellazzi R, Zupan B. Predictive data mining in clinical medicine: current issues and guidelines. Int J Med Inform. 2008;77(2)</Citation><ArticleIdList><ArticleId IdType="pubmed">17188928</ArticleId></ArticleIdList></Reference><Reference><Citation>Batal I, Fradkin D, Harrison J, Moerchen F, Hauskrecht M. Proceedings of Knowledge Discovery and Data Mining (KDD) Beijing, China: 2012. Mining recent temporal patterns for event detection in multivariate time series data, in.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414327</ArticleId><ArticleId IdType="pubmed">25937993</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitch R, Shahar Y. Fast time intervals mining using transitivity of temporal relations. Knowl Inf Syst. 2015;42:1.</Citation></Reference><Reference><Citation>Ng K, Ghoting A, Steinhubl SR, Stewart WF, Malin B, Sun J. PARAMO: a PARAllel predictive MOdeling platform for healthcare analytic research using electronic health records. J Biomed Inform. 2014;48:160&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075460</ArticleId><ArticleId IdType="pubmed">24370496</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, McNaughton CD, Zhang P, Perer A, Gkoulalas-Divanis A, Denny JC, Kirby J, Lasko T, Saip A, Malin BA. Predicting changes in hypertension control using electronic health records from a chronic disease management program. J Am Med Inform Assoc. 2014;21:337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932462</ArticleId><ArticleId IdType="pubmed">24045907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G. Physics of the Medical Record: Handling Time in Health Record Studies, Artificial Intelligence in Medicine. Pavia, Italy: 2015.</Citation></Reference><Reference><Citation>Rana S, Gupta S, Phung D, Venkatesh S. A predictive framework for modeling healthcare data with evolving clinical interventions. Stat Anal Data Min: ASA Data Sci J. 2015;8(3):162&#x2013;182.</Citation></Reference><Reference><Citation>Moskovitch R, Shahar Y. Classification of multivariate time series via temporal abstraction and time intervals mining. Knowl Inf Syst. 2015;45(1):35&#x2013;74.</Citation></Reference><Reference><Citation>Moskovitch R, Shahar Y. Classification driven temporal discretization of multivariate time series. Data Min Knowl Disc. 2015;29(4):871&#x2013;913.</Citation></Reference><Reference><Citation>Huang Z, Dong W, Bath P, Ji L, Duan H. On mining latent treatment patterns from electronic medical records. Data Min Knowl Disc. 2015;29:914&#x2013;949.</Citation></Reference><Reference><Citation>Nissim N, Moskovitch R, BarAd O, Rokach L, Elovici Y. ALDROID: efficient update of android anti-virus software using designated active learning methods. Knowl Inf Syst. 2016:1&#x2013;39.</Citation></Reference><Reference><Citation>Moskovitch R, Nissim N, Elovici Y. IEEE International Conference on Intelligence and Security Informatics (IEEE ISI-2007) Rutgers University; New Jersey, USA: 2007. Malicious code detection and acquisition using active learning.</Citation></Reference><Reference><Citation>Nissim Nir, Cohen Aviad, Moskovitch Robert, Barad Oren, Edry Mattan, Shabatai Assaf, Elovici Yuval. ALPD: active learning framework for enhancing the detection of malicious PDF files, in: Intelligence and Security Informatics Conference (JISIC) 2014 IEEE Joint. 2014:91&#x2013;98.</Citation></Reference><Reference><Citation>Moskovitch R, Nissim N, Englert R, Elovici Y. The 11th International Conference on Information Fusion. Cologne, Germany: 2008. Detection of unknown computer worms activity using active learning, in.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27099532</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1365</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Drug, healthcare and patient safety</Title><ISOAbbreviation>Drug Healthc Patient Saf</ISOAbbreviation></Journal><ArticleTitle>Seasonality in acute liver injury? Findings in two health care claims databases.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>48</EndPage><MedlinePgn>39-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/DHPS.S95399</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Presumed seasonal use of acetaminophen-containing products for relief of cold/influenza ("flu") symptoms suggests that there might also be a corresponding seasonal pattern for acute liver injury (ALI), a known clinical consequence of acetaminophen overdose.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to determine whether there were any temporal patterns in hospitalizations for ALI that would correspond to assumed acetaminophen use in cold/flu season.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the period 2002-2010, monthly hospitalization rates for ALI using a variety of case definitions were calculated. Data sources included Truven MarketScan(&#xae;) Commercial Claims and Encounters (CCAE) and Medicare Supplemental and Coordination of Benefits (MDCR) databases. We performed a statistical test for seasonality of diagnoses using the periodic generalized linear model. To validate that the test can distinguish seasonal from nonseasonal patterns, we included two positive controls (ie, diagnoses of the common cold [acute nasopharyngitis] and influenza), believed to change with seasons, and two negative controls (female breast cancer and diabetes), believed to be insensitive to season.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A seasonal pattern was observed in monthly rates for common cold and influenza diagnoses, but this pattern was not observed for monthly rates of ALI, with or without comorbidities (cirrhosis or hepatitis), breast cancer, or diabetes. The statistical test for seasonality was significant for positive controls (P&lt;0.001 for each diagnosis in both databases) and nonsignificant for ALI and negative controls.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">No seasonal pattern was observed in the diagnosis of ALI. The positive and negative controls showed the expected patterns, strengthening the validity of the statistical and visual tests used for detecting seasonality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Rachel B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research and Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research and Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research and Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research and Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Healthc Patient Saf</MedlineTA><NlmUniqueID>101544775</NlmUniqueID><ISSNLinking>1179-1365</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acetaminophen</Keyword><Keyword MajorTopicYN="N">acute liver injury</Keyword><Keyword MajorTopicYN="N">seasonality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27099532</ArticleId><ArticleId IdType="pmc">PMC4824282</ArticleId><ArticleId IdType="doi">10.2147/DHPS.S95399</ArticleId><ArticleId IdType="pii">dhps-8-039</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Sloan survey. JAMA. 2002;287(3):337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790213</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Census Bureau [webpage on the Internet]  USA Quick Facts from the US Census Bureau.  [Accessed 12 August 2015].  Available from:  http://quickfacts.census.gov/qfd/states/00000.html.</Citation></Reference><Reference><Citation>Shiffman S, Rohay JM, Kelly JP, Malone MK, Weinstein RB, Kaufman DW. Acetaminophen use patterns associated with excess dosing; Presented at the 28th International Conference on Pharmaco-epidemiology and Therapeutic Risk Management August 23&#x2013;26; Barcelona: 2012.</Citation></Reference><Reference><Citation>Ayonrinde OT, Phelps GJ, Hurley JC, Ayonrinde OA. Paracetamol overdose and hepatotoxicity at a regional Australian hospital: a 4-year experience. Intern Med J. 2005;35(11):655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">16248859</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper SC, Aldridge RC, Shah T, et al. Outcomes of liver transplantation for paracetamol (acetaminophen)-induced hepatic failure. Liver Transpl. 2009;15(10):1351&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">19790165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostapowicz G, Fontana RJ, Schi&#xf8;dt FV, et al. U.S. Acute Liver Failure Study Group Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">12484709</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson AM, Polson J, Fontana RJ, et al. Acute Liver Failure Study Group Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">16317692</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. Am Med Inform Assoc. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart MA, Rothman KJ. Simple estimators of the intensity of seasonal occurrence. BMC Med Res Methodol. 2008;8:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2596789</ArticleId><ArticleId IdType="pubmed">18945366</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz AJ, Ryan PB, Racoosin JA, Stang PE. Assessment of case definitions for identifying acute liver injury in large observational databases. Drug Saf. 2013;36(8):651&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">23670723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Re V, 3rd, Haynes K, Goldberg D, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration&#x2019;s Mini-Sentinel Distributed Database. Pharmaco-epidemiol Drug Saf. 2013;22(8):861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409951</ArticleId><ArticleId IdType="pubmed">23801638</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo J-M, Okusaga O, Postolache TT. Seasonality of suicidal behavior. Int J Environ Res Public Health. 2012;9(2):531&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315262</ArticleId><ArticleId IdType="pubmed">22470308</ArticleId></ArticleIdList></Reference><Reference><Citation>Manthripragada AD, Zhou EH, Budnitz DS, Lovegrove MC, Willy ME. Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States. Pharmacoepidemiol Drug Saf. 2011;20(8):819&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">21294217</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulose-Ram R, Hirsch R, Dillon C, Gu Q. Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among U.S. adults. Pharmacoepidemiol Drug Saf. 2005;14(4):257&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">15386703</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27174893</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Learning statistical models of phenotypes using noisy labeled training data.</ArticleTitle><Pagination><StartPage>1166</StartPage><EndPage>1173</EndPage><MedlinePgn>1166-1173</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocw028</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Traditionally, patient groups with a phenotype are selected through rule-based definitions whose creation and validation are time-consuming. Machine learning approaches to electronic phenotyping are limited by the paucity of labeled training datasets. We demonstrate the feasibility of utilizing semi-automatically labeled training sets to create phenotype models via machine learning, using a comprehensive representation of the patient medical record.</AbstractText><AbstractText Label="METHODS">We use a list of keywords specific to the phenotype of interest to generate noisy labeled training data. We train L1 penalized logistic regression models for a chronic and an acute disease and evaluate the performance of the models against a gold standard.</AbstractText><AbstractText Label="RESULTS">Our models for Type 2 diabetes mellitus and myocardial infarction achieve precision and accuracy of 0.90, 0.89, and 0.86, 0.89, respectively. Local implementations of the previously validated rule-based definitions for Type 2 diabetes mellitus and myocardial infarction achieve precision and accuracy of 0.96, 0.92 and 0.84, 0.87, respectively.We have demonstrated feasibility of learning phenotype models using imperfectly labeled data for a chronic and acute phenotype. Further research in feature engineering and in specification of the keyword list can improve the performance of the models and the scalability of the approach.</AbstractText><AbstractText Label="CONCLUSIONS">Our method provides an alternative to manual labeling for creating training sets for statistical models of phenotypes. Such an approach can accelerate research with large observational healthcare datasets and may also be used to create local phenotype models.</AbstractText><CopyrightInformation>&#xa9; The Author 2016. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Vibhu</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Training Program, Stanford University, Stanford CA 94305-5479, USA vibhua@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Podchiyska</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Training Program, Stanford University, Stanford CA 94305-5479, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford University, Stanford CA 94305-5479, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goel</LastName><ForeName>Veena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University School of Medicine, Stanford CA 94305-5208, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Informatics, Stanford Children's Health, Stanford CA 94305-5474, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Tiffany I</ForeName><Initials>TI</Initials><AffiliationInfo><Affiliation>Division of General Medical Disciplines, Stanford University, Stanford CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Training Program, Stanford University, Stanford CA 94305-5479, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Calgary, Calgary Alberta, T2N 4N1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Training Program, Stanford University, Stanford CA 94305-5479, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Stanford Hospital &amp; Clinics, Stanford CA 94305-2200, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gyang</LastName><ForeName>Elsie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, Stanford Hospital &amp; Clinics, Stanford CA 94305-5642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford University, Stanford CA 94305-5479, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM011369</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG004028</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM101430</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008492" MajorTopicYN="N">Medical Informatics Computing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="N">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electronic health record</Keyword><Keyword MajorTopicYN="N">high throughput</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">noisy labels</Keyword><Keyword MajorTopicYN="N">phenotyping</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27174893</ArticleId><ArticleId IdType="pmc">PMC5070523</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocw028</ArticleId><ArticleId IdType="pii">ocw028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Longhurst CA &#xa0;Harrington RA &#xa0;Shah NH . A &#x2018;green button' for using aggregate patient data at the point of care .Health Aff (Millwood). 2014. ; 33 ( 7 ): 1229 &#x2013; 1235 .</Citation><ArticleIdList><ArticleId IdType="pubmed">25006150</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak J &#xa0;Kho AN &#xa0;Denny JC . Electronic health records-driven phenotyping: challenges, recent advances, and perspectives .J Am Med Inform Assoc. 2013. ; 20 ( e2 ): e206 &#x2013; e211 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861925</ArticleId><ArticleId IdType="pubmed">24302669</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NH . Mining the ultimate phenome repository .Nat Biotechnol. 2013. ; 31 ( 12 ): 1095 &#x2013; 1097 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036679</ArticleId><ArticleId IdType="pubmed">24316646</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivade C &#xa0;Raghavan P &#xa0;Fosler-Lussier E &#xa0;Embi PJ &#xa0;Elhadad N &#xa0;Johnson SB &#xa0;et al. . A review of approaches to identifying patient phenotype cohorts using electronic health records .J Am Med Inform Assoc. 2014. ; 21 ( 2 ): 221 &#x2013; 230 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932460</ArticleId><ArticleId IdType="pubmed">24201027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman O &#xa0;Kuivaniemi H &#xa0;Tromp G &#xa0;Faucett WA &#xa0;Li R &#xa0;Manolio TA &#xa0;et al. . The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future .Genet Med. 2013. ; 15 ( 10 ): 761 &#x2013; 771 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795928</ArticleId><ArticleId IdType="pubmed">23743551</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty CA &#xa0;Chisholm RL &#xa0;Chute CG &#xa0;Kullo IJ &#xa0;Jarvik GP &#xa0;Larson EB &#xa0;et al. . The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies .BMC Med Genomics. 2011. ; 4 : 13 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038887</ArticleId><ArticleId IdType="pubmed">21269473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei WQ &#xa0;Denny JC . Extracting research-quality phenotypes from electronic health records to support precision medicine .Genome Med. 2015. ; 7 ( 1 ): 41 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416392</ArticleId><ArticleId IdType="pubmed">25937834</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC &#xa0;Bastarache L &#xa0;Ritchie MD &#xa0;Carroll RJ &#xa0;Zink R &#xa0;Mosley JD &#xa0;et al. . Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data .Nat Biotechnol. 2013. ; 31 ( 12 ): 1102 &#x2013; 1110 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969265</ArticleId><ArticleId IdType="pubmed">24270849</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ &#xa0;Eyler AE &#xa0;Denny JC . Intelligent use and clinical benefits of electronic health records in rheumatoid arthritis .Expert Rev Clin Immunol. 2015. ; 11 ( 3 ): 329 &#x2013; 337 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518025</ArticleId><ArticleId IdType="pubmed">25660652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie MD &#xa0;Verma SS &#xa0;Hall MA &#xa0;Goodloe RJ &#xa0;Berg RL &#xa0;Carrell DS &#xa0;et al. . Electronic medical records and genomics (eMERGE) network exploration in cataract: several new potential susceptibility loci .Mol Vis. 2014. ; 20 : 1281 &#x2013; 1295 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4168835</ArticleId><ArticleId IdType="pubmed">25352737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C &#xa0;Karlson EW &#xa0;Dligach D &#xa0;Ramirez MP &#xa0;Miller TA &#xa0;Mo H &#xa0;et al. . Automatic identification of methotrexate-induced liver toxicity in patients with rheumatoid arthritis from the electronic medical record .J Am Med Inform Assoc. 2014. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901122</ArticleId><ArticleId IdType="pubmed">25344930</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M &#xa0;Chen Y &#xa0;Liu M &#xa0;Rosenbloom ST &#xa0;Mani S &#xa0;Denny JC &#xa0;et al. . A study of machine-learning-based approaches to extract clinical entities and their assertions from discharge summaries .J Am Med Inform Assoc. 2011. ; 18 ( 5 ): 601 &#x2013; 606 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168315</ArticleId><ArticleId IdType="pubmed">21508414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright A &#xa0;Pang J &#xa0;Feblowitz JC &#xa0;Maloney FL &#xa0;Wilcox AR &#xa0;Ramelson HZ &#xa0;et al. . &#xa0;A method and knowledge base for automated inference of patient problems from structured data in an electronic medical record &#xa0;. &#xa0;J Am Med Inform Assoc. &#xa0;2011. ; 18 ( 6 ): 859 &#x2013; 867 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197992</ArticleId><ArticleId IdType="pubmed">21613643</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton KM &#xa0;Peissig PL &#xa0;Kho AN &#xa0;Bielinski SJ &#xa0;Berg RL &#xa0;Choudhary V &#xa0;et al. . Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network .J Am Med Inform Assoc. 2013. ; 20 ( e1 ): e147 &#x2013; e154 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Overby CL &#xa0;Pathak J &#xa0;Gottesman O &#xa0;Haerian K &#xa0;Perotte A &#xa0;Murphy S &#xa0;et al. . A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury .J Am Med Inform Assoc. 2013. ; 20 ( e2 ): e243 &#x2013; e252 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861914</ArticleId><ArticleId IdType="pubmed">23837993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayley KB &#xa0;Belnap T &#xa0;Savitz L &#xa0;Masica AL &#xa0;Shah N &#xa0;Fleming NS . Challenges in using electronic health record data for CER: experience of 4 learning organizations and solutions applied .Med Care. 2013. ; 51 ( 8 Suppl 3 ): S80 &#x2013; S86 .</Citation><ArticleIdList><ArticleId IdType="pubmed">23774512</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlas S . Hospitals scramble to meet deadlines for adopting electronic health records: pharmacy systems will be updated slowly but surely .P T. 2011. ; 36 ( 1 ): 37 &#x2013; 40 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046613</ArticleId><ArticleId IdType="pubmed">21386936</ArticleId></ArticleIdList></Reference><Reference><Citation>
PheKB
.
Phenotype KnowledgeBase
.

Available from:
http://www.phekb.org
. Accessed 12 February 2015.
</Citation></Reference><Reference><Citation>Liao KP &#xa0;Cai T &#xa0;Gainer V &#xa0;Goryachev S &#xa0;Zeng-treitler Q &#xa0;Raychaudhuri S &#xa0;et al. . Electronic medical records for discovery research in rheumatoid arthritis .Arthritis Care Res (Hoboken). 2010. ; 62 ( 8 ): 1120 &#x2013; 1127 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121049</ArticleId><ArticleId IdType="pubmed">20235204</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrell DS &#xa0;Halgrim S &#xa0;Tran DT &#xa0;Buist DS &#xa0;Chubak J &#xa0;Chapman WW &#xa0;et al. . Using natural language processing to improve efficiency of manual chart abstraction in research: the case of breast cancer recurrence .Am J Epidemiol. 2014. ; 179 ( 6 ): 749 &#x2013; 758 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939853</ArticleId><ArticleId IdType="pubmed">24488511</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ &#xa0;Thompson WK &#xa0;Eyler AE &#xa0;Mandelin AM &#xa0;Cai T &#xa0;Zink RM &#xa0;et al. . Portability of an algorithm to identify rheumatoid arthritis in electronic health records .J Am Med Inform Assoc. 2012. ; 19 ( e1 ): e162 &#x2013; e169 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392871</ArticleId><ArticleId IdType="pubmed">22374935</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR &#xa0;Hripcsak G &#xa0;Shen Y &#xa0;Chung WK &#xa0;Weng C . Defining a comprehensive verotype using electronic health records for personalized medicine .J Am Med Inform Assoc. 2013. ; 20 ( e2 ): e232 &#x2013; e238 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861934</ArticleId><ArticleId IdType="pubmed">24001516</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian TY &#xa0;Zlateva I &#xa0;Anderson DR . Using electronic health records data to identify patients with chronic pain in a primary care setting .J Am Med Inform Assoc. 2013. ; 20 ( e2 ): e275 &#x2013; e280 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861913</ArticleId><ArticleId IdType="pubmed">23904323</ArticleId></ArticleIdList></Reference><Reference><Citation>Chute CG . Invited commentary: Observational research in the age of the electronic health record .Am J Epidemiol. 2014. ; 179 ( 6 ): 759 &#x2013; 761 .</Citation><ArticleIdList><ArticleId IdType="pubmed">24488512</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro VM &#xa0;Apperson WK &#xa0;Gainer VS &#xa0;Ananthakrishnan AN &#xa0;Goodson AP &#xa0;Wang TD &#xa0;et al. . Evaluation of matched control algorithms in EHR-based phenotyping studies: a case study of inflammatory bowel disease comorbidities .J Biomed Inform. 2014. ; 52 : 105 &#x2013; 111 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261034</ArticleId><ArticleId IdType="pubmed">25196084</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y &#xa0;Carroll RJ &#xa0;Hinz ER &#xa0;Shah A &#xa0;Eyler AE &#xa0;Denny JC &#xa0;et al. . Applying active learning to high-throughput phenotyping algorithms for electronic health records data .J Am Med Inform Assoc. 2013. ; 20 ( e2 ): e253 &#x2013; e259 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861916</ArticleId><ArticleId IdType="pubmed">23851443</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinnott JA &#xa0;Dai W &#xa0;Liao KP &#xa0;Shaw SY &#xa0;Ananthakrishnan AN &#xa0;Gainer VS &#xa0;et al. . Improving the power of genetic association tests with imperfect phenotype derived from electronic medical records .Hum Genet. 2014. ; 133 ( 11 ): 1369 &#x2013; 1382 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185241</ArticleId><ArticleId IdType="pubmed">25062868</ArticleId></ArticleIdList></Reference><Reference><Citation>Peissig PL &#xa0;Santos Costa V &#xa0;Caldwell MD &#xa0;Rottscheit C &#xa0;Berg RL &#xa0;Mendonca EA &#xa0;et al. . Relational machine learning for electronic health record-driven phenotyping .J Biomed Inform. 2014. ; 52 : 260 &#x2013; 270 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261015</ArticleId><ArticleId IdType="pubmed">25048351</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon HU . General bounds on the number of examples needed for learning probabilistic concepts .J Comput Syst Sci. 1996. ; 52 ( 2 ): 239 &#x2013; 254 .</Citation></Reference><Reference><Citation>Aslam JA &#xa0;Decatur SE . On the sample complexity of noise-tolerant learning .Inform Process Lett. 1996. ; 57 ( 4 ): 189 &#x2013; 195 .</Citation></Reference><Reference><Citation>
Observational Medical Outcomes Partnership
.
Health Outcomes of Interest
.

Available from:
http://omop.org/HOI
Accessed 13 December 2014

.
</Citation></Reference><Reference><Citation>Halpern Y &#xa0;Choi Y &#xa0;Horng S &#xa0;Sontag D . Electronic Medical Record Phenotyping using the Anchor &amp; Learn Framework .J Am Med Inform Assoc. 2016. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4926745</ArticleId><ArticleId IdType="pubmed">27107443</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K &#xa0;LePendu P &#xa0;Iyer S &#xa0;Bauer-Mehren A &#xa0;Percha B &#xa0;Shah NH . Functional evaluation of out-of-the-box text-mining tools for data-mining tasks .J Am Med Inform Assoc. 2015. ; 22 ( 1 ): 121 &#x2013; 131 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433377</ArticleId><ArticleId IdType="pubmed">25336595</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V &#xa0;Lependu P &#xa0;Podchiyska T &#xa0;Barber R &#xa0;Boland M &#xa0;Hripcsak G &#xa0;et al. . Using narratives as a source to automatically learn phenotype models 2014AMIA: in 1st Workshop on Data Mining for Medical Informatics. 2014; Annual Symposium: Washington DC .</Citation></Reference><Reference><Citation>Hastie T &#xa0;Tibshirani R &#xa0;Friedman J . The Elements of Statistical Learning . Vol. 2 . New York: : Springer; ; 2009. .</Citation></Reference><Reference><Citation>Friedman J &#xa0;Hastie T &#xa0;Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent .J Stat Softw. 2010. ; 33 ( 1 ): 1 &#x2013; 22 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedregosa F &#xa0;Varoquaux G &#xa0;Gramfort A &#xa0;Michel V &#xa0;Thirion B &#xa0;Grisel O &#xa0;et al. . Scikit-learn: Machine learning in Python .J Machine Learning Res. 2011. ; 12 : 2825 &#x2013; 2830 .</Citation></Reference><Reference><Citation>Yu S &#xa0;Liao KP &#xa0;Shaw SY &#xa0;Gainer VS &#xa0;Churchill SE &#xa0;Szolovits P &#xa0;et al. . Toward high-throughput phenotyping: unbiased automated feature extraction and 90 selection from knowledge sources .J Am Med Inform Assoc. 2015. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986664</ArticleId><ArticleId IdType="pubmed">25929596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei WQ &#xa0;Leibson CL &#xa0;Ransom JE &#xa0;Kho AN &#xa0;Caraballo PJ &#xa0;Chai HS &#xa0;et al. . Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitus .J Am Med Inform Assoc. 2012. ; 19 ( 2 ): 219 &#x2013; 224 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277630</ArticleId><ArticleId IdType="pubmed">22249968</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R &#xa0;Carnahan RM &#xa0;Brown JS &#xa0;Chrischilles E &#xa0;Curtis LH &#xa0;Hennessy S &#xa0;et al. . The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction .Pharmacoepidemiol Drug Saf. 2012. ; 21 Suppl 1 : 1 &#x2013; 8 .</Citation><ArticleIdList><ArticleId IdType="pubmed">22262586</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak J &#xa0;Bailey KR &#xa0;Beebe CE &#xa0;Bethard S &#xa0;Carrell DC &#xa0;Chen PJ &#xa0;et al. . Normalization and standardization of electronic health records for high-throughput phenotyping: the SHARPn consortium .J Am Med Inform Assoc. 2013. ; 20 ( e2 ): e341 &#x2013; e348 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861933</ArticleId><ArticleId IdType="pubmed">24190931</ArticleId></ArticleIdList></Reference><Reference><Citation>
OHDSI
.
Aphrodite
.
2015. 
;

Available from:
https://github.com/OHDSI/Aphrodite
. Accessed 7 November 2015

.
</Citation></Reference><Reference><Citation>
OHDSI
.
Observational Health Data Sciences and Informatics
.

Available from:
http://www.ohdsi.org
. Accessed 7 November 2015

.
</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC . Chapter 13: Mining electronic health records in the genomics era .PLoS Comput Biol. 2012. ; 8 ( 12 ): e1002823 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531280</ArticleId><ArticleId IdType="pubmed">23300414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K &#xa0;Sun J &#xa0;Hu J &#xa0;Wang F . Personalized Predictive Modeling and Risk Factor Identification using Patient Similarity .AMIA Jt Summits Transl Sci Proc. 2015. ; 2015 : 132 &#x2013; 136 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525240</ArticleId><ArticleId IdType="pubmed">26306255</ArticleId></ArticleIdList></Reference><Reference><Citation>Celi LAG &#xa0;Tang RJ &#xa0;Villarroel MC &#xa0;Davidzon GA &#xa0;Lester WT &#xa0;Chueh HC . A clinical database-driven approach to decision support: Predicting mortality among patients with acute kidney injury .J Healthcare Engineering. 2011. ; 2 ( 1 ): 97 &#x2013; 110 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3404157</ArticleId><ArticleId IdType="pubmed">22844575</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G &#xa0;Albers DJ . Next-generation phenotyping of electronic health records .J Am Med Inform Assoc. 2013. ; 20 ( 1 ): 117 &#x2013; 121 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S &#xa0;Yu H . Biomedical negation scope detection with conditional random fields .J Am Med Inform Assoc. 2010. ; 17 ( 6 ): 696 &#x2013; 701 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000754</ArticleId><ArticleId IdType="pubmed">20962133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27193236</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2052-4463</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2016</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Scientific data</Title><ISOAbbreviation>Sci Data</ISOAbbreviation></Journal><ArticleTitle>A curated and standardized adverse drug event resource to accelerate drug safety research.</ArticleTitle><Pagination><StartPage>160026</StartPage><MedlinePgn>160026</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">160026</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/sdata.2016.26</ELocationID><Abstract><AbstractText>Identification of adverse drug reactions (ADRs) during the post-marketing phase is one of the most important goals of drug safety surveillance. Spontaneous reporting systems (SRS) data, which are the mainstay of traditional drug safety surveillance, are used for hypothesis generation and to validate the newer approaches. The publicly available US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data requires substantial curation before they can be used appropriately, and applying different strategies for data cleaning and normalization can have material impact on analysis results. We provide a curated and standardized version of FAERS removing duplicate case records, applying standardized vocabularies with drug names mapped to RxNorm concepts and outcomes mapped to SNOMED-CT concepts, and pre-computed summary statistics about drug-outcome relationships for general consumption. This publicly available resource, along with the source code, will accelerate drug safety research by reducing the amount of time spent performing data management on the source FAERS reports, improving the quality of the underlying data, and enabling standardized analyses using common vocabularies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-8499-824X</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LTS Computing LLC, West Chester, Pennsylvania 19380, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanguri</LastName><ForeName>Rami S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp;Development, LLC, Titusville, New Jersey 08869, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>Dryad</DataBankName><AccessionNumberList><AccessionNumber>10.5061/dryad.8q0s4</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM101430</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA209997</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D064886">Dataset</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Data</MedlineTA><NlmUniqueID>101640192</NlmUniqueID><ISSNLinking>2052-4463</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.M.B., N.H., R.S.V. and N.P.T. have no conflicts of interest. L.E. is the owner of LTS Computing LLC. A company that performs commercial IT projects for life science companies, including large bio-pharmaceutical companies. P.B.R. is an employee of Janssen Research and Development and shareholder of Johnson &amp; Johnson.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27193236</ArticleId><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="doi">10.1038/sdata.2016.26</ArticleId><ArticleId IdType="pii">sdata201626</ArticleId></ArticleIdList><ReferenceList><Title>Data Citations</Title><Reference><Citation>Banda J. M. 2016. Dryad. http://dx.doi.org/10.5061/dryad.8q0s4</Citation><ArticleIdList><ArticleId IdType="doi">10.5061/dryad.8q0s4</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ernst F. R. &amp; Grizzle A. J. Drug-related morbidity and mortality: updating the cost-of-illness model. Journal of the American Pharmaceutical Association (Washington, D.C.: 1996) 41, 192&#x2013;199 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11297331</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lucado J., Paez K. &amp; Elixhauser A.

Medication-Related Adverse Outcomes in U.S. Hospitals and Emergency Departments, 2008. HCUP Statistical Brief #109 (Agency for Healthcare Research and Quality, Rockville, MD, USA). http://www.hcup-us.ahrq.gov/reports/statbriefs/sb109.pdf (April 2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21595139</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerian K. et al. Detection of Pharmacovigilance-Related adverse Events Using Electronic Health Records and automated Methods. Clinical pharmacology and therapeutics 92, 228&#x2013;234 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685297</ArticleId><ArticleId IdType="pubmed">22713699</ArticleId></ArticleIdList></Reference><Reference><Citation>LePendu P. et al. Pharmacovigilance Using Clinical Notes. Clin. Pharmacol. Ther. 93, 547&#x2013;555 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3846296</ArticleId><ArticleId IdType="pubmed">23571773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lependu P., Iyer S. V., Fairon C. &amp; Shah N. H. Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. Journal of biomedical semantics 3(Suppl 1): S5 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337270</ArticleId><ArticleId IdType="pubmed">22541596</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang P. E. et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Annals of internal medicine 153, 600&#x2013;606 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R. et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Ther. 91, 1010&#x2013;1021 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti N. P., Fernald G. H. &amp; Altman R. B. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. Journal of the American Medical Informatics Association: JAMIA 19, 79&#x2013;85 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240755</ArticleId><ArticleId IdType="pubmed">21676938</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig P. K. Advancing the science of pharmacovigilance. Clin. Pharmacol. Ther. 93, 474&#x2013;475 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23689213</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikfarjam A., Sarker A., O'Connor K., Ginn R. &amp; Gonzalez G. Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J. Am. Med. Inform. Assoc. 22, 671&#x2013;681 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457113</ArticleId><ArticleId IdType="pubmed">25755127</ArticleId></ArticleIdList></Reference><Reference><Citation>Freifeld C. C. et al. Digital drug safety surveillance: monitoring pharmaceutical products in twitter. Drug Saf. 37, 343&#x2013;350 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013443</ArticleId><ArticleId IdType="pubmed">24777653</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R. et al. Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf. 37, 777&#x2013;790 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4217510</ArticleId><ArticleId IdType="pubmed">25151493</ArticleId></ArticleIdList></Reference><Reference><Citation>Leaman R. et al. in Proceedings of the 2010 Workshop on Biomedical Natural Language Processing 117&#x2013;125 (Association for Computational Linguistics, 2010).</Citation></Reference><Reference><Citation>Sarker A. et al. Utilizing social media data for pharmacovigilance: A review. J. Biomed. Inform. 54, 202&#x2013;212 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408239</ArticleId><ArticleId IdType="pubmed">25720841</ArticleId></ArticleIdList></Reference><Reference><Citation>Avillach P. et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. Journal of the American Medical Informatics Association: JAMIA 20, 446&#x2013;452 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628051</ArticleId><ArticleId IdType="pubmed">23195749</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontes H., Clement M. &amp; Rollason V. Safety signal detection: the relevance of literature review. Drug Saf. 37, 471&#x2013;479 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24895178</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty K. D. &amp; Dalal S. Using information mining of the medical literature to improve drug safety. Journal of the American Medical Informatics Association 18, 668&#x2013;674 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168306</ArticleId><ArticleId IdType="pubmed">21546507</ArticleId></ArticleIdList></Reference><Reference><Citation>Winnenburg R. et al. Leveraging MEDLINE indexing for pharmacovigilance&#x2014;Inherent limitations and mitigation strategies. J. Biomed. Inform. 57, 425&#x2013;435 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4775467</ArticleId><ArticleId IdType="pubmed">26342964</ArticleId></ArticleIdList></Reference><Reference><Citation>Odgers D. J., Harpaz R., Callahan A., Stiglic G. &amp; Shah N. H. Analyzing search behavior of healthcare professionals for drug safety surveillance. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299876</ArticleId><ArticleId IdType="pubmed">25592591</ArticleId></ArticleIdList></Reference><Reference><Citation>White R. W., Harpaz R., Shah N. H., DuMouchel W. &amp; Horvitz E. Toward enhanced pharmacovigilance using patient-generated data on the internet. Clin. Pharmacol. Ther. 96, 239&#x2013;246 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111778</ArticleId><ArticleId IdType="pubmed">24713590</ArticleId></ArticleIdList></Reference><Reference><Citation>White R. W., Tatonetti N. P., Shah N. H., Altman R. B. &amp; Horvitz E. Web-scale pharmacovigilance: listening to signals from the crowd. J. Am. Med. Inform. Assoc. 20, 404&#x2013;408 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628066</ArticleId><ArticleId IdType="pubmed">23467469</ArticleId></ArticleIdList></Reference><Reference><Citation>Yom-Tov E. &amp; Gabrilovich E. Postmarket Drug Surveillance Without Trial Costs: Discovery of Adverse Drug Reactions Through Large-Scale Analysis of Web Search Queries. Journal of Medical Internet Research 15, e124 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3713931</ArticleId><ArticleId IdType="pubmed">23778053</ArticleId></ArticleIdList></Reference><Reference><Citation>Abernethy D. R., Woodcock J. &amp; Lesko L. J. Pharmacological mechanism-based drug safety assessment and prediction. Clin. Pharmacol. Ther. 89, 793&#x2013;797 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21490594</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang A. P. &amp; Butte A. J. Data-driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events. Clinical. pharmacology and therapeutics 85, 259&#x2013;268 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726746</ArticleId><ArticleId IdType="pubmed">19177064</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S. et al. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. Journal of the American Medical Informatics Association: JAMIA 18, i73&#x2013;i80 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241177</ArticleId><ArticleId IdType="pubmed">21946238</ArticleId></ArticleIdList></Reference><Reference><Citation>
Advera Health Analytics. http://www.adverahealth.com (2016).</Citation></Reference><Reference><Citation>
DrugLogic - Your Partner in Risk Management. http://www.druglogic.com (2014).</Citation></Reference><Reference><Citation>
FDAble - Frequently Asked Questions. http://www.fdable.com/information/faq (2016).</Citation></Reference><Reference><Citation>
Oracle Health Sciences Pharmacovigilance and Risk Management Solutions. http://www.oracle.com/us/products/applications/health-sciences/pharmacovigilance/index.html (2016).</Citation></Reference><Reference><Citation>
UBC - Risk Management &amp; Pharmacovigilance. http://www.ubc.com/services/safety/risk-management-pharmacovigilance (2016).</Citation></Reference><Reference><Citation>Hripcsak G. et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud. Health. Technol. Inform. 216, 574&#x2013;578 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 11, 3&#x2013;10 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S. &amp; Rothman K.J. in Modern Epidemiology 2 edn (eds Greenland S. &amp; Rothman K. J. ) 231&#x2013;252 (Lippincott-Raven, Philadelphia, PA, USA, 2001).</Citation></Reference><Reference><Citation>Evans S. J., Waller P. C. &amp; Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10, 483&#x2013;486 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavali D. K., Kulkarni K. S., Kumar A. &amp; Chakraborty B. S. Therapeutic class-specific signal detection of bradycardia associated with propranolol hydrochloride. Indian Journal of Pharmacology 41, 162&#x2013;166 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875734</ArticleId><ArticleId IdType="pubmed">20523866</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Jung K., Winnenburg R. &amp; Shah N. H. A method for systematic discovery of adverse drug events from clinical notes. Journal of the American Medical Informatics Association 22, 1196&#x2013;1204 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4921953</ArticleId><ArticleId IdType="pubmed">26232442</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatonetti N. P., Ye P. P., Daneshjou R. &amp; Altman R. B. Data-Driven Prediction of Drug Effects and Interactions. Science Translational Medicine 4, 125ra131 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382018</ArticleId><ArticleId IdType="pubmed">22422992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P. B. et al. Defining a reference set to support methodological research in drug safety. Drug Saf. 36(Suppl 1) S33&#x2013;S47 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Ryan P. B., DuMouchel W., Suchard M. A. &amp; Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Statistics in medicine 33, 209&#x2013;218 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer S. V., Harpaz R., LePendu P., Bauer-Mehren A. &amp; Shah N. H. Mining clinical text for signals of adverse drug-drug interactions. J. Am. Med. Inform. Assoc. 21, 353&#x2013;362 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932451</ArticleId><ArticleId IdType="pubmed">24158091</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda J. et al. Feasibility of Prioritizing Drug-Drug-Event Associations Found in Electronic Health Records. Drug Saf. 39, 45&#x2013;57 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712252</ArticleId><ArticleId IdType="pubmed">26446143</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce R. D. et al. Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest. Drug Saf. 37, 557&#x2013;567 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134480</ArticleId><ArticleId IdType="pubmed">24985530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayvaz S. et al. Toward a complete dataset of drug-drug interaction information from publicly available sources. Journal of Biomedical Informatics 55, 206&#x2013;217 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4464899</ArticleId><ArticleId IdType="pubmed">25917055</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda J. M., Kuhn T., Shah N. H. &amp; Dumontier M. in Lecture Notes in Computer Science: The Semantic Web - ISWC 2015, Vol. 9367, 293&#x2013;300 (Springer International Publishing, 2015).</Citation></Reference><Reference><Citation>Wang L., Jiang G., Li D. &amp; Liu H. Standardizing adverse drug event reporting data. Journal of biomedical semantics 5, 36&#x2013;36 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142531</ArticleId><ArticleId IdType="pubmed">25157320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27226264</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort.</ArticleTitle><Pagination><StartPage>247</StartPage><EndPage>260</EndPage><MedlinePgn>247-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12391</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Thyroid abnormalities in patients with bipolar disorder (BD) have been linked to lithium treatment for decades, yet other drugs have been less well studied. Our objective was to compare hypothyroidism risk for lithium versus the anticonvulsants and second-generation antipsychotics commonly prescribed for BD.</AbstractText><AbstractText Label="METHODS">Administrative claims data on 24,574 patients with BD were analyzed with competing risk survival analysis. Inclusion criteria were (i) one&#xa0;year of no prior hypothyroid diagnosis nor BD drug treatment, (ii) followed by at least one thyroid test during BD monotherapy on lithium carbonate, mood-stabilizing anticonvulsants (lamotrigine, valproate, oxcarbazepine, or carbamazepine) or antipsychotics (aripiprazole, olanzapine, risperidone, or quetiapine). The outcome was cumulative incidence of hypothyroidism per drug, in the presence of the competing risk of ending monotherapy, adjusted for age, sex, physician visits, and thyroid tests.</AbstractText><AbstractText Label="RESULTS">Adjusting for covariates, the four-year cumulative risk of hypothyroidism for lithium (8.8%) was 1.39-fold that of the lowest risk therapy, oxcarbazepine (6.3%). Lithium was non-statistically significantly different from quetiapine. While lithium conferred a higher risk when compared to all other treatments combined as a group, hypothyroidism risk error bars overlapped for all drugs. Treatment (p&#xa0;=&#xa0;3.86e-3), age (p&#xa0;=&#xa0;6.91e-10), sex (p&#xa0;=&#xa0;3.93e-7), and thyroid testing (p&#xa0;=&#xa0;2.79e-87) affected risk. Patients taking lithium were tested for hypothyroidism 2.26-3.05 times more frequently than those on other treatments.</AbstractText><AbstractText Label="CONCLUSIONS">Thyroid abnormalities occur frequently in patients with BD regardless of treatment. Therefore, patients should be regularly tested for clinical or subclinical thyroid abnormalities on all therapies and treated as indicated to prevent adverse effects of hormone imbalances on mood.</AbstractText><CopyrightInformation>&#xa9; 2016 The Authors. Bipolar Disorders Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Translational Informatics, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazurie</LastName><ForeName>Aur&#xe9;lien J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Bioinformatics Core, Montana State University, Bozeman, MT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauve</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Computer Science, University of New Mexico, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurwitz</LastName><ForeName>Nathaniel G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>New Mexico Behavioral Health Institute, Las Vegas, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>S Stanley</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>CGStat, LLC, Raleigh, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obenchain</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Risk Benefit Statistics, LLC, Bella Vista, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hengartner</LastName><ForeName>Nicolas W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Los Alamos National Laboratory, Los Alamos, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkins</LastName><ForeName>Douglas J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerner</LastName><ForeName>Berit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticonvulsants</Keyword><Keyword MajorTopicYN="N">antipsychotics</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">competing risks</Keyword><Keyword MajorTopicYN="N">hypothyroidism</Keyword><Keyword MajorTopicYN="N">lithium</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27226264</ArticleId><ArticleId IdType="pmc">PMC5089566</ArticleId><ArticleId IdType="doi">10.1111/bdi.12391</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
American Psychiatric Association
. Diagnostic and Statistical Manual of Mental Disorders, (DSM&#x2010;5&#xae;) [Internet]. American Psychiatric Pub, 2013.  Available from: http://dx.doi.org/10.1176/appi.books.9780890425596 [accessed April 2015].</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.books.9780890425596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12&#x2010;month DSM&#x2010;IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847357</ArticleId><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Schou M, Juel&#x2010;Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503195</ArticleId><ArticleId IdType="pubmed">13212414</ArticleId></ArticleIdList></Reference><Reference><Citation>Baastrup PC, Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic&#x2010;depressive psychosis. Arch Gen Psychiatry 1967; 16: 162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">6019331</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggs R. Treatment of manic illness with lithium carbonate. Br J Psychiatry. RCP; 1963; 109: 56&#x2013;65.</Citation></Reference><Reference><Citation>Goodwin FK, Murphy DL, Bunney WE Jr. Lithium&#x2010;carbonate treatment in depression and mania. A longitudinal double&#x2010;blind study. Arch Gen Psychiatry 1969; 21: 486&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">4896983</ArticleId></ArticleIdList></Reference><Reference><Citation>Angst J, Weis P, Grof P, Baastrup PC, Schou M. Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 1970; 116: 604&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">4916293</ArticleId></ArticleIdList></Reference><Reference><Citation>Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: double blind discontinuation in manic&#x2010;depressive and recurrent&#x2010;depressive disorders. Lancet 1970; 296: 326&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">4194439</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes PE, Shamoian CA, Stoll PM, Patton MJ. Efficacy of lithium as acute treatment of manic&#x2010;depressive illness. Lancet 1971; 297: 1319&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">4103395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden CL, Calabrese JR, McElroy SL et&#xa0;al. A randomized, placebo&#x2010;controlled 12&#x2010;month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. American Medical Association; 2000; 57: 481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">10807488</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck PEJr, McElroy SL. Pharmacological treatments for bipolar disorder In: Nathan PE, Gorman JM. eds. A Guide to Treatments that Work, fourth edition. New York, NY: Oxford University Press, 2015: 273&#x2013;306.</Citation></Reference><Reference><Citation>Machado&#x2010;Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009; 11 (Suppl. 2): 92&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2800957</ArticleId><ArticleId IdType="pubmed">19538689</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppen A, Standish&#x2010;Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1774419</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all&#x2010;cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162: 1805&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">16199826</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long&#x2010;term lithium treatment: a meta&#x2010;analytic review. Bipolar Disord 2006; 8: 625&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17042835</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68: 380&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">17388706</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston AM, Eagles JM. Lithium&#x2010;associated clinical hypothyroidism. Prevalence and risk factors. Br J Psychiatry 1999; 175: 336&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross&#x2010;sectional and a prospective study of thyroid disorders in lithium&#x2010;treated patients. J Affect Disord 2005; 87: 313&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16051025</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry C. Lithium side&#x2010;effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci 2002; 27: 104&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC161639</ArticleId><ArticleId IdType="pubmed">11944505</ArticleId></ArticleIdList></Reference><Reference><Citation>Schou M, Amdisen A, Eskjaer Jensen S, Olsen T. Occurrence of goitre during lithium treatment. Br Med J 1968; 3: 710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1989588</ArticleId><ArticleId IdType="pubmed">17016877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers MP, Whybrow PC. Clinical hypothyroidism occurring during lithium treatment: two case histories and a review of thyroid function in 19 patients. Am J Psychiatry 1971; 128: 158&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">4107030</ArticleId></ArticleIdList></Reference><Reference><Citation>Candy J. Severe hypothyroidism&#x2013;an early complication of lithium therapy. Br Med J 1972; 3: 277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1785737</ArticleId><ArticleId IdType="pubmed">5065279</ArticleId></ArticleIdList></Reference><Reference><Citation>McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta&#x2010;analysis. Lancet 2012; 379: 721&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265699</ArticleId></ArticleIdList></Reference><Reference><Citation>
UpToDate
. Lithium: Drug Information [Internet]. 2015.  Available from: http://www.uptodate.com/contents/lithium-drug-information [accessed April 2015].</Citation></Reference><Reference><Citation>Cho JT, Bone S, Dunner DL, Colt E, Fieve RR. The effect of lithium treatment on thyroid function in patients with primary affective disorder. Am J Psychiatry 1979; 136: 115&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">758817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuruvilla K, Karunanidhi A, Kanagasabapathy AS. Effects of long&#x2010;term lithium carbonate treatment on thyroid function in psychiatric patients. Indian J Psychiatry 1983; 25: 98&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012349</ArticleId><ArticleId IdType="pubmed">21847264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupka RW, Nolen WA, Post RM et&#xa0;al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002; 51: 305&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh WR, Weiner MG, Embi PJ et&#xa0;al. Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care 2013; 51 (8 Suppl. 3): S30&#x2013;S37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748381</ArticleId><ArticleId IdType="pubmed">23774517</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Rusanov A, Weng C. Sick patients have more data: the non&#x2010;random completeness of electronic health records. AMIA Annu Symp Proc 2013; 16: 1472&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900159</ArticleId><ArticleId IdType="pubmed">24551421</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusanov A, Weiskopf NG, Wang S, Weng C. Hidden in plain sight: bias towards sick patients when sampling patients with sufficient electronic health record data for research. BMC Med Inform Decis Mak 2014; 11: 51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4062889</ArticleId><ArticleId IdType="pubmed">24916006</ArticleId></ArticleIdList></Reference><Reference><Citation>
Reagan&#x2010;Udall Foundation for the Food and Drug Administration
. Innovation in Medical Evidence Development and Surveillance (IMEDS) Program [Internet]. 2015.  Available from: http://www.reaganudall.org/our-work/safety-and-better-evidence/imeds-program/ [accessed April 2015].</Citation></Reference><Reference><Citation>
Regan&#x2010;Udall Foundation for the Food and Drug Administration
. Innovation in Medical Evidence Development and Surveillance (IMEDS) Charter [Internet]. 2013.  p. 28&#x2013;9. Available from: http://www.reaganudall.org/wp-content/uploads/2013/04/RUF_IMEDS_IMEDS-Charter_041813-DRAFT2.pdf [accessed September 2015].</Citation></Reference><Reference><Citation>Quint JB. Health Research Data for the Real World: The Marketscan Databases. Truven Health Analytics, 2015.</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A et&#xa0;al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015; 22: 553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Ma W, Moore R, Ganesan V, Nelson S. RxNorm: prescription for electronic drug information exchange. IT Prof 2005; 7: 17&#x2013;23.</Citation></Reference><Reference><Citation>Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real&#x2010;world comparison of adherence and economic outcomes. Med Care 2006; 44: 300&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">16565629</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer JA, Roy A, Burrell A et&#xa0;al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">18237359</ArticleId></ArticleIdList></Reference><Reference><Citation>Satagopan JM, Ben&#x2010;Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 1229&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2410013</ArticleId><ArticleId IdType="pubmed">15305188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray RJ. A class of K&#x2010;sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141&#x2013;1154.</Citation></Reference><Reference><Citation>Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982; 69: 553&#x2013;566.</Citation></Reference><Reference><Citation>Pepe MS, Mori M. Kaplan&#x2013;meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993; 12: 737&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">8516591</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintilie M. Competing Risks: A Practical Perspective. West Sussex, England: John Wiley &amp; Sons, 2006.</Citation></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496&#x2013;509.</Citation></Reference><Reference><Citation>Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">20062101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gau C&#x2010;S, Chang C&#x2010;J, Tsai F&#x2010;J, Chao P&#x2010;F, Gau SS&#x2010;F. Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case&#x2010;control study. Bipolar Disord 2010; 12: 253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">20565432</ArticleId></ArticleIdList></Reference><Reference><Citation>
Depakote&#xae;
[package insert] [Internet]. AbbVie Inc., 2015.  Available from: http://www.rxabbvie.com/pdf/dep3.pdf [accessed January 2016].</Citation></Reference><Reference><Citation>Ezzaher A, Haj Mouhamed D, Mechri A et&#xa0;al. Thyroid function and lipid profile in bipolar I patients. Asian J Psychiatr 2011; 4: 139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">23051081</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui KYQ. The impact of Lithium on thyroid function in Chinese psychiatric population. Thyroid Res 2015; 4: 14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4558876</ArticleId><ArticleId IdType="pubmed">26339294</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lamactil&#xae;
[package insert] [Internet]. GlaxoSmithKline;  Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal/pdf/LAMICTAL-PI-MG.PDF [accessed January 2016].</Citation></Reference><Reference><Citation>Benedetti MS, Whomsley R, Baltes E, Tonner F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 2005; 61: 863&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16307266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamed SA. The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert Rev Clin Pharmacol 2015; 8: 741&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437373</ArticleId></ArticleIdList></Reference><Reference><Citation>Post RM, Weiss SRB, Leverich GS, Smith M, Zhang L&#x2010;X. Sensitization and kindling&#x2010;like phenomena in bipolar disorder: implications for psychopharmacology. Clin Neurosci Res 2001; 1: 69&#x2013;81.</Citation></Reference><Reference><Citation>Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007; 31: 858&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">17555817</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiglusz MS, Landowski J, Cuba&#x142;a WJ, Agius M. Overlapping phenomena of bipolar disorder and epilepsy&#x2013;a common pharmacological pathway. Psychiatr Danub 2015; 27 (Suppl. 1): S177&#x2013;S181.</Citation><ArticleIdList><ArticleId IdType="pubmed">26417756</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott S, Forty L, Craddock N, Thomas RH. Epilepsy and bipolar disorder. Epilepsy Behav. 2015; 52 (Pt A): 267&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">26316422</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamijani SMS, Karimi B, Amini E et&#xa0;al. Thyroid hormones: possible roles in epilepsy pathology. Seizure 2015; 31: 155&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">26362394</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Rastogi N, Mittal H, Chillar N, Patil R. Thyroid hormone levels in children receiving carbamazepine or valproate. Pediatr Neurol 2011; 45: 159&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">21824562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Chung HR, Kim SH et&#xa0;al. Subclinical hypothyroidism during valproic acid therapy in children and adolescents with epilepsy. Neuropediatrics 2012; 43: 135&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">22618302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EC&#x2010;C, Yang Y&#x2010;HK, Lin S&#x2010;J, Hsieh C&#x2010;Y. Use of antiepileptic drugs and risk of hypothyroidism. Pharmacoepidemiol Drug Saf. 2013; 22: 1071&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">23946049</ArticleId></ArticleIdList></Reference><Reference><Citation>Verrotti A, Scardapane A, Manco R, Chiarelli F. Antiepileptic drugs and thyroid function. J Pediatr Endocrinol Metab 2008; 21: 401&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">18655520</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tegretol&#xae;
[package insert] [Internet]. Novartis Pharmaceuticals Corporation, 2015.  Available from: https://www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf [accessed January 2016].</Citation></Reference><Reference><Citation>
Trileptal&#xae;
[package insert] [Internet]. Novartis Pharmaceuticals Corporation, 2014.  Available from: https://www.pharma.us.novartis.com/product/pi/pdf/trileptal.pdf [accessed January 2016 ].</Citation></Reference><Reference><Citation>Miller J, Carney P. Central hypothyroidism with oxcarbazepine therapy. Pediatr Neurol 2006; 34: 242&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lania A, Persani L, Beck&#x2010;Peccoz P. Central hypothyroidism. Pituitary 2008; 11: 181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">18415684</ArticleId></ArticleIdList></Reference><Reference><Citation>Feret BM, Caley CF. Possible hypothyroidism associated with quetiapine. Ann Pharmacother 2000; 34: 483&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">10772436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy S, Siddiqui Z, Saharan S, Gabel TL, Bhatia SC. Quetiapine&#x2010;induced hypothyroidism. J Psychiatry Neurosci 2005; 30: 57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC543843</ArticleId><ArticleId IdType="pubmed">15645000</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenspan A, Gharabawi G, Kwentus J. Thyroid dysfunction during treatment with atypical antipsychotics. J Clin Psychiatry 2005; 66: 1334&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">16259552</ArticleId></ArticleIdList></Reference><Reference><Citation>Liappas J, Paparrigopoulos T, Mourikis I, Soldatos C. Hypothyroidism induced by quetiapine: a case report. J Clin Psychopharmacol 2006; 26: 208&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">16633154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontaxakis V, Karaiskos D, Havaki&#x2010;Kontaxaki B et&#xa0;al. P03&#x2010;10 Quetiapine and hypothyroidism: a literature review. Eur Psychiatry 2009; 24 (Suppl. 1): S1009.</Citation></Reference><Reference><Citation>Poutanen O, Iso&#x2010;Koivisto E, Ty&#xf6;l&#xe4;j&#xe4;rvi M, Leinonen E. Quetiapine&#x2010;associated hypothyroidism in young female patients: a report of three cases. Pharmacopsychiatry 2010; 43: 237&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">20614417</ArticleId></ArticleIdList></Reference><Reference><Citation>Findling RL, Pathak S, Earley WR, Liu S, DelBello MP. Efficacy and safety of extended&#x2010;release quetiapine fumarate in youth with bipolar depression: an 8&#xa0;week, double&#x2010;blind, placebo&#x2010;controlled trial. J Child Adolesc Psychopharmacol 2014; 24: 325&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4137347</ArticleId><ArticleId IdType="pubmed">24956042</ArticleId></ArticleIdList></Reference><Reference><Citation>Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double&#x2010;blind, randomized, placebo&#x2010;controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pubmed">12364843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly DL, Conley RR. Thyroid function in treatment&#x2010;resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005; 66: 80&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15669892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontaxakis VP, Karaiskos D, Havaki&#x2010;Kontaxaki BJ, Ferentinos P, Papadimitriou GN. Can quetiapine&#x2010;induced hypothyroidism be reversible without quetiapine discontinuation? Clin Neuropharmacol 2009; 32: 295&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">19820433</ArticleId></ArticleIdList></Reference><Reference><Citation>Suppes T, Vieta E, Liu S, Brecher M, Paulsson B; Trial 127 Investigators . Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">19289454</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y&#x2010;M, Kang S&#x2010;G, Lee B&#x2010;H, Lee H&#x2010;J. Decreased thyroid function in Korean women with bipolar disorder receiving valproic acid. Gen Hosp Psychiatry. 2011; 33: 200.e13&#x2013;200.e15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21596216</ArticleId></ArticleIdList></Reference><Reference><Citation>
Seroquel XR&#xae;
[package insert] [Internet]. AstraZeneca Pharmaceuticals LP, 2013.  Available from: http://www.azpicentral.com/seroquel-xr/seroquelxr.pdf [accessed January 2016].</Citation></Reference><Reference><Citation>Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 2010; 32 (Suppl. 1): S3&#x2013;S20.</Citation><ArticleIdList><ArticleId IdType="pubmed">20152550</ArticleId></ArticleIdList></Reference><Reference><Citation>Church CO, Callen EC. Myxedema coma associated with combination aripiprazole and sertraline therapy. Ann Pharmacother 2009; 43: 2113&#x2013;2116.</Citation><ArticleIdList><ArticleId IdType="pubmed">19934393</ArticleId></ArticleIdList></Reference><Reference><Citation>
Zyprexa&#xae;
[package insert] [Internet]. Eli Lilly and Company, 2015.  Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [accessed January 2016].</Citation></Reference><Reference><Citation>
Risperdal&#xae;
[package insert] [Internet]. Janssen Pharmaceuticals, Inc., 2014.  Available from: http://www.janssen.com/us/sites/www_janssen_com_usa/files/products-documents/risperdal.pdf [accessed January 2016].</Citation></Reference><Reference><Citation>
Abilify&#xae;
[package insert] [Internet]. Bristol&#x2010;Myers Squibb Company, 2014.  Available from: http://packageinserts.bms.com/pi/pi_abilify.pdf [accessed January 2016].</Citation></Reference><Reference><Citation>Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs 2009; 23: 1003&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">19958039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium&#x2010;induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999; 60: 249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221287</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagiolini A, Kupfer DJ, Scott J et&#xa0;al. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. Epidemiol Psichiatr Soc 2006; 15: 123&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">16865933</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate CA, Tohen M, Zarate SB. Thyroid function tests in first&#x2010;episode bipolar disorder manic and mixed types. Biol Psychiatry 1997; 42: 302&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">9270910</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lithobid&#xae;
[package insert] [Internet]. Noven Therapeutics, LLC,
2011.  Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018027s056lbl.pdf [accessed January 2016].</Citation></Reference><Reference><Citation>Valle J, Ayuso&#x2010;Gutierrez JL, Abril A, Ayuso&#x2010;Mateos JL. Evaluation of thyroid function in lithium&#x2010;naive bipolar patients. Eur Psychiatry 1999; 14: 341&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">10572366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraszewska A, Chlopocka&#x2010;Wozniak M, Abramowicz M, Sowinski J, Rybakowski JK. A cross&#x2010;sectional study of thyroid function in 66 patients with bipolar disorder receiving lithium for 10&#x2013;44&#xa0;years. Bipolar Disord 2015; 17: 375&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">25359625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin&#x2010;releasing hormone. Thyroid 1998; 8: 909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">9827658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 723&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">19942149</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonk R, van der Schot AC, Kahn RS, Nolen WA, Drexhage HA. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry 2007; 62: 135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">17141745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer M, Glenn T, Pilhatsch M, Pfennig A, Whybrow PC. Gender differences in thyroid system function: relevance to bipolar disorder and its treatment. Bipolar Disord 2014; 16: 58&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24245529</ArticleId></ArticleIdList></Reference><Reference><Citation>Shine B, McKnight RF, Leaver L, Geddes JR. Long&#x2010;term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015; 386: 461&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">26003379</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27274072</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>27</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Characterizing treatment pathways at scale using the OHDSI network.</ArticleTitle><Pagination><StartPage>7329</StartPage><EndPage>7336</EndPage><MedlinePgn>7329-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1510502113</ELocationID><Abstract><AbstractText>Observational research promises to complement experimental research by providing large, diverse populations that would be infeasible for an experiment. Observational research can test its own clinical hypotheses, and observational studies also can contribute to the design of experiments and inform the generalizability of experimental research. Understanding the diversity of populations and the variance in care is one component. In this study, the Observational Health Data Sciences and Informatics (OHDSI) collaboration created an international data network with 11 data sources from four countries, including electronic health records and administrative claims data on 250 million patients. All data were mapped to common data standards, patient privacy was maintained by using a distributed model, and results were aggregated centrally. Treatment pathways were elucidated for type 2 diabetes mellitus, hypertension, and depression. The pathways revealed that the world is moving toward more consistent therapy over time across diseases and across locations, but significant heterogeneity remains among sources, pointing to challenges in generalizing clinical trial results. Diabetes favored a single first-line medication, metformin, to a much greater extent than hypertension or depression. About 10% of diabetes and depression patients and almost 25% of hypertension patients followed a treatment pathway that was unique within the cohort. Aside from factors such as sample size and underlying population (academic medical center versus general population), electronic health records data and administrative claims data revealed similar results. Large-scale international observational research is feasible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032; Medical Informatics Services, NewYork-Presbyterian Hospital, New York, NY 10032; Observational Health Data Sciences and Informatics, New York, NY 10032; hripcsak@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Epidemiology Analytics, Janssen Research and Development, Titusville, NJ 08560;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN 46205;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Center for Biomedical Informatics Research, Stanford University, CA 94305;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea, 443-380;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Lister Hill National Center for Biomedical Communications (National Library of Medicine), National Institutes of Health, Bethesda, MD 20894;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Department of Biomathematics, University of California, Los Angeles, CA 90095; Department of Biostatistics, University of California, Los Angeles, CA 90095; Department of Human Genetics, University of California, Los Angeles, CA 90095;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Epidemiology Analytics, Janssen Research and Development, Titusville, NJ 08560;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Epidemiology Analytics, Janssen Research and Development, Titusville, NJ 08560;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perotte</LastName><ForeName>Adler</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032; Observational Health Data Sciences and Informatics, New York, NY 10032;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Center for Biomedical Informatics Research, Stanford University, CA 94305;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Real World Evidence Solutions, IMS Health, Burlington, MA 01809;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37212; Geriatric Research, Education and Clinical Center, VA Tennessee Valley Healthcare System, Nashville, TN 37212;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90089; Department of Pediatrics, University of Southern California, Los Angeles, CA 90089;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Division of Health Sciences, University of South Australia, Adelaide, SA, Australia 5001;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY 10032; Department of Statistics, Columbia University, New York, NY 10027.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM101430</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011369</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008680</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data network</Keyword><Keyword MajorTopicYN="N">observational research</Keyword><Keyword MajorTopicYN="N">treatment pathways</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27274072</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pii">1510502113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Etheredge LM. Rapid learning: A breakthrough agenda. Health Aff (Millwood) 2014;33(7):1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006141</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins D, et al. GRADE Working Group Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC428525</ArticleId><ArticleId IdType="pubmed">15205295</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an american college of chest physicians task force. Chest. 2006;129(1):174&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424429</ArticleId></ArticleIdList></Reference><Reference><Citation>Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1557642</ArticleId><ArticleId IdType="pubmed">10861325</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861324</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. Value Health. 2009;12(8):1044&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">19793072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, et al. Empirical assessment of methods for risk identification in healthcare data: Results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401&#x2013;4415.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, et al. A systematic statistical approach to evaluating evidence from observational studies. Annu Rev Stat Appl. 2014;1:11&#x2013;39.</Citation></Reference><Reference><Citation>McCray AT. Better access to information about clinical trials. Ann Intern Med. 2000;133(8):609&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">11033590</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, et al. A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records. Appl Clin Inform. 2014;5(2):463&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081748</ArticleId><ArticleId IdType="pubmed">25024761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynaden D, et al. Administering intramuscular injections: How does research translate into practice over time in the mental health setting? Nurse Educ Today. 2015;35(4):620&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">25596035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendrick T, Stuart B, Newell C, Geraghty AW, Moore M. Did NICE guidelines and the Quality Outcomes Framework change GP antidepressant prescribing in England? Observational study with time trend analyses 2003-2013. J Affect Disord. 2015;186:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">26241666</ArticleId></ArticleIdList></Reference><Reference><Citation>Daubresse M, et al. Effect of Direct-to-Consumer Advertising on Asthma Medication Sales and Healthcare Use. Am J Respir Crit Care Med. 2015;192(1):40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4511422</ArticleId><ArticleId IdType="pubmed">25879303</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford WD, Kleit AN. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication. Health Econ. 2015;24(7):859&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">25059655</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay JB, Trachtenberg F, Marceau LD, Katz JN, Fischer MA. Effects of patient medication requests on physician prescribing behavior: Results of a factorial experiment. Med Care. 2014;52(4):294&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4151257</ArticleId><ArticleId IdType="pubmed">24848203</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven DJ, Rubenfeld GD, Kramer AA, Stelfox HT. Effect of published scientific evidence on glycemic control in adult intensive care units. JAMA Intern Med. 2015;175(5):801&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">25775163</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation> Observational Health Data Sciences and Informatics (OHDSI) OMOP Common Data Model V5.0. Available at  www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:single-page. Accessed June 1, 2015.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson SE, et al. Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics. 2013;69(4):893&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117144</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: Why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation> American Association of Clinical Endocrinologists AACE/ACE Comprehensive Diabetes Management Algorithm 2015 and AACE/ACE Diabetes Clinical Practice Guidelines. Available at  https://www.aace.com/publications/algorithm. Accessed June 4, 2015.</Citation></Reference><Reference><Citation> WHO Collaborating Centre for Drug Statistics Methodology ATC: Structure and principles. Available at  www.whocc.no/atc/structure_and_principles/. Accessed May 31, 2015.</Citation></Reference><Reference><Citation>Madigan D, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F, Chou S, Pan S, Chen Y. Mining time dependency patterns in clinical pathways. Int J Med Inform. 2001;62(1):11&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11340003</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Lu X, Duan H. Using recommendation to support adaptive clinical pathways. J Med Syst. 2012;36(3):1849&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pubmed">21207121</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Lu X, Duan H, Fan W. Summarizing clinical pathways from event logs. J Biomed Inform. 2013;46(1):111&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">23085455</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan CL, Puelles J, Poole CD, Currie CJ. The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: A retrospective cohort study. J Diabetes Complications. 2014;28(3):360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">24529918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez AF, Fleurence RL, Rothman RL. The ADAPTABLE trial and PCORnet: Shining light on a new research paradigm. Ann Intern Med. 2015;163(8):635&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">26301537</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl J. Causal inference in statistics: An overview. Stat Surv. 2009;3:96&#x2013;146.</Citation></Reference><Reference><Citation>Hill AB. The environment and disease: Association or causation? Proc R Soc Med. 1965;58:295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1898525</ArticleId><ArticleId IdType="pubmed">14283879</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41&#x2013;55.</Citation></Reference><Reference><Citation>Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: The self-controlled case series method. Stat Med. 2006;25(10):1768&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pubmed">16220518</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberg S, Hripcsak G. A review of causal inference for biomedical informatics. J Biomed Inform. 2011;44(6):1102&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219814</ArticleId><ArticleId IdType="pubmed">21782035</ArticleId></ArticleIdList></Reference><Reference><Citation>Victora CG, Habicht JP, Bryce J. Evidence-based public health: Moving beyond randomized trials. Am J Public Health. 2004;94(3):400&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1448265</ArticleId><ArticleId IdType="pubmed">14998803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman E, Grieve R, Ramsahai R, Sekhon JS. From sample average treatment effect to population average treatment effect on the treated: Combining experimental with observational studies to estimate population treatment effects. J R Stat Soc Ser A Stat Soc. 2015;178(3):757&#x2013;778.</Citation></Reference><Reference><Citation>Fuller J, Flores LJ. The Risk GP Model: The standard model of prediction in medicine. Stud Hist Philos Biol Biomed Sciences. 2015;54:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26212043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornet R, de Keizer N. Forty years of SNOMED: A literature review. BMC Med Inform Decis Mak. 2008;8(Suppl 1):S2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582789</ArticleId><ArticleId IdType="pubmed">19007439</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18(4):441&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald CJ, et al. LOINC, a universal standard for identifying laboratory observations: A 5-year update. Clin Chem. 2003;49(4):624&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">12651816</ArticleId></ArticleIdList></Reference><Reference><Citation> MedDRA MSSO Vision: About MedDRA. Available at  www.meddra.org/about-meddra/vision. Accessed May 31, 2015.</Citation></Reference><Reference><Citation> International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at  www.cdc.gov/nchs/icd/icd9cm.htm. Accessed May 28, 2015.</Citation></Reference><Reference><Citation> First Databank, Inc. Multilex. Available at  www.fdbhealth.com/multilex-drug-terminology/. Accessed May 31, 2015.</Citation></Reference><Reference><Citation> Observational Health Data Sciences and Informatics (OHDSI). Treatment Pathways in Chronic Disease. Available at  www.ohdsi.org/web/wiki/doku.php?id=research:treatment_pathways_in_chronic_disease. Accessed June 1, 2015)</Citation></Reference><Reference><Citation>Venables WN, Smith DM. R Development Core Team 2009. An Introduction to R (Network Theory Limited, Bristol, UK)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27418432</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association.</ArticleTitle><Pagination><StartPage>973</StartPage><EndPage>981</EndPage><MedlinePgn>973-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.4065</ELocationID><Abstract><AbstractText Label="BACKGROUND">We reviewed the results of the Observational Medical Outcomes Research Partnership (OMOP) 2010 Experiment in hopes of finding examples where apparently well-designed drug studies repeatedly produce anomalous findings. OMOP had applied thousands of designs and design parameters to 53 drug-outcome pairs across 10 electronic data resources. Our intent was to use this repository to elucidate some sources of error in observational studies.</AbstractText><AbstractText Label="METHOD">From the 2010 OMOP Experiment, we sought drug-outcome-method combinations (DOMCs) that met consensus design criteria, yet repeatedly produced results contrary to expectation. We set aside DOMCs for which we could not agree on the suitability of the designs, then selected for an in-depth scrutiny one drug-outcome pair analyzed by a seemingly plausible methodological approach, whose results consistently disagreed with the a priori expectation.</AbstractText><AbstractText Label="RESULTS">The OMOP "all-by-all" assessment of possible DOMCs yielded many combinations that would not be chosen by researchers as actual study options. Among those that passed a first level of scrutiny, two of seven drug-outcome pairs for which there were plausible research designs had anomalous results. The use of benzodiazepines was unexpectedly associated with acute renal failure and upper gastrointestinal bleeding. We chose the latter as an example for in-depth study. The factitious appearance of a bleeding risk may have been partly driven by an excess of procedures on the first day of treatment. A risk window definition that excluded the first day largely removed the spurious association.</AbstractText><AbstractText Label="CONCLUSION">One cause of reproducible "error" may be repeated failure to tie design choices closely enough to the research question at hand. Copyright &#xa9; 2016 John Wiley &amp; Sons, Ltd.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reagan-Udall Foundation for the FDA, Innovation in Medical Evidence Development and Surveillance, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakravarty</LastName><ForeName>Aloka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckbert</LastName><ForeName>Susan R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levenson</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Office of the Center Director, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Biostatistics Unit, Group Health Research Institute, Department of Biostatistics, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinheiro</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>RWE Systems, IMS Health, Burlington, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toh</LastName><ForeName>Sengwee</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Alexander M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>WHISCON, Newton, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">insurance claim data</Keyword><Keyword MajorTopicYN="N">medical product safety</Keyword><Keyword MajorTopicYN="N">monitoring</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27418432</ArticleId><ArticleId IdType="doi">10.1002/pds.4065</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">27592566</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-0258</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>22</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Statistics in medicine</Title><ISOAbbreviation>Stat Med</ISOAbbreviation></Journal><ArticleTitle>Robust empirical calibration of p-values using observational data.</ArticleTitle><Pagination><StartPage>3883</StartPage><EndPage>3888</EndPage><MedlinePgn>3883-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/sim.6977</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, NJ, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, NJ, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biomathematics and Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HG006139</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Med</MedlineTA><NlmUniqueID>8215016</NlmUniqueID><ISSNLinking>0277-6715</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Stat Med. 2016 Sep 30;35(22):3869-82. doi: 10.1002/sim.6936.</RefSource><PMID Version="1">26970249</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="Y">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="Y">Data Interpretation, Statistical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27592566</ArticleId><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="doi">10.1002/sim.6977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p&#x2010;values. Statistics in Medicine 2014; 33:209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber S, Tchetgen Tchetgen E. Limitations of empirical calibration of p&#x2010;values using observational data. Statistics in Medicine 2016; 35(22):3869&#x2013;3882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5012943</ArticleId><ArticleId IdType="pubmed">26970249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Safety 2013; 36(Suppl 1):S59&#x2013;S72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruns SB, Ioannidis JP. p&#x2010;Curve and p&#x2010;hacking in observational research. PLoS One 2016; 11:e0149144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4757561</ArticleId><ArticleId IdType="pubmed">26886098</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27600407</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>GIST 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies.</ArticleTitle><Pagination><StartPage>325</StartPage><EndPage>336</EndPage><MedlinePgn>325-336</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2016.09.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(16)30115-0</ELocationID><Abstract><AbstractText>The design of randomized controlled clinical studies can greatly benefit from iterative assessments of population representativeness of eligibility criteria. We propose a multi-trait metric - GIST 2.0 that can compute the a priori generalizability based on the population representativeness of a clinical study by explicitly modeling the dependencies among all eligibility criteria. We evaluate this metric on twenty clinical studies of two diseases and analyze how a study's eligibility criteria affect its generalizability (collectively and individually). We statistically analyze the effects of trial setting, trait selection and trait summarizing technique on GIST 2.0. Finally we provide theoretical as well as empirical validations for the expected properties of GIST 2.0.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>Anando</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY 10032, United States. Electronic address: as5050@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarti</LastName><ForeName>Shreya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY 10032, United States. Electronic address: sc4025@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY 10032, United States; Department of Medicine, New York University, New York NY 10016, United States. Electronic address: ag3304@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Columbia University, New York, NY 10032, United States. Electronic address: sw2206@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY 10032, United States; Janssen Research and Development, Titusville, NJ 08560, United States. Electronic address: ryan@ohdsi.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY 10032, United States. Electronic address: cw2384@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008680</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000040</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Eligibility criteria</Keyword><Keyword MajorTopicYN="N">Generalizability</Keyword><Keyword MajorTopicYN="N">Population representativeness</Keyword><Keyword MajorTopicYN="N">Trait dependencies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27600407</ArticleId><ArticleId IdType="mid">NIHMS817522</ArticleId><ArticleId IdType="pmc">PMC5077682</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2016.09.003</ArticleId><ArticleId IdType="pii">S1532-0464(16)30115-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Green LW, Glasgow RE. Evaluating the relevance, generalization, and applicability of research issues in external validation and translation methodology. Evaluation &amp; the Health Professions. 2006;29(1):126&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16510882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Ganguli M. Generalizability the trees, the forest, and the low-hanging fruit. Neurology. 2012;78(23):1886&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3369519</ArticleId><ArticleId IdType="pubmed">22665145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey A. What researchers mean by generalizability. At Work. 2006;45:2.</Citation></Reference><Reference><Citation>Weng C, Tu S, Sim I, Richesson R. Formal representation of eligibility criteria: A literature review. Journal of Biomedical Informatics. 2010;43(3):451&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878905</ArticleId><ArticleId IdType="pubmed">20034594</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker N, Gool WAV. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. The Lancet Neurology. 2004;3:627&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380160</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Americal Heart Journal. 2003;146:250&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, Weng C. Identification of questionable exclusion criteria in mental disorder clinical trials using a medical encyclopedia. Pacific Symposium on Biocomputing. 2016;21:219&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4717913</ArticleId><ArticleId IdType="pubmed">26776188</ArticleId></ArticleIdList></Reference><Reference><Citation>Musen M, Rohn J, Fagan L, Shortliffe E. Knowledge engineering for a clinical trial advice system: Uncovering errors in protocol specification. Bulletin du Cancer. 1987;74(3):291&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">3620734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross J, Tu S, CS, Sim I. Analysis of eligibility criteria complexity in clinical trials. AMIA Summits Translational Science Proceedings; 2010. pp. 46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041539</ArticleId><ArticleId IdType="pubmed">21347148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T, Rusanov A, Boland M, Weng C. Clustering clinical trials with similar eligibility criteria features. Journal of Biomedical Informatics. 2014;52:112&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119097</ArticleId><ArticleId IdType="pubmed">24496068</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin D, Gennari J, Musen M. Knowledge representation and tool support for critiquing clinical trial protocols. Proceedings of AMIA Annual Symposium; 2000. pp. 724&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243914</ArticleId><ArticleId IdType="pubmed">11079979</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan AL, Hudgens MG, Cole SR, Mollan K, Sax PE, Daar E, Adimora AA, Eron J, Mugavero M. Generalizing evidence from randomized trials using inverse probability of sampling weights. tech rep. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289264</ArticleId><ArticleId IdType="pubmed">30555215</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C. Optimizing clinical research participant selection with informatics. Trends in pharmacological sciences. 2015;36(11):706&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4686428</ArticleId><ArticleId IdType="pubmed">26549161</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Ryan P, Hoxha J, Wang S, Carini S, Sim I, Weng C. Multivariate analysis of the population representativeness of related clinical studies. Journal of Biomedical Informatics. 2016;60:66&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4837055</ArticleId><ArticleId IdType="pubmed">26820188</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16(1):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632358</ArticleId><ArticleId IdType="pubmed">26530985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bress AP, Tanner RM, MPH, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of results from the systolic blood pressure intervention trial (SPRINT) to the us adult population. Journal of the American College of Cardiology. 2016;67(5):463&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237387</ArticleId><ArticleId IdType="pubmed">26562046</ArticleId></ArticleIdList></Reference><Reference><Citation>Pressler TR, Kaizar EE. The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias. Statistics in Medicine. 2013;32:3552&#x2013;3568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967586</ArticleId><ArticleId IdType="pubmed">23553373</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhouse JB, Kaizar EE, Kelleher K, Seltman H, Gardner W. Generalizing from clinical trial data: A case study. the risk of suicidality among pediatric antidepressant users. Statistics in Medicine. 2008;27:1801&#x2013;1813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963861</ArticleId><ArticleId IdType="pubmed">18381709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Lubsen-Derksen G, Grobbee DE, Moons KG. External validation is necessary in prediction research: A clinical example. Journal of Clinical Epidemiology. 2003;56(9):826&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505766</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TS, Hellkamp AS, Patel CB, Ezekowitz JA, Fonarow GC, Hernandez AF. Representativeness of relax-ahf clinical trial population in acute heart failure. Circulation: Cardiovascular Quality and Outcomes. 2014;7(2):259&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">24594552</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target populations the actg 320 trial. American journal of epidemiology. 2010;172(1):107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2915476</ArticleId><ArticleId IdType="pubmed">20547574</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Li Y, Ryan P, Zhang Y, Liu F, Gao J, Bigger J, Hripcsak G. A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records. Applied Clinical Informatics. 2014;5(2):463&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081748</ArticleId><ArticleId IdType="pubmed">25024761</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Chander P, Ryan P, Weng C. Simulation-based evaluation of the generalizability index for study traits. AMIA Annual Symposium Proceedings; 2015. pp. 594&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765558</ArticleId><ArticleId IdType="pubmed">26958194</ArticleId></ArticleIdList></Reference><Reference><Citation> [Accessed: 2016-02-16];External validity.   https://en.wikipedia.org/wiki/Externalvalidity.</Citation></Reference><Reference><Citation>Saeed M, Villarroel M, Reisner AT, Clifford G, Lehman LW, Moody G, Heldt T, Kyaw TH, Moody B, Mark RG. Multi-parameter intelligent monitoring in intensive care II (MIMIC-II): A public-access intensive care unit database. Critical care medicine. 2011;39(5):952&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124312</ArticleId><ArticleId IdType="pubmed">21283005</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Hripcsak G, Swaminathan S, Weng C. Defining and measuring completeness of electronic health records for secondary use. Journal of Biomedical Informatics. 2013;46:830&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810243</ArticleId><ArticleId IdType="pubmed">23820016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T, Liu H, Weng C. Valx: A system for extracting and structuring numeric lab test comparison statements from text. Methods of information in medicine. 2016;55(3):266&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573874</ArticleId><ArticleId IdType="pubmed">26940748</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard AF, McIntyre A, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut. 2000;46(suppl 4):iv1&#x2013;iv5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766761</ArticleId><ArticleId IdType="pubmed">10862605</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SB. Generic data modeling for clinical repositories. Journal of the American Medical Informatics Association. 1996;3(5):328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC116317</ArticleId><ArticleId IdType="pubmed">8880680</ArticleId></ArticleIdList></Reference><Reference><Citation>Fort D, Weng C, Bakken S, Wilcox AB. Considerations for using research data to verify clinical data accuracy. AMIA Summits on Translational Science Proceedings; 2014; 2014. p. 211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333689</ArticleId><ArticleId IdType="pubmed">25717415</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson M, Weng C. Desiderata for major eligibility criteria in breast cancer trials. AMIA Annual Symposium Proceedings; 2015. pp. 2025&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765677</ArticleId><ArticleId IdType="pubmed">26958302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukey JW. Comparing individual means in the analysis of variance. Biometrics. 1949;5(2):99&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">18151955</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. Journal of the american statistical association. 1937;32(200):675&#x2013;701.</Citation></Reference><Reference><Citation>Sen A, Ryan P, Goldstein A, Chakrabarti S, Wang S, Weng C. Assessing eligibility criteria generalizability and their correlations with adverse events using big data for ehrs and clinical trials. Proceedings of the Data Science Learning and Applications to Biomedical and Health Sciences Conference (Big Data Workshop organized by New York Academy of Sciences); 2016. pp. 74&#x2013;79.</Citation></Reference><Reference><Citation>Huang LW, Inouye SK, Jones RN, Fong TG, Rudolph JL, O&#x2019;Connor MG, Metzger ED, Crane PK, Marcantonio ER. Identifying indicators of important diagnostic features of delirium. Journal of the American Geriatrics Society. 2012;60(6):1044&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3376010</ArticleId><ArticleId IdType="pubmed">22690980</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf N, Rusanov A, Weng C. Sick patients have more data: the non-random completeness of electronic health records. AMIA Annual Symposium Proceedings; 2013. pp. 1472&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900159</ArticleId><ArticleId IdType="pubmed">24551421</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren L, Zhu D, Wei Y, Pan X, Liang L, Xu J, Zhong Y, Xue Z, Jin L, Zhan S, et al. Enhanced recovery after surgery (eras) program attenuates stress and accelerates recovery in patients after radical resection for colorectal cancer: a prospective randomized controlled trial. World journal of surgery. 2012;36(2):407&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">22102090</ArticleId></ArticleIdList></Reference><Reference><Citation>Vira T, Colquhoun M, Etchells E. Reconcilable differences: correcting medication errors at hospital admission and discharge. Quality and Safety in Health Care. 2006;15(2):122&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2464829</ArticleId><ArticleId IdType="pubmed">16585113</ArticleId></ArticleIdList></Reference><Reference><Citation>Idorn T, Knop FK, J&#xf8;rgensen MB, Jensen T, Resuli M, Hansen PM, Christensen KB, Holst JJ, Hornum M, Feldt-Rasmussen B. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes care. 2016;39(2):206&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">26283739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27713905</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2327-9214</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>EGEMS (Washington, DC)</Title><ISOAbbreviation>EGEMS (Wash DC)</ISOAbbreviation></Journal><ArticleTitle>A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data.</ArticleTitle><Pagination><StartPage>1244</StartPage><MedlinePgn>1244</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1244</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Harmonized data quality (DQ) assessment terms, methods, and reporting practices can establish a common understanding of the strengths and limitations of electronic health record (EHR) data for operational analytics, quality improvement, and research. Existing published DQ terms were harmonized to a comprehensive unified terminology with definitions and examples and organized into a conceptual framework to support a common approach to defining whether EHR data is 'fit' for specific uses.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">DQ publications, informatics and analytics experts, managers of established DQ programs, and operational manuals from several mature EHR-based research networks were reviewed to identify potential DQ terms and categories. Two face-to-face stakeholder meetings were used to vet an initial set of DQ terms and definitions that were grouped into an overall conceptual framework. Feedback received from data producers and users was used to construct a draft set of harmonized DQ terms and categories. Multiple rounds of iterative refinement resulted in a set of terms and organizing framework consisting of DQ categories, subcategories, terms, definitions, and examples. The harmonized terminology and logical framework's inclusiveness was evaluated against ten published DQ terminologies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Existing DQ terms were harmonized and organized into a framework by defining three DQ categories: (1) Conformance (2) Completeness and (3) Plausibility and two DQ assessment contexts: (1) Verification and (2) Validation. Conformance and Plausibility categories were further divided into subcategories. Each category and subcategory was defined with respect to whether the data may be verified with organizational data, or validated against an accepted gold standard, depending on proposed context and uses. The coverage of the harmonized DQ terminology was validated by successfully aligning to multiple published DQ terminologies.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Existing DQ concepts, community input, and expert review informed the development of a distinct set of terms, organized into categories and subcategories. The resulting DQ terms successfully encompassed a wide range of disparate DQ terminologies. Operational definitions were developed to provide guidance for implementing DQ assessment procedures. The resulting structure is an inclusive DQ framework for standardizing DQ assessment and reporting. While our analysis focused on the DQ issues often found in EHR data, the new terminology may be applicable to a wide range of electronic health data such as administrative, research, and patient-reported data.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A consistent, common DQ terminology, organized into a logical framework, is an initial step in enabling data owners and users, patients, and policy makers to evaluate and communicate data quality findings in a well-defined manner with a shared vocabulary. Future work will leverage the framework and terminology to develop reusable data quality assessment and reporting methods.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Tiffany J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnard</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauck</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Northwest.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harvard Pilgrim Health Care Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Bruce N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Hoag Memorial Hospital Presbyterian.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estiri</LastName><ForeName>Hossein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Washington, Institute of Translational Health Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goerg</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holve</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>AcademyHealth.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>University of Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liaw</LastName><ForeName>Siaw-Teng</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>UNSW School of Public Health &amp; Community Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton-Lopez</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Academy of Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Southern California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Toan C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>National Academy of Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research and Development.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiskopf</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Oregon Health &amp; Science University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zozus</LastName><ForeName>Meredith N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>University of Arkansas for Medical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Academy of Sciences.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EGEMS (Wash DC)</MedlineTA><NlmUniqueID>101629606</NlmUniqueID><ISSNLinking>2327-9214</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data completeness</Keyword><Keyword MajorTopicYN="N">data use &amp; quality</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27713905</ArticleId><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="doi">10.13063/2327-9214.1244</ArticleId><ArticleId IdType="pii">egems1244</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sanson-Fisher RW, Bonevski B, Green LW, D&#x2019;Este C. Limitations of the randomized controlled trial in evaluating population-based health interventions. Am J Prev Med. 2007 Aug;33(2):155&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">17673104</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran C, Bloomrosen M, Hammond WE, Labkoff S, Markel-Fox S, Tang PC, et al. Toward a National Framework for the Secondary Use of Health Data: An American Medical Informatics Association White Paper. J Am Med Inform Assoc. 2007 Jan 1;14(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329823</ArticleId><ArticleId IdType="pubmed">17077452</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MG, Embi PJ. Toward Reuse of Clinical Data for Research and Quality Improvement: The End of the Beginning? Annals of Internal Medicine. 2009;151(5):359&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez MH, Holve E, Sarkar IN, Segal C. Building the informatics infrastructure for Comparative Effectiveness Research (CER): A review of the literature. Medical care. 2012 Jul;50(Suppl):S38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692258</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality. J Am Med Inform Assoc. 2014 May 12;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078299</ArticleId><ArticleId IdType="pubmed">24821744</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace WD, Cifuentes M, Valuck RJ, Staton EW, Brandt EC, West DR. An electronic practice-based network for observational comparative effectiveness research. Ann Intern Med. 2009 Sep 1;151(5):338&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638402</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Medical care. 2010;48(6):S45&#x2013;S51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20473204</ArticleId></ArticleIdList></Reference><Reference><Citation>Randhawa GS, Slutsky JR. Building sustainable multi-functional prospective electronic clinical data systems. Med Care. 2012 Jul;50(Suppl):S3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692255</ArticleId></ArticleIdList></Reference><Reference><Citation>Randhawa GS. Building electronic data infrastructure for comparative effectiveness research: accomplishments, lessons learned and future steps. J Comp Eff Res. 2014 Nov;3(6):567&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">25494561</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc. 2014 May 12;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis LH, Brown J, Platt R. Four Health Data Networks Illustrate The Potential For A Shared National Multipurpose Big-Data Network. Health Affairs. 2014 Jul 1;33(7):1178&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh WR. Adding value to the electronic health record through secondary use of data for quality assurance, research, and surveillance. Am J Manag Care. 2007 Jun;13(6 Part 1):277&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17567224</ArticleId></ArticleIdList></Reference><Reference><Citation>Immanuel V, Johnson K, Young B, Hart G. Testimony on secondary uses of health data to the National Committee on Vital and Health Statistics. 2007</Citation></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J Am Med Inform Assoc. 2010 Mar 1;17(2):124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Chute CG, Pathak J, Savova GK, Bailey KR, Schor MI, Hart LA, et al. The SHARPn project on secondary use of Electronic Medical Record data: Progress, plans, and possibilities. AMIA. Annual Symposium proceedings/AMIA Symposium AMIA Symposium. 2011;2011:248&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243296</ArticleId><ArticleId IdType="pubmed">22195076</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer K, Gall W. Utilizing IHE-based Electronic Health Record systems for secondary use. Methods of information in medicine. 2011;50:319&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21431246</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth C, Shivade CP, Foraker RE, Embi PJ. Integrating population- and patient-level data for secondary use of electronic health records to study overweight and obesity. Stud Health Technol Inform. 2013;192:1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">23920874</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EK, Broder-Fingert S, Tanpowpong P, Bickel J, Lightdale JR, Nelson CP. Use of the i2b2 research query tool to conduct a matched case&#x2013;control clinical research study: advantages, disadvantages and methodological considerations. BMC Med Res Methodol. 2014 Jan 30;14:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3909388</ArticleId><ArticleId IdType="pubmed">24479726</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmer KG, Ambite JL, Ames J, Ananthakrishnan R, Burns G, Chervenak AL, et al. Enabling collaborative research using the Biomedical Informatics Research Network (BIRN) Journal of the American Medical Informatics Association : JAMIA. 2011 Jul;18:416&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128398</ArticleId><ArticleId IdType="pubmed">21515543</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurry AJ, Murphy SN, MacFadden D, Weber G, Simons WW, Orechia J, et al. SHRINE: Enabling Nationally Scalable Multi-Site Disease Studies. PLoS ONE. 2013 Mar 7;8(3):e55811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591385</ArticleId><ArticleId IdType="pubmed">23533569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross TR, Ng D, Brown JS, Pardee R, Hornbrook MC, Hart G, et al.  The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. eGEMs (Generating Evidence &amp; Methods to improve patient outcomes) [Internet] 2014. Mar 24,  [cited 2014 Apr 16];2(1). Available from:  http://repository.academyhealth.org/egems/vol2/iss1/2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371424</ArticleId><ArticleId IdType="pubmed">25848584</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH Collaboratory Health Care Systems Research Collaboratory home page [Internet]   [cited 2016 Jun 8]. Available from:  https://www.nihcollaboratory.org/about-us/Pages/default.aspx.</Citation></Reference><Reference><Citation>De Moor G, Sundgren M, Kalra D, Schmidt A, Dugas M, Claerhout B, et al. Using electronic health records for clinical research: the case of the EHR4CR project. J Biomed Inform. 2015 Feb;53:162&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">25463966</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lei J. Use and abuse of computer-stored medical records. Methods Inf Med. 1991 Apr;30(2):79&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1857252</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan PF, Stead WW. Assessing data quality: from concordance, through correctness and completeness, to valid manipulatable representations. J Am Med Inform Assoc. 2000 Jan;7:106&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61460</ArticleId><ArticleId IdType="pubmed">10641968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Eliason BB, Bathurst J. Quantifying clinical data quality using relative gold standards. AMIA. Annual Symposium proceedings / AMIA Symposium AMIA Symposium. 2010;2010:356&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041459</ArticleId><ArticleId IdType="pubmed">21347000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh WR, Weiner MG, Embi PJ, Logan JR, Payne PRO, Bernstam EV, et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care. 2013 Aug;51(8 Suppl 3):S30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748381</ArticleId><ArticleId IdType="pubmed">23774517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan WR, Wagner MM. Accuracy of data in computer-based patient records. J Am Med Inform Assoc. 1997 Oct;4(5):342&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61252</ArticleId><ArticleId IdType="pubmed">9292840</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronsky D, Haug PJ. Assessing the quality of clinical data in a computer-based record for calculating the pneumonia severity index. J Am Med Inform Assoc. 2000 Feb;7(1):55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61455</ArticleId><ArticleId IdType="pubmed">10641963</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts D, de Keizer N, Scheffer G-J, de Jonge E. Quality of data collected for severity of illness scores in the Dutch National Intensive Care Evaluation (NICE) registry. Intensive Care Med. 2002 May;28(5):656&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12029418</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiru K, Hassey A, Sullivan F. Systematic review of scope and quality of electronic patient record data in primary care. BMJ. 2003 May 15;326(7398):1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155692</ArticleId><ArticleId IdType="pubmed">12750210</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan S, Padman R. Analyzing the effect of data quality on the accuracy of clinical decision support systems: a computer simulation approach. AMIA Annu Symp Proc. 2006:324&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839724</ArticleId><ArticleId IdType="pubmed">17238356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Correia RJ, Rodrigues P, Freitas A, Almeida FC, Chen R, Costa-Pereira A. Data quality and integration issues in electronic health records. In: Hristidis V, editor. Information discovery on electronic health records. Chapman and Hall/CRC; 2009. pp. 55&#x2013;95.</Citation></Reference><Reference><Citation>Botsis T, Hartvigsen G, Chen F, Weng C. Secondary use of EHR: Data quality issues and informatics opportunities. AMIA Summits on Translational Science proceedings AMIA Summit on Translational Science. 2010;2010:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041534</ArticleId><ArticleId IdType="pubmed">21347133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton G. Bias associated with mining electronic health records. J Biomed Discov Collab. 2011;6:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149555</ArticleId><ArticleId IdType="pubmed">21647858</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Kahn M, Toh S. Data quality assessment for comparative effectiveness research in distributed data networks. Medical care. 2013;51:S22&#x2013;S29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306391</ArticleId><ArticleId IdType="pubmed">23793049</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusanov A, Weiskopf NG, Wang S, Weng C. Hidden in plain sight: bias towards sick patients when sampling patients with sufficient electronic health record data for research. BMC Med Inform Decis Mak. 2014;14:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4062889</ArticleId><ArticleId IdType="pubmed">24916006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Ranade D. The impact of electronic medical records data sources on an adverse drug event quality measure. J Am Med Inform Assoc. 2010 Mar 1;17(2):185&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000787</ArticleId><ArticleId IdType="pubmed">20190062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KS, Fowles JB, Weiner JP. Electronic Health Records and Reliability and Validity of Quality Measures: A Review of the Literature. Medical Care Research and Review [Internet] 2010. Feb,  [cited 2010 Jul 6]; Available from:  http://0-mcr.sagepub.com.impulse.ucdenver.edu/cgi/rapidpdfsidebar/1077558709359007v1?&amp;frameset_url=http%3A%2F%2Fmcr.sagepub.com%2Fcgi%2Frapidpdf%2F1077558709359007v1.</Citation><ArticleIdList><ArticleId IdType="pubmed">20150441</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons A, McCullough C, Wang J, Shih S. Validity of electronic health record-derived quality measurement for performance monitoring. Journal of the American Medical Informatics Association. 2012 Jul 1;19(4):604&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384112</ArticleId><ArticleId IdType="pubmed">22249967</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Chun A, Davidson BN, Holve E, Kahn MG, Hamilton Lopez M, et al. Recommendations for transparent reporting of data quality assessment results for observational healthcare data. eGEMs (Generating Evidence &amp; Methods to improve patient outcomes) 2015. accepted for publication;</Citation></Reference><Reference><Citation>Wang R, Strong D. Beyond accuracy: What data quality means to data consumers. J Management Information Systems. 1996;12:5&#x2013;34.</Citation></Reference><Reference><Citation>Redman TC. Data Quality: The Field Guide. Boston: Digital Press; 2001. p. 241.</Citation></Reference><Reference><Citation>Kahn MG, Raebel MA, Glanz JM, Riedlinger K, Steiner JF. A pragmatic framework for single-site and multisite data quality assessment in electronic health record-based clinical research. Medical care. 2012 Jul;50(Suppl):S21&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833692</ArticleId><ArticleId IdType="pubmed">22692254</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. Journal of the American Medical Informatics Association : JAMIA. 2013 Jan 1;20:144&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaw ST, Rahimi A, Ray P, Taggart J, Dennis S, de Lusignan S, et al. Towards an ontology for data quality in integrated chronic disease management: A realist review of the literature. International Journal of Medical Informatics. 2013 Jan;82(1):10&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23122633</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadiq S, editor. Handbook of Data Quality. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013.</Citation></Reference><Reference><Citation>Weiskopf NG, Hripcsak G, Swaminathan S, Weng C. Defining and measuring completeness of electronic health records for secondary use. J Biomed Inform. 2013 Oct;46(5):830&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810243</ArticleId><ArticleId IdType="pubmed">23820016</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi A, Liaw S-T, Ray P, Taggart J, Yu H. Ontological specification of quality of chronic disease data in EHRs to support decision analytics: a realist review. Decision Analytics. 2014 Feb 19;1(1):5.</Citation></Reference><Reference><Citation>Zozus MN, Hammond WE, Green BB, Kahn MG, Richesson RL, Rusincovitch SA, et al.  Assessing Data Quality for Healthcare Systems Data Used in Clinical Research (Version 1.0) [Internet]  [cited 2014 Sep 13] Available from:  http://sites.duke.edu/rethinkingclinicaltrials/assessing-data-quality/</Citation></Reference><Reference><Citation>Johnson SG, Speedie S, Simon G, Kumar V, Westra BL. A Data Quality Ontology for the Secondary Use of EHR Data. Proceedings 2015 American Medical Informatics Association Fall Symposium; San Francisco, CA. accepted for publication.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765682</ArticleId><ArticleId IdType="pubmed">26958293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Brown J, Chun A, Davidson B, Meeker D, Ryan P, et al.  Transparent Reporting of Data Quality in Distributed Data Networks. eGEMs (Generating Evidence &amp; Methods to improve patient outcomes) [Internet] 2015 Mar 23;3(1) Available from:  http://repository.academyhealth.org/egems/vol3/iss1/7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434997</ArticleId><ArticleId IdType="pubmed">25992385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mini-Sentinel Coordinating Center  Mini-Sentinel Standard Operating Procedure: Data Quality Checking and Profiling. 20 Available from:  http://www.mini-sentinel.org/work_products/About_Us/Mini-Sentinel_SOP_Data-Quality-Checking-and-Profiling.pdf.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership  OSCAR - Observational Source Characteristics Analysis Report (OSCAR) Design Specification and Feasibility Assessment [Internet] 2011.  [cited 2013 Apr 1]. Available from:  http://omop.fnih.org/OSCAR.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership  Generalized Review of OSCAR Unified Checking [Internet] 2011.  [cited 2013 Apr 1]. Available from:  http://omop.fnih.org/GROUCH.</Citation></Reference><Reference><Citation>Canadian Institute for Health Information  . The CIHI data quality framework [Internet] Ottawa, Ont.: CIHI; 2009.  Available from:  http://www.cihi.ca/CIHI-ext-portal/pdf/internet/DATA_QUALITY_FRAMEWORK_2009_EN.</Citation></Reference><Reference><Citation>Nahm M. Data quality in clinical research In: Clinical Research Informatics. London: Springer-Verlag; 2012. pp. 175&#x2013;201. (Health Informatics).</Citation></Reference><Reference><Citation>Maydanchik A. Data quality assessment. Bradley Beach, NJ: Technics Publications; 2007. p. xiv.p. 321. (Data quality for practitioners series).</Citation></Reference><Reference><Citation>Magnusson D, Bergman LR. European Network on Longitudinal Studies on Individual Development Data quality in longitudinal research Cambridge [England] New York: Cambridge University Press; 1990. p. xii.p. 285.</Citation></Reference><Reference><Citation>Singh S. Evaluation of data quality. [London, England]: International Statistical Institute by Oxford University Press; 1987. pp. 618&#x2013;643.</Citation></Reference><Reference><Citation>Little RJ, Rubin DB. Statistical Analysis with Missing Data. 2nd Ed. New York, N.Y: Wiley; 2002. (Series in probability and statistics; Vol. 1).</Citation></Reference><Reference><Citation>Haziza D.  Imputation and Inference in the Presence of Missing Data. In: Rao CR, editor. Handbook of Statistics [Internet] New York, N.Y: Elsevier; 2009. pp. 215&#x2013;46. [cited 2013 May 6]. Available from:  http://www.sciencedirect.com/science/article/pii/S0169716108000102.</Citation></Reference><Reference><Citation>Donders ART, van der Heijden GJMG, Stijnen T, Moons KGM. Review: A gentle introduction to imputation of missing values. Journal of Clinical Epidemiology. 2006 Oct;59(10):1087&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980149</ArticleId></ArticleIdList></Reference><Reference><Citation>McGilvray D. Executing Data Quality Projects: Ten Steps to Quality Data and Trusted Information. 1 edition. Amsterdam; Boston: Morgan Kaufmann; 2008. p. 352.</Citation></Reference><Reference><Citation>Eppler M, Helfert M. A Classification and Analysis of Data Quality Costs. Miami; Florida, USA: 2004.</Citation></Reference><Reference><Citation>Juran JM, Godfrey AB, editors. Juran&#x2019;s quality handbook. 5th ed. New York: McGraw Hill; 1999. p. 1. (McGraw-Hill handbooks).</Citation></Reference><Reference><Citation>International Organization for Standardization Accuracy (trueness and precision) of measurement methods and results-Part 1: General principles and definitions. ISO. 1994. Report No.: ISO 5725-1.</Citation></Reference><Reference><Citation>Menditto A, Patriarca M, Magnusson B. Understanding the meaning of accuracy, trueness and precision. Accreditation and Quality Assurance. 2007 Jan 9;12(1):45&#x2013;7.</Citation></Reference><Reference><Citation>Johnson KE, Kamineni A, Fuller S, Olmstead D, Wernli KJ. How the Provenance of Electronic Health Record Data Matters for Research: A Case Example Using System Mapping. eGEMs (Generating Evidence &amp; Methods to improve patient outcomes) [Internet] 2014. Apr 16,  [cited 2016 Mar 13];2(1). Available from:  http://repository.edm-forum.org/egems/vol2/iss1/4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371416</ArticleId><ArticleId IdType="pubmed">25821838</ArticleId></ArticleIdList></Reference><Reference><Citation>Creswell JW. Qualitative, Quantitative, Mixed Methods Approaches (Crewell, Research Design: Qualitative, Quantitative, and Mixed Methods Approaches) 4th edition. Thousand Oaks, California: SAGE Publications, Inc; 2013. p. 273. Fourth Edition edition.</Citation></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Medical care. 2012 Jul;50(Suppl):S60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI)  ACHILLES for data characterization | OHDSI [Internet]  [cited 2015 Jul 6]. Available from:  http://www.ohdsi.org/analytic-tools/achilles-for-data-characterization/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27764192</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.</ArticleTitle><Pagination><StartPage>e0164972</StartPage><MedlinePgn>e0164972</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0164972</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0164972</ELocationID><Abstract><AbstractText>Pre-emptive pharmacogenomic (PGx) testing of a panel of genes may be easier to implement and more cost-effective than reactive pharmacogenomic testing if a sufficient number of medications are covered by a single test and future medication exposure can be anticipated. We analysed the incidence of exposure of individual patients in the United States to multiple drugs for which pharmacogenomic guidelines are available (PGx drugs) within a selected four-year period (2009-2012) in order to identify and quantify the incidence of pharmacotherapy in a nation-wide patient population that could be impacted by pre-emptive PGx testing based on currently available clinical guidelines. In total, 73 024 095 patient records from private insurance, Medicare Supplemental and Medicaid were included. Patients enrolled in Medicare Supplemental age &gt; = 65 or Medicaid age 40-64 had the highest incidence of PGx drug use, with approximately half of the patients receiving at least one PGx drug during the 4 year period and one fourth to one third of patients receiving two or more PGx drugs. These data suggest that exposure to multiple PGx drugs is common and that it may be beneficial to implement wide-scale pre-emptive genomic testing. Future work should therefore concentrate on investigating the cost-effectiveness of multiplexed pre-emptive testing strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Samwald</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4855-2571</Identifier><AffiliationInfo><Affiliation>Section for Artificial Intelligence and Decision Support; Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Section for Artificial Intelligence and Decision Support; Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blagec</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Section for Artificial Intelligence and Decision Support; Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Empey</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>College of Pharmacy, University of Arizona, Tucson, Arizona, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Seid Mussa</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, College of public health and medical sciences, Jimma University, Jimma, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section for Artificial Intelligence and Decision Support; Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG044433</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR000146</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011838</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071185" MajorTopicYN="Y">Pharmacogenomic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>PR is an employee of Janssen Research and Development. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27764192</ArticleId><ArticleId IdType="pmc">PMC5072717</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0164972</ArticleId><ArticleId IdType="pii">PONE-D-16-27304</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>US Department of Health and Human Services. National action plan for adverse drug event prevention. Washington, DC. 2014;</Citation></Reference><Reference><Citation>Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annu Rev Pharmacol Toxicol. 2015;55: 89&#x2013;106. 10.1146/annurev-pharmtox-010814-124835</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010814-124835</ArticleId><ArticleId IdType="pmc">PMC4607278</ArticleId><ArticleId IdType="pubmed">25292429</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SG, Gruntowicz D, Chua T, Morlock RJ. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention. J Manag Care Spec Pharm. 2015;21: 552&#x2013;557. 10.18553/jmcp.2015.21.7.552</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2015.21.7.552</ArticleId><ArticleId IdType="pmc">PMC10398109</ArticleId><ArticleId IdType="pubmed">26108379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92: 87&#x2013;95. 10.1038/clpt.2011.371</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.371</ArticleId><ArticleId IdType="pmc">PMC3581305</ArticleId><ArticleId IdType="pubmed">22588608</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews KR, Hicks JK, Pui C- H, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92: 467&#x2013;475. 10.1038/clpt.2012.120</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.120</ArticleId><ArticleId IdType="pmc">PMC3589526</ArticleId><ArticleId IdType="pubmed">22948889</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, et al. PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014;166: 45&#x2013;55. 10.1002/ajmg.c.31391</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.c.31391</ArticleId><ArticleId IdType="pmc">PMC4056586</ArticleId><ArticleId IdType="pubmed">24619595</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet. 2014;166C: 56&#x2013;67. 10.1002/ajmg.c.31390</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.c.31390</ArticleId><ArticleId IdType="pmc">PMC4076109</ArticleId><ArticleId IdType="pubmed">24616371</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy. 2013;33: 1156&#x2013;1164. 10.1002/phar.1329</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.1329</ArticleId><ArticleId IdType="pmc">PMC3985126</ArticleId><ArticleId IdType="pubmed">23864527</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O&#x2019;Neill C, et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet. 2014;166C: 76&#x2013;84. 10.1002/ajmg.c.31396</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.c.31396</ArticleId><ArticleId IdType="pmc">PMC4066997</ArticleId><ArticleId IdType="pubmed">24616408</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95: 423&#x2013;431. 10.1038/clpt.2013.229</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.229</ArticleId><ArticleId IdType="pmc">PMC3961508</ArticleId><ArticleId IdType="pubmed">24253661</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush WS, Crosslin DR, Owusu-Obeng A, Wallace J, Almoguera B, Basford MA, et al. Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. Clin Pharmacol Ther. 2016;100: 160&#x2013;169. 10.1002/cpt.350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.350</ArticleId><ArticleId IdType="pmc">PMC5010878</ArticleId><ArticleId IdType="pubmed">26857349</ArticleId></ArticleIdList></Reference><Reference><Citation>Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther. 2012;92: 235&#x2013;242. 10.1038/clpt.2012.66</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.66</ArticleId><ArticleId IdType="pmc">PMC3785311</ArticleId><ArticleId IdType="pubmed">22739144</ArticleId></ArticleIdList></Reference><Reference><Citation>Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Curr Drug Metab. 2014;15: 209&#x2013;217. 10.2174/1389200215666140130124910</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389200215666140130124910</ArticleId><ArticleId IdType="pmc">PMC3977533</ArticleId><ArticleId IdType="pubmed">24479687</ArticleId></ArticleIdList></Reference><Reference><Citation>Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89: 464&#x2013;467. 10.1038/clpt.2010.279</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2010.279</ArticleId><ArticleId IdType="pmc">PMC3098762</ArticleId><ArticleId IdType="pubmed">21270786</ArticleId></ArticleIdList></Reference><Reference><Citation>Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: From Bench to Byte&#x2014;An Update of Guidelines. Clinical Pharmacology &amp; Therapeutics. 2011;89: 662&#x2013;673. 10.1038/clpt.2011.34</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.34</ArticleId><ArticleId IdType="pubmed">21412232</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein WS, Maglott DR, Lee JM, Kattman BL, Malheiro AJ, Ovetsky M, et al. The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res. 2013;41: D925&#x2013;935. 10.1093/nar/gks1173</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1173</ArticleId><ArticleId IdType="pmc">PMC3531155</ArticleId><ArticleId IdType="pubmed">23193275</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips MS. www.pharmaadme.org [Internet]. 2013 [cited 19 Apr 2012]. Available: http://www.pharmaadme.org/</Citation></Reference><Reference><Citation>Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics. 2010;11: 501&#x2013;505. 10.2217/pgs.10.15</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pgs.10.15</ArticleId><ArticleId IdType="pmc">PMC3098752</ArticleId><ArticleId IdType="pubmed">20350130</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Gini R, Coloma PM, Straatman H, Herings RMC, Pedersen L, et al. Replication of the OMOP Experiment in Europe: Evaluating Methods for Risk Identification in Electronic Health Record Databases. Drug Saf. 2013;36: 159&#x2013;169. 10.1007/s40264-013-0109-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0109-8</ArticleId><ArticleId IdType="pubmed">24166232</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for evidence based epidemiology. Drug Saf. 2013;36 Suppl 1: S5&#x2013;14. 10.1007/s40264-013-0102-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0102-2</ArticleId><ArticleId IdType="pubmed">24166219</ArticleId></ArticleIdList></Reference><Reference><Citation>Don Torok. OMOP Common Data Model (CDM V4.0) ETL Mapping Specification for Truven CCAE. Observational Medical Outcomes Partnership. [Internet]. 2012 [cited 24 Feb 2015]. Available: http://75.101.131.161/download/loadfile.php?docname=CCAE%20ETL%20Mapping%20V4.0</Citation></Reference><Reference><Citation>Don Torok. OMOP Common Data Model (CDM V4.0) ETL Mapping Specification for Truven MDCR. Observational Medical Outcomes Partnership [Internet]. 2012 [cited 24 Feb 2015]. Available: http://75.101.131.161/download/loadfile.php?docname=MDCR%20ETL%20Mapping%20V4.0</Citation></Reference><Reference><Citation>Mark Khayter. OMOP Common Data Model (CDM V4.0) ETL Mapping Specification for Truven MDCD 0108. Observational Medical Outcomes Partnership [Internet]. 2012 [cited 24 Feb 2015]. Available: http://75.101.131.161/download/loadfile.php?docname=MDCD%20ETL%20Mapping%20V4.0</Citation></Reference><Reference><Citation>Database queries. In: GitHub [Internet]. [cited 7 Sep 2015]. Available: purl.org/net/nlprepository/PGxQueriesIMEDS</Citation></Reference><Reference><Citation>Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18: 441&#x2013;448. 10.1136/amiajnl-2011-000116</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000116</ArticleId><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>SQL Workbench/J&#x2014;Home [Internet]. [cited 24 Feb 2015]. Available: http://www.sql-workbench.net/</Citation></Reference><Reference><Citation>Innovation in Medical Evidence Development and Surveillance (IMEDS) [Internet]. [cited 10 Nov 2014]. Available: http://imeds.reaganudall.org/</Citation></Reference><Reference><Citation>OHDSI/StudyProtocols. In: GitHub [Internet]. [cited 21 Aug 2015]. Available: https://github.com/OHDSI/StudyProtocols</Citation></Reference><Reference><Citation>Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui C- H, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update. Clinical Pharmacology &amp; Therapeutics. 2013;93: 324&#x2013;325. 10.1038/clpt.2013.4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.4</ArticleId><ArticleId IdType="pmc">PMC3604643</ArticleId><ArticleId IdType="pubmed">23422873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks J, Bishop J, Sangkuhl K, M&#xfc;ller D, Ji Y, Leckband S, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacology &amp; Therapeutics. 2015;98: 127&#x2013;134. 10.1002/cpt.147</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.147</ArticleId><ArticleId IdType="pmc">PMC4512908</ArticleId><ArticleId IdType="pubmed">25974703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks J, Bishop J, Sangkuhl K, M&#xfc;ller D, Ji Y, Leckband S, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacology &amp; Therapeutics. 2015;98: 127&#x2013;134. 10.1002/cpt.147</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.147</ArticleId><ArticleId IdType="pmc">PMC4512908</ArticleId><ArticleId IdType="pubmed">25974703</ArticleId></ArticleIdList></Reference><Reference><Citation>Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing. Clinical Pharmacology &amp; Therapeutics. 2013;94: 640&#x2013;645. 10.1038/clpt.2013.172</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.172</ArticleId><ArticleId IdType="pmc">PMC3831181</ArticleId><ArticleId IdType="pubmed">23988873</ArticleId></ArticleIdList></Reference><Reference><Citation>Gammal R, Court M, Haidar C, Iwuchukwu O, Gaur A, Alvarellos M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clinical Pharmacology &amp; Therapeutics. 2016;99: 363&#x2013;369. 10.1002/cpt.269</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.269</ArticleId><ArticleId IdType="pmc">PMC4785051</ArticleId><ArticleId IdType="pubmed">26417955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clinical Pharmacology &amp; Therapeutics. 2014;96: 423&#x2013;428. 10.1038/clpt.2014.125</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2014.125</ArticleId><ArticleId IdType="pmc">PMC4169720</ArticleId><ArticleId IdType="pubmed">24918167</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical Pharmacology &amp; Therapeutics. 2011;90: 625&#x2013;629. 10.1038/clpt.2011.185</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.185</ArticleId><ArticleId IdType="pmc">PMC3187550</ArticleId><ArticleId IdType="pubmed">21900891</ArticleId></ArticleIdList></Reference><Reference><Citation>13 M, 2013. Health Coverage by Race and Ethnicity: The Potential Impact of the Affordable Care Act [Internet]. [cited 22 Aug 2016]. Available: http://kff.org/disparities-policy/issue-brief/health-coverage-by-race-and-ethnicity-the-potential-impact-of-the-affordable-care-act/</Citation></Reference><Reference><Citation>09 M, 2016. Profile of Medicare Beneficiaries by Race and Ethnicity: A Chartpack&#x2014;Chartpack [Internet]. [cited 22 Aug 2016]. Available: http://kff.org/report-section/profile-of-medicare-beneficiaries-by-race-and-ethnicity-chartpack/</Citation></Reference><Reference><Citation>Ubiquitous Pharmacogenomics (U-PGx) | Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen [Internet]. [cited 22 Aug 2016]. Available: http://upgx.eu/</Citation></Reference><Reference><Citation>Samwald M, Adlassnig K-P. Pharmacogenomics in the pocket of every patient? A prototype based on quick response codes. J Am Med Inform Assoc. 2013;20: 409&#x2013;412. 10.1136/amiajnl-2012-001275</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-001275</ArticleId><ArticleId IdType="pmc">PMC3628061</ArticleId><ArticleId IdType="pubmed">23345409</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthias Samwald, Richard Boyce. OHDSI Research Study Homepage: Incidence of exposure to drugs for which pre-emptive pharmacogenomic testing is available [Internet]. [cited 25 Feb 2015]. Available: http://purl.org/net/drug-interaction-knowledge-base/OHDSI-PGx-incidence-protocol</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27891528</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2327-9214</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>EGEMS (Washington, DC)</Title><ISOAbbreviation>EGEMS (Wash DC)</ISOAbbreviation></Journal><ArticleTitle>Preparing Nursing Home Data from Multiple Sites for Clinical Research - A Case Study Using Observational Health Data Sciences and Informatics.</ArticleTitle><Pagination><StartPage>1252</StartPage><MedlinePgn>1252</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1252</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">A potential barrier to nursing home research is the limited availability of research quality data in electronic form. We describe a case study of converting electronic health data from five skilled nursing facilities to a research quality longitudinal dataset by means of open-source tools produced by the Observational Health Data Sciences and Informatics (OHDSI) collaborative.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Long-Term Care Minimum Data Set (MDS), drug dispensing, and fall incident data from five SNFs were extracted, translated, and loaded into version 4 of the OHDSI common data model. Quality assurance involved identifying errors using the Achilles data characterization tool and comparing both quality measures and drug exposures in the new database for concordance with externally available sources.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Records for a total 4,519 patients (95.1%) made it into the final database. Achilles identified 10 different types of errors that were addressed in the final dataset. Drug exposures based on dispensing were generally accurate when compared with medication administration data from the pharmacy services provider. Quality measures were generally concordant between the new database and Nursing Home Compare for measures with a prevalence &#x2265; 10%. Fall data recorded in MDS was found to be more complete than data from fall incident reports.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The new dataset is ready to support observational research on topics of clinical importance in the nursing home including patient-level prediction of falls. The extraction, translation, and loading process enabled the use of OHDSI data characterization tools that improved the quality of the final dataset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>University of Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handler</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>University of Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karp</LastName><ForeName>Jordan F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>University of Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perera</LastName><ForeName>Subashan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>University of Pittsburgh.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG044433</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH090333</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011838</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EGEMS (Wash DC)</MedlineTA><NlmUniqueID>101629606</NlmUniqueID><ISSNLinking>2327-9214</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">individuals who need chronic care</Keyword><Keyword MajorTopicYN="N">informatics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27891528</ArticleId><ArticleId IdType="pmc">PMC5108634</ArticleId><ArticleId IdType="doi">10.13063/2327-9214.1252</ArticleId><ArticleId IdType="pii">egems1252</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dornin J, Ferguson-Rome JC, Castle NG. Long-Term Care In an Aging Society. Morris Plains, NJ: Springer; 2015. Nursing Facilities. (Chapter 11) pp. 295&#x2013;313. (in press)</Citation></Reference><Reference><Citation>Administration on Aging Administration for Community Living . A Profile of Older Americans: 2014. Washington DC: U.S. Department of Health and Human Services; 2014.</Citation></Reference><Reference><Citation>Hardy S. Nursing Home Research. In: Newman AB, Cauley J, editors. The Epidemiology of Aging. 2012th ed. 2012.</Citation></Reference><Reference><Citation>Magaziner J, German P, Zimmerman SI, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Epidemiology of Dementia in Nursing Homes Research Group. Gerontologist. 2000;40(6):663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">11131083</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association  . Alzheimer&#x2019;s Disease Facts and Figures. Alzheimer&#x2019;s Association; 2010. 2010.   http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf. Accessed March 7, 2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">20298981</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Observational Health Data Sciences and Informatics    http://www.ohdsi.org/. Accessed May 15, 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  . National Nursing Home Survey (NNHS) Centers for Disease Control and Prevention; 2004.   http://www.cdc.gov/nchs/nnhs.htm.</Citation></Reference><Reference><Citation>Duke University. National Long Term Care Survey (NLTCS) Home Page    http://www.nltcs.aas.duke.edu/index.htm Published 2015. Accessed February 6, 2015.</Citation></Reference><Reference><Citation>AHCA  What is OSCAR Data?   http://www.ahcancal.org/research_data/oscar_data/pages/whatisoscardata.aspx. Published 2015. Accessed February 6, 2015.</Citation></Reference><Reference><Citation>Saliba D, Buchanan J. Development and validation of a revised nursing home assessment tool: MDS 3.0. Rand Corporation Health, Santa Monica. 2008</Citation></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services MDS 3.0 RAI Manual    http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/MDS30RAIManual.html. Published 2015. Accessed May 15, 2015.</Citation></Reference><Reference><Citation>Abramson EL, McGinnis S, Moore J, Kaushal R, HITEC investigators A statewide assessment of electronic health record adoption and health information exchange among nursing homes. Health Serv Res. 2014;49(1 Pt 2):361&#x2013;372. doi: 10.1111/1475-6773.12137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1475-6773.12137</ArticleId><ArticleId IdType="pmc">PMC3925407</ArticleId><ArticleId IdType="pubmed">24359612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang NM. The promise of simultaneous transformation of practice and research with the use of clinical information systems. Nursing outlook. 2008;56(5):232&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">18922275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hook ML, Devine EC, Lang NM.  Using a Computerized Fall Risk Assessment Process to Tailor Interventions in Acute Care. In: Henriksen K, Battles JB, Keyes MA, Grady ML, editors. Advances in Patient Safety: New Directions and Alternative Approaches (Vol I: Assessment) Rockville (MD): Agency for Healthcare Research and Quality; 2008.  Advances in Patient Safety.  http/www.ncbi.nlm.nih.gov/books/NBK43610/. Accessed June 11, 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">21249848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chodosh J, Edelen MO, Buchanan JL, et al. Nursing home assessment of cognitive impairment: development and testing of a brief instrument of mental status. J Am Geriatr Soc. 2008;56(11):2069&#x2013;2075. doi: 10.1111/j.1532-5415.2008.01944.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2008.01944.x</ArticleId><ArticleId IdType="pubmed">19016941</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. the index of ADL: A standardized measure of biological and psychosocial function. JAMA. 1963;185:914&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">14044222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW, L&#xf6;we B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345&#x2013;359. doi: 10.1016/j.genhosppsych.2010.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2010.03.006</ArticleId><ArticleId IdType="pubmed">20633738</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei LA, Fearing MA, Sternberg EJ, Inouye SK. The Confusion Assessment Method (CAM): A Systematic Review of Current Usage. J Am Geriatr Soc. 2008;56(5):823&#x2013;830. doi: 10.1111/j.1532-5415.2008.01674.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2008.01674.x</ArticleId><ArticleId IdType="pmc">PMC2585541</ArticleId><ArticleId IdType="pubmed">18384586</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. OHDSI/CommonDataModel    https://github.com/OHDSI/CommonDataModel. Published 2015. Accessed May 15, 2015.</Citation></Reference><Reference><Citation>OHDSI. Observational Health Data Sciences and Informatics Vocabulary Resources    http://www.ohdsi.org/data-standardization/vocabulary-resources/. Published 2015. Accessed July 9, 2015.</Citation></Reference><Reference><Citation>Liu S, Ma W, Moore R, Ganesan V, Nelson S. RxNorm: prescription for electronic drug information exchange. IT Professional. 2005;7(5):17&#x2013;23. doi: 10.1109/MITP.2005.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MITP.2005.122</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelle Dougherty, Jennie Harvell.  Opportunities for Engaging Long-Term and Post-Acute Care Providers in Health Information Exchange Activities: Exchanging Interoperable Patient Assessment information. Washington DC: Office of Disability, Aging and Long-Term Care Policy, U.S. Department of Health and Human Services; 2011.   http://aspe.hhs.gov/daltcp/reports/2011/StratEng.htm. Accessed July 31, 2015.</Citation></Reference><Reference><Citation>Python Software Foundation   Welcome to  Python.org.  https://www.python.org/. Published 2015. Accessed May 15, 2015.</Citation></Reference><Reference><Citation>&#x201c;RTI International&#x201d;  . MDS 30 Quality Measures User&#x2019;s Manual - v80. Washington D.C.: 2013.   https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/Downloads/MDS-30-QM-User%E2%80%99s-Manual-V80.pdf. Accessed July 31, 2015.</Citation></Reference><Reference><Citation>OHDSI. ACHILLES for data characterization | OHDSI  2015.   http://www.ohdsi.org/analytic-tools/achilles-for-data-characterization/. Accessed May 15, 2015.</Citation></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services  Medicare.gov Nursing Home Compare    http://www.medicare.gov/nursinghomecompare/search.html. Published 2015. Accessed May 15, 2015.</Citation></Reference><Reference><Citation>Rubenstein LZ. Falls in older people: epidemiology, risk factors and strategies for prevention. Age Ageing. 2006;35 Suppl 2:ii37&#x2013;ii41. doi: 10.1093/ageing/afl084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afl084</ArticleId><ArticleId IdType="pubmed">16926202</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterke CS, Verhagen AP, van Beeck EF, van der Cammen TJM. The influence of drug use on fall incidents among nursing home residents: a systematic review. Int Psychogeriatr. 2008;20(5):890&#x2013;910. doi: 10.1017/S104161020800714X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S104161020800714X</ArticleId><ArticleId IdType="pubmed">18416875</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27940627</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>09</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Automatic identification of type 2 diabetes, hypertension, ischaemic heart disease, heart failure and their levels of severity from Italian General Practitioners' electronic medical records: a validation study.</ArticleTitle><Pagination><StartPage>e012413</StartPage><MedlinePgn>e012413</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e012413</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2016-012413</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The Italian project MATRICE aimed to assess how well cases of type 2 diabetes (T2DM), hypertension, ischaemic heart disease (IHD) and heart failure (HF) and their levels of severity can be automatically extracted from the Health Search/CSD Longitudinal Patient Database (HSD). From the medical records of the general practitioners (GP) who volunteered to participate, cases were extracted by algorithms based on diagnosis codes, keywords, drug prescriptions and results of diagnostic tests. A random sample of identified cases was validated by interviewing their GPs.</AbstractText><AbstractText Label="SETTING">HSD is a database of primary care medical records. A panel of 12 GPs participated in this validation study.</AbstractText><AbstractText Label="PARTICIPANTS">300 patients were sampled for each disease, except for HF, where 243 patients were assessed.</AbstractText><AbstractText Label="OUTCOME MEASURES">The positive predictive value (PPV) was assessed for the presence/absence of each condition against the GP's response to the questionnaire, and Cohen's &#x3ba; was calculated for agreement on the severity level.</AbstractText><AbstractText Label="RESULTS">The PPV was 100% (99% to 100%) for T2DM and hypertension, 98% (96% to 100%) for IHD and 55% (49% to 61%) for HF. Cohen's kappa for agreement on the severity level was 0.70 for T2DM and 0.69 for hypertension and IHD.</AbstractText><AbstractText Label="CONCLUSIONS">This study shows that individuals with T2DM, hypertension or IHD can be validly identified in HSD by automated identification algorithms. Automatic queries for levels of severity of the same diseases compare well with the corresponding clinical definitions, but some misclassification occurs. For HF, further research is needed to refine the current algorithm.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gini</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6250-877X</Identifier><AffiliationInfo><Affiliation>Agenzia regionale di sanit&#xe0; della Toscana, Osservatorio di epidemiologia, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Janssen Research &amp; Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzaglia</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francesconi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Agenzia regionale di sanit&#xe0; della Toscana, Osservatorio di epidemiologia, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasqua</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchini</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montalbano</LastName><ForeName>Carmelo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genomedics, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberto</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Agenzia regionale di sanit&#xe0; della Toscana, Osservatorio di epidemiologia, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barletta</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Agenzia regionale di sanit&#xe0; della Toscana, Osservatorio di epidemiologia, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cricelli</LastName><ForeName>Iacopo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Genomedics, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cricelli</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Italian College of General Practitioners and Primary Care, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dal Co</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Agenzia Nazionale per il Servizi Sanitari Regionali, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellentani</LastName><ForeName>Mariadonata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Agenzia Nazionale per il Servizi Sanitari Regionali, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturkenboom</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klazinga</LastName><ForeName>Niek</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017202" MajorTopicYN="N">Myocardial Ischemia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DIABETES &amp; ENDOCRINOLOGY</Keyword><Keyword MajorTopicYN="N">PRIMARY CARE</Keyword><Keyword MajorTopicYN="N">Validation study</Keyword><Keyword MajorTopicYN="N">electronic medical records</Keyword></KeywordList><CoiStatement>MJS is an employee of a pharmaceutical company. Genomedics is a private company owned by IC. RG, FL, GR and MS have conducted pharmacoepidemiological studies funded by pharmaceutical companies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27940627</ArticleId><ArticleId IdType="pmc">PMC5168667</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2016-012413</ArticleId><ArticleId IdType="pii">bmjopen-2016-012413</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>OECD. OECD reviews of health care quality. Italy 2014: raising standards. OECD Publishing, 2015.</Citation></Reference><Reference><Citation>Agenzia nazionale per i Servizi Sanitari Regionali. Programma Mattoni del SSN&#x2014;Progetto MATRICE. http://www.agenas.it/images/agenas/In%20primo%20piano/Matrice/Progetto_MATRICE_Scheda_informativa.pdf (accessed Aug 2016) [Italian].</Citation></Reference><Reference><Citation>Agenzia regionale di sanit&#xe0; della Toscana. Data integration for chronic diseases management in outpatient settings (MATRICE Project). https://www.ars.toscana.it/en/project/chronic-diseases/2460-matrice-project.html (accessed Aug 2016).</Citation></Reference><Reference><Citation>Cricelli C, Mazzaglia G, Samani F et al. . Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003;25:254&#x2013;7. 10.1093/pubmed/fdg060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdg060</ArticleId><ArticleId IdType="pubmed">14575204</ArticleId></ArticleIdList></Reference><Reference><Citation>Savica R, Beghi E, Mazzaglia G et al. . Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000&#x2013;2005. Eur J Neurol 2007;14:1317&#x2013;21. 10.1111/j.1468-1331.2007.01970.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2007.01970.x</ArticleId><ArticleId IdType="pubmed">17903210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchetti E, Trifir&#xf2; G, Caputi A et al. . Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol (Oxford) 2008;22:39&#x2013;46. 10.1177/0269881107080792</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881107080792</ArticleId><ArticleId IdType="pubmed">18187531</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzaglia G, Ambrosioni E, Alacqua M et al. . Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598&#x2013;605. 10.1161/CIRCULATIONAHA.108.830299</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.830299</ArticleId><ArticleId IdType="pubmed">19805653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravera M, Noberasco G, Re M et al. . Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. Nephrol Dial Transplant 2009;24:1528&#x2013;33. 10.1093/ndt/gfn692</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfn692</ArticleId><ArticleId IdType="pubmed">19073656</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzola M, Bettoncelli G, Sessa E et al. . Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010;80:112&#x2013;9. 10.1159/000281880</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000281880</ArticleId><ArticleId IdType="pubmed">20134148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzola M, Calzetta L, Lauro D et al. . Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. Respir Med 2013;107:1417&#x2013;22. 10.1016/j.rmed.2013.04.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2013.04.021</ArticleId><ArticleId IdType="pubmed">23702090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultana J, Italiano D, Spina E et al. . Changes in the prescribing pattern of antidepressant drugs in elderly patients: an Italian, nationwide, population-based study. Eur J Clin Pharmacol 2014;70:469&#x2013;78. 10.1007/s00228-013-1636-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-013-1636-z</ArticleId><ArticleId IdType="pubmed">24425146</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Search Web page. https://www.healthsearch.it/?lang=en (accessed Aug 2016).</Citation></Reference><Reference><Citation>Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097&#x2013;9. 10.1016/S0140-6736(97)04248-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(97)04248-7</ArticleId><ArticleId IdType="pubmed">10213569</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JD, Schinnar R, Bilker WB et al. . Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393&#x2013;401. 10.1002/pds.1335</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1335</ArticleId><ArticleId IdType="pubmed">17066486</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Stables D, Pringle M. QRESEARCH: a new general practice database for research. Inform Prim Care 2004;12:49&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140353</ArticleId></ArticleIdList></Reference><Reference><Citation>Birtwhistle RV. Canadian Primary Care Sentinel Surveillance Network: a developing resource for family medicine and public health. Can Fam Physician 2011;57:1219&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192094</ArticleId><ArticleId IdType="pubmed">21998241</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlug AE, van der Lei J, Mosseveld BM et al. . Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805025</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador Rosa A, Moreno P&#xe9;rez JC, Sonego D et al. . El Proyecto BIFAP: Base de datos para la Investigaci&#xf3;n Farmacoepidemiol&#xf3;gica en. Aten Primaria 2002;30:655&#x2013;61. 10.1016/S0212-6567(02)79129-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0212-6567(02)79129-4</ArticleId><ArticleId IdType="pmc">PMC7679749</ArticleId><ArticleId IdType="pubmed">12525343</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan K, Porcheret M, Croft P. Quality of morbidity coding in general practice computerized medical records: a systematic review. Fam Pract 2004;21:396&#x2013;412. 10.1093/fampra/cmh409</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmh409</ArticleId><ArticleId IdType="pubmed">15249528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadhim-Saleh A, Green M, Williamson T et al. . Validation of the diagnostic algorithms for 5 chronic conditions in the Canadian Primary Care Sentinel Surveillance Network (CPCSSN): a Kingston Practice-based Research Network (PBRN) report. J Am Board Fam Med 2013;26:159&#x2013;67. 10.3122/jabfm.2013.02.120183</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2013.02.120183</ArticleId><ArticleId IdType="pubmed">23471929</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu K, Manuel D, Lam K et al. . Diabetics can be identified in an electronic medical record using laboratory tests and prescriptions. J Clin Epidemiol 2011;64:431&#x2013;5. 10.1016/j.jclinepi.2010.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.04.007</ArticleId><ArticleId IdType="pubmed">20638237</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Thomas SL, Schoonen WM et al. . Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4&#x2013;14. 10.1111/j.1365-2125.2009.03537.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2009.03537.x</ArticleId><ArticleId IdType="pmc">PMC2805870</ArticleId><ArticleId IdType="pubmed">20078607</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128&#x2013;36. 10.3399/bjgp10X483562</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp10X483562</ArticleId><ArticleId IdType="pmc">PMC2828861</ArticleId><ArticleId IdType="pubmed">20202356</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson T, Green ME, Birtwhistle R et al. . Validating the 8 CPCSSN case definitions for chronic disease surveillance in a primary care database of electronic health records. Ann Fam Med 2014;12:367&#x2013;72. 10.1370/afm.1644</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.1644</ArticleId><ArticleId IdType="pmc">PMC4096475</ArticleId><ArticleId IdType="pubmed">25024246</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Valkhoff VE, Mazzaglia G et al. . Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open 2013;3;pii: e002862 10.1136/bmjopen-2013-002862</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2013-002862</ArticleId><ArticleId IdType="pmc">PMC3686251</ArticleId><ArticleId IdType="pubmed">23794587</ArticleId></ArticleIdList></Reference><Reference><Citation>Valkhoff VE, Coloma PM, Masclee GMC et al. . Validation study in four health-care databases: upper gastrointestinal bleeding misclassification affects precision but not magnitude of drug-related upper gastrointestinal bleeding risk. J Clin Epidemiol 2014;67:921&#x2013;31. 10.1016/j.jclinepi.2014.02.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.02.020</ArticleId><ArticleId IdType="pubmed">24794575</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Scalzo A, Donatini A, Orzella L et al. . Italy: Health system review. Health Syst Transit 2009;11:1&#x2013;216.</Citation></Reference><Reference><Citation>Fihn SD, Gardin JM, Abrams J et al. . 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126:3097&#x2013;137. 10.1161/CIR.0b013e3182776f83</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e3182776f83</ArticleId><ArticleId IdType="pubmed">23166210</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt SA, Abraham WT, Chin MH et al. . ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005;112:e154&#x2013;235. 10.1161/CIRCULATIONAHA.105.167586</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.167586</ArticleId><ArticleId IdType="pubmed">16160202</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Bari M, Pozzi C, Cavallini MC et al. . The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARe Dicomano Study. J Am Coll Cardiol 2004;44:1601&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15489092</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach S, Blais C, Quan H. Administrative data have high variation in validity for recording heart failure. Can J Cardiol 2010;26:e306&#x2013;12. 10.1016/S0828-282X(10)70438-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0828-282X(10)70438-4</ArticleId><ArticleId IdType="pmc">PMC2954539</ArticleId><ArticleId IdType="pubmed">20931099</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini R, Francesconi P, Mazzaglia G et al. . Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey. BMC Public Health 2013;13:15 10.1186/1471-2458-13-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-13-15</ArticleId><ArticleId IdType="pmc">PMC3551838</ArticleId><ArticleId IdType="pubmed">23297821</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform 2014;48:193&#x2013;204. 10.1016/j.jbi.2014.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2014.02.013</ArticleId><ArticleId IdType="pubmed">24582925</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27989817</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Evaluating common data models for use with a longitudinal community registry.</ArticleTitle><Pagination><StartPage>333</StartPage><EndPage>341</EndPage><MedlinePgn>333-341</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2016.10.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(16)30153-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate common data models (CDMs) to determine which is best suited for sharing data from a large, longitudinal, electronic health record (EHR)-based community registry.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Four CDMs were chosen from models in use for clinical research data: Sentinel v5.0 (referred to as the Mini-Sentinel CDM in previous versions), PCORnet v3.0 (an extension of the Mini-Sentinel CDM), OMOP v5.0, and CDISC SDTM v1.4. Each model was evaluated against 11 criteria adapted from previous research. The criteria fell into six categories: content coverage, integrity, flexibility, ease of querying, standards compatibility, and ease and extent of implementation.</AbstractText><AbstractText Label="RESULTS">The OMOP CDM accommodated the highest percentage of our data elements (76%), fared well on other requirements, and had broader terminology coverage than the other models. Sentinel and PCORnet fell short in content coverage with 37% and 48% matches respectively. Although SDTM accommodated a significant percentage of data elements (55% true matches), 45% of the data elements mapped to SDTM's extension mechanism, known as Supplemental Qualifiers, increasing the number of joins required to query the data.</AbstractText><AbstractText Label="CONCLUSION">The OMOP CDM best met the criteria for supporting data sharing from longitudinal EHR-based studies. Conclusions may differ for other uses and associated data element sets, but the methodology reported here is easily adaptable to common data model evaluation for other uses.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2016. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garza</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Duke Translational Medicine Institute, Duke University, 2424 Erwin Road, Hock Plaza Box 3850, Durham, NC 27705, USA. Electronic address: maryam.garza@duke.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Fiol</LastName><ForeName>Guilherme</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Utah School of Medicine, 421 Wakara Way, Room: Suite 140, Salt Lake City, UT 84108, USA. Electronic address: guilherme.delfiol@utah.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenenbaum</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, 2424 Erwin Road, Suite 1102 Hock Plaza Box 2721, Durham, NC 27705, USA. Electronic address: jessie.tenenbaum@duke.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Duke Translational Medicine Institute, Duke University, 2424 Erwin Road, Hock Plaza Box 3850, Durham, NC 27705, USA; Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, 501 Jack Stephens Drive, Mail Slot # 782, Little Rock, AR 72205, USA. Electronic address: acwalden@uams.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zozus</LastName><ForeName>Meredith Nahm</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, 2424 Erwin Road, Suite 1102 Hock Plaza Box 2721, Durham, NC 27705, USA; Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, 501 Jack Stephens Drive, Mail Slot # 782, Little Rock, AR 72205, USA. Electronic address: mzozus@uams.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R00 LM011128</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 DA040317</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001117</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Data model evaluation</Keyword><Keyword MajorTopicYN="N">Electronic health records</Keyword></KeywordList><CoiStatement>Competing Interests. None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27989817</ArticleId><ArticleId IdType="mid">NIHMS1534566</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pii">S1532-0464(16)30153-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mosley M, ed. The DAMA Dictionary of Data Management, 1st ed. Denville, NJ: Technics Publications; 2008.</Citation></Reference><Reference><Citation>Abdelhak M, Grostick S, Hanken MA. Health Information: Management of a Strategic Resource, 3rd ed. St. Louis, MO: Elsevier Health Sciences; 2007.</Citation></Reference><Reference><Citation>Sentinel Common Data Model v5.0. http://www.mini-sentinel.org/ (accessed
1 Feb 2016).</Citation></Reference><Reference><Citation>The National Patient-Centered Clinical Research Network (PCORnet) Common Data Model v3.0. http://www.pcornet.org/resource-center/pcornet-common-data-model/ (accessed
1 Feb 2016).</Citation></Reference><Reference><Citation>Ross TR, Ng D, Brown JS, et al. The HMO Research Network Virtual Data Warehouse: A public data model to support collaboration. EGEMS. 2014:2(1): 1049 Doi: 10.1306372327-9214.1049. eCollection 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371424</ArticleId><ArticleId IdType="pubmed">25848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Medical Outcomes Partnership (OMOP) Common Data Model v5.0. http://omop.org/ (accessed
14 Oct 2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Data Interchange Standards Consortium. Submission Data Standards Team. Study Data Tabulation Model 2013 (v1.4):1&#x2013;40. http://www.cdisc.org/sdtm (accessed
1 Jun 2014).</Citation></Reference><Reference><Citation>Clinical Data Interchange Standards Consortium. Submission Data Standards Team. Study Data Tabulation Model Implementation Guide: Human Clinical Trials. 2013 (v3.1.2):1&#x2013;398. http://www.cdisc.org/sdtm (accessed
1 Jun 2014).</Citation></Reference><Reference><Citation>Olson S, Downey AS, eds. Sharing Clinical Research Data: Workshop Summary. Washington DC: National Academies Press; 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">23700647</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH Data Sharing Policy and Implementation Guidance. http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm (accessed
1 Jul 2015).</Citation></Reference><Reference><Citation>National Science Foundation. Grant Proposal Guide, NSF 11&#x2013;1 January 2011. Chapter II.C.2.j. http://www.nsf.gov/pubs/policydocs/pappguide/nsf11001/gpg_index.jsp (accessed
30 Jun 2015).</Citation></Reference><Reference><Citation>Organisation for Economic Co-operation and Development (OECD). Science, Technology and Innovation for the 21st Century. Meeting of the OECD Committee for Scientific and Technological Policy at Ministerial Level, 29&#x2013;30 January 2004 - Final Communique.
http://www.oecd.org/science/scitech/sciencetechnologyandinnovationforthe21stcenturymeetingoftheoecdcommitteeforscientificandtechnologicalpolicyatministeriallevel29-30january2004-finalcommunique.htm (accessed
1 Jul 2015).</Citation></Reference><Reference><Citation>Moody DL. Theoretical and practical issues in evaluating the quality of conceptual models: current state and future directions. Data Knowl Eng. 2005;55:243&#x2013;276.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunyemi OI, Meeker D, Kim HE, et al. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Med Care. 2013;51(8 Suppl 3):S45&#x2013;S52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care. 2012;50(Suppl):S60&#x2013;S67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zhou X, Suehs BT, et al. A comparative assessment of Observational Medical Outcomes Partnership and Mini-Sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf. 2015;38(8):749&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">26055920</ArticleId></ArticleIdList></Reference><Reference><Citation>HL7 Version 3 Domain Analysis Model: Emergency Medical Services, Release 1. HL7 Informative Document: HL7 V3 DAM EMS R1&#x2013;2013. Available from www.HL7.org: http://www.hl7.org/implement/standards/product_brief.cfm?product_id=39 (accessed on
1 Jul 2015).</Citation></Reference><Reference><Citation>HL7 Version 3 Domain Analysis Model: Trauma Registry Data Submission, Release 1, July 2014. HL7 Informative Document: HL7 V3DAM TRAUMA, R1. A Technical Report prepared by Health Level Seven International and registered with ANSI: August/24/2014. 
Available from www.HL7.org: https://www.hl7.org/implement/standards/product_brief.cfm?product_id=363 (accessed on
1 Jul 2015).</Citation></Reference><Reference><Citation>Kawamoto K, Del Fiol G, Strasberg HR, et al. Multi-national, multi-institutional analysis of clinical decision support data needs to inform development of the HL7 virtual medical record standard. AMIA Annu Symp Proc. 2010. November 13;2010:377&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041317</ArticleId><ArticleId IdType="pubmed">21347004</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenenbaum JD, Christian V, Cornish MA, et al. The MURDOCK study: A long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res. 2012;4(3):291&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426390</ArticleId><ArticleId IdType="pubmed">22937207</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody DL, Shanks GG. Improving the quality of data models: empirical validation of a quality management framework. Inf Syst. 2003;28:619&#x2013;650.</Citation></Reference><Reference><Citation>Recker J, Rosemann M. Measuring perceived representational deficiencies in conceptual modeling: instrument development and test. In: 29th International Conference on Information Systems (ICIS 2008): Proceedings of a Meeting Held 14&#x2013;17 December 2008, Paris, France.</Citation></Reference><Reference><Citation>Wand Y, Weber R. On the ontological expressiveness of information systems analysis and design grammars. Inf Syst J. 1993;3(4):217&#x2013;237.</Citation></Reference><Reference><Citation>Huser V, Cimino JJ. Desiderata for healthcare integrated data repositories based on architectural comparisons for informatics development of three public repositories. AMIA Annual Symposium Proceedings. 2013;2013:648&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900207</ArticleId><ArticleId IdType="pubmed">24551366</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie SL, Wyatt MC, Schuff R, et al. Practices and perspectives on building integrated data repositories: Results from a 2010 CTSA survey. J Am Med Inform Assoc. 2012;19:e119&#x2013;e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392848</ArticleId><ArticleId IdType="pubmed">22437072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes N, Warfel P, Oladapo O, et al. CDISC implementation mostly in Clintrial&#x2122; at the Duke Clinical Research Institute. Society for Clinical Data Management Annual Meeting, Toronto, Ontario, Canada, September 2004.</Citation></Reference><Reference><Citation>Cimino JJ, Ayres EJ, Remennik L, et al. The National Institutes of Health&#x2019;s Biomedical Translational Research Information System (BTRIS): Design, contents, functionality and experience to date. J Biomed Inform. 2014;52:11&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026354</ArticleId><ArticleId IdType="pubmed">24262893</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28154833</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2327-9214</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>EGEMS (Washington, DC)</Title><ISOAbbreviation>EGEMS (Wash DC)</ISOAbbreviation></Journal><ArticleTitle>Multisite Evaluation of a Data Quality Tool for Patient-Level Clinical Data Sets.</ArticleTitle><Pagination><StartPage>1239</StartPage><MedlinePgn>1239</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1239</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.13063/2327-9214.1239</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Data quality and fitness for analysis are crucial if outputs of analyses of electronic health record data or administrative claims data should be trusted by the public and the research community.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We describe a data quality analysis tool (called Achilles Heel) developed by the Observational Health Data Sciences and Informatics Collaborative (OHDSI) and compare outputs from this tool as it was applied to 24 large healthcare datasets across seven different organizations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We highlight 12 data quality rules that identified issues in at least 10 of the 24 datasets and provide a full set of 71 rules identified in at least one dataset. Achilles Heel is a freely available software that provides a useful starter set of data quality rules with the ability to add additional rules. We also present results of a structured email-based interview of all participating sites that collected qualitative comments about the value of Achilles Heel for data quality evaluation.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our analysis represents the first comparison of outputs from a data quality tool that implements a fixed (but extensible) set of data quality rules. Thanks to a common data model, we were able to compare quickly multiple datasets originating from several countries in America, Europe and Asia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Institute of Health; National Library of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development; Observational Health Data Sciences and Informatics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velez</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Regenstrief Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khare</LastName><ForeName>Ritu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utidjian</LastName><ForeName>Levon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG044433</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011838</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EGEMS (Wash DC)</MedlineTA><NlmUniqueID>101629606</NlmUniqueID><ISSNLinking>2327-9214</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">Data Use and Quality</Keyword><Keyword MajorTopicYN="N">Electronic Health Record (EHR)</Keyword><Keyword MajorTopicYN="N">Informatics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28154833</ArticleId><ArticleId IdType="pmc">PMC5226382</ArticleId><ArticleId IdType="doi">10.13063/2327-9214.1239</ArticleId><ArticleId IdType="pii">egems1239</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Friedman C, Rubin J, Brown J, et al. Toward a science of learning systems: a research agenda for the high-functioning Learning Health System. J Am Med Inform Assoc. 2015;22(1):43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433378</ArticleId><ArticleId IdType="pubmed">25342177</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101938</ArticleId><ArticleId IdType="pubmed">25635347</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model. EGEMS (Wash DC) 2014;2(1):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman N, Halas G, Peeler W, Casaclang N, Williamson T, Katz A. From patient care to research: a validation study examining the factors contributing to data quality in a primary care electronic medical record database. BMC Family Practice. 2015;16(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324413</ArticleId><ArticleId IdType="pubmed">25649201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho AN, Pacheco JA, Peissig PL, et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med. 2011;3(79):79re71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690272</ArticleId><ArticleId IdType="pubmed">21508311</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter J. EHR Science: EHR Data Quality (collection of relevant references; updated March 2016) 2016.   http://ehrscience.com/ehr-data-quality. Accessed March 11, 2016.</Citation></Reference><Reference><Citation>Psaty BM, Breckenridge AM. Mini-Sentinel and regulatory science--big data rendered fit and functional. N Engl J Med. 2014;370(23):2165&#x2013;2167.</Citation><ArticleIdList><ArticleId IdType="pubmed">24897081</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zhou X, Suehs BT, et al. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. Drug safety : an international journal of medical toxicology and drug experience. 2015;38(8):749&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">26055920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, et al. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug safety : an international journal of medical toxicology and drug experience. 2013;36(2):119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vlymen J, de Lusignan S. A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Inform Prim Care. 2005;13(4):281&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">16510025</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S, Liaw ST, Krause P, et al. Key concepts to assess the readiness of data for international research: data quality, lineage and provenance, extraction and processing errors, traceability, and curation. Contribution of the IMIA Primary Health Care Informatics Working Group. Yearb Med Inform. 2011;6(1):112&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">21938335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross TR, Ng D, Brown JS, et al. The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. EGEMS (Wash DC) 2014;2(1):1049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371424</ArticleId><ArticleId IdType="pubmed">25848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Brown JS. Transparent Reporting of Data Quality in Distributed Data Networks. EGEMS (Wash DC) 2015;3(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434997</ArticleId><ArticleId IdType="pubmed">25992385</ArticleId></ArticleIdList></Reference><Reference><Citation>Health A. Data Quality Collaborative. 2015  http://repository.academyhealth.org/dqc/. Accessed May 15, 2015.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Studies in health technology and informatics. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI  OHSDI Mission, Vision &amp; Values. 2014.   http://www.ohdsi.org/who-we-are/mission-vision-values/. Accessed Sep 10, 2015.</Citation></Reference><Reference><Citation>OHDSI  Common Data Model. 2015.   http://www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:single-page. Accessed June 10, 2015.</Citation></Reference><Reference><Citation>OHDSI  Observational Health Data Sciences and Informatics Wiki: Achilles Documentation. 2015.   http://www.ohdsi.org/web/wiki/doku.php?id=documentation:software:achilles. Accessed June 22, 2015.</Citation></Reference><Reference><Citation>OHDSI  Code in Structured Query Language that contains all Achilles Heel data quality rules (CDM v5 and v4 variants) 2015.   https://github.com/OHDSI/Achilles/tree/master/inst/sql/sql_server. Accessed June 15, 2015.</Citation></Reference><Reference><Citation>OHDSI  List of Achilles precomputed analyses. 2016.   https://github.com/OHDSI/Achilles/blob/master/inst/csv/analysisDetails.csv. Accessed Feb 15, 2016.</Citation></Reference><Reference><Citation>OHDSI  List of Achilles Heel Rules (Achilles Heel version 1.2) 2016.   https://github.com/OHDSI/Achilles/blob/master/inst/csv/achilles_rule.csv. Accessed March 10, 2016.</Citation></Reference><Reference><Citation>Achilles Web software (interactive web site for reviewing the results of the Achilles and Achilles Heel analysis) 2014.   https://github.com/OHDSI/Achillesweb. Accessed Sep 15, 2015.</Citation></Reference><Reference><Citation>OHDSI Introduction to using &#x2018;White Rabbit&#x2019; and &#x2018;Rabbit In A Hat&#x2019; tools for facilitating of loading your local data into OHDSI Common Data Model repository. 2015.</Citation></Reference><Reference><Citation>OHDSI  Data network overview. 2016.   http://www.ohdsi.org/web/wiki/doku.php?id=resources:data_network. Accessed Feb 16, 2016.</Citation></Reference><Reference><Citation>OHDSI  Observational Health Data Sciences and Informatics Wiki: Documentation. 2015.   http://www.ohdsi.org/web/wiki/doku.php?id=documentation:overview. Accessed June 22, 2015.</Citation></Reference><Reference><Citation>OMOP  Observational Medical Outcomes Partnership: ETL Documentation. 2014.   http://omop.org/CDM. Accessed June 22, 2015.</Citation></Reference><Reference><Citation>OHDSI  IRIS: Data size comparison tool. 2015.   https://github.com/OHDSI/Iris. Accessed July 16, 2015.</Citation></Reference><Reference><Citation>Lowe HJ, Ferris TA, Hernandez PM, Weber SC. STRIDE--An integrated standards-based translational research informatics platform. AMIA Annu Symp Proc. 2009;2009:391&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815452</ArticleId><ArticleId IdType="pubmed">20351886</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath MM, Winfield S, Evans S, Slopek S, Shang H, Ferranti J. The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement. Journal of biomedical informatics. 2011;44(2):266&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063322</ArticleId><ArticleId IdType="pubmed">21130181</ArticleId></ArticleIdList></Reference><Reference><Citation>Dentler K, Cornet R, ten Teije A, et al. Influence of data quality on computed Dutch hospital quality indicators: a case study in colorectal cancer surgery. BMC medical informatics and decision making. 2014;14:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004502</ArticleId><ArticleId IdType="pubmed">24721489</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts DG, De Keizer NF, Scheffer GJ. Defining and improving data quality in medical registries: a literature review, case study, and generic framework. J Am Med Inform Assoc. 2002;9(6):600&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC349377</ArticleId><ArticleId IdType="pubmed">12386111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Raebel MA, Glanz JM, Riedlinger K, Steiner JF. A pragmatic framework for single-site and multisite data quality assessment in electronic health record-based clinical research. Med Care. 2012;50(Suppl):S21&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833692</ArticleId><ArticleId IdType="pubmed">22692254</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Kahn M, Toh S. Data quality assessment for comparative effectiveness research in distributed data networks. Med Care. 2013;51(8 Suppl 3):S22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306391</ArticleId><ArticleId IdType="pubmed">23793049</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI  ATHENA standardized vocabularies. 2016.   http://www.ohdsi.org/analytic-tools/athena-standardized-vocabularies/. Accessed Feb 19, 2016.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28269868</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2016</Volume><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Feasibility of Representing Data from Published Nursing Research Using the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>715</StartPage><EndPage>723</EndPage><MedlinePgn>715-723</MedlinePgn></Pagination><Abstract><AbstractText>We explored the feasibility of representing nursing research data with the Observational Medical Outcomes Partners (OMOP) Common Data Model (CDM) to understand the challenges and opportunities in representing various types of health data not limited to diseases and drug treatments. We collected 1,431 unique data items from 256 nursing articles and mapped them to the OMOP CDM. A deeper level of mapping was explored by simulating 10 data search use cases. Although the majority of the data could be represented in the OMOP CDM, potential information loss was identified in contents related to patient reported outcomes, socio-economic information, and locally developed nursing intervention protocols. These areas will be further investigated in a follow up study. We will use lessons learned in this study to inform the metadata development efforts for data discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyeoneui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Health System Department of Biomedical Informatics, UC San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jeeyae</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Nursing, University of Wisconsin at Milwaukee, Milwaukee, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Imho</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Biological Sciences, UC San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quach</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, UC San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno-Machado</LastName><ForeName>Lucila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Health System Department of Biomedical Informatics, UC San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AI117966</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000043" MajorTopicYN="N">Abstracting and Indexing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="Y">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015399" MajorTopicYN="Y">Nursing Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039781" MajorTopicYN="N">PubMed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011642" MajorTopicYN="N">Publications</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28269868</ArticleId><ArticleId IdType="pmc">PMC5333244</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moses C, Celi LA, Marshall J. Pharmacovigilance: an active surveillance system to proactively identify risks for adverse events. Population health management [Internet] 2013 Jun.16(3):147&#x2013;9. [cited 2016 Mar 6] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/23530466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704747</ArticleId><ArticleId IdType="pubmed">23530466</ArticleId></ArticleIdList></Reference><Reference><Citation>Badawi O, Brennan T, Celi LA, Feng M, Ghassemi M, Ippolito A, et al.  Making big data useful for health care: a summary of the inaugural mit critical data conference. JMIR medical informatics [Internet] 2014 Jan.2(2):e22. [cited 2016 Mar 6] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4288071&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4288071</ArticleId><ArticleId IdType="pubmed">25600172</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran C, Bloomrosen M, Hammond WE, Labkoff S, Markel-Fox S, Tang PC, et al.  Toward a national framework for the secondary use of health data: an American Medical Informatics Association White Paper. Journal of the American Medical Informatics Association: JAMIA [Internet] Jan.14(1):1&#x2013;9. [cited 2016 Mar 6] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2329823&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329823</ArticleId><ArticleId IdType="pubmed">17077452</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plastic and reconstructive surgery [Internet] 2011 Jul.128(1):305&#x2013;10. [cited 2015 Oct 15] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3124652&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124652</ArticleId><ArticleId IdType="pubmed">21701348</ArticleId></ArticleIdList></Reference><Reference><Citation>Low YS, Caster O, Bergvall T, Fourches D, Zang X, Nor&#xe9;n GN, et al.  Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome. Journal of the American Medical Informatics Association: JAMIA [Internet]. The Oxford University Press. 2015 Oct. [cited 2016 Mar 5] ocv127 Available from:  http://jamia.oxfordjournals.org/content/early/2015/10/23/jamia.ocv127.abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997030</ArticleId><ArticleId IdType="pubmed">26499102</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy AB, Cox ZL, Neal EB, Waitman LR, Peterson NB, Bhave G, et al.  Real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury: a randomized, controlled trial. Applied clinical informatics [Internet] 2012 Jan.3(2):221&#x2013;38. [cited 2016 Mar 5] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3377180&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377180</ArticleId><ArticleId IdType="pubmed">22719796</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund JL, Sturmer T, Sanoff HK. Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy. Journal of geriatric oncology [Internet] 2016 Feb. [cited 2016 Mar 5] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/26926829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871747</ArticleId><ArticleId IdType="pubmed">26926829</ArticleId></ArticleIdList></Reference><Reference><Citation>Widdifield J, Moura CS, Wang Y, Abrahamowicz M, Paterson JM, Huang A, et al.  The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery. The Journal of rheumatology [Internet] 2016 Feb. [cited 2016 Mar 5] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/26879353.</Citation><ArticleIdList><ArticleId IdType="pubmed">26879353</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson N, Abend A, Mandel A, Geraghty E, Gabriel D, Wynden R, et al.  Implementation of a deidentified federated data network for population-based cohort discovery. Journal of the American Medical Informatics Association: JAMIA [Internet] 2012 Jun.19(e1):e60&#x2013;7. [cited 2016 Mar 6] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3392860&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392860</ArticleId><ArticleId IdType="pubmed">21873473</ArticleId></ArticleIdList></Reference><Reference><Citation>Namjou B, Marsolo K, Lingren T, Ritchie MD, Verma SS, Cobb BL, et al.  A GWAS Study on Liver Function Test Using eMERGE Network Participants. PloS one [Internet] 2015 Jan.10(9):e0138677. [cited 2016 Mar 6] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4586138&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586138</ArticleId><ArticleId IdType="pubmed">26413716</ArticleId></ArticleIdList></Reference><Reference><Citation>BD2K Home Page | Data Science at NIH [Internet]  [cited 2015 Sep 10]Available from:  https://datascience.nih.gov/bd2k.</Citation></Reference><Reference><Citation>Margolis R, Derr L, Dunn M, Huerta M, Larkin J, Sheehan J, et al.  The National Institutes of Health&#x2019;s Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data. Journal of the American Medical Informatics Association: JAMIA [Internet] Jan.21(6):957&#x2013;8. [cited 2015 Dec 9] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4215061&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215061</ArticleId><ArticleId IdType="pubmed">25008006</ArticleId></ArticleIdList></Reference><Reference><Citation>bioCADDIE | biomedical and healthCAre Data Discovery and Indexing Ecosystem [Internet]  [cited 2015 May 31] Available from:  https://biocaddie.org/</Citation></Reference><Reference><Citation>Ohno-machado L, Alter G, Fore I, Martone M, Sansone S-A, Xu H. bioCADDIE White Paper; 2015.</Citation></Reference><Reference><Citation>Sansone S-A, Rocca-Serra P, Gonzalez-Beltran A, Vardigan M. Members bioCADDIE W. Working Group 3: Metadata Specifications bioCADDIE [Internet]; 2015.  [cited 2015 Sep 10] Available from:  https://biocaddie.org/group/working-group/working-group-3-metadata-specifications.</Citation></Reference><Reference><Citation>Kim H, Marmor R, Singh S, Ohno-Machado L. Exploring clinical research data network metdata for phenotype dataset discovery; Workshop on Data Science, Learning and Applications to Biomedical and Health Sciences (DSLA-BHS2016); 2016. pp. 7&#x2013;11.</Citation></Reference><Reference><Citation>Observational Medical Outcomes Partnership [Internet]  [cited 2015 Nov 29] Available from:  http://omop.org/</Citation></Reference><Reference><Citation>OHDSI | Observational Health Data Sciences and Informatics [Internet]  [cited 2015 Nov 29] Available from:  http://www.ohdsi.org/</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al.  Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Studies in health technology and informatics [Internet] 2015 Jan.216:574&#x2013;8. [cited 2015 Nov 4] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/26262116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality. Journal of the American Medical Informatics Association: JAMIA [Internet] Jan;21(4):576&#x2013;7. [cited 2015 Nov 29] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4078299&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078299</ArticleId><ArticleId IdType="pubmed">24821744</ArticleId></ArticleIdList></Reference><Reference><Citation>PCORnet, the National Patient-Centered Clinical Research Network - PCORnet [Internet]  [cited 2015 Nov 29] Available from:  http://www.pcornet.org/</Citation></Reference><Reference><Citation>Ohno-Machado L, Agha Z, Bell DS, Dahm L, Day ME, Doctor JN, et al.  pSCANNER: patient-centered Scalable National Network for Effectiveness Research. Journal of the American Medical Informatics Association: JAMIA [Internet] Jan;21(4):621&#x2013;6. [cited 2015 May 31] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4078293&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078293</ArticleId><ArticleId IdType="pubmed">24780722</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Patient-Centered Clinical Research Network. PCORnet Common Data Model (CDM) Specification. 2015. Version 3.0.</Citation></Reference><Reference><Citation>Belenkaya R, Mirhaji P, Khayter M, Torok D, Khare R, Ong T, et al. Establishing Interoperability Standards between OMOP CDM v4, v5, and PCORnet CDM v1; OHDSI workshop; 2015.</Citation></Reference><Reference><Citation>Rijnbeek PR. Converting to a common data model: what is lost in translation?: Commentary on &#x201c;fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model.&#x201d;. Drug safety [Internet] 2014 Nov;37(11):893&#x2013;6. [cited 2015 Nov 30] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25187018.</Citation><ArticleIdList><ArticleId IdType="pubmed">25187018</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug safety [Internet] 2014 Nov.37(11):945&#x2013;59. [cited 2015 Nov 22] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4206771&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model; EGEMS; (Washington, DC) [Internet]. 2014. Jan. 1110 pp. [cited 2016 Feb 16] Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4371500&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunyemi OI, Meeker D, Kim H-E, Ashish N, Farzaneh S, Boxwala A. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Medical care [Internet] 2013 Aug.51(8) 3:S45&#x2013;52. [cited 2015 Nov 30] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/23774519.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al.  Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association: JAMIA [Internet] 2015 May;22(3):553&#x2013;64. [cited 2015 Nov 3] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25670757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Varmus H. A New Initiative on Precision Medicine. The New England journal of medicine [Internet] 2015 Jan.372(9):793&#x2013;5. [cited 2015 Feb 6] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25635347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101938</ArticleId><ArticleId IdType="pubmed">25635347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Forrest CB, Brennan PF, Stead WW. Informatics to support the IOM social and behavioral domains and measures. Journal of the American Medical Informatics Association: JAMIA [Internet] 2015 Jul.22(4):921&#x2013;4. [cited 2016 Feb 16] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25914098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482277</ArticleId><ArticleId IdType="pubmed">25914098</ArticleId></ArticleIdList></Reference><Reference><Citation>Vittorini P, Tarquinio A, di Orio F. XML technologies for the Omaha System: a data model, a Java tool and several case studies supporting home healthcare. Computer methods and programs in biomedicine [Internet] 2009 Mar.93(3):297&#x2013;312. [cited 2016 Mar 6]  http://www.ncbi.nlm.nih.gov/pubmed/19070934.</Citation><ArticleIdList><ArticleId IdType="pubmed">19070934</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris MR, Langford LH, Miller H, Hook M, Dykes PC, Matney SA. Harmonizing and extending standards from a domain-specific and bottom-up approach: an example from development through use in clinical applications. Journal of the American Medical Informatics Association: JAMIA [Internet] 2015 May;22(3):545&#x2013;52. [cited 2016 Mar 6] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25670750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11737593</ArticleId><ArticleId IdType="pubmed">25670750</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabanales Sotos J, L&#xf3;pez Gonzalez &#xc1;, P&#xe1;rraga Mart&#xed;nez I, Campos Rosa M, Simarro Herraez MJ, L&#xf3;pez-Torres Hidalgo J. Prevalence of hazardous drinking among nursing students. Journal of advanced nursing [Internet] 2015 Mar.71(3):581&#x2013;90. [cited 2016 Mar 4] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25363658.</Citation><ArticleIdList><ArticleId IdType="pubmed">25363658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchini A, De Felippis C, Elli S, Schifano L, Rolla F, Pegoraro F, et al.  Nursing Activities Score (NAS): 5 years of experience in the intensive care units of an Italian University hospital. Intensive &amp; critical care nursing: the official journal of the British Association of Critical Care Nurses [Internet] 2014 Jun.30(3):152&#x2013;8. [cited 2016 Mar 4] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/24370275.</Citation><ArticleIdList><ArticleId IdType="pubmed">24370275</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher DA, Seetoh T, Oh May-Lin H, Viswanathan S, Toh Y, Yin WC, et al.  Automated measures of hand hygiene compliance among healthcare workers using ultrasound: validation and a randomized controlled trial; Infection control and hospital epidemiology [Internet]; 2013. Sep. pp. 919&#x2013;28. [cited 2016 Mar 4] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/23917905.</Citation><ArticleIdList><ArticleId IdType="pubmed">23917905</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun AW, Boone MC, Dauer AK, Campbell DR, Montgomery VL. Using simulation to investigate the impact of hours worked on task performance in an intensive care unit. American journal of critical care: an official publication, American Association of Critical-Care Nurses [Internet] 2014 Sep.23(5):387&#x2013;95. [cited 2016 Mar 4] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25179034.</Citation><ArticleIdList><ArticleId IdType="pubmed">25179034</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Casbas MT, Ruzafa-Martinez M, Rol MA, Madrid JA, Serrano Pinto A, Gonz&#xe1;lez-Mar&#xed;a E, et al.  Sleepiness in Spanish nursing staff--influence of chronotype and care unit in circadian rhythm impairment: research protocol. Journal of advanced nursing [Internet] 2014 Jan;70(1):211&#x2013;9. [cited 2016 Mar 4] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/23834526.</Citation><ArticleIdList><ArticleId IdType="pubmed">23834526</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan PF, Bakken S. Nursing Needs Big Data and Big Data Needs Nursing. Journal of nursing scholarship: an official publication of Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau [Internet] 2015 Aug.47(5):477&#x2013;84. [cited 2015 Sep 1]  http://www.ncbi.nlm.nih.gov/pubmed/26287646.</Citation><ArticleIdList><ArticleId IdType="pubmed">26287646</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra BL, Clancy TR, Sensmeier J, Warren JJ, Weaver C, Delaney CW. Nursing Knowledge: Big Data Science-Implications for Nurse Leaders. Nursing administration quarterly [Internet] Jan.39(4):304&#x2013;10. [cited 2015 Sep 9] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/26340241.</Citation><ArticleIdList><ArticleId IdType="pubmed">26340241</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28503249</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1932-1864</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Statistical analysis and data mining</Title><ISOAbbreviation>Stat Anal Data Min</ISOAbbreviation></Journal><ArticleTitle>Hierarchical Models for Multiple, Rare Outcomes Using Massive Observational Healthcare Databases.</ArticleTitle><Pagination><StartPage>260</StartPage><EndPage>268</EndPage><MedlinePgn>260-268</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/sam.11324</ELocationID><Abstract><AbstractText>Clinical trials often lack power to identify rare adverse drug events (ADEs) and therefore cannot address the threat rare ADEs pose, motivating the need for new ADE detection techniques. Emerging national patient claims and electronic health record databases have inspired post-approval early detection methods like the Bayesian self-controlled case series (BSCCS) regression model. Existing BSCCS models do not account for multiple outcomes, where pathology may be shared across different ADEs. We integrate a pathology hierarchy into the BSCCS model by developing a novel informative hierarchical prior linking outcome-specific effects. Considering shared pathology drastically increases the dimensionality of the already massive models in this field. We develop an efficient method for coping with the dimensionality expansion by reducing the hierarchical model to a form amenable to existing tools. Through a synthetic study we demonstrate decreased bias in risk estimates for drugs when using conditions with different true risk and unequal prevalence. We also examine observational data from the MarketScan Lab Results dataset, exposing the bias that results from aggregating outcomes, as previously employed to estimate risk trends of warfarin and dabigatran for intracranial hemorrhage and gastrointestinal bleeding. We further investigate the limits of our approach by using extremely rare conditions. This research demonstrates that analyzing multiple outcomes simultaneously is feasible at scale and beneficial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaddox</LastName><ForeName>Trevor R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, New Jersey USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, New Jersey USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, California, U.S.A.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HG006139</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008185</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stat Anal Data Min</MedlineTA><NlmUniqueID>101492808</NlmUniqueID><ISSNLinking>1932-1864</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28503249</ArticleId><ArticleId IdType="mid">NIHMS799155</ArticleId><ArticleId IdType="pmc">PMC5423675</ArticleId><ArticleId IdType="doi">10.1002/sam.11324</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cannon CP, Cannon PJ. COX-2 inhibitors and cardiovascular risk. Science. 2012;336(6087):1386&#x2013;1387.</Citation><ArticleIdList><ArticleId IdType="pubmed">22700906</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlton B, Redberg R. The trouble with dabigatran. BMJ. 2014;349:g4681.</Citation><ArticleIdList><ArticleId IdType="pubmed">25055830</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Ezekowitz MD, Yusuf Salim, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM. 2009;361(12):228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">19717844</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the re-ly trial. NEJM. 2010;363:1875&#x2013;1876.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047252</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooks CJ, Prieto-Merino D, Evans SJW. Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing. Drug Safety. 2012;35(1):61&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">22136183</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Cheng H, Delzell E, Fram D, Kilgore M, Saag K, Yun H, Dumouchel W. Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Medical Care. 2008;46(9):969&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694945</ArticleId><ArticleId IdType="pubmed">18725852</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel W. Multivariate Bayesian logistic regression for analysis of clinical study safety issues. Statistical Science. 2012;27(3):319&#x2013;339.</Citation></Reference><Reference><Citation>Farrington C. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51:228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">7766778</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear modes via coordinate descent. Journal of Statistical Software. 2010;33:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference><Reference><Citation>Genkin A, Lewis DD, Madigan D. Large-scale Bayesian logistic regression for text categorization. Technometrics. 2009;49:291&#x2013;304.</Citation></Reference><Reference><Citation>Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events. American Journal of Epidemiology. 1991;133:144&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">1985444</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Ryan P, Simpson S, Zorych Ivan. Bayesian methods in pharmacovigilance. In: Bernardo JM, Bayarri MJ, Berger JO, Dawid AP, Heckerman D, Smith AFM, West M, editors. Bayesian Statistics 9. Oxford, England: Oxford University Press; 2011. 2011.</Citation></Reference><Reference><Citation>Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, Suchard MA, DuMouchel W, Berlin JA. Evaluating the impact of database heterogeneity on observational study results. American Journal of Epidemiology. 2013;178(4):645&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Stang PE, Berlin JA, Schuemie M, Overhage JM, Suchard MA, Dumouchel B, Hartzema AG, Ryan PB. A systematic statistical approach to evaluating evidence from observational studies. Annual Review of Statistics and Its Application 1. 2014;1:11&#x2013;39.</Citation></Reference><Reference><Citation>Majeed A, Hwang HG, Connolly SJ, Eidleboom JW, Exekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325&#x2013;2332.</Citation><ArticleIdList><ArticleId IdType="pubmed">24081972</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage J, Ryan P, Reich C, Hartzema A, Stang P. Validation of a common data model for active safety surveillance research. Journal of American Medical Informatics Association. 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L on behalf of the RE-LY Investigators. The effects of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol. 2014;63:321&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">24076487</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman JK, Greenland S, Lash T. Modern Epidemiology. 3rd. Philadelphia, PA: Wolters Kluwer; 2008. edition.</Citation></Reference><Reference><Citation>Ryan PB. Statistical challenges in systematic evidence generation through analysis of observational health-care data networks. Statistical Methods in Medical Research. 2013;22(1):3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23439684</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson SE, Madigan D, Zorych I, Schuemie MJ, Ryan PB, Suchard MA. Multiple self-controlled cases series for large-scale longitudinal observational databases. Biometrics. 2013;69:893&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117144</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J. Advancing the science for active surveillance: Rationale and design for the observational medical outcomes partnership. Annals of Internal Medicine. 2010;153(9):600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Transactions on Modeling and Computer Simulation. 2013;23(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Thuraisingham B, Khan L, Awad M, Wang L. Design and Implementation of Data Mining Tools. CRC Press; 2009.</Citation></Reference><Reference><Citation>Wu TT, Lange K. Coordinate descent algorithms for lasso penalized regression. Annals of Applied Statistics. 2013;2(1):224&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212875</ArticleId><ArticleId IdType="pubmed">22081779</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu TT, Chen YF, Hastie T, Sobel E, Lange K. Genome-wide association analysis by lasso penalized logistic regression. Bioinformatics. 2009;25(6):714&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732298</ArticleId><ArticleId IdType="pubmed">19176549</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27993747</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Accuracy of an automated knowledge base for identifying drug adverse reactions.</ArticleTitle><Pagination><StartPage>72</StartPage><EndPage>81</EndPage><MedlinePgn>72-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2016.12.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(16)30179-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Drug safety researchers seek to know the degree of certainty with which a particular drug is associated with an adverse drug reaction. There are different sources of information used in pharmacovigilance to identify, evaluate, and disseminate medical product safety evidence including spontaneous reports, published peer-reviewed literature, and product labels. Automated data processing and classification using these evidence sources can greatly reduce the manual curation currently required to develop reference sets of positive and negative controls (i.e. drugs that cause adverse drug events and those that do not) to be used in drug safety research.</AbstractText><AbstractText Label="METHODS">In this paper we explore a method for automatically aggregating disparate sources of information together into a single repository, developing a predictive model to classify drug-adverse event relationships, and applying those predictions to a real world problem of identifying negative controls for statistical method calibration.</AbstractText><AbstractText Label="RESULTS">Our results showed high predictive accuracy for the models combining all available evidence, with an area under the receiver-operator curve of &#x2a7e;0.92 when tested on three manually generated lists of drugs and conditions that are known to either have or not have an association with an adverse drug event.</AbstractText><AbstractText Label="CONCLUSIONS">Results from a pilot implementation of the method suggests that it is feasible to develop a scalable alternative to the time-and-resource-intensive, manual curation exercise previously applied to develop reference sets of positive and negative controls to be used in drug safety research.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>E A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, LLC, Raritan, NJ, United States; Erasmus University Medical Center, Rotterdam, Netherlands; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States. Electronic address: evoss3@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>R D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh, PA, United States; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>P B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, LLC, Raritan, NJ, United States; Columbia University, New York, NY, United States; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lei</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Erasmus University Medical Center, Rotterdam, Netherlands; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>P R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Erasmus University Medical Center, Rotterdam, Netherlands; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, LLC, Raritan, NJ, United States; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG044433</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011838</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001330" MajorTopicYN="Y">Electronic Data Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051188" MajorTopicYN="Y">Knowledge Bases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse drug reaction</Keyword><Keyword MajorTopicYN="N">Health outcome</Keyword><Keyword MajorTopicYN="N">Knowledge base</Keyword><Keyword MajorTopicYN="N">Machine-learning experiment</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27993747</ArticleId><ArticleId IdType="mid">NIHMS841934</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pii">S1532-0464(16)30179-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Safety of Medicines: A guide to detecting and reporting adverse drug reactions.  [PDF] 2002 03/24/2012]. Available from:  http://whqlibdoc.who.int/hq/2002/WHO_EDM_QSM_2002.2.pdf.</Citation></Reference><Reference><Citation>Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician&#x2019;s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in europe: a review of recent observational studies. Drug Saf. 2015;38(5):437&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412588</ArticleId><ArticleId IdType="pubmed">25822400</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel A, et al. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2012;21(11):1139&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pubmed">22761169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998;279(15):1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">9555760</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J, Friedlin J, Ryan P. A quantitative analysis of adverse events and &#x201c;overwarning&#x201d; in drug labeling. Arch Intern Med. 2011;171(10):944&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">21606101</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf. 2013;22(3):294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">23042584</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment.  [PDF] 2005.03.22; Available from:  http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071696.pdf.</Citation></Reference><Reference><Citation>Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98(8):1366&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2446471</ArticleId><ArticleId IdType="pubmed">18556607</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrman RE, et al. Developing the Sentinel System &#x2014; A National Resource for Evidence Development. New England Journal of Medicine. 2011;364(6):498&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">21226658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;(36 Suppl 1):S143&#x2013;S158.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, et al. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401&#x2013;4415.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50(10):890&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">22929992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce RD, et al. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf. 2014;37(8):557&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134480</ArticleId><ArticleId IdType="pubmed">24985530</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI) Vocabulary Resources.  [web page] 2015 2015.06.03]; Available from:  http://www.ohdsi.org/data-standardization/vocabulary-resources/</Citation></Reference><Reference><Citation>Huser V, et al.  Piloting a Comprehensive Knowledge Base for Pharmacovigilance Using Standardized Vocabularies.  [Web Page] 03/26/2015; Available from:  http://www.slideshare.net/boycer/piloting-acomprehensivepharmacovigilanceknowledgebase2015v2.</Citation></Reference><Reference><Citation>KnowledgeBase GitHub.  [Web Page]; Available from:  https://github.com/OHDSI/KnowledgeBase/</Citation></Reference><Reference><Citation>Boyce R, et al.  LAERTES: An open scalable architecture for linking pharmacovigilance evidence sources with clinical data.  2016 1-AUG-2016; Available from:  http://icbo.cgrb.oregonstate.edu/node/354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5341176</ArticleId><ArticleId IdType="pubmed">28270198</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek EP, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Scientific Data. 2016;3:160026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="pubmed">27193236</ArticleId></ArticleIdList></Reference><Reference><Citation>Avillach P, et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. J Am Med Inform Assoc. 2013;20(3):446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628051</ArticleId><ArticleId IdType="pubmed">23195749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilicoglu H, et al. Constructing a semantic predication gold standard from the biomedical literature. BMC Bioinformatics. 2011;12:486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281188</ArticleId><ArticleId IdType="pubmed">22185221</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT): Adverse Drug Reactions Database.  [web page] 2015.05.07]; Available from:  http://www.imi-protect.eu/adverseDrugReactions.shtml.</Citation></Reference><Reference><Citation>Ryan PB, et al. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;(36 Suppl 1):S33&#x2013;S47.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166222</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36(1):13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23315292</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, et al. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series. Stat Methods Med Res. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24685766</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, et al. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Saf. 2013;(36 Suppl 1):S159&#x2013;S169.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166232</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisdale J, Miller D. Drug-Induced Diseases: Prevention, Detection and Management. 2. American Society of Health-System Pharmacists (ASHP); 2010.</Citation></Reference><Reference><Citation>Trifiro G, et al. The EU-ADR project: preliminary results and perspective. Stud Health Technol Inform. 2009;148:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">19745234</ArticleId></ArticleIdList></Reference><Reference><Citation>CredibleMeds(R)  [web page] 2015.06.18]; Available from:  https://www.crediblemeds.org/</Citation></Reference><Reference><Citation>Woosley RL, Romero K. Assessing cardiovascular drug safety for clinical decision-making. Nat Rev Cardiol. 2013;10(6):330&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">23591268</ArticleId></ArticleIdList></Reference><Reference><Citation>Usagi.  [web page] 2015.05.21 2015.06.17]; Available from:  http://www.ohdsi.org/web/wiki/doku.php?id=documentation:software:usagi.</Citation></Reference><Reference><Citation>Airola A, et al. An experimental comparison of cross-validation techniques for estimating the area under the ROC curve. Computational Statistics &amp; Data Analysis. 2011;55(4):1828&#x2013;1844.</Citation></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria: R Core Team; 2015.</Citation></Reference><Reference><Citation>Suchard MA, et al. Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. ACM Trans. Model. Comput. Simul. 2013;23(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben M, Aronson JK, Ferner RE. Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard &#x2018;Negative Controls&#x2019; by the Observational Medical Outcomes Partnership (OMOP) Drug Saf. 2016;39(5):421&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">26879560</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P, Schuemie M. Evaluating Performance of Risk Identification Methods Through a Large-Scale Simulation of Observational Data. Drug Safety. 2013;36(1):171&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, et al. Text Mining for Adverse Drug Events: the Promise, Challenges, and State of the Art. Drug Safety. 2014;37(10):777&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4217510</ArticleId><ArticleId IdType="pubmed">25151493</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, et al. A supervised adverse drug reaction signalling framework imitating Bradford Hill&#x2019;s causality considerations. Journal of Biomedical Informatics. 2015;56:356&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">26116429</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files.  [web page] 2015.09.29 2015.11.13]; Available from:  http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28103227</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7358</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>PLoS computational biology</Title><ISOAbbreviation>PLoS Comput Biol</ISOAbbreviation></Journal><ArticleTitle>Ten Simple Rules to Enable Multi-site Collaborations through Data Sharing.</ArticleTitle><Pagination><StartPage>e1005278</StartPage><MedlinePgn>e1005278</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1005278</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pcbi.1005278</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Mary Regina</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-8576-6408</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karczewski</LastName><ForeName>Konrad J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0003-2878-4671</Identifier><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0002-2700-2597</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TL1 RR024158</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR000082</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM107145</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR001875</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT3 TR002027</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Comput Biol</MedlineTA><NlmUniqueID>101238922</NlmUniqueID><ISSNLinking>1553-734X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="Y">Cooperative Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017408" MajorTopicYN="Y">Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28103227</ArticleId><ArticleId IdType="pmc">PMC5245793</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.1005278</ArticleId><ArticleId IdType="pii">PCOMPBIOL-D-16-01506</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reichman OJ, Jones MB, Schildhauer MP. Challenges and opportunities of open data in ecology. Science. 2011;331(6018):703&#x2013;5. 10.1126/science.1197962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1197962</ArticleId><ArticleId IdType="pubmed">21311007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozeman B, Fay D, Slade CP. Research collaboration in universities and academic entrepreneurship: the-state-of-the-art. The Journal of Technology Transfer. 2013;38(1):1&#x2013;67.</Citation></Reference><Reference><Citation>Brown P, Morello-Frosch R, Brody JG, Altman RG, Rudel RA, Senier L, et al., editors. IRB challenges in multi-partner community-based participatory research. the American Sociological Association annual meeting; Sheraton Boston the Boston Marriott Copley Place; 2008.</Citation></Reference><Reference><Citation>Vicens Q, Bourne PE. Ten simple rules for a successful collaboration. PLoS Comput Biol. 2007;3(3):e44 10.1371/journal.pcbi.0030044</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.0030044</ArticleId><ArticleId IdType="pmc">PMC1847992</ArticleId><ArticleId IdType="pubmed">17397252</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BF, Wuchty S, Uzzi B. Multi-university research teams: Shifting impact, geography, and stratification in science. science. 2008;322(5905):1259&#x2013;62. 10.1126/science.1158357</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1158357</ArticleId><ArticleId IdType="pubmed">18845711</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;rner K, Contractor N, Falk-Krzesinski HJ, Fiore SM, Hall KL, Keyton J, et al. A multi-level systems perspective for the science of team science. Science Translational Medicine. 2010;2(49):49cm24&#x2013;49cm24. 10.1126/scitranslmed.3001399</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001399</ArticleId><ArticleId IdType="pmc">PMC3527819</ArticleId><ArticleId IdType="pubmed">20844283</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al. The electronic medical records and genomics (eMERGE) network: past, present, and future. Genetics in Medicine. 2013;15(10):761&#x2013;71. 10.1038/gim.2013.72</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2013.72</ArticleId><ArticleId IdType="pmc">PMC3795928</ArticleId><ArticleId IdType="pubmed">23743551</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Wei W, Chung C, Levinson R, Bastarache L, Denny J, et al. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. The pharmacogenomics journal. 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995153</ArticleId><ArticleId IdType="pubmed">26902539</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Ezerskiy LA, Bertelsen S, Goate AM. Alzheimer&#x2019;s Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PloS ONE. 2016;11(2):e0148717 10.1371/journal.pone.0148717</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0148717</ArticleId><ArticleId IdType="pmc">PMC4769299</ArticleId><ArticleId IdType="pubmed">26919393</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R, Traylor M, Pulit SL, Bevan S, Hopewell JC, Holliday EG, et al. Low-frequency and common genetic variation in ischemic stroke The METASTROKE collaboration. Neurology. 2016;86(13):1217&#x2013;26. 10.1212/WNL.0000000000002528</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002528</ArticleId><ArticleId IdType="pmc">PMC4818561</ArticleId><ArticleId IdType="pubmed">26935894</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Annals of internal medicine. 2010;153(9):600&#x2013;6. 10.7326/0003-4819-153-9-201011020-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Prli&#x107; A, Procter JB. Ten Simple Rules for the Open Development of Scientific Software. PLoS Comput Biol. 2012;8(12):e1002802 10.1371/journal.pcbi.1002802</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002802</ArticleId><ArticleId IdType="pmc">PMC3516539</ArticleId><ArticleId IdType="pubmed">23236269</ArticleId></ArticleIdList></Reference><Reference><Citation>Masum H, Rao A, Good BM, Todd MH, Edwards AM, Chan L, et al. Ten Simple Rules for Cultivating Open Science and Collaborative R&amp;D. PLoS Comput Biol. 2013;9(9):e1003244 10.1371/journal.pcbi.1003244</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003244</ArticleId><ArticleId IdType="pmc">PMC3784487</ArticleId><ArticleId IdType="pubmed">24086123</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlson G. Multisite Collaborations and Large Databases in Psychiatric Neuroimaging: Advantages, Problems, and Challenges. Schizophrenia Bulletin. 2009;35(1):1&#x2013;2. 10.1093/schbul/sbn166</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbn166</ArticleId><ArticleId IdType="pmc">PMC2643967</ArticleId><ArticleId IdType="pubmed">19023121</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber GM, Murphy SN, McMurry AJ, MacFadden D, Nigrin DJ, Churchill S, et al. The Shared Health Research Information Network (SHRINE): A Prototype Federated Query Tool for Clinical Data Repositories. Journal of the American Medical Informatics Association. 2009;16(5):624&#x2013;30. 10.1197/jamia.M3191</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M3191</ArticleId><ArticleId IdType="pmc">PMC2744712</ArticleId><ArticleId IdType="pubmed">19567788</ArticleId></ArticleIdList></Reference><Reference><Citation>Merriel RB, Gibbs P, O'Brien TJ, Hibbert M. BioGrid Australia facilitates collaborative medical and bioinformatics research across hospitals and medical research institutes by linking data from diverse disease and data types. Human mutation. 2011;32(5):517&#x2013;25. 10.1002/humu.21437</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21437</ArticleId><ArticleId IdType="pubmed">21309032</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle DIR, Rafael N, editors. BioGrid Australia and GRHANITE: Privacy-Protecing Subject Matching. HIC; 2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">21893908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al.
Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285&#x2013;91. http://www.nature.com/nature/journal/v536/n7616/abs/nature19057.html&#x2014;supplementary-information. 10.1038/nature19057
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19057</ArticleId><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>El Emam K, Rodgers S, Malin B. Anonymising and sharing individual patient data. bmj. 2015;350:h1139 10.1136/bmj.h1139</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h1139</ArticleId><ArticleId IdType="pmc">PMC4707567</ArticleId><ArticleId IdType="pubmed">25794882</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandve GK, Nekrutenko A, Taylor J, Hovig E. Ten Simple Rules for Reproducible Computational Research. PLoS Comput Biol. 2013;9(10):e1003285 10.1371/journal.pcbi.1003285</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003285</ArticleId><ArticleId IdType="pmc">PMC3812051</ArticleId><ArticleId IdType="pubmed">24204232</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis B. Standardizing global gene expression analysis between laboratories and across platforms. Nature methods. 2005;2(5):351&#x2013;6. 10.1038/nmeth754</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth754</ArticleId><ArticleId IdType="pubmed">15846362</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene&#x2013;disease associations. Bioinformatics. 2010;26(9):1205&#x2013;10. 10.1093/bioinformatics/btq126</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq126</ArticleId><ArticleId IdType="pmc">PMC2859132</ArticleId><ArticleId IdType="pubmed">20335276</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, Bielinski SJ, Berg RL, Choudhary V, et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. Journal of the American Medical Informatics Association. 2013;20(e1):e147&#x2013;e54. 10.1136/amiajnl-2012-000896</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000896</ArticleId><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak J, Wang J, Kashyap S, Basford M, Li R, Masys DR, et al. Mapping clinical phenotype data elements to standardized metadata repositories and controlled terminologies: the eMERGE Network experience. Journal of the American Medical Informatics Association. 2011;18(4):376&#x2013;86. 10.1136/amiajnl-2010-000061</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2010-000061</ArticleId><ArticleId IdType="pmc">PMC3128396</ArticleId><ArticleId IdType="pubmed">21597104</ArticleId></ArticleIdList></Reference><Reference><Citation>Diener E, Oishi S, Lucas RE. Personality, culture, and subjective well-being: Emotional and cognitive evaluations of life. Annual review of psychology. 2003;54(1):403&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">12172000</ArticleId></ArticleIdList></Reference><Reference><Citation>Human Fertility Database. Max Planck Institute for Demographic Research (Germany) and Vienna Institute of Demography (Austria). 2016; http://www.humanfertility.org (data accessed on October 6, 2016).</Citation></Reference><Reference><Citation>Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). 2016; http://www.mortality.org or http://www.humanmortality.de (data accessed on October 6, 2016).</Citation></Reference><Reference><Citation>Senn SJ. Overstating the evidence&#x2013;double counting in meta-analysis and related problems. BMC Medical Research Methodology. 2009;9(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2653069</ArticleId><ArticleId IdType="pubmed">19216779</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28124262</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1969</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Drugs &amp; aging</Title><ISOAbbreviation>Drugs Aging</ISOAbbreviation></Journal><ArticleTitle>Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.</ArticleTitle><Pagination><StartPage>211</StartPage><EndPage>219</EndPage><MedlinePgn>211-219</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40266-016-0430-x</ELocationID><Abstract><AbstractText Label="OBJECTIVE">A recently published analysis of population-based claims data from Ontario, Canada reported higher risks of acute kidney injury (AKI) and related outcomes among older adults who were new users of atypical antipsychotics (AAPs) compared with unexposed patients. In light of these findings, the objective of the current study was to further investigate the risks of AKI and related outcomes among older adults receiving AAPs.</AbstractText><AbstractText Label="METHODS">A replication of the previously published analysis was performed using the US Truven MarketScan Medicare Supplemental database (MDCR) among patients aged 65&#xa0;years and older. Compared with non-users of AAPs, the study compared the risk of AKI and related outcomes with users of AAPs (quetiapine, risperidone, olanzapine, aripiprazole, or paliperidone) using a 1-to-1 propensity score matched analysis. In addition, we performed adapted analyses that: (1) included all covariates used to fit propensity score models in outcome models; and (2) required patients to have a diagnosis of schizophrenia, bipolar disorder, or major depression and a healthcare visit within 90&#xa0;days prior to the index date.</AbstractText><AbstractText Label="RESULTS">AKI effect estimates [as odds ratios (ORs) with 95% confidence intervals (CIs)] were significantly elevated in our MDCR replication analyses (OR 1.45, 95% CI 1.32-1.60); however, in adapted analyses, associations were not significant (OR 0.91, 95% CI 0.78-1.07)). In analyses of AKI and related outcomes, results were mostly consistent between the previously published and the MDCR replication analyses. The primary change that attenuated associations in adapted analyses was the requirement for patients to have a mental health condition and a healthcare visit prior to the index date.</AbstractText><AbstractText Label="CONCLUSIONS">The MDCR analysis yielded similar results when the methodology of the previously published analysis was replicated, but, in adapted analyses, we did not find significantly higher risks of AKI and related outcomes. The contrast of results between our replication and adapted analyses may be due to the analytic approach used to compare patients (and potential confounding by indication). Further research is warranted to evaluate these associations, while also examining methods to account for differences in older adults who do and do not use these medications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Global Research and Development Epidemiology, 1125 Trenton Harbourton Road, Rm K30205, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Global Research and Development Epidemiology, 1125 Trenton Harbourton Road, Rm K30205, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramcharran</LastName><ForeName>Darmendra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Global Research and Development Epidemiology, 1125 Trenton Harbourton Road, Rm K30205, Titusville, NJ, 08560, USA. dramchar@ITS.JNJ.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Global Research and Development Epidemiology, 1125 Trenton Harbourton Road, Rm K30205, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs Aging</MedlineTA><NlmUniqueID>9102074</NlmUniqueID><ISSNLinking>1170-229X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28124262</ArticleId><ArticleId IdType="doi">10.1007/s40266-016-0430-x</ArticleId><ArticleId IdType="pii">10.1007/s40266-016-0430-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmacopsychiatry. 2015 Nov;48(7):265-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26398280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1994 Dec 17;344(8938):1705</Citation><ArticleIdList><ArticleId IdType="pubmed">7527886</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2008 Apr;56(4):661-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18266664</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Pharmacother. 2007 Sep;5(3):241-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17996664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 2004 May;38(5):899-900</Citation><ArticleIdList><ArticleId IdType="pubmed">15039480</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2013 Aug 15;178(4):645-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):1074-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18281139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Drug Saf. 2013 Apr;4(2):53-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25083251</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2014 Jan 30;33(2):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2005 Aug;2(8):e124</Citation><ArticleIdList><ArticleId IdType="pubmed">16060722</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nephrol. 2000 Jul;54(1):78-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10939762</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Jan 15;360(3):225-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19144938</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2012 Apr 23;172(8):648-53; discussion 654-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22450214</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2013 Oct;36 Suppl 1:S143-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Kong Med J. 2015 Aug;21(4):372-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26238137</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2006 Feb;21(2):171-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16416458</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2012 Feb;32(1):128</Citation><ArticleIdList><ArticleId IdType="pubmed">22217944</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Inform. 2012 Aug;45(4):689-96</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Sep;10(6):662-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18837860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2014 Aug 19;161(4):242-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25133360</ArticleId></ArticleIdList></Reference><Reference><Citation>ACM Trans Model Comput Simul. 2013 Jan;23(1):null</Citation><ArticleIdList><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2010 Jan;24(1):125-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18801826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2004 Dec;52(12 Suppl):S258-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15541166</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 2012 Jun;30(6):1233-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22499292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28225746</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-712X</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Atypical Antipsychotics and the Risk of Falls and Fractures Among Older Adults: An Emulation Analysis and an Evaluation of Additional Confounding Control Strategies.</ArticleTitle><Pagination><StartPage>162</StartPage><EndPage>168</EndPage><MedlinePgn>162-168</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000000647</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to investigate the risk of falls and fractures among older adults receiving atypical antipsychotics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An emulation analysis of a previously published study was performed using the US Truven MarketScan Medicare Supplemental database (MDCR). In addition, modified analyses were implemented to evaluate alternative confounding control strategies that (1) included all covariates used to fit propensity score models in outcome models and (2) required patients to have a mental health condition diagnosis and a health care visit within 90 days prior to the index date.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The MDCR emulation analyses yielded similar results as the previous study. For the previous study and our emulation analysis, the results were: nonvertebral osteoporotic fractures (odds ratio [OR], 1.51; 95% confidence interval [CI], 1.41-1.60; and OR, 1.49; 95% CI, 1.37-1.63, respectively), hip fractures (OR, 1.67; 95% CI, 1.53-1.81; and OR, 1.59; 95% CI, 1.43-1.77, respectively), any fracture (OR, 1.29; 95% CI, 1.24-1.34; and OR, 1.32; 95% CI, 1.23-1.41, respectively), and falls (OR, 1.54; 95% CI, 1.47-1.61; and OR, 1.45; 95% CI, 1.11-1.89, respectively). However, in modified analyses, no associations were significant. The primary change that resulted in the attenuation of associations was the requirement for patients to have a mental health condition diagnosis and a health care visit prior to the index date.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our MDCR emulation analysis yielded similar results as a previous study; however, in modified analyses, the associations between fractures and falls and atypical antipsychotics were no longer significant. The contrast of results between the emulation and modified analyses may be due to the analytic approach used to compare patients (and potential confounding by indication). Further research is warranted to evaluate these associations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramcharran</LastName><ForeName>Darmendra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From Global Research &amp; Development Epidemiology, Janssen Research &amp; Development, LLC, Titusville, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050723" MajorTopicYN="N">Fractures, Bone</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="N">Hip Fractures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058866" MajorTopicYN="N">Osteoporotic Fractures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28225746</ArticleId><ArticleId IdType="doi">10.1097/JCP.0000000000000647</ArticleId><ArticleId IdType="pii">00004714-201704000-00009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28261525</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2093-3681</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Healthcare informatics research</Title><ISOAbbreviation>Healthc Inform Res</ISOAbbreviation></Journal><ArticleTitle>Sharing Clinical Big Data While Protecting Confidentiality and Security: Observational Health Data Sciences and Informatics.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>3</EndPage><MedlinePgn>1-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4258/hir.2017.23.1.1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Healthc Inform Res</MedlineTA><NlmUniqueID>101534553</NlmUniqueID><ISSNLinking>2093-3681</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28261525</ArticleId><ArticleId IdType="pmc">PMC5334126</ArticleId><ArticleId IdType="doi">10.4258/hir.2017.23.1.1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mayer-Schonberger V. Big data for cardiology: novel discovery? Eur Heart J. 2016;37(12):996&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">26705386</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network: improving the evidence of medical-product safety. N Engl J Med. 2009;361(7):645&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635947</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329&#x2013;7336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Go AS, Magid DJ, Wells B, Sung SH, Cassidy-Bushrow AE, Greenlee RT, et al. The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research. Circ Cardiovasc Qual Outcomes. 2008;1(2):138&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20031802</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdoch TB, Detsky AS. The inevitable application of big data to health care. JAMA. 2013;309(13):1351&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">23549579</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28270198</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1480</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Journal of biomedical semantics</Title><ISOAbbreviation>J Biomed Semantics</ISOAbbreviation></Journal><ArticleTitle>Large-scale adverse effects related to treatment evidence standardization (LAERTES): an open scalable system for linking pharmacovigilance evidence sources with clinical data.</ArticleTitle><Pagination><StartPage>11</StartPage><MedlinePgn>11</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13326-017-0115-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Integrating multiple sources of pharmacovigilance evidence has the potential to advance the science of safety signal detection and evaluation. In this regard, there is a need for more research on how to integrate multiple disparate evidence sources while making the evidence computable from a knowledge representation perspective (i.e., semantic enrichment). Existing frameworks suggest well-promising outcomes for such integration but employ a rather limited number of sources. In particular, none have been specifically designed to support both regulatory and clinical use cases, nor have any been designed to add new resources and use cases through an open architecture. This paper discusses the architecture and functionality of a system called Large-scale Adverse Effects Related to Treatment Evidence Standardization (LAERTES) that aims to address these shortcomings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">LAERTES provides a standardized, open, and scalable architecture for linking evidence sources relevant to the association of drugs with health outcomes of interest (HOIs). Standard terminologies are used to represent different entities. For example, drugs and HOIs are represented in RxNorm and Systematized Nomenclature of Medicine -- Clinical Terms respectively. At the time of this writing, six evidence sources have been loaded into the LAERTES evidence base and are accessible through prototype evidence exploration user interface and a set of Web application programming interface services. This system operates within a larger software stack provided by the Observational Health Data Sciences and Informatics clinical research framework, including the relational Common Data Model for observational patient data created by the Observational Medical Outcomes Partnership. Elements of the Linked Data paradigm facilitate the systematic and scalable integration of relevant evidence sources.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prototype LAERTES system provides useful functionality while creating opportunities for further research. Future work will involve improving the method for normalizing drug and HOI concepts across the integrated sources, aggregated evidence at different levels of a hierarchy of HOI concepts, and developing more advanced user interface for drug-HOI investigations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>Knowledge Base workgroup of the Observational Health Data Sciences and Informatics (OHDSI) collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG044433</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT3 TR002027</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011838</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA209997</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Semantics</MedlineTA><NlmUniqueID>101531992</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical terminologies</Keyword><Keyword MajorTopicYN="N">Linked-data</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword><Keyword MajorTopicYN="N">Post-market drug safety</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Boyce</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorberbaum</LastName><ForeName>Tal</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dumontier</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauben</LastName><ForeName>Manfred</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallberg</LastName><ForeName>Magnus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peng</LastName><ForeName>Lili</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dempster</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>He</LastName><ForeName>Yongqun</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koutkias</LastName><ForeName>Vassilis</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Natsiavas</LastName><ForeName>Pantelis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28270198</ArticleId><ArticleId IdType="pmc">PMC5341176</ArticleId><ArticleId IdType="doi">10.1186/s13326-017-0115-3</ArticleId><ArticleId IdType="pii">10.1186/s13326-017-0115-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>&#x201c;US Department of Health and Human Services.&#x201d; National action plan for adverse drug event prevention [Internet]. Washington D.C.: U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion.; 2014 [cited 2015 Jul 3]. Available from: www.health.gov/hcq/pdfs/ADE-Action-Plan-508c.pdf.</Citation></Reference><Reference><Citation>O&#x2019;Connor K, Pimpalkhute P, Nikfarjam A, Ginn R, Smith KL, Gonzalez G. Pharmacovigilance on twitter? mining tweets for adverse drug reactions. AMIA Annu Symp Proc. 2014;2014:924&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419871</ArticleId><ArticleId IdType="pubmed">25954400</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutkias VG, Lillo-Le Lou&#xeb;t A, Jaulent M-C. Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies. Expert Opin Drug Saf. 2017;16(2):113&#x2013;24. doi:10.1080/14740338.2017.1257604.</Citation><ArticleIdList><ArticleId IdType="pubmed">27813420</ArticleId></ArticleIdList></Reference><Reference><Citation>Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, Dasgupta N. Digital drug safety surveillance: monitoring pharmaceutical products in twitter. Drug Saf. 2014;37(5):343&#x2013;350. doi: 10.1007/s40264-014-0155-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0155-x</ArticleId><ArticleId IdType="pmc">PMC4013443</ArticleId><ArticleId IdType="pubmed">24777653</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang N, Xu H, Rindflesch TC, Cohen T. Identifying plausible adverse drug reactions using knowledge extracted from the literature. J Biomed Inform. 2014;52:293&#x2013;310. doi: 10.1016/j.jbi.2014.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2014.07.011</ArticleId><ArticleId IdType="pmc">PMC4261011</ArticleId><ArticleId IdType="pubmed">25046831</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron D, Smith GA, Daniulaityte R, Sheth AP, Dave D, Chen L, Anand G, Carlson R, Watkins KZ, Falck R. PREDOSE: a semantic web platform for drug abuse epidemiology using social media. J Biomed Inform. 2013;46(6):985&#x2013;997. doi: 10.1016/j.jbi.2013.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2013.07.007</ArticleId><ArticleId IdType="pmc">PMC3844051</ArticleId><ArticleId IdType="pubmed">23892295</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Kiang M, Shang W. Filtering big data from social media--building an early warning system for adverse drug reactions. J Biomed Inform. 2015;54:230&#x2013;240. doi: 10.1016/j.jbi.2015.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.01.011</ArticleId><ArticleId IdType="pubmed">25688695</ArticleId></ArticleIdList></Reference><Reference><Citation>Cami A, Manzi S, Arnold A, Reis BY. Pharmacointeraction network models predict unknown drug-drug interactions. PLoS One. 2013;8(4):e61468. doi: 10.1371/journal.pone.0061468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0061468</ArticleId><ArticleId IdType="pmc">PMC3631217</ArticleId><ArticleId IdType="pubmed">23620757</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ryan PB, Wei Y, Friedman C. A method to combine signals from spontaneous reporting systems and observational healthcare data to detect adverse drug reactions. Drug Saf. 2015;38(10):895&#x2013;908. doi: 10.1007/s40264-015-0314-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0314-8</ArticleId><ArticleId IdType="pmc">PMC4579260</ArticleId><ArticleId IdType="pubmed">26153397</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Wu Y, Chen Y, Sun J, Zhao Z, Chen X, Matheny ME, Xu H. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc JAMIA. 2012;19(e1):e28&#x2013;e35. doi: 10.1136/amiajnl-2011-000699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000699</ArticleId><ArticleId IdType="pmc">PMC3392844</ArticleId><ArticleId IdType="pubmed">22718037</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, Vilar S, Dumouchel W, Salmasian H, Haerian K, Shah NH, Chase HS, Friedman C. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc JAMIA. 2013;20(3):413&#x2013;419. doi: 10.1136/amiajnl-2012-000930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000930</ArticleId><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutkias VG, Jaulent M-C. Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks. Drug Saf. 2015;38(3):219&#x2013;232. doi: 10.1007/s40264-015-0278-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0278-8</ArticleId><ArticleId IdType="pmc">PMC4374117</ArticleId><ArticleId IdType="pubmed">25749722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Solbrig HR, Chute CG. ADEpedia: a scalable and standardized knowledge base of adverse drug events using semantic web technology. AMIA Annu Symp Proc AMIA Symp AMIA Symp. 2011;2011:607&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243176</ArticleId><ArticleId IdType="pubmed">22195116</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Wang C, Zhu Q, Chute CG. A framework of knowledge integration and discovery for supporting pharmacogenomics target predication of adverse drug events: a case study of drug-induced long QT syndrome. AMIA Summits Transl Sci Proc. 2013;2013:88&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814489</ArticleId><ArticleId IdType="pubmed">24303306</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Li W, Wang X, Zhou Y, Wu Z, Shen J, Tang Y. Adverse drug events: database construction and in silico prediction. J Chem Inf Model. 2013;53(4):744&#x2013;752. doi: 10.1021/ci4000079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci4000079</ArticleId><ArticleId IdType="pubmed">23521697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Xu. CATTLE - Cancer Treatment with Linked Evidence [Internet]. 2015 [cited 2015 Jul 3]. Available from: http://www.drugkb.org/about.php.</Citation></Reference><Reference><Citation>Callahan A, Cruz-Toledo J, Ansell P, Dumontier M. Bio2rdf release 2: Improved coverage, interoperability and provenance of life science linked data. In: The Semantic Web: Semantics and Big Data. New York City: Springer; 2013. p. 200&#x2013;12.</Citation></Reference><Reference><Citation>Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010&#x2013;1021. doi: 10.1038/clpt.2012.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.50</ArticleId><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH. Mining clinical text for signals of adverse drug-drug interactions. J Am Med Inform Assoc. 2014;21(2):353&#x2013;362. doi: 10.1136/amiajnl-2013-001612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-001612</ArticleId><ArticleId IdType="pmc">PMC3932451</ArticleId><ArticleId IdType="pubmed">24158091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilicoglu H, Shin D, Fiszman M, Rosemblat G, Rindflesch TC. SemMedDB: a PubMed-scale repository of biomedical semantic predications. Bioinformatics. 2012;28(23):3158&#x2013;3160. doi: 10.1093/bioinformatics/bts591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts591</ArticleId><ArticleId IdType="pmc">PMC3509487</ArticleId><ArticleId IdType="pubmed">23044550</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, Vilar S, Brochhausen M, Samwald M, Rastegar-Mojarad M, Dumontier M, Boyce RD. Toward a complete dataset of drug-drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206&#x2013;217. doi: 10.1016/j.jbi.2015.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.04.006</ArticleId><ArticleId IdType="pmc">PMC4464899</ArticleId><ArticleId IdType="pubmed">25917055</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumontier M. Bo2RDF RDFization Guide [Internet]. 2015 [cited 2015 Jul 4]. Available from: https://github.com/bio2rdf/bio2rdf-scripts/wiki/RDFization-Guide.</Citation></Reference><Reference><Citation>Boyce RD, Ryan PB, Nor&#xe9;n GN, Schuemie MJ, Reich C, Duke J, Tatonetti NP, Trifir&#xf2; G, Harpaz R, Overhage JM, Hartzema AG, Khayter M, Voss EA, Lambert CG, Huser V, Dumontier M. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf. 2014;37(8):557&#x2013;567. doi: 10.1007/s40264-014-0189-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0189-0</ArticleId><ArticleId IdType="pmc">PMC4134480</ArticleId><ArticleId IdType="pubmed">24985530</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Observational Health Data Sciences and Informatics [Internet]. [cited 2015 May 15]. Available from: http://www.ohdsi.org/.</Citation></Reference><Reference><Citation>&#x201c;Open Annotation Community Group.&#x201d; Open Annotation Data Model [Internet]. 2015 [cited 2015 Jul 3]. Available from: http://www.openannotation.org/spec/core/.</Citation></Reference><Reference><Citation>&#x201c;W3C.&#x201d; RDF 1.1 Primer [Internet]. RDF 1.1 Primer. 2014 [cited 2016 Nov 12]. Available from: https://www.w3.org/TR/rdf11-primer/.</Citation></Reference><Reference><Citation>Dumontier M, Gray AJG, Marshall MS, Alexiev V, Ansell P, Bader G, Baran J, Bolleman JT, Callahan A, Cruz-Toledo J, Gaudet P, Gombocz EA, Gonzalez-Beltran AN, Groth P, Haendel M, Ito M, Jupp S, Juty N, Katayama T, Kobayashi N, Krishnaswami K, Laibe C, Le Nov&#xe8;re N, Lin S, Malone J, Miller M, Mungall CJ, Rietveld L, Wimalaratne SM, Yamaguchi A. The health care and life sciences community profile for dataset descriptions. PeerJ. 2016;4:e2331. doi: 10.7717/peerj.2331.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.2331</ArticleId><ArticleId IdType="pmc">PMC4991880</ArticleId><ArticleId IdType="pubmed">27602295</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI) Vocabulary Resources [Internet]. 2015 [cited 2015 Jul 9]. Available from: http://www.ohdsi.org/data-standardization/vocabulary-resources/.</Citation></Reference><Reference><Citation>Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf. 2013;22(3):294&#x2013;301. doi:10.1002/pds.3351.</Citation><ArticleIdList><ArticleId IdType="pubmed">23042584</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3&#x2013;10. doi: 10.1002/pds.668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.668</ArticleId><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. OHDSI Virtuoso SPARQL Query Editor [Internet]. OHDSI Virtuoso Endpoint. 2016 [cited 2016 Nov 12]. Available from: http://virtuoso.ohdsi.org:8890/sparql.</Citation></Reference><Reference><Citation>OHDSI/KnowledgeBase [Internet]. GitHub. [cited 2015 May 19]. Available from: https://github.com/OHDSI/KnowledgeBase.</Citation></Reference><Reference><Citation>&#x201c;Harry Jerry.&#x201d; Harry Jerry Linx [Internet]. 2015 [cited 2015 Jul 4]. Available from: https://harryjerry.com/web/create-your-own-url-shortening-service/.</Citation></Reference><Reference><Citation>&#x201c;OHDSI Team.&#x201d; OHDSI/KnowledgeBaseWeb [Internet]. GitHub. 2016 [cited 2016 Jul 29]. Available from: https://github.com/OHDSI/KnowledgeBaseWeb.</Citation></Reference><Reference><Citation>Tatonetti NP, May B, Boyce RD. Experimental LAERTES Evidence Base Explorer [Internet]. 2016 [cited 2016 Jul 29]. Available from: http://www.ohdsi.org/web/knowledgebaseweb/.</Citation></Reference><Reference><Citation>&#x201c;OHDSI Team.&#x201d; WebAPI Overview and REST calls [Internet]. 2016 [cited 2016 May 11]. Available from: http://www.ohdsi.org/web/wiki/doku.php?id=documentation:software:splicer.</Citation></Reference><Reference><Citation>&#x201c;OHDSI Team.&#x201d; OHDSI/Atlas [Internet]. GitHub. 2016 [cited 2016 May 11]. Available from: https://github.com/OHDSI/Atlas.</Citation></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy&#xa0;of an Automated Knowledge Base for Identifying Drug Adverse Reactions. J BiomedInform. 2016. doi:10.1016/j.jbi.2016.12.005. [Epub ahead of print] PubMed PMID: 27993747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Martijn Schuemie, PhD. The Journey Toward Population-Level Effect Estimation [Internet]. Podium Presentation presented at; [cited 2016 Nov 12]; Washington, DC, USA. Available from: http://www.ohdsi.org/wp-content/uploads/2016/09/OHDSI-Sympsium-2016-Schuemie-estimation-23sept2016.pdf.</Citation></Reference><Reference><Citation>Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1898525</ArticleId><ArticleId IdType="pubmed">14283879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Evans. Download page for LTS Computing LLC [Internet]. LTS Computing LLC. [cited 2016 Nov 12]. Available from: http://www.ltscomputingllc.com/downloads/.</Citation></Reference><Reference><Citation>Lee Evans. LAERTES Data Source Extraction Translate and Load Documentation [Internet]. 2015 [cited 2015 Jul 10]. Available from: http://www.ohdsi.org/web/wiki/doku.php?id=documentation:laertes_etl.</Citation></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209&#x2013;218. doi: 10.1002/sim.5925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes BT, Pedersen T, Pakhomov SVS. UMLS-Interface and UMLS-Similarity : open source software for measuring paths and semantic similarity. AMIA Annu Symp Proc AMIA Symp AMIA Symp. 2009;2009:431&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815481</ArticleId><ArticleId IdType="pubmed">20351894</ArticleId></ArticleIdList></Reference><Reference><Citation>A curated and standardized adverse drug event resource to accelerate drug safety research&#x202f;: Scientific Data [Internet]. [cited 2016 May 14]. Available from: http://www.nature.com/articles/sdata201626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="pubmed">27193236</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. OHDSI/Usagi [Internet]. GitHub for OHDSI Usagi. 2016 [cited 2016 Nov 15]. Available from: https://github.com/OHDSI/Usagi.</Citation></Reference><Reference><Citation>Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3:160026. doi: 10.1038/sdata.2016.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.26</ArticleId><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="pubmed">27193236</ArticleId></ArticleIdList></Reference><Reference><Citation>Avillach P, Dufour J-C, Diallo G, Salvo F, Joubert M, Thiessard F, Mougin F, Trifir&#xf2; G, Fourrier-R&#xe9;glat A, Pariente A, Fieschi M. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. J Am Med Inform Assoc JAMIA. 2013;20(3):446&#x2013;452. doi: 10.1136/amiajnl-2012-001083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-001083</ArticleId><ArticleId IdType="pmc">PMC3628051</ArticleId><ArticleId IdType="pubmed">23195749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28379377</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>EliIE: An open-source information extraction system for clinical trial eligibility criteria.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1071</EndPage><MedlinePgn>1062-1071</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocx019</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To develop an open-source information extraction system called Eligibility Criteria Information Extraction (EliIE) for parsing and formalizing free-text clinical research eligibility criteria (EC) following Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) version 5.0.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">EliIE parses EC in 4 steps: (1) clinical entity and attribute recognition, (2) negation detection, (3) relation extraction, and (4) concept normalization and output structuring. Informaticians and domain experts were recruited to design an annotation guideline and generate a training corpus of annotated EC for 230 Alzheimer's clinical trials, which were represented as queries against the OMOP CDM and included 8008 entities, 3550 attributes, and 3529 relations. A sequence labeling-based method was developed for automatic entity and attribute recognition. Negation detection was supported by NegEx and a set of predefined rules. Relation extraction was achieved by a support vector machine classifier. We further performed terminology-based concept normalization and output structuring.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In task-specific evaluations, the best F1 score for entity recognition was 0.79, and for relation extraction was 0.89. The accuracy of negation detection was 0.94. The overall accuracy for query formalization was 0.71 in an end-to-end evaluation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study presents EliIE, an OMOP CDM-based information extraction system for automatic structuring and formalization of free-text EC. According to our evaluation, machine learning-based EliIE outperforms existing systems and shows promise to improve.</AbstractText><CopyrightInformation>Published by Oxford University Press on behalf of the American Medical Informatics Association 2017. This work is written by US Government employees and is in the public domain in the United States.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shaodian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Youlan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Human Nutrition, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hruby</LastName><ForeName>Gregory W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusanov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elhadad</LastName><ForeName>No&#xe9;mie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004608" MajorTopicYN="N">Eligibility Determination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">named entity recognition</Keyword><Keyword MajorTopicYN="N">natural language processing</Keyword><Keyword MajorTopicYN="N">patient selection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28379377</ArticleId><ArticleId IdType="pmc">PMC6259668</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocx019</ArticleId><ArticleId IdType="pii">3098256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lovato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Controlled Clinical Trials. 1997;184:328&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9257072</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald AM, Knight RC, Campbell MK. et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006;71:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1475627</ArticleId><ArticleId IdType="pubmed">16603070</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Tu SW, Sim I, Richesson R. Formal representation of eligibility criteria: a literature review. J Biomed Inform. 2010;433:451&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878905</ArticleId><ArticleId IdType="pubmed">20034594</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Yaman A, Lin K, He Z. Trend and network analysis of common eligibility features for cancer trials in ClinicalTrials.gov. Smart Health. 2014;8549:130&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4795902</ArticleId><ArticleId IdType="pubmed">26998530</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Carini S, Sim I, Weng C. Visual aggregate analysis of eligibility features of clinical trials. J Biomed Inform. 2015;54:241&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408222</ArticleId><ArticleId IdType="pubmed">25615940</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Wang S, Borhanian E, Weng C. Assessing the collective population representativeness of related type 2 diabetes trials by combining public data from ClinicalTrials.gov and NHANES. Stud Health Technol Inform. 2015;216:569&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586087</ArticleId><ArticleId IdType="pubmed">26262115</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Li Y, Ryan P. et al. Distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records. Appl Clin Inform. 2014;52:463&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081748</ArticleId><ArticleId IdType="pubmed">25024761</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez AF, Fleurence RL, Rothman RL. The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm. Ann Intern Med. 2015;1638:635&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">26301537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD. et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci USA. 2016;11327:7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu SW, Musen MA. The EON model of intervention protocols and guidelines. In: Cimino JJ, ed. Proc AMIA Annu Fall Symp. Philadelphia: Hanley &amp; Belfus; 1996:587&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2233213</ArticleId><ArticleId IdType="pubmed">8947734</ArticleId></ArticleIdList></Reference><Reference><Citation>Niland J. ASPIRE: Agreement on Standardized Protocol Inclusion Requirements for Eligibility; 2007. Disponible sur: (Consult&#xe9; le 03/02/2010); 2007.</Citation></Reference><Reference><Citation>Weng C, Wu X, Luo Z, Boland MR, Theodoratos D, Johnson SB. EliXR: an approach to eligibility criteria extraction and representation. J Am Med Inform Assoc. 2011;18(Suppl 1): i116&#x2013;i124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241167</ArticleId><ArticleId IdType="pubmed">21807647</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu S, Peleg M, Carini S, Rubin D, Sim I. Ergo: A Template-based Expression Language for Encoding Eligibility Criteria. 2009, Technical report.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;191:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH. et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler-Milstein J, DesRoches CM, Kralovec P. et al. Electronic health record adoption in US hospitals: progress continues, but challenges persist. Health Aff (Millwood). 2015;3412:2174&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">26561387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AM, Hersh WR. A survey of current work in biomedical text mining. Briefings Bioinformatics. 2005;61:57&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15826357</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman C, Hripcsak G, Shagina L, Liu H. Representing information in patient reports using natural language processing and the extensible markup language. J Am Med Inform Assoc. 1999;61:76&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61346</ArticleId><ArticleId IdType="pubmed">9925230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Liu F, Simpson P. et al. AskHERMES: An online question answering system for complex clinical questions. J Biomed Inform. 2011;442:277&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433744</ArticleId><ArticleId IdType="pubmed">21256977</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, Callahan A, Tamang S. et al. Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Safety. 2014;3710:777&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4217510</ArticleId><ArticleId IdType="pubmed">25151493</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Chen J, Jagannatha A, Yu H. Learning for Biomedical Information Extraction: Methodological Review of Recent Advances. arXiv preprint arXiv:1606.07993, 2016.</Citation></Reference><Reference><Citation>Kim J-D, Ohta T, Tsuruoka Y, Tateisi Y, Collier N. Introduction to the bio-entity recognition task at JNLPBA. In Proc International Joint Workshop on Natural Language Processing in Biomedicine and Its Applications. Geneva, Switzerland: Association for Computational Linguistics; 2004:70&#x2013;75.</Citation></Reference><Reference><Citation>Kim J-D, Ohta T, Pyysalo S, Kano Y, Tsujii JI. Overview of BioNLP&#x2019;09 shared task on event extraction. In Proceedings of the Workshop on Current Trends in Biomedical Natural Language Processing: Shared Task. Boulder, Colorado: Association for Computational Linguistics; 2009:1&#x2013;9.</Citation></Reference><Reference><Citation>Kim J-D, Pyysalo S, Ohta T, Bossy R, Nguyen N, Tsujii JI. Overview of BioNLP shared task 2011. In Proceedings of the BioNLP Shared Task 2011 Workshop. Association for Computational Linguistics; 2011:1&#x2013;6.</Citation></Reference><Reference><Citation>Uzuner &#xd6;, South BR, Shen S, DuVall SL. 2010 i2b2/VA challenge on concepts, assertions, and relations in clinical text. J Am Med Inform Assoc. 2011;185:552&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168320</ArticleId><ArticleId IdType="pubmed">21685143</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzuner &#xd6;, Solti I, Cadag E. Extracting medication information from clinical text. J Am Med Inform Assoc. 2010;175:514&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995677</ArticleId><ArticleId IdType="pubmed">20819854</ArticleId></ArticleIdList></Reference><Reference><Citation>Suominen H, Salanter&#xe4; S, Velupillai S. et al. Overview of the ShARe/CLEF eHealth evaluation lab 2013. In International Conference of the Cross-Language Evaluation Forum for European Languages. Springer; 2013:212&#x2013;31.</Citation></Reference><Reference><Citation>Pradhan S, Elhadad N, South BR. et al. Evaluating the state of the art in disorder recognition and normalization of the clinical narrative. J Am Med Inform Assoc. 2015;221:143&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433360</ArticleId><ArticleId IdType="pubmed">25147248</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhadad N, Pradhan S, Chapman W, Manandhar S, Savova G. SemEval-2015 task 14: analysis of clinical text. In Proc of Workshop on Semantic Evaluation. Denver: Association for Computational Linguistics; 2015:303&#x2013;10.</Citation></Reference><Reference><Citation>Pradhan S, Elhadad N, Chapman W, Manandhar S, Savova G. SemEval-2014 task 7: analysis of clinical text. SemEval. Dublin 2014;19999:54.</Citation></Reference><Reference><Citation>Smith L, Tanabe LK, nee Ando RJ. et al. Overview of BioCreative II gene mention recognition. Genome Biol. 2008;92:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2559986</ArticleId><ArticleId IdType="pubmed">18834493</ArticleId></ArticleIdList></Reference><Reference><Citation>Krallinger M, Leitner F, Rodriguez-Penagos C, Valencia A. Overview of the protein-protein interaction annotation extraction task of BioCreative II. Genome Biology. 2008;92:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2559988</ArticleId><ArticleId IdType="pubmed">18834495</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Landeghem S, Bj&#xf6;rne J, Wei C-H. et al. Large-scale event extraction from literature with multi-level gene normalization. PloS One. 2013;84:e55814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629104</ArticleId><ArticleId IdType="pubmed">23613707</ArticleId></ArticleIdList></Reference><Reference><Citation>Piskorski J, Yangarber R. Information extraction: past, present and future. In Multi-source, Multilingual Information Extraction and Summarization. Berlin: Springer; 2013:23&#x2013;49.</Citation></Reference><Reference><Citation>Tang B, Cao H, Wu Y, Jiang M, Xu H. Recognizing clinical entities in hospital discharge summaries using Structural Support Vector Machines with word representation features. BMC Med Inform Decis Mak. 2013;13(Suppl 1):S1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618243</ArticleId><ArticleId IdType="pubmed">23566040</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruijn B, Cherry C, Kiritchenko S, Martin J, Zhu X. Machine-learned solutions for three stages of clinical information extraction: the state of the art at i2b2 2010. J Am Med Inform Assoc. 2011;185:557&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168309</ArticleId><ArticleId IdType="pubmed">21565856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, Chen Y, Liu M. et al. A study of machine-learning-based approaches to extract clinical entities and their assertions from discharge summaries. J Am Med Inform Assoc. 2011;185:601&#x2013;06.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168315</ArticleId><ArticleId IdType="pubmed">21508414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweigenbaum P, Demner-Fushman D, Yu H, Cohen KB. Frontiers of biomedical text mining: current progress. Briefings Bioinformatics. 2007;85:358&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2516302</ArticleId><ArticleId IdType="pubmed">17977867</ArticleId></ArticleIdList></Reference><Reference><Citation>Banko M, Cafarella MJ, Soderland S, Broadhead M, Etzioni O. Open information extraction from the web. In IJCAI. 2007;2670&#x2013;6.</Citation></Reference><Reference><Citation>Wu H, Gu Y, Sun S, Gu X. Aspect-based Opinion Summarization with Convolutional Neural Networks. In Neural Networks (IJCNN), Vancouver, Canada: International Joint Conference on; 2016:3157&#x2013;63. IEEE.</Citation></Reference><Reference><Citation>Marujo L, Ling W, Ribeiro R. et al. Exploring events and distributed representations of text in multi-document summarization. Knowledge-Based Sys. 2016;94:33&#x2013;42.</Citation></Reference><Reference><Citation>Huang H, Heck L, Ji H. Leveraging Deep Neural Networks and Knowledge Graphs for Entity Disambiguation. arXiv preprint arXiv:1504.07678, 2015.</Citation></Reference><Reference><Citation>Nguyen TH, Grishman R. Combining Neural Networks and Log-linear Models to Improve Relation Extraction. arXiv preprint arXiv:1511.05926, 2015.</Citation></Reference><Reference><Citation>Xu Y, Mou L, Li G, Chen Y, Peng H, Jin Z. Classifying relations via long short term memory networks along shortest dependency paths. In Proceedings of Conference on Empirical Methods in Natural Language Processing. 2015.</Citation></Reference><Reference><Citation>Miwa M, Bansal M. End-to-end Relation Extraction using LSTMs on Sequences and Tree Structures. In Proceedings of the 54th Annual Meeting of the Association for Computational Linguistics. Berlin, Germany; 2016 (Volume 1: Long Papers):1105&#x2013;16.</Citation></Reference><Reference><Citation>Mikolov T, Chen K, Corrado G, Dean J. Efficient Estimation of Word Representations in Vector Space. arXiv preprint arXiv:1301.3781, 2013.</Citation></Reference><Reference><Citation>Jagannatha AN, Yu H. Bidirectional RNN for medical event detection in electronic health records. In Proceedings of the conference. Association for Computational Linguistics. North American Chapter. Meeting; 2016:473. NIH Public Access.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119627</ArticleId><ArticleId IdType="pubmed">27885364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Kang T, Zhang X, Wen D, Elhadad N, Lei J. Speculation detection for Chinese clinical notes: Impacts of word segmentation and embedding models. J Biomed Inform. 2016;60:334&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5282586</ArticleId><ArticleId IdType="pubmed">26923634</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Fix G, Yamin A, Weng C. Structuring clinical trial eligibility criteria with common data model. In Proc of 2015 AMIA Joint Summits for Translational Science. San Francisco, CA: AMIA; 2015.</Citation></Reference><Reference><Citation>Tuason O, Chen L, Liu H, Blake JA, Friedman C. Biological nomenclatures: a source of lexical knowledge and ambiguity. In Proceedings of the Pacific Symposium of Biocomputing. 2003;9:238.</Citation><ArticleIdList><ArticleId IdType="pubmed">14992507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T, Liu H, Weng C. Valx: a system for extracting and structuring numeric lab test comparison statements from text. Methods Inform Med. 2016;553:266&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573874</ArticleId><ArticleId IdType="pubmed">26940748</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health. ClinicalTrials.gov. http://clinicaltrials.gov. Accessed March 15, 2017.</Citation></Reference><Reference><Citation>Alzheimer&#x2019;s Association. Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s Dementia. 2015;113:332.</Citation><ArticleIdList><ArticleId IdType="pubmed">25984581</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuyler PL, Hole WT, Tuttle MS, Sherertz DD. The UMLS Metathesaurus: representing different views of biomedical concepts. Bull Med Library Assoc. 1993;812:217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC225764</ArticleId><ArticleId IdType="pubmed">8472007</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenetorp P, Pyysalo S, Topi&#x107; G, Ohta T, Ananiadou S, Tsujii JI. BRAT: a web-based tool for NLP-assisted text annotation. In Proceedings of the Demonstrations at the 13th Conference of the European Chapter of the Association for Computational Linguistics. Avignon, France: Association for Computational Linguistics; 2012:102&#x2013;07.</Citation></Reference><Reference><Citation>
Kudo T.
CRF++: Yet another CRF toolkit. Software. http://crfpp/. Sourceforge. Net, 2005.</Citation></Reference><Reference><Citation>Bird S. NLTK: the natural language toolkit. In Proceedings of the COLING/ACL on Interactive Presentation Sessions. Association for Computational Linguistics; 2006:69&#x2013;72.</Citation></Reference><Reference><Citation>Aronson AR. Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program. In Proceedings of the AMIA Symposium. American Medical Informatics Association; 2001:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2243666</ArticleId><ArticleId IdType="pubmed">11825149</ArticleId></ArticleIdList></Reference><Reference><Citation>Turian J, Ratinov L, Bengio Y. Word representations: a simple and general method for semi-supervised learning. In Proceedings of the 48th Annual Meeting of the Association for Computational Linguistics. Association for Computational Linguistics; 2010:384&#x2013;94.</Citation></Reference><Reference><Citation>Blei DM, Ng AY, Jordan MI. Latent dirichlet allocation. J Machine Learning Res. 2003;3:993&#x2013;1022.</Citation></Reference><Reference><Citation>Hofmann T. Probabilistic latent semantic analysis. In Proceedings of the 15th Conference on Uncertainty in Artificial Intelligence. Morgan Kaufmann Publishers; 1999:289&#x2013;96.</Citation></Reference><Reference><Citation>Brown DE, Huntley CL. A practical application of simulated annealing to clustering. Pattern Recognition. 1992;254:401&#x2013;12.</Citation></Reference><Reference><Citation>Collobert R, Weston J, Bottou L, Karlen M, Kavukcuoglu K, Kuksa P. Natural language processing (almost) from scratch. J Machine Learning Res. 2011;12:2493&#x2013;537.</Citation></Reference><Reference><Citation>Tang B, Cao H, Wang X, Chen Q, Xu H. Evaluating word representation features in biomedical named entity recognition tasks. BioMed Res Int. 2014;2014:240403. doi:10.1155/2014/240403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963372</ArticleId><ArticleId IdType="pubmed">24729964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman WW, Bridewell W, Hanbury P, Cooper GF, Buchanan BG. A simple algorithm for identifying negated findings and diseases in discharge summaries. J Biomed Inform. 2001;345:301&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">12123149</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-C, Lin C-J. LIBSVM: a library for support vector machines. ACM Transact Intell Syst Technol. 2011;23:27.</Citation></Reference><Reference><Citation>Yim W-W, Denman T, Kwan S, Yestigen M. Tumor information extraction in radiology reports for hepatocellular carcinoma patients. In American Medical Informatics Association Summit on Clinical Research Informatics. San Francisco, CA; 2016:2016:455&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001784</ArticleId><ArticleId IdType="pubmed">27570686</ArticleId></ArticleIdList></Reference><Reference><Citation>Boag W, Wacome K, Tristan Naumann M, Rumshisky A.. CliNER: A Lightweight Tool for Clinical Named Entity Recognition. AMIA Joint Summits on Clinical Research Informatics (poster). 2015.</Citation></Reference><Reference><Citation>Kang T, Elhadad N, Weng C. Initial readability assessment of clinical trial eligibility criteria. AMIA Annu Symp Proc. 2015;2015:687&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765646</ArticleId><ArticleId IdType="pubmed">26958204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28392100</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8511</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</Title><ISOAbbreviation>J Stroke Cerebrovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Risk Prediction for Ischemic Stroke and Transient Ischemic Attack in Patients Without Atrial Fibrillation: A Retrospective Cohort Study.</ArticleTitle><Pagination><StartPage>1721</StartPage><EndPage>1731</EndPage><MedlinePgn>1721-1731</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jstrokecerebrovasdis.2017.03.036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1052-3057(17)30151-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Stroke mainly occurs in patients without atrial fibrillation (AF). This study explored risk prediction models for ischemic stroke and transient ischemic attack (TIA) in patients without AF.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three US-based healthcare databases (Truven MarketScan Commercial Claims and Encounters [CCAE], Medicare Supplemental [MDCR], and Optum Clinformatics [Optum]) were used to establish patient cohorts without AF during the index period of 2008-2012. The performance of 2 existing models (CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc) for predicting stroke and TIA was examined by fitting a logistic regression to a training dataset and evaluating predictive accuracy in a validation dataset (area under the curve, AUC) using patients with complete follow-up of 1 or 3 years, separately.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The commercial populations were younger and had fewer comorbidities than Medicare-eligible population. The incidence proportions of ischemic stroke and TIA during 1 and 3 years of follow-up were .5% and 1.9% (CCAE), .6% and 2.2% (Optum), and 4.6% and 13.1% (MDCR), respectively. The models performed consistently across all 3 databases, with the AUC ranging from .69 to .77 and from .68 to .73 for 1- and 3-year prediction, respectively. Predictive accuracy was lower than the initial work of CHADS<sub>2</sub> evaluation in patients with AF (AUC: .82), but consistent with a subsequent meta-analysis of CHADS<sub>2</sub> (.60-.80) and CHA<sub>2</sub>DS<sub>2</sub>-VASc performance (.64-.79).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although the existing schemes for predicting ischemic stroke and TIA in patients with AF can be applied to patients without AF with comparable predictive accuracy, the evidence suggests that there is room for improvement in these models' performance.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey. Electronic address: zyuan6@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Guohua</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yannicelli</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Scientific Affairs, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nessel</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Stroke Cerebrovasc Dis</MedlineTA><NlmUniqueID>9111633</NlmUniqueID><ISSNLinking>1052-3057</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="Y">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002546" MajorTopicYN="N">Ischemic Attack, Transient</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016345" MajorTopicYN="N">Medicare Part B</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Stroke</Keyword><Keyword MajorTopicYN="N">risk prediction</Keyword><Keyword MajorTopicYN="N">stroke prevention</Keyword><Keyword MajorTopicYN="N">transient ischemic attack</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28392100</ArticleId><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2017.03.036</ArticleId><ArticleId IdType="pii">S1052-3057(17)30151-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>